CBM 92-9
Multidrug Resistance
January 1988 through September 1992
2250 Citations
Prepared by:
Loretta D. Ulincy, M.L.S., National Library of Medicine
Michael M. Gottesman, M.D., National Cancer Institute
U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health
National Library of Medicine
Reference Section
8600 Rockville Pike
Bethesda, Maryland 20894
1992
SERIES NOTE
Current Bibliographies in Medicine (CBM) is a continuation in
part of the National Library of Medicine's Literature Search
Series, which ceased in 1987 with No. 87-15. In 1989 it also
subsumed the Specialized Bibliography Series. Each
bibliography in the new series covers a distinct subject area
of biomedicine and is intended to fulfill a current awareness
function. Citations are usually derived from searching a
variety of online databases. NLM databases utilized include
MEDLINE, AVLINE, BIOETHICSLINE, CANCERLIT, CATLINE,
HEALTH, POPLINE and TOXLINE. The only criterion for the
inclusion of a particular published work is its relevance to the
topic being presented; the format, ownership, or location of the
material is not considered.
Comments and suggestions on this series may be addressed to:
Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD 20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: patrias@nlm.nih.gov
Ordering Information:
Current Bibliographies in Medicine is sold by the
Superintendent of Documents, U.S. Government Printing Office,
Washington, D.C. 20402. To order the entire CBM series for
the calendar year 1992 (approx. 14 bibliographies), send
$41.00 ($51.25 foreign) to the Superintendent of Documents
citing GPO List ID: CBM92. Orders for individual
bibliographies in the series ($3.25, $4.06 foreign) should be
sent to the Superintendent of Documents citing the title, CBM
number, and the GPO List ID given above.
MULTIDRUG RESISTANCE
The resistance of cancer cells to multiple chemotherapeutic
drugs which are structurally unrelated has been termed
"multidrug resistance." In the past several years, several
mechanisms of multidrug resistance have been described,
including the expression of a cell surface multidrug efflux
pump (P-glycoprotein or the multidrug transporter), altered
glutathione metabolism, reduced activity of topoisomerase II,
and various less clearly defined changes in cellular proteins.
Because of evidence that expression of P-glycoprotein is
associated with drug-resistance in cancer, P-glycoprotein has
been studied extensively from the point of view of its
biochemistry and mechanism of action in order to develop
inhibitors which can be used clinically to reverse drug
resistance of cancers in patients. The clinical significance
of the other mechanisms of multidrug resistance are less well-
established, but many model systems indicate that they may
contribute to clinical resistance.
This bibliography lists journal articles, conference
proceedings and abstracts, letters, and monographs published
from January 1988 through September 1992. Arrangement of the
bibliography is by mechanism of this resistance (or by the
fact that a novel, but unknown mechanism is responsible for
resistance), and deals with both the basic biochemistry and
the clinical implications of these mechanisms. The P-
glycoprotein section is further subdivided by neoplasm type
and by antineoplastic/immunosuppressive drug categories.
Citations may be in more than one category. The monographs
are listed in a separate category at the end of the
bibliography.
SEARCH STRATEGY
A variety of online databases are usually searched in
preparing bibliographies in the CBM series. To assist you in
updating or otherwise manipulating the material in this
search, the strategy used for the NLM's MEDLINE database is
given below. Please note that the search strategies presented
here differ from individual demand searches in that they are
generally broadly formulated and irrelevant citations edited
out prior to printing.
SS 1 = (TW) MULTIPLE AND DRUG AND ALL RESISTAN:
SS 2 = (TW) MDR OR MDR1
SS 3 = (TW) MULTIDRUG AND ALL RESISTAN:
SS 4 = (TW) MULTI AND DRUG AND ALL RESISTAN:
SS 5 = P-GLYCOPROTEIN (NM) OR GP170 (TW)
SS 6 = EXP DRUG RESISTANCE
SS 7 = 6 AND MULTI (TW) OR 6 AND MULTIDRUG (TW) OR
6 AND MULTIPLE (TW)
SS 8 = 1 OR 2 OR 3 OR 4 OR 5 OR 7
SS 9 = 8 AND NEOPLASMS (PX) OR 8 AND
ALL CHEMOTHERAP: (TW) OR 8 AND
EXP ANTINEOPLASTIC AGENTS OR 8 AND
TUMOR NECROSIS FACTOR OR 8 AND
EXP GENE EXPRESSION OR 8 AND DNA, NEOPLASM OR
8 AND EXP TUMOR CELLS, CULTURED
SS 10 = 8 AND EXP MUTAGENESIS, SITE DIRECTED OR 8 AND
RNA, NEOPLASM OR 8 AND SEQUENCE ALIGNMENT OR 8 AND
EXP MOLECULAR SEQUENCE DATA OR 8 AND EXP PHENOTYPE
SS 11 = 8 AND EXP DNA OR 8 AND EXP DNA PROBES
SS 12 = 8 AND GENETICS (SH)
SS 13 = 9 OR 10 OR 11 OR 12
GRATEFUL MED
To make online searching easier and more efficient, the
Library offers GRATEFUL MED, microcomputer-based software that
provides a user-friendly interface to most NLM databases.
This software was specifically developed for health
professionals and features multiple choice menus and "fill in
the blank" screens for easy search preparation. GRATEFUL MED
runs on an IBM PC (or IBM-compatible) with DOS 2.0 or a
Macintosh, and requires a Hayes (or Hayes-compatible) modem.
It may be purchased from the National Technical Information
Service in Springfield, Virginia, for $29.95 (plus $3.00 per
order for shipping).
SAMPLE CITATIONS
Citations in this bibliographic series are formatted according
to the rules established for Index Medicus*. Sample journal
and monograph citations appear below. For journal articles
written in a foreign language, the English translation of the
title is placed in brackets; for monographs, the title is
given in the original language. In both cases the language of
publication is shown by a three letter abbreviation appearing
at the end of the citation. Note also that a colon (:) may
appear within an author's name or article title. The NLM
computer system automatically inserts this symbol in the place
of a diacritical mark.
Journal Article:
Authors Article Title
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler
JL. Multidrug resistance in human neuroblastoma
cells. J Pediatr Surg 1991 Sep; 26(9):1107-12.
Abbreviated Journal Date Volume Issue Pages
Title
Monograph:
Authors/Editors Title
Chou, T.C.; Rideout, D.C., editors. Synergism and
antagonism in chemotherapy.
New York: Academic Press; 1991. 752 p.
Place of Publisher Date Total No.
Publication of Pages
_________________________________
*For details of the formats used for references, see the
following publication:
Patrias, Karen. National Library of Medicine recommended
formats for bibliographic citation. Bethesda (MD): The
Library; 1991 Apr. Available from: NTIS, Springfield, VA;
PB91-182030.
TABLE OF CONTENTS
P-Glycoproteins
By Neoplasm Type
Brain neoplasms
Breast neoplasms
Colorectal neoplasms
Fibrosarcomas
Kidney neoplasms
Leukemias
Liver neoplasms
Lung neoplasms
Lymphomas
Myelomas
Prostate neoplasms
Neoplasms (other specific)
Neoplasms (general)
By Antineoplastic/Immunosuppressive Agent Type
Anthracyclines
Antimetabolites
Immunosuppressive agents
Nitrogen mustard compounds
Phytogenic compounds
Other antineoplastic agents
Other
Glutathione
Topoisomerase
Unknown Mechanism
Other
Monographs
P-GLYCOPROTEIN
By Neoplasm Type
-Brain neoplasms
Akiyama SI, Tisgunyram A, Ichikawa M, Sumizawa T, Furukawa T. A
molecular basis for multidrug-resistance and reversal of the
resistance. In: Tabuchi K, editor. Biological aspects of
brain tumors. 8th Nikko Brain Tumor Conference; 1990 Nov 6-
8; Karatsu-shi, Japan. New York: Springer-Verlag; 1991. p.
63-72.
Bates SE, Shieh CY, Tsokos M. Expression of mdr-1/P-
glycoprotein in human neuroblastoma. Am J Pathol 1991
Aug;139(2):305-15.
Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler JL,
Fojo AT. Expression of a drug resistance gene in human
neuroblastoma cell lines: modulation by retinoic acid-
induced differentiation. Mol Cell Biol 1989
Oct;9(10):4337-44.
Becker I, Becker KF, Meyermann R, Hollt V. The multidrug-
resistance gene MDR1 is expressed in human glial tumors.
Acta Neuropathol (Berl) 1991; 82(6):516-9.
Benard J, Bourhis J, Hartmann O, Boccon-Gibod L, Duvillard P,
Lhomme C, Michel G, Lemerle J, Goldstein L, Gottesman M, et
al. Overexpression of human MDR1 gene is related to prior
chemotherapy in ovarian carcinomas and in neuroblastomas.
Paper presented at: Symposium on Mechanisms of Drug and
Radiation Resistance of Tumor Cells; 1989 Jun 28-30;
Villejuif, France.
Benard J, Bourhis J, Riou G. [Activation of N-myc oncogene and
associated genes to chemoresistance, prognostic value for
neuroblastoma]. Bull Cancer (Paris) 1991 Jan;78(1):91-7.
(Fre).
Biedler JL, Casals D, Chang TD, Meyers MB, Spengler BA, Ross RA.
Multidrug-resistant human neuroblastoma cells are more
differentiated than controls and retinoic acid further
induces lineage-specific differentiation. Prog Clin Biol
Res 1991;366:181-91.
Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou
G. Correlation of mdr1 gene expression with chemotherapy
in neuroblastoma. J Natl Cancer Inst 1989;81(18):1401-5.
Bradley G, Georges E, Ling V. Immunohistochemical localization
of P-glycoprotein isoforms [abstract]. J Chemother Infect
Dis Malig 1989;Suppl 1:A306.
Chan HS, Haddad G, Thorner PS, Deboer G, Lin YP, Ondrusek N,
Yeger H, Ling V. P-glycoprotein expression as a predictor
of the outcome of therapy for neuroblastoma. N Engl J Med
1991;325(23):1608-14.
Chan HS, Thorner PS, Weitzman S, Solh H, Koren G, Thiessen J,
Haddad G, Giesbrecht E, Verjee Z, Greenberg ML, et al.
Cyclosporin A for reversal of multidrug resistance in
childhood malignancies [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2854.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler
JL, Melamed MR, Bertino JR. Multidrug-resistance gene p-
glycoprotein is expressed by endothelial cells at blood-
brain barrier sites. Proc Natl Acad Sci U S A
1989;86(2):695-8.
Doz F, Michon J, Quintana E, Pacquement H, Zucker JM.
[Multidrug resistance of solid tumors in children]. Arch Fr
Pediatr 1991 Oct;48(8):585-8. (Fre).
Feun L, Landy H, Lu K, Li DJ, Kuo MT, Lampidis T, Green B,
Savaraj N. MDR1 gene expression in primary malignant brain
tumor (MBT) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1989;8:A343.
Fleming GF, Amato JM, Agresti M, Safa AR. Megestrol acetate
reverses multidrug resistance and interacts with P-
glycoprotein. Cancer Chemother Pharmacol 1992;29(6):445-9.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein LJ, Fojo AT, Ueda K, Crist W, Green A, Brodeur G,
Pastan I, Gottesman MM. Expression of the multidrug
resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990
Jan; 8(1): 128-36.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular Diagnostics of Human Cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S.
Modulators of the multidrug-transporter, P-glycoprotein,
exist in the human plasma. Biochem Biophys Res Commun 1990
Jan 15;166(1):74-80.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y,
Akiyama SI. Glycosylation of P-glycoprotein in a
multidrug-resistant KB cell line and in the human tissues.
Biochim Biophys Acta 1991;1073(2):309-15.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Altered state of transformation and/or differentiation in
multidrug-resistant human neuroblastoma cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1704.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Multidrug resistance in human neuroblastoma cells. J
Pediatr Surg 1991 Sep; 26(9):1107-12.
Mehta BM, Rosa E, Fissekis JD, Bading JR, Biedler JL, Larson SM.
In-vivo identification of tumor multidrug resistance with
tritium-3-colchicine. J Nucl Med 1992 Jul;33(7):1373-7.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR.
Characterization of monoclonal antibodies recognizing a m-r
180000 p-glycoprotein differential expression of the m-r
180000 and m-r 170000 p-glycoproteins in multidrug-resistant
human tumor cells. Cancer Res 1989;49(12):3209-14.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR, Cordon-Cardo
C, Biedler JL. The 180-KD resistance-related membrane
protein recognized by monoclonal antibodies raised against
vincristine-resistant human neuroblastoma cells is a P-
glycoprotein [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2008.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Murakami T, Ohmori H, Katoh T, Abe T, Higashi K. Cadmium causes
increases of N-myc and multidrug-resistance gene mRNA in
neuroblastoma cells. Sangyo Ika Daigaku Zasshi 1991 Dec
1;13(4): 271-8.
Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC,
Grossman SA, Brem H, Colvin OM. Multidrug resistance gene
(MDR1) expression in human brain tumors. J Neurosurg 1991
Dec; 75(6):941-6.
Nabors MW, Griffin CA, Zehnbauer BA, Kaufmann SH, Grossman SA,
Zhao XL, Brem H, Long DM, Chu YW, Phillips PC, et al. MDR1
expression in human brain tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2102.
Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K,
Nose Y, Kuwano M. Inverse correlation between expression
of multidrug resistance gene and N-myc oncogene in human
neuroblastomas. Cancer Res 1990 May 15;50(10): 3043-7.
O'Brien JP, Spengler BA, Rittmann-Grauer L, Bertino JR, Biedler
JL. Collateral sensitivity of human multidrug-resistant
cells to verapamil is potentiated by monoclonal antibody
HYB-241 recognizing P-glycoprotein [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2114.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F,
Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et
al. Immunohistochemical detection of the multidrug
transport protein P170 in human normal tissues and malignant
lymphomas. Histopathology 1991 Aug; 19(2):131-40.
Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal
of Vinca alkaloid resistance by anti-P-glycoprotein
monoclonal antibody HYB-241 in a human tumor xenograft.
Cancer Res 1992 Apr 1; 52(7):1810-6.
Schluesener HJ. Multidrug transport in human glioblastoma cells
is inhibited by transforming growth factors type beta 1,
beta 2, and beta 1.2. J Neurosci Res 1991 Feb;28(2):310-4.
Schluesener HJ. Transforming growth factors type beta inhibit
multidrug transport in rat astrocyte cell lines.
Autoimmunity 1991;9(3):269-75.
Schluesener HJ, Meyermann R. Spontaneous multidrug transport in
human glioma cells is regulated by transforming growth
factors type beta. Acta Neuropathol (Berl)
1991;81(6):641-8.
Tebbi CK, Chervinsky D, Baker RM. Modulation of drug resistance
in homoharringtonine-resistant C-1300 neuroblastoma cells
with cyclosporine A and dipyridamole. J Cell Physiol 1991
Sep;148(3): 464-71.
Tebbi CK, Yaeger E, Chervinsky D, Chen Y, Baker R. Dipyrimidole
(DPM) is highly effective in reversing multidrug resistance
of C1300 neuroblastoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1990;31:A2096.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I,
Willingham MC. Immunohistochemical localization in normal
tissues of different epitopes in the multidrug transport
protein p170 evidence for localization in brain capillaries
and crossreactivity of one antibody with a muscle protein.
J Histochem Cytochem 1989;37(2):159-64.
Tishler DM, Raffel C. Development of multidrug resistance in a
primitive neuroectodermal tumor cell line. J Neurosurg 1992
Mar;76(3):502-6.
Tishler DM, Weinberg KI, Sender LS, Nolta JA, Raffel C.
Multidrug resistance gene expression in pediatric primitive
neuroectodermal tumors of the central nervous system. J
Neurosurg 1992 Mar; 76(3):507-12.
-Breast neoplasms
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Aftab DT, Hait WN. Multiple forms of protein kinase C in
multidrug resistant MCF-7 human breast cancer cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1428.
Ahmad S, Trepel J, Glazer RI. Protein kinase C isoform-specific
mediation of multidrug resistance (MDR) in MDR1-expressing
MCF-7 cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2722.
Ahn CH, Fine RL, Anderson WB. Possible involvement of protein-
kinase C in the modulation of multidrug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1182.
Akman S, Forrest G, Chu FF, Esworthy RS, Stetzler J, Doroshow J.
Antioxidant enzyme gene expression in multidrug-resistant
MCF-7 breast cancer cells (MCF-7/ADR) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A1973.
Arredondo M, Guimaraes M, Tsangaris T, Slocum H, Rustum YM. P-
glycoprotein content of aneuploid and diploid populations of
human breast carcinoma [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1992;11:A212.
Assaraf YG, Molina A, Schimke RT. Cross-resistance to the
lipid-soluble antifolate trimetrexate in human carcinoma
cells with the multidrug-resistant phenotype. J Natl Cancer
Inst 1989 Feb 15;81(4): 290-4.
Baird WM, Ferin M, Morgan S, Averbuch SD, Ivy SP, Cowan KH, Myers
CE. Metabolism of benzo(a)pyrene (BaP) in the human breast
adenocarcinoma cell line MCF-7 and an adriamycin resistant
subline Adr(R)MDF-7 [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A486.
Bates SE, Denicoff AM, Cowan K, Tucker E, Begley M, Goldspiel B,
Myers C, Fojo T. A study of MDR-1 expression and
pharmacologic reversal in human breast cancer [abstract].
Proc Annu Meet Am Soc Clin Oncol 1991;10:A148.
Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione
depletion in human and in rat multi-drug resistant breast
cancer cell lines. Biochem Pharmacol 1991 Feb
15;41(4):631-5.
Battifora H. Specificity of immunohistochemical expression of
P-glycoprotein [letter]. Hum Pathol 1991 May;22(5):506-7.
Benchekroun MM, Schott B, Bennis S, Montaudon D, Robert J.
Doxorubicin-induced lipid peroxidation (DILP) and
glutathione peroxidase (GPx) activity in multidrug-resistant
(MDR) cell lines [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2208.
Berry JM, Brophy NA, Smith SD, Bergstrom SK, Scudder SA, Roninson
IB, Sikic BI. Increased expression of the multidrug
resistance gene MDR1 in human cancers [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1988;7:A193.
Botti G, De Matteis A, Chiappetta G, D'Aiuto G, Esposito G,
Picone A. Mammary carcinoma. A multiparametric (MDR-P-
glycoprotein expression, regional node status, tumor cells
kinetics and receptor status) and immunohistochemical study.
J Nucl Med Allied Sci 1990 Oct-Dec;34(4 Suppl): 221-3.
Brown R, Keith N, Stallard S, Kaye SB. Expression of mdr1 and
gst-pi in breast tumors: correlations with
chemoresponsiveness in vitro [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2054.
Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JP, Pinedo HM.
Towards functional screening for multidrug resistant cells
in human malignancies. Pezcoller Found Symp 1990;1:309-29.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure
and expression of the human mdr p-glycoprotein gene family.
Mol Cell Biol 1989; 9(9):3808-20.
Cohen D, Piekarz RL, Hsu SI, DePinho RA, Carrasco N, Horwitz SB.
Structural and functional analysis of the mouse mdr1b gene
promoter. J Biol Chem 1991 Feb 5;266(4):2239-44.
Coon JS, Koukoulis G, Roninson I, Weinstein RS. Expression of
mdr-1 gene product in benign and malignant breast
[abstract]. Lab Invest 1989; 60(1):19A.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Boccia J, Bertino JR.
Immunoanatomic and immunopathologic expression of the
multidrug resistance gene product. Cancer Cells 1989;
7:87-93.
Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Flavonoids modulate
drug accumulation in HCT-15 cells and drug-resistant MCF-7
cells: P-glycoprotein as a possible target [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A793.
Cuvier C, Roblot-Treupel L, Millot JM, Couvreur P, Manfait M,
Poupon MF. Doxorubicin, loaded on nanospheres, bypasses
multidrug resistance and is detectable as bound to nuclear
DNA by microspectrofluorometry. Paper presented at:
Symposium on Mechanisms of Drug and Radiation Resistance of
Tumor Cells; 1989 Jun 28-30; Villejuif, France.
Dalton WS. Mechanisms of drug resistance in breast cancer.
Semin Oncol 1990 Aug;17(4 Suppl 7): 37-9.
Dalton WS, Grogan TM. Does P-glycoprotein predict response to
chemotherapy and if so is there a reliable way to detect it?
J Natl Cancer Inst 1991; 83(2):80-1.
Degregorio MW, Ford JM, Benz CC, Wiebe VJ. Toremifene
pharmacologic and pharmacokinetic basis of reversing
multidrug resistance. J Clin Oncol 1989;7(9):1359-64.
Dorr RT, Alberts DS, Sami SM, Remers WA. Consistent cytotoxic
activity in multidrug resistant tumors for azonafide, a new
anthracene analog of amonafide [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:408.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Salmon SE, Grogan T, Meltzer PS, Dalton WS. Relevance of
multidrug resistance to neoadjuvant therapy of cancer.
Paper presented at: 2nd International Congress on Neo-
Adjuvant Chemotherapy; 1988 Feb 19-21; Paris.
Fairchild CR, Cowan KH. Keynote address: Multidrug resistance:
a pleiotropic response to cytotoxic drugs. Int J Radiat
Oncol Biol Phys 1991 Feb;20(2):361-7.
Fairchild CR, Ivy SP, Kao Shan CS, Whang Peng J, Rosen N, Israel
MA, Melera PW, Cowan KH, Goldsmith ME. Isolation of
amplified and overexpressed DNA sequences from Adriamycin
resistant human breast cancer cells. Cancer Res
1987;47(19):5141-8.
Fairchild CR, Moscow JA, Ivy SP, Vickers PJ, Cowan KH. An
inducible expression vector containing a P-glycoprotein cDNA
isolated from adriamycin-resistant MCF-7 cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1248.
Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. Multidrug
resistance in cells transfected with human genes encoding a
variant P-glycoprotein and glutathione S-transferase-pi.
Mol Pharmacol 1990 Jun;37(6):801-9.
Fine RL, Carmichael J, Cowan KH, Chabner BA, Patel J.
Phosphoprotein and protein kinase C changes in human
multidrug-resistant cancer cells. In: Woolley PV III, Tew
KD, editors. Mechanisms of drug resistance in neoplastic
cells; 1986 Oct 15-16; Washington, DC. San Diego (CA):
Academic Press, Inc.; 1988. p. 87-96. (Bristol-Myers
cancer symposia; 9).
Fine RL, Patel J, Carmichael J, Chabner BA. Multidrug
resistance in human cancer cells: changes in protein
phosphorylation and protein kinase. In: Zenser TV, Coe RM,
editors. Cancer and aging: progress in research and
treatment. New York: Springer Publishing; 1989. p. 158-70.
Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug
resistance in human breast cancer cells. Proc Natl Acad Sci
U S A 1988;85(2):582-6.
Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN.
Cellular and biochemical characterization of thioxanthenes
for reversal of multidrug resistance in human and murine
cell lines. Cancer Res 1990 Mar 15;50(6):1748-56.
Ford JM, Hait WN. Further characterization of the thioxanthene
class of multidrug resistance antagonists [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:570.
Ford JM, Prozialeck WC, Hait WN. Identification of active
pharmaceuticals against multi-drug resistance through
structure activity relationships of calmodulin antagonists
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:313.
Ford JM, Prozialeck WC, Hait WN. Structural features
determining activity of phenothiazines and related drugs for
inhibition of cell growth and reversal of multidrug
resistance. Mol Pharmacol 1989;35(1):105-15.
Ford JM, Yang JM, Hait WN. Effect of buthionine sulfoximine on
toxicity of verapamil and doxorubicin to multidrug
resistant cells and to mice. Cancer Res 1991;51(1):67-72.
Fuqua SAW, Fitzgerald SD, Fatette NF, Mcguire WL. Expression of
mdr-1 in breast cancer [abstract]. Breast Cancer Res Treat
1989;14(1):173.
Gewirtz DA, Grant S, Woods KE. Modulation of adriamycin
sensitivity in multidrug-resistant MCF-7 breast tumor cells
by tomoxifen [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2898.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991;12(5): 359-73.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Grandi M, Ballinari D, Capolongo L, Pastori A, Ripamonti M,
Suarato A, Spreafico F. [New anthracyclines and multidrug
resistance]. Haematologica 1991 Jun;76 Suppl 3:181-3.
(Ita).
Grandi M, Capolongo L, Ballinari D, Giuliani FC, Mongelli N.
Cytotoxicity and intracellular levels of distamycin A in
sensitive and DX-resistant cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2015.
Guimaraes MA, Arredondo MA, Harstrick A, Slocum HK, Perrapato S,
Huben R, Rustum YM. Cell cycle phase analysis of P-
glycoprotein overexpression [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2810.
Hait WN, Gesmonde JF, Murren JR, Ahmad H, Reiss M, Yang JM.
Terfenadine (seldane): a potent sensitizer of multidrug-
resistant cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1992;33: A2863.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Harris AL. Mechanisms of anticancer drug resistance. Dev Oncol
1990;58:107-15.
Harris AL. Mechanisms of cytotoxic drug resistance in breast
cancer. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992;31(2):205-13.
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH.
Effect of P-glycoprotein expression on the accumulation and
cytotoxicity of topotecan (SK&F 104864), a new camptothecin
analogue. Cancer Res 1992 Apr 15; 52(8):2268-78.
Hill BT, Whelan RD, Hosking LK, de Vries EG, Mulder NH, Dunn T.
Evaluation of S9788 as a potential modulator of drug
resistance against human tumor sublines expressing differing
resistance mechnaisms in vitro [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2881.
Hochhauser D, Harris AL. Drug resistance. Br Med Bull 1991
Jan;47(1):178-96.
Jamis-Dow CA, Myers CE, Yeh GC. Increased lactate production
associated with early stages of adriamycin resistance in
human breast cancer cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A1991.
Jardillier JC, Larbre H, Rallet A, Deivincourt C. Presence of
increased alkaline phosphatase activity in multidrug
resistant MCF7 cells [abstract]. Breast Cancer Res Treat
1991;19(2):193.
Jaroszewski JW, Kaplan O, Cohen JS. Action of gossypol and
rhodamine 123 on wild type and multidrug-resistant MCF-7
human breast cancer cells: 31P nuclear magnetic resonance
and toxicity studies. Cancer Res 1990 Nov 1;50(21):6936-43.
Jaroszewski JW, Kaplan O, Syi JL, Sehested M, Faustino PJ, Cohen
JS. Concerning antisense inhibition of the multiple drug
resistance gene. Cancer Commun 1990;2(8):287-94.
Jett M, Fine RL, Cowan KC, Chabenr BA. Reversal of drug-
sensitivity profiles in wild type and multidrug-resistant
MCF-7 breast cancer cells by liposomes comprised of
cytotoxic phospholipids [abstract]. J Cell Biochem Suppl
1988;(12 Pt B): 256.
Jett M, Fine RL, Jelsema C, Cowan KC, Chabner BA. The signal
transduction cascade is more responsive to stimulation in
multidrug-resistant mcf-7 breast cancer cells than in the
wild type cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29: A80.
Jett M, Fine RL, Jelsema C, Cowan KC, Poston C, Chabner B.
MCF-7 multidrug-resistant human breast cancer cells but not
the parent cells show insensitivity to inhibitors of GTP-
binding proteins [abstract]. J Cell Biochem Suppl 1988;12
Pt E:47.
Jett M, Fine RL, Pallansch L. Modifying multidrug-resistance by
manipulating signal transduction pathways [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A1993.
Kacinski BM, Yee LD, Carter D. Quantitation of tumor cell
expression of the P-glycoprotein mdr1 gene in human breast
carcinoma clinical specimens. Cancer Bull 1989;41(1):44-8.
Kacinski BM, Yee LD, Carter D, Li D, Kuo MT. Human breast
carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts
correlate in vivo inversely and reciprocally with tumor
progesterone receptor content. Cancer Commun 1989;1(1):1-6.
Kaplan O, Jaroszewski JW, Clarke R, Fairchild CR, Schoenlein P,
Goldenberg S, Gottesman MM, Cohen JS. The multidrug
resistance phenotype: 31P nuclear magnetic resonance
characterization and 2-deoxyglucose toxicity. Cancer Res
1991 Mar 15;51(6):1638-44.
Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, Cohen JS.
P-31 and C-13 nuclear magnetic resonance studies of 2-
deoxyglucose metabolism in sensitive and resistant breast
tumor cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30: A2213.
Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-pi in
human breast tumours: comparison to in vitro
chemosensitivity. Br J Cancer 1990 May; 61(5):712-6.
Kellen JA, George E, Ling V. Decreased P-glycoprotein in a
tamoxifen-tolerant breast carcinoma model. Anticancer Res
1991 May-Jun; 11(3):1243-4.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Lee FYF, Sciandra J, Siemann DW. A study of the mechanism of
resistance to adriamycin in-vivo glutathione metabolism P-
glycoprotein expression and drug transport. Biochem
Pharmacol 1989; 38(21):3697-706.
Lee SA, Karaszkiewicz JW, Anderson WB. Elevated level of
nuclear protein kinase C in multidrug-resistant MCF-7 human
breast carcinoma cells. Cancer Res 1992 Jul
1;52(13):3750-9.
Leonessa F, Lippman J, Clarke R. Mechanisms of tamoxifen- and
ORG2058-induced reversal of the MDR1 phenotype [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2900.
Liley DTJ, Wiggins PM, Baguley BC. Localization of a
nonintercalative DNA binding antitumor drug in mitochondria
relationship to multidrug resistance. Eur J Cancer Clin
Oncol 1989;25(9):1287-94.
Lonn U, Lonn S, Nylen U, Stenkvist B. Appearance and detection
of multiple copies of the mdr-1 gene in clinical samples of
mammary carcinoma. Int J Cancer 1992 Jul 9;51(5):682-6.
Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, Mcguire WL.
Electrophoretic analysis of 248 clinical breast cancer
specimens for p-glycoprotein overexpression of gene
amplification. J Clin Oncol 1989;7(8):1129-36.
Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK. Biochemical
and pharmacological characterization of MCF-7 drug-sensitive
and AdrR multidrug-resistant human breast tumor xenografts
in athymic nude mice. Biochem Pharmacol 1991 Jul 5;42(2):
391-402.
Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK. Biochemical
characterization of MCF-7 sensitive and ADRR multidrug-
resistant human breast tumors in nude mice [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1990;31:A2092.
Mimnaugh EG, Sinha BK, Rajagopolan S, Myers CE. Subcellular
sites of enzymatic doxorubicin activation, oxyradical
production and detoxification in sensitive and multidrug
resistant MCF-7 human breast tumors [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2233.
Mitchell JB, Glatstein E, Cowan KH, Russo A. Photodynamic
therapy of multi-drug resistant cell lines [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:A1254.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Molina A, Assaraf YG, Schimke RT. Acquisition of resistance to
the lipophilic antifolate trimetrexate in human breast
carcinoma cells [abstract]. Clin Res 1989;37(2):469a.
Morgan PF, Fine RL, Montgomery P, Marangos PJ. Multidrug
resistance in MCF-7 human breast cancer cells is associated
with increased expression of nucleoside transporters and
altered uptake of adenosine. Cancer Chemother Pharmacol
1991; 29(2):127-32.
Mukaiyama T, Minowa S, Ogawa M. Analysis of MDR1 mRNA
expression in breast cancer specimens by reverse-
transcription polymerase chain reaction (RT-PCR) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2786.
Myers CE. Anthracyclines. Cancer Chemother Biol Response Modif
1988;10:33-9.
Nakagawa M, Dixon KH, Gilbert L, Goldsmith ME, Cowan KH.
Characterization of mitoxantrone resistant human breast
cancer cell line [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2204.
Noonan KE, Chin JE, Roninson IB. Analysis of multidrug
resistance gene expression by enzymatic amplification of
randomly primed cDNA [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A1982.
Ozols RF. Reversal of drug resistance: clinical trials based on
experimental studies in human tumor model systems. Paper
presented at: Symposium on Mechanisms of Drug and Radiation
Resistance of Tumor Cells; 1989 Jun 28-30; Villejuif,
France.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and Therapy of
Breast Cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Payne C, Bellamy W, North J, Bjore C Jr, Weinstein R.
Quantitative electron microscopic analysis of surface
negative charge on multidrug-resistant and -sensitive breast
carcinoma cell lines [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33: A2831.
Philip PA, Monkman S, Idle J, Carmichael J, Harris AL. A phase
I study of nifedipine with etoposide in metastatic tumors
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1990;9:A323.
Pinedo HM, van Groeningen CJ, van Kalken CK. Cellular
pharmacology and drug resistance in breast cancer. Paper
presented at: Biology and Therapy of Breast Cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a
resistance modifier in vitro in drug resistant human tumour
cell lines is not stereospecific. Biochem Pharmacol 1990
Feb 15; 39(4):787-92.
Politi PM, Sinha BK. Role of differential drug uptake efflux
and binding of etoposide in sensitive and resistant human
tumor cell lines implications for the mechanisms of drug
resistance. Mol Pharmacol 1989;35(3):271-8.
Ragaz J, Goldie J, Coldman A, Simpson-Herren L, Barnett M,
Phillips G. Kinetic and biological effects of high-dose
intensity consolidation chemotherapy (HDICC) regimens for
solid tumors requiring autologous bone marrow (ABM)-
peripheral stem cell (PBSC) support. Rationale for multiple
transplants [abstract]. Proc Annu Meet Am Soc Clin Oncol
1991;10:A301.
Ries F, Dicato M. Treatment of advanced and refractory breast
cancer with doxorubicin, vincristine and continuous infusion
of verapamil. A phase I-II clinical trial. Med Oncol Tumor
Pharmacother 1991;8(1):39-43.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M.
Immunohistochemical analysis of P-glycoprotein expression
correlated with chemotherapy resistance in locally advanced
breast cancer. Hum Pathol 1990 Aug;21(8):787-91.
Ronchi E, Sanfilippo O, Di Fronzo G, Bani MR, Della Torre G,
Catania S, Silvestrini R. Detection of the 170 kDa P-
glycoprotein in neoplastic and normal tissues. Tumori 1989
Dec 31;75(6):542-6.
Roninson IB, Chin JE, Choi K, Morse BS, Noonan KE, Chen CJ, Patel
MC, Coon JS, Lee I, Weinstein RS. Molecular biology of
multidrug resistance in human tumor cells. Paper presented
at: 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy;
1989 Mar 7-10; Amsterdam.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Ryffel B, Woerly G, Rodriguez C, Foxwell BM. Identification of
the multidrug resistance-related membrane glycoprotein as an
acceptor for cyclosporine. J Recept Res
1991;11(1-4):675-86.
Sachs C, Schnur D, Ballas L, Hannun Y, Loomis C, Carroll I, Bell
R, Fine RL. Protein kinase C (PKC) inhibitors increase
drug accumulation and are cytotoxic to a human multidrug-
resistant (MDR) breast cancer line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:A2128.
Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS.
Prediction of doxorubicin resistance in-vitro in myeloma
lymphoma and breast cancer by p-glycoprotein staining. J
Natl Cancer Inst 1989; 81(8):696-701.
Sanfilippo O, Di Fronzo G, Ronchi E. Natural or acquired drug
resistance and GP170 (GP) expression in human breast cancers
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2209.
Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R.
Expression of P-glycoprotein in breast cancer tissue and in
vitro resistance to doxorubicin and vincristine. Eur J
Cancer 1991; 27(2):155-8.
Sanfilippo O, Silvestrini R, Ronchi E, Di Fronzo G. P-
glycoprotein (PGP) expression and resistance to doxorubicin
(DX) inhuman tumors [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A217.
Savaraj N, Lu K, Guo T, Castello C, Tapiero H, Lampidis T.
Reduced drug accumulation with increased p-glycoprotein
expression in normal cell line [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1164.
Scala S, Murphy LD, Tortora G, Cho-Chung Y, Bates S. Effects of
differentiating agents (DA) on P-glycoprotein (Pgp)
expression in a multidrug resistant breast cancer cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2240.
Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M.
P-glycoprotein expression in treated and untreated human
breast cancer. Br J Cancer 1989;60(6):815-8.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
activity and multidrug resistance in MOLT-3 human
lymphoblastic leukemia cells resistant to trimetrexate.
Cancer Res 1991 Jan 1; 51(1):55-61.
Shieh CY, Fojo AT, Bates SE. Expression of a multidrug
resistance gene (mdr-1/Pgp) in human breast carcinoma
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2073.
Sikic BI, Brophy NA, Berry JM, Marie JP, Ehsan MN, Tsuruo T,
Roninson IB, Smith SD. Multidrug resistance gene
expression in ovarian and breast cancers, leukemias, and
lymphomas. Paper presented at: 6th NCI-EORTC Symposium on
New Drugs in Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama
S, Mori S. Tissue distribution of P-glycoprotein encoded
by a multidrug-resistant gene as revealed by a monoclonal
antibody MRK 16. Cancer Res 1988;48(7):1926-9.
Taylor CW, Dalton WS. Multiple mechanisms of drug resistance in
MCF-7 human breast cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2109.
Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT,
Thompson FH, Roe DJ, Trent JM. Different mechanisms of
decreased drug accumulation in doxorubicin and mitoxantrone
resistant variants of the MCF7 human breast cancer cell
line. Br J Cancer 1991 Jun;63(6):923-9.
Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH. An
immunohistochemical study of pi class glutathione S-
transferase expression in normal human tissue. Am J Pathol
1990 Oct;137(4): 845-53.
Thierry AR, Vige D, Dritschilo A, Rahman A. Modulation of
multidrug resistance by liposomally encapsulated doxorubicin
in two human MDR tumor cell lines [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2214.
Treupel L, Poupon MF, Couvreur P, Puisieux F. [Vectorisation of
doxorubicin in nanospheres and reversion of pleiotropic
resistance of tumor cells]. C R Acad Sci III
1991;313(3):171-4. (Fre).
Vaughan WP, Bierman PJ, Reed EC, Vose J, Kessinger A, Armitage
JO. High-dose hydroxyurea (HU) incorporation into
autologous marrow transplant (ABMT) regimes [abstract].
Proc Annu Meet Am Soc Clin Oncol 1991;10:A344.
Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C,
Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance
of immunohistochemical detection of multidrug resistance P-
glycoprotein in breast carcinoma. J Natl Cancer Inst 1991
Jan 16; 83(2):111-6.
Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. Multidrug
resistant MCF-7 human breast cancer cells display hormone-
independent tumor growth [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1988;29:A1247.
Wallace RE, Lindh D, Greenberger L, Raventos-Suarez C, Durr FE.
Development of a human breast carcinoma (MX-1E) cell line
resistant to calicheamicin [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2163.
Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H,
Pirker R. MDR1 gene expression and prognostic factors in
primary breast carcinomas. Eur J Cancer 1991;27(11):1352-5.
Wang L, Yang CP, Trail P, Horwitz SB, Casazza AM. Reversal of
the multidrug resistance (MDR) phenotype with megestrol
acetate (MA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2239.
Whang-Peng J. Double minutes (DMs) and homogeneously staining
regions (HSRs). Int Congr Ser 1989;807:63-74.
Wishart GC, Kaye SB. Is multidrug resistance relevant in breast
cancer? Eur J Surg Oncol 1991 Oct;17(5):485-8.
Wishart GC, Plumb JA, George WD, Kaye SB. P-glycoprotein
expression is found in stromal cells of breast cancer but
not those of normal breast [abstract]. Br J Cancer 1991;64
Suppl 15:8.
Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Kaye SB.
Is C219 specific for P-glycoprotein? [abstract]. Br J
Cancer 1990;62(3): 534.
Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB.
Adequate tumour quinidine levels for multidrug resistance
modulation can be achieved in vivo. Eur J Cancer
1992;28(1):28-31.
Yau J, Li D, Tsao J, Kuo T, Lu K. Mdr-1 gene expression in bone
marrow cells of breast cancer patients after combination
chemotherapy [abstract]. Breast Cancer Res Treat
1988;12(1):126.
Yee LD, Kacinski BM, Bloodgood RS, Carter D. Human breast
carcinoma cell levels of expression of the multiple drug
resistance gene mdr-1 P-glycoprotein correlate negatively
and reciprocally with their progesterone receptor content
[abstract]. Lab Invest 1989;60(1):107A.
Yeh GC, Chou JY, Jamis-Dow CA, Occhipinti SJ, Myers CE. Genetic
and biochemical differences of glucose-6-phosphate
dehydrogenase in adriamycin-sensitive and -resistant human
breast cancer cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2087.
Yeh GC, Phang JM. Modulation of drug efflux pump P-glycoprotein
by chemical carcinogen benzo(a)pyrene in adriamycin-
resistant human breast cancer cells [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2564.
Young RC. Mechanisms to improve chemotherapy effectiveness.
Cancer 1990 Feb 1;65(3 Suppl): 815-22.
Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki
K, Tsuruo T, Cowan KH, Glazer RI. Transfection with
protein kinase C alpha confers increased multidrug
resistance to MCF-7 cells expressing P-glycoprotein. Cancer
Commun 1991 Jun;3(6):181-9.
-Colorectal neoplasms
Barrand MA, Twentyman PR. Variations in P-glycoprotein
expression in response to drug treatment in mouse tumor cell
lines [abstract]. Br J Cancer 1991;63 Suppl 13:12.
Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-
glycoprotein phosphorylation and drug transport by sodium
butyrate. Biochemistry 1992 Jul 21;31(28):6366-72.
Bates SE, Currier SJ, Fojo AT. Modulation of P-glycoprotein
(Pgp) specificity by sodium butyrate (NaB) [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2164.
Bates SE, Scala S, Dickstein B, Fojo AT. Modulation of P-
glycoprotein (Pgp) function by dephosphorylation [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2905.
Biedler JL. Genetic aspects of multidrug resistance (MDR).
Paper presented at: American Cancer Society National
Conference on Integration of Molecular Genetics into Cancer
Management; 1991 Apr 10-12; Miami, FL.
Bousquet P, Wardwell S, Keilhauer G, Romerdahl CA. Modulation
of multidrug resistance in human xenograft models
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2886.
Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF.
Camptothecin overcomes MDR1-mediated resistance in human KB
carcinoma cells. Cancer Res 1991 Nov 15;51(22):6039-44.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure
and expression of the human mdr p-glycoprotein gene family.
Mol Cell Biol 1989; 9(9):3808-20.
Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr
RNA levels in response to cytotoxic drugs in rodent cells.
Cell Growth Differ 1990 Aug;1(8):361-5.
Choi PM, Weinstein IB. Multidrug resistance is independent of
protein kinase C activity in HT29 colon cancer cells
[abstract]. Gastroenterology 1991;100(5 Pt 2):A354.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Boccia J, Bertino JR.
Immunoanatomic and immunopathologic expression of the
multidrug resistance gene product. Cancer Cells 1989;7:
87-93.
Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Flavonoids modulate
drug accumulation in HCT-15 cells and drug-resistant MCF-7
cells: P-glycoprotein as a possible target [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A793.
DeHerdt SV, Andrews EL, Marder P, Moore RE, Hoskins J, Bumol TF.
Characterization of the multiple drug resistance phenotype
of several human colorectal carcinoma cell lines selected
with vinca alkaloids [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1419.
Deutsch Murphy L, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use
of the polymerase chain reaction in the quantitation of
MDR-1 gene expression. Biochemistry 1990;29(45):10351-6.
Dinota A, Tazzari PL, Michieli M, Visani G, Gobbi M, Bontadini A,
Tassi C, Fanin R, Damiani D, Grandi M, et al. In vitro
bone marrow purging of multidrug-resistant cells with a
mouse monoclonal antibody directed against Mr 170,000
glycoprotein and a saporin-conjugated anti-mouse antibody.
Cancer Res 1990 Jul 15;50(14):4291-4.
Dorr RT, Alberts DS, Sami SM, Remers WA. Consistent cytotoxic
activity in multidrug resistant tumors for azonafide, a new
anthracene analog of amonafide [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:408.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Duensing TD, Slate DL. Characterization of p-glycoprotein
(p170) expression and the multidrug (MDR) phenotype in a
panel of human cell lines representing chemoresistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2801.
Durand RE, LePard NE. Doxorubicin uptake and efflux in
spheroids of human WiDR versus hamster V79 cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2172.
Durivage HJ, Buzaid AC, Todd MB, Poo WJ, March JC, Davis CA, Hait
WN. A phase I-II study of pulse cyclosporin-A (CsA) plus
vinblastine (VBL) in selected refractory malignancies
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A335.
Elliott WL, Roberts BJ, Steinkampf RW, Leopold WR, Klohs WD. In
vivo studies on multidrug-resistant (MDR) tumors with the
new chemosensitizer, tioperidone [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2858.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Fan D, Wilmanns C, O'Brian CA, Kuo MT, Teeter LD, Bucana CD, Ward
NE, Fidler IJ. Orthotopic and ectopic modulation of P-
glycoprotein and resistance to adriamycin of human colon
carcinoma cells in nude mice [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2794.
Ferguson PJ, Cheng YC. Phenotypic instability of drug
sensitivity in a human colon carcinoma cell line. Cancer
Res 1989;49(5):1148-53.
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Fojo T, McAtee N, Allegra C, Bates S, Mickley L, Keiser H,
Linehan M, Steinberg S, Tucker E, Goldstein L, et al. Use
of quinidine and amiodarone to modulate multidrug resistance
mediated by the mdr1 gene [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1989;8:A262.
Fuqua SAW, Fitzgerald SD, Kern DH, Mcguire WL. The use of
polymerase chain reaction to detect expression of MDR-1 RNA
in human tumors [abstract]. J Cell Biochem Suppl 1989;13 Pt
E: 284.
Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp
O, Petit JM, Martin F, Chauffert B. Cinchonine, a potent
efflux inhibitor to circumvent anthracycline resistance in
vivo. Cancer Res 1992 May 15;52(10):2797-801.
Georges E, Bradley G, Gariepy J, Ling V. Detection of P-
glycoprotein isoforms by gene-specific monoclonal
antibodies. Proc Natl Acad Sci U S A 1990 Jan;87(1):152-6.
Goldsmith ME, Morrow CS, Madden MJ, Cowan KH. Nucleoprotein
binding sites on the human MDR1 promoter [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2818.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular Diagnostics of Human Cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Grandi M, Capolongo L, Ballinari D, Giuliani FC, Mongelli N.
Cytotoxicity and intracellular levels of distamycin A in
sensitive and DX-resistant cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2015.
Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT. Various
methods of analysis of mdr-1/P-glycoprotein in human colon
cancer cell lines. J Natl Cancer Inst 1992 May 6;
84(9):711-6.
Herzog CE, Tsokos M, Fojo AT, Bates SE. Calcium channel
blockers (CCBs) induce P-glycoprotein (Pgp) in human colon
carcinoma (HCC) cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2185.
Hitselberger Kanitz MH, Mastro JM, Starling JJ. In vivo
expression of P-glycoprotein in two human colon carcinoma
xenografts is rapidly modulated following therapy with a
free or monoclonal antibody-conjugated vinca alkaloid
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2805.
Hitselberger MH, Starling JJ. Two human colon tumor cell lines
which express comparable P-glycoprotein display a five
thousand-fold difference in in vitro sensitivity to a vinca
alkaloid [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2207.
Hunter J, Hirst BH, Simmons NL. Epithelial secretion of
vinblastine by human intestinal adenocarcinoma cell (HCT-8
and T84) layers expressing P-glycoprotein. Br J Cancer 1991
Sep;64(3):437-44.
Husain SR, Sela S, Rafaeloff R, Potkul RK, Rahman A. Combination
of verapamil and liposomal encapsulated doxorubicin (LED)
potentiates cytotoxicity in MCF-7/ADR cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2882.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S.
Modulators of the multidrug-transporter, P-glycoprotein,
exist in the human plasma. Biochem Biophys Res Commun 1990
Jan 15;166(1):74-80.
Ikegami T, Kubota N, Matsui K, Funabiki T, Shuin T, Natsumeda Y.
Dipyridamole enhances the cellular accumulation of etoposide
and its cytotoxic effect in various cancer cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2031.
Ince P, Appleton DR, Finney KJ, Moorghen M, Sunter JP, Watson AJ.
Verapamil sensitizes normal and neoplastic rodent
intestinal tissues to the stathmokinetic effect of
vincristine in-vivo. Br J Cancer 1988;57(4):348-52.
Ince P, Elliott K, Appleton DR, Moorghen M, Finney KJ, Sunter JP,
Harris AL, Watson AJ. Modulation by verapamil of
vincristine pharmacokinetics and sensitivity to metaphase
arrest of the normal rat colon in organ culture. Biochem
Pharmacol 1991 Apr 15;41(8):1217-25.
Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-pi in
human breast tumours: comparison to in vitro
chemosensitivity. Br J Cancer 1990 May; 61(5):712-6.
Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA,
Hiestand PC. Pharmacologic interactions between the
resistance-modifying cyclosporine SDZ PSC 833 and etoposide
(VP 16-213) enhance in vivo cytostatic activity and
toxicity. Int J Cancer 1992 May 28;51(3):433-8.
Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K.
Factors contributing to adriamycin sensitivity in human
xenograft tumors: the relationship between expression of the
MDR1, GST-pi and topoisomerase II genes and tumor
sensitivity to adriamycin. Anticancer Res 1992 Jan-
Feb;12(1):241-5.
Kramer RA, Arceci R, Weber T, Summerhayes I. Both glycosylation
and phosphorylation are required for P-glycoprotein function
in human colon carcinoma cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2842.
Kramer RA, Morse B, Summerhayes I. C-HA-RAS-I oncogene-induced
differentiation and decreased MDR1 gene expression in a
human colorectal carcinoma cell line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2189.
Krapcho AP, Getahun Z, Avery KL Jr, Vargas KJ, Hacker MP,
Spinelli S, Pezzoni G, Manzotti C. Synthesis and antitumor
evaluations of symmetrically and unsymmetrically substituted
1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-
bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
J Med Chem 1991 Aug;34(8):2373-80.
Kuo-Pao PY, Samaan NA. Intrinsic drug resistance in a human
medullary thyroid carcinoma cell line: association with a
multidrug resistance gene expression and low proliferation
fraction [abstract]. Anticancer Res 1990;10(5B):1404.
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. Intrinsic and
acquired resistance (R) to adriamycin (Ad) in human colon
carcinoma cell lines (HCCCL) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2254.
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein
expression and schedule dependence of adriamycin
cytotoxicity in human colon carcinoma cell lines. Int J
Cancer 1991;49(5): 696-703.
Lai GM, Currier SJ, Mickley LA, Herzog CE, Tsokos M, Bates SE,
Fojo AT. Modulation of P-glycoprotein (Pgp)
phosphorylation and multidrug resistance (MDR) by sodium
butyrate (NaB) [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2242.
Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE. Contribution
of glutathione and glutathione-dependent enzymes in the
reversal of adriamycin resistance in colon carcinoma cell
lines. Int J Cancer 1991;49(5):688-95.
Lai GM, Shieh CY, Fojo AT, Bates SE. Multidrug resistance in
adriamycin-selected SW620 colon carcinoma cells [abstract].
Proc Annu Meet Am Soc Clin Oncol 1989;8:A322.
Lee KY, Park JG, Gazdar AF, Goldstein LJ, Hwang ES, Kim JP.
Correlation between MDR1 gene expression and in vitro drug
sensitivity testing (DST) of human cancer cell lines
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1990;9:A219.
Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza M.
Mechanisms of resistance to etoposide and teniposide in
acquired resistant human colon and lung carcinoma cell
lines. Cancer Res 1991;51(19):5275-83.
Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Emmer G. SDZ 280-446, a novel semi-synthetic
cyclopeptolide: in vitro and in vivo circumvention of the P-
glycoprotein-mediated tumour cell multidrug resistance. Br
J Cancer 1992 Jan;65(1):11-8.
McEwan GT, Hunter J, Hirst BH, Simmons NL. Volume-activated Cl-
secretion and transepithelial vinblastine secretion mediated
by P-glycoprotein are not correlated in cultured human T84
intestinal epithelial layers. FEBS Lett 1992 Jun
15;304(2-3): 233-6.
Mickley L, Spengler B, Biedler JL, Fojo AT. Genetic
polymorphism as a tool for examining the evolution of
mdr-1/P-glycoprotein (PGP) expression in multidrug-resistant
cell lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2832.
Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F,
Rosen N, Fojo AT. Modulation of the expression of a
multidrug resistance gene mdr-1-P-glycoprotein by
differentiating agents. J Biol Chem 1989;264(30):18031-40.
Mickley LA, Rothenberg ML, Hamilton TC, Ozols RF, Fojo AT.
Expression of a multidrug resistance gene in normal tissue
and human tumors [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29: A1180.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Moore R, Hoskins J, Deherdt S, Bumol T. Cloning of full-length
human mdr-1 and its use as a probe to study the expression
of mdr-1 in caco-2 calcium carbonate colorectal carcinoma
cells [abstract]. In: Hershberger CL, Queener SW, Hegeman
G, editors. Genetics and molecular biology of industrial
microorganisms. 4th ASM Conference; 1988; Bloomington, IN.
Washington (DC): American Society for Microbiology; 1989.
p. 368.
Morrow CS, Nakagawa M, Goldsmith ME, Madden MJ, Cowan KH.
Mechanism of sodium butyrate-mediated induction of mdr1 gene
expression in human colon cancer cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2817.
Muindi JF, Young CW. Characterization of the sodium-proton
exchanger of the multidrug resistant human colon
adenocardinoma cell line (LoVo/Dx) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1170.
Mukaiyama T, Mitsui I, Shibata H, Inoue K, Ogawa M. Analysis of
multidrug-resistance gene expression in human cancers:
correlation between expression level and chemosensitivity
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:
A1218.
Mukhopadhyay T, Batsakis JG, Kuo MT. Expression of the mdr P-
glycoprotein gene in Chinese hamster digestive tracts. J
Natl Cancer Inst 1988;80(4): 269-75.
Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the
polymerase chain reaction in the quantitation of mdr-1 gene
expression. Biochemistry 1990 Nov 13;29(45):10351-6.
Nasioulas G, Granzow C, Stohr M, Ponstingl H. Sensitization of
multidrug-resistant mouse ascites HD33 and Chinese hamster
ovary CHRC5S3 cells by a photoreactive vinblastine
derivative, NAPAVIN. Cancer Res 1990 Jan 15;50(2):403-8.
Noonan KE, Chin JE, Roninson IB. Analysis of multidrug
resistance gene expression by enzymatic amplification of
randomly primed cDNA [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A1982.
Nooter K, Herweijer H, Sonneveld P, Verweij J, Hagenbeek A,
Stoter G. Detection of multidrug resistance (MDR) in
refractory cancer patients [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2092.
O'Brian CA, Fan D, Ward NE, Dong Z, Iwamoto L, Gupta KP, Earnest
LE, Fidler IJ. Transient enhancement of multidrug
resistance by the bile acid deoxycholate in murine
fibrosarcoma cells in vitro. Biochem Pharmacol 1991 Mar
1;41(5): 797-806.
Ohkouchi E, Takamori R, Kawabata H, Sugimoto Y, Hamada H, Tsuruo
T. Expression of P-glycoprotein and its mRNA in human
renal and colon tumorcell lines, as a determinant for
natural drug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1217.
Oudard S, Thierry A, Jorgensen TJ, Rahman A. Sensitization of
multidrug-resistant colon cancer cells to doxorubicin
encapsulated in liposomes. Cancer Chemother Pharmacol
1991;28(4):259-65.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and Therapy of
Breast Cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pavelic ZP, Sever Z, Fontaine RN, Baker VV, Reising J, Denton DM,
Pavelic L, Khalily M. Detection of P-glycoprotein with
JSB-1 monoclonal antibody in B-5 fixed and paraffin-embedded
cell lines and tissues. Sel Cancer Ther 1991
Summer;7(2):49-58.
Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E,
Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T, et al.
Reversal of drug resistance in a human colon cancer
xenograft expressing MDR1 complementary DNA by in vivo
administration of MRK-16 monoclonal antibody. J Natl Cancer
Inst 1991 Oct 2;83(19):1386-91.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F,
Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et
al. Immunohistochemical detection of the multidrug
transport protein P170 in human normal tissues and malignant
lymphomas. Histopathology 1991 Aug; 19(2):131-40.
Pirker R, Wallner J, Gsur A, Gotzl M, Scheithauer W, Depisch D.
MDR1 gene expression does not indicate prognosis in primary
colorectal carcinomas [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2785.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey
M, Margison G, Cerny T. Assessment of P-glycoprotein,
glutathione-based detoxifying enzymes and O6-alkylguanine-
DNA alkyltransferase as potential indicators of constitutive
drug resistance in human colorectal tumors. Cancer Res 1991
Apr 15;51(8):2092-7.
Riccardi A, Invernizzi R, Ucci G, Luoni R, Danova M, Giordano M,
Zambelli ML, Rastaldi MP, Ascari E. [p170 in multiple
myeloma and acute leukemia]. Haematologica 1991 Jun;76
Suppl 3:177-80. (Ita).
Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T,
Parmiani G. Modulation of multidrug resistance by
verapamil or mdr1 anti-sense oligodeoxynucleotide does not
change the high susceptibility to lymphokine-activated
killers in mdr-resistant human carcinoma (LoVo) line. Int J
Cancer 1990 Oct 15;46(4):727-32.
Ronchi E, Sanfilippo O, Di Fronzo G, Bani MR, Della Torre G,
Catania S, Silvestrini R. Detection of the 170 kDa P-
glycoprotein in neoplastic and normal tissues. Tumori 1989
Dec 31;75(6):542-6.
Roninson IB, Chin JE, Choi K, Morse BS, Noonan KE, Chen CJ, Patel
MC, Coon JS, Lee I, Weinstein RS. Molecular biology of
multidrug resistance in human tumor cells. Paper presented
at: 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy;
1989 Mar 7-10; Amsterdam.
Roninson IB, Patel MC, Lee I, Noonan KE, Chen CJ, Choi K, Chin
JE, Kaplan R, Tsuruo T. Molecular mechanism and
diagnostics of multidrug resistance in human tumor cells.
Cancer Cells 1989;7:81-6.
Satta T, Isobe K, Yamauchi M, Nakashima I, Akiyama S, Itou K,
Watanabe T, Takagi H. Establishment of drug resistance in
human gastric and colon carcinoma xenograft lines. Jpn J
Cancer Res 1991 May;82(5):593-8.
Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression
of MDR1 and glutathione S transferase-pi genes and
chemosensitivities in human gastrointestinal cancer. Cancer
1992 Feb 15;69(4):941-6.
Scala S, Murphy LD, Tortora G, Cho-Chung Y, Bates S. Effects of
differentiating agents (DA) on P-glycoprotein (Pgp)
expression in a multidrug resistant breast cancer cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2240.
Slate DL, Bruno N, Carver LA, Rabier M. Isolation and
characterization of multiple drug resistant carcinoma cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1975.
Slovak ML, Coccia M, Meltzer PS, Trent JM. Molecular analysis
of two human doxorubicin-resistant cell lines: evidence for
differing multidrug resistance mechanisms. Anticancer Res
1991 Jan-Feb;11(1):423-8.
Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and
biological evidence for differing mechanisms of doxorubicin
resistance in two human tumor cell lines. Cancer Res 1988;
48(10):2793-7.
Slovak ML, Mirski SEL, Cole SPC, Gerlach JH, Yohem KH, Trent JM.
Tumorigenic multidrug-resistant HT1080 cells do not
overexpress receptors for epidermal growth factor. Br J
Cancer 1991;64(2):296-8.
Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy
H. Sufficient levels of quinine in the serum circumvent
the multidrug resistance of the human leukemic cell line
K562/ADM. Cancer 1991 Oct 15;68(8):1714-9.
Spoelstra EC, Dekker H, Broxterman HJ, Lankelma J. The effect
of cyclosporin A and verapamil on daunomycin accumulation
rate in the murine colon carcinoma cell line C-26
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1929.
Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, Lankelma J.
P-glycoprotein drug efflux pump involved in the mechanisms
of intrinsic drug resistance in various colon cancer cell
lines. Evidence for a saturation of active daunorubicin
transport. Biochem Pharmacol 1991;41(3):349-60.
Thorgeirsson SS, Silverman JA, Gant TW, Marino PA. Multidrug
resistance gene family and chemical carcinogens. Pharmacol
Ther 1991;49(3):283-92.
Toffoli G, Viel A, Maestro R, Tumiotto L, Biscontin G, Boiocchi
M. In-vitro and in-vivo studies on multidrug-resistance
gene (mdr1) in human colon carcinomas [abstract]. Invest
New Drugs 1989; 7(4):440.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Boiocchi M.
Multidrug-resistance in human colon carcinoma cell lines
[abstract]. Anticancer Res 1990;10(5B):1406-7.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Rossi C, Boiocchi M.
Pleiotropic-resistant phenotype is a multifactorial
phenomenon in human colon carcinoma cell lines. Br J Cancer
1991 Jan; 63(1):51-6.
Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi
M. Prognostic significance of mdr-1 mRNA expression in
untreated human colon carcinomas. Paper presented at:
Symposium on Mechanisms of Drug and Radiation Resistance of
Tumor Cells; 1989 Jun 28-30; Villejuif, France.
Trujillo JM, Yang LY, Su YZ, Gercovich G, Hai S, Williams A.
Cytotoxicity synergism of interferon (IFN) and adriamycin
(AdR) on lovo human colon tumor cell line and its multidrug
resistant (MDR) subclone [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2033.
Tsuruo T. Mechanisms of multidrug resistance and implications
for therapy. Jpn J Cancer Res 1988 Mar;79(3):285-96.
Tsuruo T. Multidrug resistance: a transport system of antitumor
agents and xenobiotics. Int Symp Princess Takamatsu Cancer
Res Fund 1990;21: 241-51.
Tsuruo T. Proteins involved in multidrug resistance and their
implication for therapy. Pezcoller Found Symp
1990;1:131-43.
Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-
containing anthracycline me-2303 as a new antitumor agent
against murine and human tumors and their multidrug-
resistant sublines. Cancer Res 1989;49(20):5537-42.
Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the
promotor region of the human multidrug resistance (P-
glycoprotein) gene. J Biol Chem 1987;262(36):17432-6.
Ueda K, Yamano Y, Kioka N, Kakehi Y, Yoshida O, Gottesman MM,
Pastan I, Komano T. Detection of multidrug resistance
(MDR1) gene RNA expression in human tumors by a sensitive
ribonuclease protection assay. Jpn J Cancer Res 1989
Nov;80(11):1127-32.
Van de Vrie W, Gheuens EE, Bijma A, De Bruijn EA, Marquet RL, Van
Oosterom AT, Eggermont AM. A syngeneic in vivo model of a
multidrug-resistant colon carcinoma, CC531 in the WAG rat
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:
A1270.
Van de Vrie W, Gheuens EE, Durante NM, De Bruijn EA, Marquet RL,
Van Oosterom AT, Eggermont AM. Cyclosporin-A and its
analog PSC 833 can reverse intrinsic multidrug resistance in
a rat colon carcinoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2893.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Timmer-Bosscha H, Mulder NH. Multidrug resistance (MDR)
modulation with amiodarone (AM) in human tumor cell lines
and patients [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2076.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Vellenga E, Mulder PO, Mulder NH. In vitro and in vivo
modulation of multi-drug resistance with amiodarone. Int J
Cancer 1991 Jun 19;48(4):616-22.
Vollrath V, Chianale J, Gonzalez S, Duarte I, Andrade L, Ibanez
L. Multidrug resistance gene and P-glycoprotein expression
in gastric adenocarcinoma and precursor lesions. Virchows
Arch B Cell Pathol 1991;60(2):133-8.
Wang L, Yang CP, Trail P, Horwitz SB, Casazza AM. Reversal of
the multidrug resistance (MDR) phenotype with megestrol
acetate (MA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2239.
Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Mx-2 a
morpholinoanthracycline as a new antitumor agent against
drug-sensitive and multidrug-resistant human and murine
tumor cells. Cancer Res 1988; 48(23):6653-7.
Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK,
Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson
IB, et al. Relationship of the expression of the multidrug
resistance gene product (P-glycoprotein) in human colon
carcinoma to local tumor aggressiveness and lymph node
metastasis. Cancer Res 1991 May 15; 51(10):2720-6.
Weinstein RS, Kuszak JR, Jakate SM, Lebovitz MD, Kluskens LF,
Coon JS. ABO blood type predicts the cytolocalization of
anti-P-glycoprotein monoclonal antibody reactivity in human
colon and ureter. Hum Pathol 1990 Sep;21(9):949-58.
Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA,
Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.
Multidrug-resistant phenotype of disease-oriented panels of
human tumor cell lines used for anticancer drug screening.
Cancer Res 1992 Jun 1;52(11):3029-34.
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI. A
phase I trial of etoposide (E) with cyclosporine (CSA) as a
modulator of multidrug resistance (MDR) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A276.
Yamauchi M, Satta T, Yaguchi T, Takeshima E, Onishi Y, Watanabe
T, Isobe K, Takagi H. Expression of a multidrug-resistance
gene and effectiveness of anticancer agents in human stomach
and colon cancer cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2060.
Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a
human medullary thyroid carcinoma cell line: association
with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res 1991;11(3):1065-8.
Yang LY, Su YZ, Trujillo JM, Hai S. Distinct P-glycoprotein (P-
GP) expressions in two different multidrug resistant (MDR)
subclones simultaneously selected from a human colon
carcinoma cell line by cisplatin (CDDP) [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2199.
Yang LY, Trujillo JM. Biological characterization of multidrug-
resistant human colon carcinoma sublines induced/selected by
two methods. Cancer Res 1990 Jun 1;50(11):3218-25.
Yang LY, Trujillo JM. Different mechanisms for multidrug
resistance in two models of adriamycin-resistant subclones
derived from a human colon carcinoma cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2053.
Young RC. Mechanisms to improve chemotherapy effectiveness.
Cancer 1990 Feb 1;65(3 Suppl): 815-22.
-Fibrosarcomas
Barrand MA, Twentyman PR. Differential recognition of mdr1a and
mdr1b gene products in multidrug resistant mouse tumour
cell lines by different monoclonal antibodies. Br J Cancer
1992 Feb;65(2):239-45.
Barrand MA, Twentyman PR. Variations in P-glycoprotein
expression in response to drug treatment in mouse tumor cell
lines [abstract]. Br J Cancer 1991;63 Suppl 13:12.
Bucana CD, Giavazzi R, Nayar R, O'Brian CA, Seid C, Earnest LE,
Fan D. Retention of vital dyes correlates inversely with
the multidrug-resistant phenotype of adriamycin-selected
murine fibrosarcoma variants. Exp Cell Res 1990 Sep;
190(1):69-75.
Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C, Fidler IJ.
Enhancement of murine tumor cell sensitivity to adriamycin
by presentation of the drug in phosphatidylcholine-
phosphatidylserine liposomes. Cancer Res 1990 Jun
15;50(12): 3619-26.
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Hofsli E, Nissen-Meyer J. Effect of erythromycin and tumor
necrosis factor on the drug resistance of multidrug-
resistant cells reversal of drug resistance by erythromycin.
Int J Cancer 1989;43(3):520-5.
Hofsli E, Nissen-Meyer J. Reversal of drug resistance by
erythromycin erythromycin increases the accumulation of
actinomycin D and doxorubicin in multidrug-resistant cells.
Int J Cancer 1989;44(1): 149-54.
O'Brian CA, Fan D, Ward NE, Dong Z, Iwamoto L, Gupta KP, Earnest
LE, Fidler IJ. Transient enhancement of multidrug
resistance by the bile acid deoxycholate in murine
fibrosarcoma cells in vitro. Biochem Pharmacol 1991 Mar
1;41(5): 797-806.
Ronchi E, Sanfilippo O, Di Fronzo G, Bani MR, Della Torre G,
Catania S, Silvestrini R. Detection of the 170 kDa P-
glycoprotein in neoplastic and normal tissues. Tumori 1989
Dec 31;75(6):542-6.
Sanfilippo O, Silvestrini R, Ronchi E, Di Fronzo G. P-
glycoprotein (PGP) expression and resistance to doxorubicin
(DX) inhuman tumors [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A217.
Seid CA, Fidler IJ, Clyne RK, Earnest LE, Fan D. Overcoming
murine tumor cell resistance to vinblastine by presentation
of the drug in multilamellar liposomes consisting of
phosphatidylcholine and phosphatidylserine. Sel Cancer Ther
1991 Fall;7(3):103-12.
Shalinsky DR, Slovak ML, Howell SB. Dipyridamole enhances
colony formation by augmenting adhesion of multidrug
resistant HT1080/DR4 cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32: A2557.
Shalinsky DR, Slovak ML, Howell SB. Modulation of vinblastine
sensitivity by dipyridamole in multidrug resistant
fibrosarcoma cells lacking mdr1 expression. Br J Cancer
1991 Oct;64(4):705-9.
Singh G, Wilson BC, Sharkey SM, Browman GP, Deschamps P.
Resistance to photodynamic therapy in radiation induced
fibrosarcoma-1 and Chinese hamster ovary-multi-drug
resistant. Cells in vitro. Photochem Photobiol 1991
Aug;54(2):307-12.
Slovak ML, Coccia M, Meltzer PS, Trent JM. Molecular analysis
of two human doxorubicin-resistant cell lines: evidence for
differing multidrug resistance mechanisms. Anticancer Res
1991 Jan-Feb;11(1):423-8.
Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and
biological evidence for differing mechanisms of doxorubicin
resistance in two human tumor cell lines. Cancer Res 1988;
48(10):2793-7.
Slovak ML, Mirski SEL, Cole SPC, Gerlach JH, Yohem KH, Trent JM.
Tumorigenic multidrug-resistant HT1080 cells do not
overexpress receptors for epidermal growth factor. Br J
Cancer 1991;64(2):296-8.
Van Belle S, Stockman D, De Smet M, Storme G. Influence of
verapamil on the uptake of vinblastine by MO4 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2253.
Ward NE, O'Brian CA. Distinct patterns of phorbol-ester-induced
downregulation of protein kinase C activity in adriamycin-
selected multidrug resistant and parental murine
fibrosarcoma cells. Cancer Lett 1991;58(3):189-94.
Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E,
Mayes J, Sie KL, Meltzer PS, Trent JM. HT1080/DR4: a P-
glycoprotein-negative human fibrosarcoma cell line
exhibiting resistance to topoisomerase II-reactive drugs
despite the presence of a drug-sensitive topoisomerase II.
J Natl Cancer Inst 1990 Oct 3;82(19):1553-61.
-Kidney neoplasms
Agarwala S, Bahnson R, Wilson J, Szumowski J, Downs M, Ernstoff
M. Evaluation of the combination of vinblastine and
quinidine in patients with metastatic renal cell carcinoma -
a phase I study [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A1161.
Bak M Jr, Efferth T, Mickisch G, Mattern J, Volm M. Detection
of drug resistance and P-glycoprotein in human renal cell
carcinomas. Eur Urol 1990; 17(1):72-5.
Baker RM, Fredericks WJ, Chen Y, Murawski MJ, Meegan RL, Rustum
YM, Karakousis C, Piver MS. Detection of P-glycoprotein in
human tumors by immunoblot analyses. Pezcoller Found Symp
1990;1:167-88.
Benson MC, Giella J, Whang IS, Buttyan R, Hensle TW, Karp F,
Olsson CA. Flow cytometric determination of the multidrug
resistant phenotype in transitional cell cancer of the
bladder: implications and applications. J Urol 1991 Oct;
146(4):982-6; discussion 986-7.
Biedler JL. Genetic aspects of multidrug resistance (MDR).
Paper presented at: American Cancer Society National
Conference on Integration of Molecular Genetics into Cancer
Management; 1991 Apr 10-12; Miami, FL.
Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass
G, Tummler B. Quantitative expression patterns of
multidrug-resistance P-glycoprotein (MDR1) and
differentially spliced cystic-fibrosis transmembrane-
conductance regulator mRNA transcripts in human epithelia.
Eur J Biochem 1992 May 15;206(1):137-49.
Broxterman HJ, Pinedo HM, Kuiper CM, Van Der Hoeven JJM, De Lange
P, Quak JJ, Scheper RJ, Keizer HG, Jan Schuurhuis G,
Lankelma J. Immunohistochemical detection of p-
glycoprotein in human tumor cells with a low degree of drug
resistance. Int J Cancer 1989;43(2):340-3.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure
and expression of the human mdr p-glycoprotein gene family.
Mol Cell Biol 1989; 9(9):3808-20.
Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr
RNA levels in response to cytotoxic drugs in rodent cells.
Cell Growth Differ 1990 Aug;1(8):361-5.
Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat
shock and arsenite increase expression of the multidrug
resistance (MDR1) gene in human renal carcinoma cells. J
Biol Chem 1990 Jan 5; 265(1):221-6.
Cohen D, Piekarz RL, Hsu SI, DePinho RA, Carrasco N, Horwitz SB.
Structural and functional analysis of the mouse mdr1b gene
promoter. J Biol Chem 1991 Feb 5;266(4):2239-44.
Cordon-Cardo C, O'Brien J, Lee A, Finstad C, Vaia V, Motzer R,
Reuter V. P-glycoprotein (Pgp) expression during fetal
kidney development: a model of Pgp expression in renal cell
carcinomas [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A1412.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Boccia J, Bertino JR.
Immunoanatomic and immunopathologic expression of the
multidrug resistance gene product. Cancer Cells 1989;
7:87-93.
Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler
JL, Melamed MR, Bertino JR. Multidrug-resistance gene p-
glycoprotein is expressed by endothelial cells at blood-
brain barrier sites. Proc Natl Acad Sci U S A
1989;86(2):695-8.
De Lannoy IAM, Koren G, Silverman M. Cyclosporin and quinidine
inhibition of the renal transport of digoxin in-vivo studies
in the dog [abstract]. J Am Soc Nephrol 1991;2(3):772.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Duensing TD, Slate DL. Characterization of p-glycoprotein
(p170) expression and the multidrug (MDR) phenotype in a
panel of human cell lines representing chemoresistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2801.
Durivage HJ, Buzaid AC, Todd MB, Poo WJ, March JC, Davis CA, Hait
WN. A phase I-II study of pulse cyclosporin-A (CsA) plus
vinblastine (VBL) in selected refractory malignancies
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A335.
Dutt A, Heath LA, Pan BF, Nelson JA. Role of P-glycoprotein in
organic cation secretion in the mammalian kidney [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A113.
Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA. Postnatal
development of MDR1 gene expression and organic cation
transport in mouse kidney [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A91.
Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA. Postnatal
development of organic cation transport and mdr gene
expression in mouse kidney. J Pharmacol Exp Ther 1992
Jun;261(3):1222-30.
Efferth T, Lohrke H, Volm M. Correlations between natural
resistance to doxorubicin, proliferative activity, and
expression of P-glycoprotein 170 in human kidney tumor cell
lines. Urol Res 1990; 18(5):309-12.
Efferth T, Lohrke H, Volm M. Reciprocal correlation between
expression of P-glycoprotein and accumulation of rhodamine
123 in human tumors. Anticancer Res 1989 Nov-
Dec;9(6):1633-7.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Fine RL, Sachs CW, Albers M, Williams A. Tamoxifen potentiates
the cytotoxicity of vinblastine by increasing intracellular
drug accumulation [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2226.
Fojo T, McAtee N, Allegra C, Bates S, Mickley L, Keiser H,
Linehan M, Steinberg S, Tucker E, Goldstein L, et al. Use
of quinidine and amiodarone to modulate multidrug resistance
mediated by the mdr1 gene [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1989;8:A262.
Fredericks WJ, Murawski MJ, Slocum HK, Gerlach JH, Ling V, Baker
RM. Incidence of elevated P-glycoprotein expression in
human tumors [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29: A1200.
Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporin
accumulation in multidrug-resistant cells. Biochem Biophys
Res Commun 1988;152(2): 552-8.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular Diagnostics of Human Cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE. Human
tumor cell line resistance to chemotherapeutic agents does
not predict resistance to natural killer or lymphokine-
activated killer cell-mediated cytolysis. Cancer Res 1990
Sep 15;50(18):5931-6.
Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium
antagonists which differ markedly in their potencies as
calcium blockers are equally effective in modulating drug
transport by P-glycoprotein. Biochem Pharmacol 1992 Jun 23;
43(12):2601-8.
Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I,
Gottesman MM, Handlers J. Transepithelial transport of
drugs by the multidrug transporter in cultured Madin-Darby
canine kidney cell epithelia. J Biol Chem
1989;264(25):14880-4.
Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ.
Modulation by verapamil of vincristine pharmacokinetics and
toxicity in mice bearing human tumor xenografts. Biochem
Pharmacol 1989;38(11):1727-36.
Hunter J, Hirst BH, Simmons NL. Transepithelial vinblastine
secretion mediated by P-glycoprotein is inhibited by
forskolin derivatives. Biochem Biophys Res Commun 1991 Dec
16;181(2):671-6.
Ichikawa M, Yashimura A, Furukawa T, Sumizawa T, Nakazima Y,
Akiyama SI. Glycosylation of P-glycoprotein in a
multidrug-resistant KB cell line and in the human tissues.
Biochim Biophys Acta 1991;1073(2):309-15.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S.
Modulators of the multidrug-transporter, P-glycoprotein,
exist in the human plasma. Biochem Biophys Res Commun 1990
Jan 15;166(1):74-80.
Ichikawa M, Yoshimura A, Sumizawa T, Shudo N, Kuwazuru Y,
Furukawa T, Akiyama S. Interaction of organic chemicals
with P-glycoprotein in the adrenal gland, kidney, and a
multidrug-resistant KB cell. J Biol Chem 1991 Jan
15;266(2): 903-8.
Ikegami T, Kubota N, Matsui K, Funabiki T, Shuin T, Natsumeda Y.
Dipyridamole enhances the cellular accumulation of etoposide
and its cytotoxic effect in various cancer cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2031.
Kageyama Y, Katoh M, Okada K, Yoshida K, Tsuruo T. Detection of
P-glycoprotein in human urogenital carcinomas and its
relationship to epidermal growth factor receptor expression.
Eur Urol 1991;20(1):58-61.
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman
MM, Pastan I. Measurement of multidrug-resistance
messenger RNA in urogenital cancers elevated expression in
renal cell carcinoma is associated with intrinsic drug
resistance. J Urol 1988;139(4):862-5.
Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman
MM. Mdr1 RNA levels in human renal cell carcinomas
correlation with grade and prediction of reversal of
doxorubicin resistance by quinidine in tumor explants. J
Natl Cancer Inst 1989;81(11):844-9.
Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA,
Bollinger P, Hiestand PC. SDZ PSC-833, a non-
immunosuppressive cyclosporine: its potency in overcoming
P-glycoprotein-mediated multidrug resistance of murine
leukemia. Int J Cancer 1992 Feb 20;50(4):593-7.
Klein EA. The multidrug resistance gene in renal cell
carcinoma. Semin Urol 1989 Nov;7(4):207-14.
Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct
activation of human multidrug resistance gene (MDR1) by
anticancer agents. Biochem Biophys Res Commun 1989 Dec
29;165(3): 1415-21.
Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M. Tissue-
specific enhancer of the human multidrug-resistance (MDR1)
gene. J Biol Chem 1990 Nov 15;265(32):19690-6.
Kramer RA, Morse B, Summerhayes I. C-HA-RAS-I oncogene-induced
differentiation and decreased MDR1 gene expression in a
human colorectal carcinoma cell line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2189.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Altered state of transformation and/or differentiation in
multidrug-resistant human neuroblastoma cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1704.
Lieberman DM, Reithmeier RAF, Ling V, Charuk JHM, Goldberg H,
Skorecki KL. Identification of p-glycoprotein in renal
brush border membranes. Biochem Biophys Res Commun
1989;162(1): 244-52.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
Mackensen DG, Resch PA, Hradecky LK, Sherwood KN, Rittmann-Grauer
LS. Localization of multidrug-resistant tumor xenografts
in nude mice with anti-p-blycoprotein monoclonal antibody
HYB-241 [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2800.
Mickisch G, Bier H, Bergler W, Bak M, Tschada R, Alken P. P-170
glycoprotein, glutathione and associated enzymes in relation
to chemoresistance of primary human renal cell carcinomas.
Urol Int 1990;45(3):170-6.
Mickisch G, Keilhauer G, Schlick E, Tschada R, Alken P. Calcium
antagonists reverse multidrug resistance (MDR) of primary
human renal cell carcinomas (RCC) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2116.
Mickisch G, Keilhauer G, Schlick E, Tschada R, Alken P. Effects
of R-verapamil (R-vpm) on P-170-mediated multidrug
resistance (mdr) of human renal cell carcinoma (rcc)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2423.
Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken
PM. Effects of calcium antagonists in multidrug resistant
primary human renal cell carcinomas. Cancer Res 1990 Jun
15; 50(12):3670-4.
Mickisch GH, Kossig J, Tschada RK, Keilhauer G, Schlick E, Alken
PM. Circumvention of multidrug resistance mediated by
P-170 glycoprotein using calcium antagonists in primary
human renal cell carcinoma. Urol Int 1991;47(3):118-25.
Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken
PM. Mechanisms and modulation of multidrug resistance in
primary human renal cell carcinoma. J Urol 1990 Sep;
144(3):755-9.
Mickley LA, Rothenberg ML, Hamilton TC, Ozols RF, Fojo AT.
Expression of a multidrug resistance gene in normal tissue
and human tumors [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29: A1180.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Moriyama M, Sugawara I, Hamada H, Tsuruo T, Kato T, Sato K,
Hikage T, Watanuki T, Mori S. Elevated expression of P-
glycoprotein in kidney and urinary bladder cancers. Tohoku
J Exp Med 1991 Jul;164(3):191-201.
Natazuka T, Ogawa R, Fujii Y, Suzuki M, Matsui T, Nakao Y, Isobe
T, Fujita T. [Ectopic salivary amylase-producing IgA-
lambda-type multiple myeloma with expression of MDR-1/P-
glycoprotein]. Rinsho Ketsueki 1991 Jun; 32(6):686-9.
(Jpn).
Noonan KE, Chin JE, Roninson IB. Analysis of multidrug
resistance gene expression by enzymatic amplification of
randomly primed cDNA [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A1982.
Nygren P, Larsson R. Verapamil and cyclosporin A sensitize
human kidney tumor cells to vincristine in absence of
membrane P-glycoprotein and without apparent changes in the
cytoplasmic free Ca2+ concentration. Biosci Rep 1990
Apr;10(2):231-7.
Ohkouchi E, Takamori R, Kawabata H, Sugimoto Y, Hamada H, Tsuruo
T. Expression of P-glycoprotein and its mRNA in human
renal and colon tumorcell lines, as a determinant for
natural drug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1217.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and Therapy of
Breast Cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV,
Willingham MC. A retrovirus carrying an mdr1 complementary
DNA confers multidrug resistance and polarized expression of
P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A
1988;85(12):4486-90.
Pastan I, Willingham MC, Gottesman M. Molecular manipulations
of the multidrug transporter: a new role for transgenic
mice. FASEB J 1991 Aug; 5(11):2523-8.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pavelic ZP, Sever Z, Fontaine RN, Baker VV, Reising J, Denton DM,
Pavelic L, Khalily M. Detection of P-glycoprotein with
JSB-1 monoclonal antibody in B-5 fixed and paraffin-embedded
cell lines and tissues. Sel Cancer Ther 1991
Summer;7(2):49-58.
Philip PA, Monkman S, Idle J, Carmichael J, Harris AL. A phase
I study of nifedipine with etoposide in metastatic tumors
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1990;9:A323.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F,
Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et
al. Immunohistochemical detection of the multidrug
transport protein P170 in human normal tissues and malignant
lymphomas. Histopathology 1991 Aug; 19(2):131-40.
Preisegger KH, Brown PC, Silverman JA, Thorgeirsson SS.
Estrahepatic induction of MDR expression in the rat by
xenobiotics [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2827.
Rochlitz CF, Lobeck H, Peter S, Reuter J, Mohr B, de Kant E, Huhn
D, Herrmann R. Multiple drug resistance gene expression in
human renal cell cancer is associated with the histologic
subtype. Cancer 1992 Jun 15;69(12):2993-8.
Ronchi E, Sanfilippo O, Di Fronzo G, Bani MR, Della Torre G,
Catania S, Silvestrini R. Detection of the 170 kDa P-
glycoprotein in neoplastic and normal tissues. Tumori 1989
Dec 31;75(6):542-6.
Sachs C, Ballas L, Hannun Y, Loomis C, Carroll I, Bell R, Fine
RL. Protein kinase C inhibitors increase drug accumulation
and decrease resistance of multidrug resistant cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2218.
Samuels B, Ratain M, Mick R, Vogelzang NJ, Schilsky R, O'Brien S,
Harrison H. Phase I trial of multidrug resistance
modulation with cyclosporine A [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A1163.
Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression
of MDR1 and glutathione S transferase-pi genes and
chemosensitivities in human gastrointestinal cancer. Cancer
1992 Feb 15;69(4):941-6.
Savaraj N, Lu K, Guo T, Castello C, Tapiero H, Lampidis T.
Reduced drug accumulation with increased p-glycoprotein
expression in normal cell line [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1164.
Shuin T, Masuda M, Yao M, Kubota Y, Sugimoto Y, Tsuruo T.
Chemosensitivity and expression of multidrug resistant gene
(MDR1 gene) in human kidney cancer cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:A1222.
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S,
Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-
resistant multiple myeloma by cyclosporin. The Leukaemia
Group of the EORTC and the HOVON. Lancet 1992 Aug 1;
340(8814):255-9.
Stavrovskaia AA, Stromskaia TP, Chernova OB, Dzhuraeva FKh.
[Multiple drug resistance and differentiation in the
population of transformed dog kidney cells MDCK]. Mol Gen
Mikrobiol Virusol 1990 May;(5):3-7. (Rus).
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama
S, Mori S. Tissue distribution of P-glycoprotein encoded
by a multidrug-resistant gene as revealed by a monoclonal
antibody MRK 16. Cancer Res 1988;48(7):1926-9.
Sugawara I, Koji T, Ueda K, Pastan I, Gottesman MM, Nakane PK,
Mori S. In situ localization of the human multidrug-
resistance gene mRNA using thymine-thymine dimerized single-
stranded cDNA. Jpn J Cancer Res 1990 Sep;81(9):949-55.
Symes MO, Collins CM, Lai T, Smith PJ. The influence of tumor
stage on in vitro sensitivity of renal carcinoma cells to
motozantrone. Paper presented at: 3rd International
Congress on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9;
France. (Eng, Fre).
Teeter LD, Eckersberg T, Tsai Y, Kuo MT. Analysis of the
Chinese hamster P-glycoprotein/multidrug resistance gene
pgp1 reveals that the AP-1 site is essential for full
promoter activity. Cell Growth Differ 1991 Sep;2(9):429-37.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I,
Willingham MC. Immunohistochemical localization in normal
tissues of different epitopes in the multidrug transport
protein p170 evidence for localization in brain capillaries
and crossreactivity of one antibody with a muscle protein.
J Histochem Cytochem 1989;37(2):159-64.
Tsuruo T. Mechanisms of multidrug resistance and implications
for therapy. Jpn J Cancer Res 1988;79(3):285-96.
Tsuruo T. Multidrug resistance: a transport system of antitumor
agents and xenobiotics. Int Symp Princess Takamatsu Cancer
Res Fund 1990;21: 241-51.
Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the
promotor region of the human multidrug resistance (P-
glycoprotein) gene. J Biol Chem 1987;262(36):17432-6.
Ueda K, Yamano Y, Kioka N, Kakehi Y, Yoshida O, Gottesman MM,
Pastan I, Komano T. Detection of multidrug resistance
(MDR1) gene RNA expression in human tumors by a sensitive
ribonuclease protection assay. Jpn J Cancer Res 1989
Nov;80(11):1127-32.
van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ,
Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ,
Pinedo HM, et al. Distribution of multi-drug resistance-
associated P-glycoprotein in normal and neoplastic human
tissues. Analysis with 3 monoclonal antibodies recognizing
different epitopes of the P-glycoprotein molecule. Ann
Oncol 1990;1(1):56-64.
van Kalken CK, van der Valk P, Hadisaputro MM, Pieters R,
Broxterman HJ, Kuiper CM, Scheffer GL, Veerman AJ, Meyer CJ,
Scheper RJ, et al. Differentiation dependent expression of
P-glycoprotein in the normal and neoplastic human kidney.
Ann Oncol 1991 Jan;2(1):55-62.
Volm M. In vivo multidrug-resistance of animal and human tumors
[abstract]. J Chemother Infect Dis Malig 1989;Suppl 1:A307.
Volm M, Efferth T. Relationship of DNA ploidy to
chemoresistance of tumors as measured by in vitro tests.
Cytometry 1990;11(3):406-10.
Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J.
Circumvention of multi-drug resistance in human kidney and
kidney carcinoma in vitro. Cancer 1991 May
15;67(10):2484-9.
Weiss GH, Mcatee N, Mickley L, Robertson CN, Gottesman MM, Pastan
IH, Linehan WM, Fojo T. Clinical trial of amiodarone to
suppress function of multidrug resistance gene product
during chemotherapy for renal cell carcinoma [abstract]. J
Urol 1990;143(4 Suppl):385a.
Willingham MC. Morphologic aspects of the basic cell biology of
cancer. Acta Histochem Cytochem 1988;21(5):507-18.
Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA,
Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.
Multidrug-resistant phenotype of disease-oriented panels of
human tumor cell lines used for anticancer drug screening.
Cancer Res 1992 Jun 1;52(11):3029-34.
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI. A
phase I trial of etoposide (E) with cyclosporine (CSA) as a
modulator of multidrug resistance (MDR) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A276.
Yamauchi M, Satta T, Yaguchi T, Takeshima E, Onishi Y, Watanabe
T, Isobe K, Takagi H. Expression of a multidrug-resistance
gene and effectiveness of anticancer agents in human stomach
and colon cancer cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2060.
-Leukemias
Abraham I, Wolf CL, Sampson KE, McGovren JP, DeKoning TF.
Tirilazad mesylate, a 21 aminosteroid, and the reversal of
multidrug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2866.
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Adamson PC, Poplack DG, Balis FM. Pharmacology and drug
resistance in childhood lymphoblastic leukemia. Hematol
Oncol Clin North Am 1990 Oct;4(5):871-94.
Ahn CH, Fine RL, Anderson WB. Possible involvement of protein-
kinase C in the modulation of multidrug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1182.
Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI,
Blume KG, Chao NJ. A combined approach for purging
multidrug-resistant leukemic cell lines in bone marrow using
a monoclonal antibody and chemotherapy. Blood 1991 May 1;
77(9):2079-84.
Alabaster O, Woods T, Ortiz-Sanchez V, Jahangeer S. Influence
of microenvironmental pH on adriamycin resistance. Cancer
Res 1989;49(20):5638-43.
Alade SL, Brown RE, Wormsley S, Wu MC. Cytostatic and
tumoricidal effects of quinacrine on a monoblastic cell line
(U937) expressing P-glycoprotein [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2247.
Alton PA, Fry A, Hickson ID, Harris AL. Use of the MTT assay in
acute myeloid leukemia to assess mechanisms of resistance
[abstract]. Br J Cancer 1991;63 Suppl 13:14.
Andolina M, Agosti E, De Manzini A, Recanati D, Ferrari M,
Padrini R, Piovan D. Vincristine and verapamil in
resistant relapses and in a conditioning regimen for BMT
[abstract]. J Cell Biochem Suppl 1991;15 Pt G:37.
Andreeff M, Hegewisch-Becker S, Haimi J, Rehermann B, Berman E,
Bertino J. Multidrug resistance, expression of P-
glycoprotein, anthracycline uptake and ARA-C resistance in
acute leukemia: assessment by flow cytometry and correlation
with response to therapy [abstract]. J Chemother Infect Dis
Malig 1989;Suppl 1:A480.
Arceci RJ, Steiglitz K, Croop JM. A monoclonal antibody to an
external epitope of the P-glycoprotein [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2815.
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A,
Pogliani EM, Corneo G, Parmiani G. Increased
susceptibility to lymphokine activated killer (LAK) lysis of
relapsing vs. newly diagnosed acute leukemic cells without
changes in drug resistance or in the expression of adhesion
molecules. Ann Oncol 1992;3(2):155-62.
Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S.
Multidrug resistance in a human leukemic cell line selected
for resistance to trimetrexate. Cancer Res 1989 Dec
1;49(23): 6556-61.
Arkin H, Ohnuma T, Schwartz GK, Cuttner J, Holland JF. Lack of
staurosporine (STSN) influence on multidrug resistance (MDR)
in human leukemic cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2004.
Arsenault AL, Ling V, Kartner N. Altered plasma membrane
ultrastructure in multidrug-resistant cells. Biochim
Biophys Acta 1988;938(2):315-21.
Baccarani M, Michieli M, Geromin A, Michelutti A, Savignano C,
Fanin R, Fasola G, Silvestri F, Velisig M. The expression
of P170 glycoprotein in acute leukemia (AL) [abstract]. Exp
Hematol 1991;19(6):534.
Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of
indole alkaloids on multidrug resistance and labeling of P-
glycoprotein by a photoaffinity analog of vinblastine.
Biochem Biophys Res Commun 1988;153(3):959-66.
Bell DR, Friedlander ML, Young G, MA DD. P-glycoprotein
expression in clinically drug-resistant hematologic
malignancies [abstract]. Proc Annu Meet Am Soc Clin Oncol
1988;7:A677.
Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B,
Andreeff M. Effect of tamoxifen on cell lines displaying
the multidrug-resistant phenotype. Blood 1991 Feb
15;77(4):818-25.
Berman E, McBride M. Comparative cellular pharmacology of
daunorubicin and idarubicin in human multidrug-resistant
leukemia cells. Blood 1992 Jun 15;79(12):3267-73.
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger
P, Loor F. In vivo circumvention of P-glycoprotein-
mediated multidrug resistance of tumor cells with SDZ PSC
833. Cancer Res 1991 Aug 15;51(16):4226-33.
Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration
of daunomycin retention in multidrug-resistant P388 cells by
submicromolar concentrations of SDZ PSC 833, a
nonimmunosuppressive cyclosporin derivative. Exp Cell Res
1991 Sep;196(1):26-32.
Bonadonna G, Santoro A. Current issues in the management of
advanced Hodgkin's disease. Blood Rev 1990 Mar;4(1):69-73.
Brophy NA, Marie JP, Berry JM, Ehsan MN, Smith SD, Warnke RA,
Sikic BI. Expression of the multidrug resistance gene MDR1
in leukemia and lymphoma cells [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1989;8:A211.
Busche R, Tuemmler B, Riordan JR, Cano-Gauci DF. Preparation
and utility of a radioiodinated analogue of daunomycin in
the study of multidrug resistance. Mol Pharmacol
1989;35(4):414-21.
Cairo MS, Knoppel E, Gillan E, Feusner J, Gold S, Wells R. MDR
expression of pediatric ALL and AML at diagnosis and relapse
by PCR amplification: rapid and sensitive detection
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A799.
Cairo MS, Plunkett JM, Gillan E, Weinthal J, Knoppel E, van de
Ven C, Sender L. A novel preparative and purging regimen
employing verapamil to modulate multiple drug resistance
during autologous bone marrow transplant in acute
lymphoblastic leukemia: a pilot study [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A1191.
Cairo MS, Plunkett JM, Kantawala S, Knoppel E, Nguyen A, van de
Ven C. Purging of multiple drug resistant acute
lymphoblastic leukemia (L100) for autologous bone marrow
transplantation with vincristine (V) and VP-16: selective
modulation by verapamil (VPL) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A1017.
Cairo MS, Toy C, Sender L, VandeVen C. The combination of VP-16
and verapamil to chemo-purge multidrug resistant leukemia
cells from human bone marrow: selective tumor cytotoxicity
versus marrow toxicity [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A932.
Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T,
Troncy J, Treille D, Fiere D. Clinical significance of
multidrug resistance P-glycoprotein expression on acute
nonlymphoblastic leukemia cells at diagnosis. Blood 1992
Jan 15; 79(2):473-6.
Campos L, Guyotat D, Archimbaud E, Tsuruo T, Solary E. Clinical
significance of MDR1/P-170 expression in acute
nonlymphoblastic leukemia (ANLL) cells [abstract]. Exp
Hematol 1991; 19(6):529.
Capranico G, De Isabella P, Castelli C, Supino R, Parmiani G,
Zunino F. P-glycoprotein gene amplification and expression
in multidrug-resistant murine p388 and b16 cell lines. Br
J Cancer 1989; 59(5):682-5.
Carulli G, Marini A, Caracciolo F. [P-glycoprotein and
treatment with plicamycin + hydroxyurea in myeloid blastic
crisis of chronic myeloid leukemia]. Medicina (Firenze)
1989 Oct-Dec;9(4):409-10. (Ita).
Carulli G, Petrini M. Multidrug resistance: focus in
hematology. Haematologica 1990 Jul-Aug;75(4): 363-74.
Carulli G, Petrini M, Marini A, Vaglini F, Caracciolo F, Grassi
B. P-glycoprotein and drug resistance in acute leukemias
and in the blastic crisis of chronic myeloid leukemia.
Haematologica 1990 Nov-Dec; 75(6):516-21.
Cass CE, Janowska-Wieczorrek A, Lynch MA, Sheinin H, Hindenburg
AA, Beck WT. Effect of duration of exposure to verapamil
on vincristine activity against multidrug-resistant human
leukemic cell lines. Cancer Res 1989;49(21):5798-804.
Cervantes A, Benet I, Ortiz De Salazar I, Solano C, Pascual A,
Marugan I, Garcia-Conde J. Immunocytochemical detection of
multidrug resistant P-glycoprotein (GP-170) in blast crisis
of chronic myeloid leukemia (BC-CML), acute leukemia (AL)
and multiple myeloma (MM) [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A1069.
Change BK, Fredericks W, Rustum YM, Baker MR. Levels of P-
glycoprotein in pancreatic cancer cell lines: relation to
inherent drug resistance [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1988;7:A443.
Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide
(VP-16) cytotoxicity by verapamil or cyclosporine in
multidrug-resistant human leukemic cell lines and normal
bone marrow. Exp Hematol 1990 Dec;18(11):1193-8.
Chen HX, Chang JY, Wang ZQ, Lee KH, Cheng YC. In vitro and in
vivo studies on the toxicity and antitumor activity of
etoposide (VP-16) and its analogs [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2254.
Chitnis M, Hegde U, Chavan S, Juvekar A, Advani S. Expression
of the multidrug transporter P-glycoprotein and in vitro
chemosensitivity: correlation with in vivo response to
chemotherapy in acute myeloid leukemia. Sel Cancer Ther
1991 Winter;7(4):165-73.
Cumber P, Padua RA, Holmes J, Carter G, Jacobs A. Multidrug
resistance in chronic lymphatic leukemia. Paper presented
at: British Association for Cancer Research/Association for
Cancer Physicians/ Leukaemia Research Fund Joint Winter
Meeting on Leukaemia and Lymphomas; 1989 Dec 11-12; London,
UK.
Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T,
Padua RA. Expression of the multiple drug resistance gene
(mdr-1) and epitope masking in chronic lymphatic leukaemia.
Br J Haematol 1990 Oct;76(2):226-30.
Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA.
Increased drug accumulation ex vivo with cyclosporin in
chronic lymphatic leukemia and its relationship to epitope
masking of P-glycoprotein. Leukemia 1991 Dec;5(12):1050-3.
Dalton WS. Approaches to clinical reversal of multidrug
resistance [abstract]. Invest New Drugs 1989;7(4):425.
Damiani D, Michieli M, Michelutti A, Geromin A, Patriarca F,
Fanin R, Russo D, Silvestri F, Baccarani M. P-170
expression in adult acute lymphoblastic leukemia (ALL)
[abstract]. Haematologica 1991;76 Suppl 4:75.
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC,
Henner WD, Goldenberg GJ. Multifactorial resistance to
adriamycin relationship of DNA repair glutathione
transferase activity drug efflux and P-glycoprotein in
cloned cell lines of adriamycin-sensitive and adriamycin-
resistant P388 leukemia. Cancer Res 1988;48(13):3595-602.
Demidova NS, Chernova OB, Siyanova EY, Goncharova AS, Kopnin BP.
Newly formed chromosome-like structures in independent mouse
P388 sublines with developed in vivo mdr1 gene
amplification. Somat Cell Mol Genet 1991 Nov; 17(6):581-90.
Dhainaut A, Regnier G, Atassi G, Pierre A, Leonce S, Kraus-
Berthier L, Prost JF. New triazine derivatives as potent
modulators of multidrug resistance. J Med Chem 1992 Jun
26;35(13): 2481-96.
DiCicco L, Gordon K, Wellham L, Thornburgh T, Krishan A.
Cellular differentiation and daunorubicin retention
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2085.
Dietel M, Bunge A, Heidebrecht HJ, Reymann A, Seidel A.
Resistance to the adriamycin-resistance reversing potency of
cyclosporin A in P-glycoprotein-positive friend leukemia
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2906.
Dordal MS, Winter JN, Atkinson AJ Jr. Kinetic analysis of P-
glycoprotein-mediated doxorubicin efflux [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2802.
Dorr RT, Alberts DS, Sami SM, Remers WA. Consistent cytotoxic
activity in multidrug resistant tumors for azonafide, a new
anthracene analog of amonafide [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:408.
Dorr RT, Liddil JD. Modulation of mitomycin C-induced multidrug
resistance in-vitro. Cancer Chemother Pharmacol
1991;27(4):290-4.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Dupuis ML, Ramoni C, Yassen A, Samoggia P, Tombesi M, Caserta M,
Cianfriglia M. The over-expression of P-glycoprotein in
K-562 and DAUDI cells, is associated with a high
susceptibility to NK and LAK cells. J Biol Regul Homeost
Agents 1991 Oct-Dec;5(4):137-41.
Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stohr M,
Volm M. Reversing multidrug resistance in L1210 tumor
cells by hycanthone or chlorophenoxamine in vitro and in
vivo. Anticancer Res 1991 May-Jun;11(3):1275-9.
Efferth T, Lohrke H, Volm M. Reciprocal correlation between
expression of P-glycoprotein and accumulation of rhodamine
123 in human tumors. Anticancer Res 1989 Nov-
Dec;9(6):1633-7.
Evans SS, Rustum YM. The combined effects of alpha-interferon
with doxorubicin (DOX) and vinblastine (VLB) on multidrug-
resistant ovarian carcinoma and leukemic cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2101.
Ferretti A, Barca S, Bozzi A, Chen LL, Di Vito M, Strom R, Podo
F, Cianfriglia M. Phosphorus-31 NMR and enzymatic studies
on metabolic alterations associated with multi-drug
resistance in human leukemic T cells [abstract]. Eur J
Cancer 1991;27(Suppl 3):S42.
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Finlay GJ, Baguley BC, Snow K, Judd W. Multiple patterns of
resistance of human leukemia cell sublines to amsacrine
analogues. J Natl Cancer Inst 1990 Apr 18;82(8):662-7.
Ford JM, Hait WN. Further characterization of the thioxanthene
class of multidrug resistance antagonists [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:570.
Fracasso PM, Slapak CA, Levy SB. Differential amplification of
the MDR gene family in two multidrug resistant murine
erythroleukemia cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2176.
Fredericks WJ, Murawski MJ, Slocum HK, Gerlach JH, Ling V, Baker
RM. Incidence of elevated P-glycoprotein expression in
human tumors [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29: A1200.
Funato T, Bando Y, Kato H, Tokuhiro H, Shimoda Y, Ohtani H.
[Analysis of P-glycoprotein in patients with acute leukemias
by flow cytometry]. Rinsho Byori 1989 Aug;37(8):899-904.
(Jpn).
Furusawa S, Fujimura T, Kawauchi H, Sasaki K, Takayanagi Y.
Potentiation of pirarubicin cytotoxicity by dipyridamole in
doxorubicin-resistant mouse P388 leukemia cells. Res Commun
Chem Pathol Pharmacol 1991 Mar;71(3):321-36.
Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
Progressive resistance to doxorubicin in mouse leukemia
L1210 cells with multidrug resistance phenotype: reductions
in drug-induced topoisomerase II-mediated DNA cleavage.
Cancer Commun 1989;1(4):217-24.
Ganapathi R, Kamath N, Constantinou A, Grabowski D, Ford J,
Anderson A. Effect of the calmodulin inhibitor
trifluoperazine on phosphorylation of P-glycoprotein and
topoisomerase II: Relationship to modulation of subcellular
distribution, DNA damage and cytotoxicity of doxorubicin in
multidrug resistant L1210 mouse leukemia cells. Biochem
Pharmacol 1991 Jun 15;41(12):R21-6.
Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship
between expression of P-glycoprotein and efficacy of
trifluoperazine in multidrug-resistant cells. Mol Pharmacol
1991 Jan;39(1):1-8.
Gekeler V, Frese G, Diddens H, Probst H. Expression of a P-
glycoprotein gene is inducible in a multidrug-resistant
human leukemia cell line. Biochem Biophys Res Commun
1988;155(2): 754-60.
Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp
O, Petit JM, Martin F, Chauffert B. Cinchonine, a potent
efflux inhibitor to circumvent anthracycline resistance in
vivo. Cancer Res 1992 May 15;52(10):2797-801.
Gervasoni JE Jr, Fields SZ, Krishna S, Baker MA, Rosado M,
Thuraisamy K, Hindenburg AA, Taub RN. Subcellular
distribution of daunorubicin in P-glycoprotein-positive
and -negative drug-resistant cell lines using laser-assisted
confocal microscopy. Cancer Res 1991 Sep 15;51(18):4955-63.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991; 12(5):359-73.
Gieseler F, Boege F, Biersack H, Spohn B, Wilms K.
Characterization of three HL-60 sublines with different
types of multidrug resistance [abstract]. Onkologie 1991;14
Suppl 2:54.
Giglio AD, Savaraj N, Castello C, Tapiero H, White L, Lampidis
TJ. Comparative effects of menogaril and adriamycin on
cardiac and multi-drug resistant tumor cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2441.
Gillan E, Knoppel E, Feusner J, Wells R, Cairo MS. Increased
detection of multiple drug-resistance expression of
pediatric leukemias at diagnosis and relapse by reverse
transcriptase polymerase chain reaction [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A1566.
Gisslinger H, Wallner J, Gsur A, Gilly B, Pirker R. MDR1 and
MDR3 gene expression in chronic lymphocytic leukemia
[abstract]. Onkologie 1991;14 Suppl 2:54.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gollapudi S, McDonald T, Gardner P, Kang N, Gupta S. Role of
chloride channels in multidrug resistance [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2192.
Gollapudi S, Patel K, Jain V, Gupta S. Protein kinase C
isoforms in multidrug resistant P388/ADR cells: a possible
role in daunorubicin transport. Cancer Lett 1992 Feb
14;62(1):69-75.
Gollapudi S, Patel K, Nguyen E, Gupta S. Effect of calphostin,
a specific inhibitor of protein kinase C (PKC), on
daunorubicin transport and cytotoxicity in multidrug-
resistant (MDR) P388/ADR and HL60/AR cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2734.
Gosland MP, Brophy NA, Duran GE, Yahanda AM, Adler KM, Hardy RI,
Halsey J, Sikic BI. Bilirubin: a physiological substrate
for the multidrug transporter [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2533.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Schoenlein PV, Currier SJ, Bruggemann EP, Pastan I.
Biochemical basis for multidrug resistance in cancer.
Biochem Mol Aspects Sel Cancers 1991;1:339-71.
Grandi M, Ballinari D, Capolongo L, Pastori A, Ripamonti M,
Suarato A, Spreafico F. [New anthracyclines and multidrug
resistance]. Haematologica 1991 Jun;76 Suppl 3:181-3.
(Ita).
Gruber A, Vitols S, Norgren S, Arestrom I, Bjorkholm M,
Reizenstein P, Peterson C, Luthman H. Quantitative
determination of mdr1 gene expression in leukemic cells from
patients with acute leukemia [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A1408.
Gupta S, Kim J, Gollapudi S. Reversal of daunorubicin
resistance in P388/ADR cells by itraconazole. J Clin Invest
1991 Apr;87(4):1467-9.
Gutierrez PL, Wilder PJ, Biswal N. In vitro multidrug
resistance of P388 murine leukemia selected for resistance
to diaziquone. Cancer Commun 1989; 1(3):181-90.
Hagiwara M, Wakusawa S, Miyamoto K, Hidaka H. Obviation of drug
resistance and affinity purification of P-glycoprotein by
isoquinolinesulfonamides. Cancer Lett 1991 Nov;60(2):103-7.
Hait WN, Aftab DT. Rational design and pre-clinical
pharmacology of drugs for reversing multidrug resistance.
Biochem Pharmacol 1992;43(1):103-7.
Hait WN, Choudhury S, Srimatkandada V. Characterization of a
human chronic myelogenous leukemia cell line expressing the
multidrug resistance gene [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2186.
Hait WN, Stein JM, Koletsky AJ, Harding MW, Handschumacher RE.
Activity of cyclosporin A and a non-immunosuppressive
cyclosporin against multidrug resistant leukemic cell lines.
Cancer Commun 1989;1(1):35-43.
Hamada H, Tsuruo T. Characterization of the ATPase activity of
the M-R 170000 to 180000 membrane glycoprotein P-
glycoprotein associated with multidrug resistance in K562-
ADM cells. Cancer Res 1988;48(17):4926-32.
Hamada H, Tsuruo T. Purification of the 170- to 180-kilodalton
membrane glycoprotein associated with multidrug resistance.
170- to 180-kilodalton membrane glycoprotein is an ATPase.
J Biol Chem 1988;263(3):1454-8.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Hasmann M, Valet GK, Tapiero H, Trevorrow K, Lampidis T.
Membrane potential differences between adriamycin-sensitive
and resistant cells as measured by flow cytometry. Biochem
Pharmacol 1989;38(2):305-12.
Hegewisch-Becker S, Fliegner M, Hossfeld D, Zander A. Clinical
relevance of P-glycoprotein expression and drug uptake
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2584.
Heike Y, Hamada H, Inamura N, Sone S, Ogura T, Tsuruo T.
Monoclonal anti-P-glycoprotein antibody-dependent killing of
multidrug-resistant tumor cells by human mononuclear cells.
Jpn J Cancer Res 1990 Nov;81(11):1155-61.
Henderson GB. Mediation of cellular anion detoxification in
leukemic cells by unidirectional efflux pumps. Adv Enzyme
Regul 1989;29:61-72.
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH.
Effect of P-glycoprotein expression on the accumulation and
cytotoxicity of topotecan (SK&F 104864), a new camptothecin
analogue. Cancer Res 1992 Apr 15; 52(8):2268-78.
Hennequin E, Delvincourt C, Okiemy MG, Jardillier JC. Detection
of MDR1 gene in cell lines and human cancers. Paper
presented at: European Association for Cancer Research 10th
Biennial Meeting; 1989 Sep 10-13; Galway, Ireland.
Herweijer H, Nooter K, Beishuizen A, Sonneveld P, Oostrum RG,
Hesseling-Janssen AL, van Dongen JJ. Expression of mdr1
and mdr3 multidrug-resistance genes in hairy cell leukaemia
[letter]. Eur J Cancer 1991;27(3):297-8.
Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1
and mdr3 multidrug-resistance genes in human acute and
chronic leukemias and association with stimulation of drug
accumulation by cyclosporine. J Natl Cancer Inst 1990 Jul
4; 82(13):1133-40.
Hill AB, Beck WT, Trent JM. Cytogenetic and molecular
characterization of tumors in nude mice derived from a
multidrug resistant human leukemia cell line. Cancer Res
1988;48(2):393-8.
Ho AD, Thaler J, Stryckmans P, Coiffier B, Luciani M, Sonneveld
P, Lechner K, Rodenhuis S, Peetermans ME, deCataldo F, et
al. Pentostatin in refractory chronic lymphocytic
leukemia: a phase II trial of the European Organization for
Research and Treatment of Cancer. J Natl Cancer Inst 1990
Sep 5;82(17):1416-20.
Hoffmann D, Gerken M, Hermentin P, Sedlacek HH. B 880308 -- a
new anthracycline derivative demonstrating maintained
activity against multidrug resistant cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2410.
Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium
antagonists which differ markedly in their potencies as
calcium blockers are equally effective in modulating drug
transport by P-glycoprotein. Biochem Pharmacol 1992 Jun 23;
43(12):2601-8.
Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP, Padua
RA. Is the mdr 1 gene relevant in chronic lymphocytic
leukemia? Leukemia 1990 Mar;4(3):216-8.
Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR. Combined use
of cyclosporin A and verapamil in modulating multidrug
resistance in human leukemia cell lines. Cancer Res 1990
May 15;50(10):2953-7.
Ikegami T, Kubota N, Matsui K, Funabiki T, Shuin T, Natsumeda Y.
Dipyridamole enhances the cellular accumulation of etoposide
and its cytotoxic effect in various cancer cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2031.
Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K,
Tsuruo T, Shimoyama M. Multidrug resistance in cultured
human leukemia and lymphoma cell lines detected by a
monoclonal antibody, MRK16. Jpn J Cancer Res 1989 Oct;
80(10):1006-13.
Ishii S, Nagasawa M, Kariya Y, Yamamoto H, Inouye S, Kondo S.
Antitumor activity of pyrindamycins A and B. J Antibiot
(Tokyo) 1989 Nov;42(11): 1713-7.
Ito T, Ohnuma T, Holland JF, Mattern MR. Altered DNA
topoisomerase (TOPO) II activity in human leukemia sublines
resistant to trimetrexate (TMQ) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2078.
Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R,
Saito H. Increased P-glycoprotein expression and
multidrug-resistant gene (mdr1) amplification are
infrequently found in fresh acute leukemia cells. Sequential
analysis of 15 cases at initial presentation and relapsed
stage. Cancer 1989 Apr 15;63(8):1534-8.
Ivy SP, Smith JK, Speciale A, Sather H, Hammond GD, Reaman GH.
Detection of mdr1 gene expression using polymerase chain
reaction (PCR) in childhood acute lymphoblastic leukemia
(ALL) at diagnosis [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2826.
Jackson RC, Leopold WR, Sebolt JS. Biochemical and experimental
chemotherapy studies of the pyrazoloacridines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:536-8.
Jaffrezou JP, Herbert JM, Levade T, Gau MN, Chatelain P, Laurent
G. Reversal of multidrug resistance by calcium channel
blocker SR33557 without photoaffinity labeling of P-
glycoprotein. J Biol Chem 1991 Oct 15;266(29):19858-64.
Kaczorowski S, Porwit A, Christensson B. Expression of P-
glycoprotein in non-Hodgkin's lymphomas. Leuk Lymphoma
1991;5(5-6):379-86.
Kamath N, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun 1991
Feb;3(2):37-44.
Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Absence of
correlation between cytotoxicity and drug transport by P-
glycoprotein in clinical leukemic cells. Eur J Haematol
1991 Aug; 47(2):146-51.
Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Mechanisms
involved in the development of adriamycin resistance in
human leukemic cells. Leuk Res 1990;14(6):567-73.
Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in
hematological malignancies. Blood Rev 1991;5(1):38-41.
Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA,
Bollinger P, Hiestand PC. SDZ PSC-833, a non-
immunosuppressive cyclosporine: its potency in overcoming
P-glycoprotein-mediated multidrug resistance of murine
leukemia. Int J Cancer 1992 Feb 20;50(4):593-7.
Kemnitz J, Freund M, Dominis M, Cohnert TR, Uysal A, Georgii A.
Detection of cells with multidrug-resistant phenotype in
myeloproliferative disorders before therapy. Hematol Pathol
1989;3(2):73-8.
Kere J, Ruutu T, Davies KA, Roninson IB, Watkins PC, Winqvist R,
De La Chapelle A. Chromosome 7 long arm deletion in
myeloid disorders a narrow breakpoint region in 7q22 defined
by molecular mapping. Blood 1989;73(1):230-4.
Kessel D. Effects of phorbol esters on doxorubicin transport
systems. Biochem Pharmacol 1988; 37(11):2297-3000.
Kessel D. Exploring multidrug resistance using rhodamine 123.
Cancer Commun 1989;1(3):145-9. Published erratum appears in
Cancer Commun 1989 Nov;1(5):335.
Kessel D. Probing modes of multi-drug resistance via
photodynamic effects of anthrapyrazoles. In: Tapiero H,
Robert J, Lampidis TJ, editors. 1st International Interface
of Clinical and Laboratory Responses to Anticancer Drugs;
1989 Mar 13-15; Villejuif, France. Paris: Les Editions
Inserm; 1989. p. 223-32. (Colloque INSERM; 191).
Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of
multidrug resistance by fluorescent dyes. Cancer Res 1991
Sep 1; 51(17):4665-70.
Kessel D, Erickson C. Porphyrin photosensitization of multi-
drug resistant cell types. Photochem Photobiol 1992
Mar;55(3):397-9.
Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos
G, Diddens H, Niethammer D. Susceptibility of multidrug-
resistant human leukemia cell lines to human interleukin 2-
activated killer cells. Cancer Res 1990 Nov
1;50(21):6793-9.
Kiue A, Sano T, Naito A, Inada H, Suzuki K, Okumura M, Kikuchi J,
Sato S, Takano H, Kohno K, et al. Reversal by two
dihydropyridine compounds of resistance to multiple
anticancer agents in mouse P388 leukemia in vivo and in
vitro. Jpn J Cancer Res 1990 Oct;81(10):1057-64.
Klohs WD, Sebolt JS, Steinkampf RW, Havlick MJ, Berman EM, Werbel
LM, Leopold WR, Jackson RC. Correlation between in vitro
and in vivo testing of DNA-binders versus antifolates in
multiple drug resistant (MDR) P388 cells (P388R) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1271.
Klohs WD, Steinkampf RW. The effect of lysosomotropic agents
and secretory inhibitors on anthracycline retention and
activity in multiple drug-resistant cells. Mol Pharmacol
1988;34(2): 180-5.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Knight C, Slade DL, Harker WG. Multidrug resistance in
mitoxantrone-selected CEM leukemia cells appears to be
unrelated to P-glycoprotein expression [abstract]. Clin Res
1991;39(1):68A.
Kobayashi H, Takemura Y, Miyachi H, Ohnuma T. Alterations of
MDR1 and dihydrofolate reductase genes in human leukemia
sublines resistant to various folate analogs [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A1932.
Koizumi S. Rapid and sensitive detection of low-grade multidrug
resistance (MDR) in leukemic cells, using the fluorescent
indicator, fluo-3 [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2875.
Konig R, Ashwell G, Hanover JA. Overexpression and biosynthesis
of CD4 in Chinese hamster ovary cells: coamplification using
the multiple drug resistance gene. Proc Natl Acad Sci U S A
1989 Dec;86(23):9188-92.
Kopnin BP, Sokova OI, Demidova NS. Regularities of karyotypic
evolution during stepwise amplification of genes determining
drug resistance. Mutat Res 1992 May;276(3):163-77.
Koseki Y, Sweatman TW, Israel M. Comparative effects of
saponins PF-3 and digitonin on adriamycin accumulation in
parent sensitive (P388/S) and multidrug resistant (P388/ADR)
murine leukemia cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2374.
Krapcho AP, Getahun Z, Avery KL Jr, Vargas KJ, Hacker MP,
Spinelli S, Pezzoni G, Manzotti C. Synthesis and antitumor
evaluations of symmetrically and unsymmetrically substituted
1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-
bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene -9,10-diones.
J Med Chem 1991 Aug;34(8): 2373-80.
Krishan A, Burke P, Gordon K, Wellham L, Sauerteig A. Flow
cytometric determination of drug efflux phenotype in human
leukemic cells. Cytometry 1988;Suppl 2:41.
Kulkarni SS, Wang ZM, Spitzer G, Taha M, Hamada H, Tsuruo T,
Dicke KA. Elimination of drug-resistant myeloma tumor cell
lines by monoclonal anti-P-glycoprotein antibody and rabbit
complement. Blood 1989 Nov 1;74(6):2244-51.
Kuo-Pao PY, Samaan NA. Intrinsic drug resistance in a human
medullary thyroid carcinoma cell line: association with a
multidrug resistance gene expression and low proliferation
fraction [abstract]. Anticancer Res 1990;10(5B):1404.
Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T,
Utsunomiya A, Ishibashi K, Saito T, Uozumi K, Maruyama M, et
al. Expression of P-glycoprotein in adult T-cell leukemia
cells. Blood 1990 Nov 15;76(10):2065-71.
Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K,
Utsunomiya A, Arima T, Akiyama S. Expression of the
multidrug transporter, P-glycoprotein, in chronic
myelogenous leukaemia cells in blast crisis. Br J Haematol
1990 Jan;74(1):24-9.
Lahmy S, Salmon JM, Vigo J, Viallet P. Identification of multi-
drug resistant cells in sensitive Friend leukemia cells by
quantitative videomicrofluorimetry. Cell Biochem Funct 1992
Mar;10(1):9-17.
Lampidis TJ, Castello C, del Giglio A, Pressman BC, Viallet P,
Trevorrow KW, Valet GK, Tapiero H, Savaraj N. Relevance of
the chemical charge of rhodamine dyes to multiple drug
resistance. Biochem Pharmacol 1989 Dec 1;38(23):4267-71.
Lampidis TJ, Castello C, Savaraj N, Kuo MT, Lu K, Li DJ, Fourcade
A, Tapiero H. Rapid induction of high levels of cross-
resistance to adriamycin and MDR1 gene expression in murine
cells by rhodamine 123 [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2107.
Lampidis TJ, Kolonias D, Tapiero H, Savaraj N, Cahn J. In-vitro
cardiac potencies of multi-drug resistance modulators
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1990;31:373.
Lee SC, Deutsch C, Beck WT. Comparison of ion channels in
multidrug-resistant and multidrug-sensitive human leukemic
cells. Proc Natl Acad Sci U S A 1988;85(6):2019-23.
Li XK, Ohnuma T, Acs G, Cuttner J, Holland JF. Expressions of
dihydrofolate reductase (DHFR) and P-glycoprotein (P-G)
genes in trimetrexate (TMQ)-resistant human leukemia cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2683.
Limonta M, Ubezio P. [Anthracycline resistance:
cytofluorometric study on infantile lymphoblastic leukemia].
Medicina (Firenze) 1989 Oct-Dec; 9(4):406-8. (Ita).
Ling YH, Yang LY, Priebe W, Perez-Soler R. Characterization of
DNA lesions induced by 2'-I-3'-oh-4'-epi-4-demethoxy-
doxorubicin (A), a non-cross-resistant doxorubicin (D)
analog with high affinity for lipid membranes [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2909.
Liso V, Specchia G, Pansini N, Mininni D, Colucci A, Mestice A,
Vaira A, Magno M, DeBillis G. Expression of P-170
glycoprotein in adult acute lymphoblastic leukemia (ALL)
[abstract]. Haematologica 1991;76 Suppl 4:75.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R,
Sandberg AA. Expression of the multidrug resistance gene
product P-glycoprotein in myelodysplasia is associated with
a stem cell phenotype. Br J Haematol 1991;78(1):28-34.
Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Emmer G. SDZ 280-446, a novel semi-synthetic
cyclopeptolide: in vitro and in vivo circumvention of the P-
glycoprotein-mediated tumour cell multidrug resistance. Br
J Cancer 1992 Jan;65(1):11-8.
Lothstein L, Sweatman TW, Israel M. P-glycoprotein (P-gp)
mediated resistance to N-benzyladriamycin- 14-valerate
AD-198 without enhanced drug efflux [abstract]. J Cancer
Res Clin Oncol 1990;116 Suppl Pt 1:415.
Lutzky J, Madrid KK, Krishna S, Bhalla K, Hindenburg AA, Taub RN.
Effect of glutathione depletion plus verapamil on HL60 and
HL60/AR cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2203.
Lyttleton MPA, Hart S, Ganeshaguru K, Prentice HG, Hoffbrand AV,
Mehta AB. Multidrug resistance in acute leukaemia: a
comparative study of immunocytochemical and RNA slot blot
detection of P-glycoprotein expression. Leuk Lymphoma 1991;
5(5-6):357-64.
Ma L, Marquardt D, Takemoto L, Center MS. Analysis of P-
glycoprotein phosphorylation in HL60 cells isolated for
resistance to vincristine. J Biol Chem 1991;266(9):5593-9.
Marie JP, Brophy NA, Berry JM, Ehsan MN, Smith SD, Warnke RA,
Sikic BI. Expression of the multidrug-resistance gene mdr1
in human leukemia and lymphoma cells: comparison of RNA slot
blotting, in situ RNA hybridization, and detection of P-
glycoprotein by immunocytochemistry [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A1976.
Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro
effect of P-glycoprotein (P-gp) modulators on drug
sensitivity of leukemic progenitors (CFU-L) in acute
myelogenous leukemia (AML). Exp Hematol 1992
Jun;20(5):565-8.
Marie JP, Seman M, Oddos T, Aumont P, Zhou D, Suberville AM,
Zittoun R. Use of MS2, a monoclonal antibody recognizing
external epitope of P-gp, in cell lines and adult acute
myeloid leukemias [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2167.
Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene
expression in adult acute leukemias: correlations with
treatment outcome and in vitro drug sensitivity. Blood 1991
Aug 1;78(3):586-92.
Marquardt D, McCrone S, Center MS. Mechanisms of multidrug
resistance in HL60 cells: detection of resistance-associated
proteins with antibodies against synthetic peptides that
correspond to the deduced sequence of P-glycoprotein.
Cancer Res 1990 Mar 1;50(5):1426-30.
Mason J, Bessent E, Mullen M, Shea T. P-glycoprotein expression
on mobilized peripheral blood progenitor cells correlated
with CD34 [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A1189.
McCrady CW, Huang X, Massey GV, Yanovich S, Pettit GR, Carchman
RA. Expression of the multidrug resistance (MDR) gene does
not confer resistance to the cytostatic effects of
bryostatin 1 [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2210.
McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS.
Mechanisms of multidrug resistance in HL60 cells. Analysis
of resistance associated membrane proteins and levels of mdr
gene expression. Biochem Pharmacol 1989 Oct 15;
38(20):3611-9.
Mclachlin JR, Eglitis MA, Ueda K, Lovelace E, Gottesman MM,
Anderson WF, Pastan I. Retroviral gene transfer and
expression of the multidrug resistance gene in murine
hematopoietic cells [abstract]. J Cell Biochem Suppl 1988;
12 Pt B:181.
McMichael A, Klohs W, Steinkampf R, Elliott W, Ramu A.
Tioperidone: a new chemosensitizer for multidrug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2243.
Meese E, Olson S, Horwitz S, Trent J. Gene amplification is
mediated by extrachromosomal elements in the multidrug
resistant J774.2 murine cell line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:A2252.
Merriman RL, Dantzig AH, Engelhardt J, Minor PL, Poore GA,
Shackelford KA, Tanzer LR, VanPelt C, Winter MA, Beck WT, et
al. Increased toxicity of vincristine (VCR) when combined
with the multidrug-resistamce (MDR) modulator,
trimethoxybenzoylyohimbine (TMBY) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990; 31:A2142.
Meyers MB, Biedler JL, Scotto K, Sirotnak FM. Antibodies to P-
glycoproetin (PGP) cross-react with a 50- to 55-KD protein
in multidrug-resistant mouse tumor cells and in lumenal
intestinal epithelium of the mouse [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:A2099.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR.
Characterization of monoclonal antibodies recognizing a m-r
180000 p-glycoprotein differential expression of the m-r
180000 and m-r 170000 p-glycoproteins in multidrug-resistant
human tumor cells. Cancer Res 1989;49(12):3209-14.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR, Cordon-Cardo
C, Biedler JL. The 180-KD resistance-related membrane
protein recognized by monoclonal antibodies raised against
vincristine-resistant human neuroblastoma cells is a P-
glycoprotein [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2008.
Michaeli J, Richon VM, Marks PA, Rifkind RA. Vincristine
resistant murine erythroleukemia and HL-60 cells have marked
sensitivity to induction of differentiation by hexamethylene
bisacetamide [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1703.
Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R,
Raspadori D, Russo D, Visani G, Dinota A, Pileri S, et al.
Overexpression of multidrug resistance-associated p170-
glycoprotein in acute non-lymphocytic leukemia. Eur J
Haematol 1992 Feb;48(2):87-92.
Michieli M, Geromin A, Michelutti A, Damiani D, Savignano C,
Patriarca F, Velisig M, Raspadori D, Baccarani M.
Multidrug resistance (MDR)-associated P-170 glycoprotein in
acute nonlymphocytic leukemia (ANLL) [abstract].
Haematologica 1991;76 Suppl 4:75.
Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C,
Michelutti A, Fanin R, Fasola G, Russo D, Tazzari P, et al.
The expression of the multidrug resistance-associated
glycoprotein in B-cell chronic lymphocytic leukaemia. Br J
Haematol 1991 Apr;77(4):460-5.
Miller LP, Bauer K, Roninson I, Tsuruo T. Detection of P-
glycoprotein by flow cytometry in pediatric acute
nonlymphoblastic leukemia (ANLL) [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1989;8:A848.
Miyachi H, Takemura Y, Kobayashi H, Ohnuma T. CB3717 induced
enhancement of multidrug resistance (MDR) in a trimetrexate
(TMQ)-resistant human acute lymphoblastic leukemia cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2251.
Miyamoto K, Wakusawa S, Inoko K, Takagi K, Koyama M. Reversal
of vinblastine resistance by a new staurosporine derivative,
NA-382, in P388/ADR cells. Cancer Lett 1992 Jun 15;
64(2):177-83.
Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K. Detection
of multidrug-resistant protein, P-glycoprotein in childhood
leukaemia and lymphoma. Eur J Pediatr 1991
Apr;150(6):416-8.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Muller MR, Twentyman PR, Lambert E, Cox H, Watson JV, Baglin TP,
Rees JH. P-glycoprotein (PGp) expression and glutathione
(GSH) content in human leukemia cells determined by flow-
cytometry (FCM). Paper presented at: British Association
for Cancer Research/Association for Cancer Physicians/
Leukaemia Research Fund Joint Winter Meeting on Leukaemia
and Lymphomas; 1989 Dec 11-12; London, UK.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Musto P, Melillo L, Lombardi G, Matera R, di Giorgio G,
Carotenuto M. High risk of early resistant relapse for
leukaemic patients with presence of multidrug resistance
associated P-glycoprotein positive cells in complete
remission. Br J Haematol 1991 Jan;77(1):50-3.
Naito M, Hamada H, Tsuruo T. ATP-magnesium-dependent binding of
vincristine to the plasma membrane of multidrug-resistant
K562 cells. J Biol Chem 1988;263(24):11887-91.
Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of
multidrug resistance by an immunosuppressive agent FK-506.
Cancer Chemother Pharmacol 1992;29(3):195-200.
Naito M, Tsuruo T. Competitive inhibition by verapamil of atp-
dependent high affinity vincristine binding to the plasma
membrane of multidrug-resistant k562 cells without calcium
ion involvement. Cancer Res 1989;49(6):1452-5.
Naito M, Tsuruo T. Functionally active homodimer of P-
glycoprotein in multidrug-resistant tumor cells. Biochem
Biophys Res Commun 1992 May 29; 185(1):284-90.
Nara N. [Multidrug resistance in acute leukemia]. Rinsho
Ketsueki 1989 Mar;30(3):275-81. (Jpn).
Narayana K, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun
1991;3(2): 37-44.
Nooter K, Herweijer H, Sonneveld P, van Dongen J, Mulder A.
Expression of the MDR3 multidrug resistance gene in human B-
cell malignancies [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A1157.
Nooter K, Oostrum R, Jonker R, Van Dekken H, Stokdijk W, Van Den
Engh G. Effect of cyclosporin A on daunorubicin
accumulation in multidrug-resistant p388 leukemia cells
measured by real-time flow cytometry. Cancer Chemother
Pharmacol 1989;23(5):296-300.
Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer
H, Valerio D, Hagemeijer A, Baas F. Expression of the mdr3
gene in prolymphocytic leukemia: association with
cyclosporin-A-induced increase in drug accumulation. Int J
Cancer 1990 Apr 15; 45(4):626-31.
Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T,
Valerio D. Overexpression of the mdr1 gene in blast cells
from patients with acute myelocytic leukemia is associated
with decreased anthracycline accumulation that can be
restored by cyclosporin-A. Int J Cancer 1990 Feb 15;45(2):
263-8.
Norris MD, Haber M, Gilbert J, Madafiglio J, Kavallaris M,
Stewart BW, Mechetner EB, Gudkov AV, Roninson IB.
Selection for MDR1 gene expression by high concentration
methotrexate [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2840.
Nuessler V, Hasmann M, Pelka-Fleischer R, Loeser R, Wilmanns W.
Droloxifene--a new modulator of the multidrug-resistance
(MDR) phenotype in a human leukemia cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A1544.
Ogura M, Takatori T, Sugimoto Y, Tsuruo T. Identification of
DNA binding proteins on MDR1 promoter in drug-sensitive and
adriamycin-resistant human myelogenous leukemia K562 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1990;31:
A2669.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents KT6149, MX 2, SM5887, menogaril, and
liblomycin using cisplatin or adriamycin resistant human
cancer cell lines. Cancer Res 1989;49(15): 4098-102.
Ohkouchi E, Takamori R, Kawabata H, Sugimoto Y, Hamada H, Tsuruo
T. Expression of P-glycoprotein and its mRNA in human
renal and colon tumorcell lines, as a determinant for
natural drug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1217.
Okabe Kado J, Hayashi M, Honma Y, Hozumi M, Tsuruo T.
Inhibition by erythroid differentiation factor (activin A)
of P-glycoprotein expression in multidrug resistant human
K562 erythroleukemia cells. Cancer Res 1991;51(10):2582-6.
Osann K, Sweet P, Slater LM. Synergistic interaction of
cyclosporin A and verapamil on vincristine and daunorubicin
resistance in multidrug-resistant human leukemia cells in
vitro. Cancer Chemother Pharmacol 1992;30(2):152-4.
Parekh H, Chavan S, Chitnis M. Modulation of thiol pools by
vitamin K3 and its effect on survival of sensitive and
resistant murine tumor cells. Anticancer Drugs 1991
Apr;2(2):159-68.
Parekh HK, Mansuri-Torshizi H, Srivastava TS, Chitnis MP.
Circumvention of adriamycin resistance: effect of 2-
methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity
in sensitive and MDR P388 leukemia cells. Cancer Lett 1992
Jan 10;61(2): 147-56.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT.
Essential features of the p-glycoprotein pharmacophore as
defined by a series of reserpine analogs that modulate
multidrug resistance. Proc Natl Acad Sci U S A 1989;86(13):
5128-32.
Pearce HL, Winter MA, Beck WT. Structural characteristics of
compounds that modulate P-glycoprotein-associated multidrug
resistance. In: Weber G, editor. 30th Symposium on
Regulation of Enzyme Activity and Synthesis in Normal and
Neoplastic Tissues; 1989 Oct 2-3; Indianapolis. Oxford
(England): Pergamon Press; 1990. p. 357-74. (Advances in
enzyme regulation; 30).
Pierre A, Leonce S, Kraus-Berthier L, Guilbaud N, Saint-Dizier D,
Atassi G. Characterization of the reversal of multidrug
resistance by S 9788, a new triazinoaminopiperidine
derivative [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2879.
Pincus R, Goldman ID. Decreased tight binding of mitoxantrone
in P388 leukemia cells with mul tiple drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1185.
Pincus R, Goldman ID. Evidence for impaired mitoxantrone and
vinblastine binding in P388 murine leukemia cells with
multidrug resistance. Biochem Pharmacol 1990 Dec
15;40(12):2625-35.
Pirker R, Goldstein L, Ludwig H, Linkesch W, Lechner C, Gottesman
MM, Pastan I. Multidrug resistance (MDR1) gene expression
in leukemias [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2056.
Pirker R, Goldstein LJ, Ludwig H, Linkesch W, Lechner C,
Gottesman MM, Pastan I. Expression of a multidrug
resistance gene in blast crisis of chronic myelogenous
leukemia. Cancer Commun 1989;1(2):141-4.
Pirker R, Gotzl M, Gsur A, Havelec L, Wallner J, Haas OA, Knapp
W, Linkesch W, Lechner K. MDR1 gene expression: an
independent prognostic factor in acute myeloid leukemia
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1992;11:A912.
Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim
P, Hopfner M, Scherrer R, Valent P, Havelec L, et al. MDR1
gene expression and treatment outcome in acute myeloid
leukemia. J Natl Cancer Inst 1991 May 15;83(10):708-12.
Pirker R, Wallner J, Geissler K, Valent P, Bettelheim P, Lechner
K, Hopfner M, Linkesch W, Ludwig H. MDR1 gene expression
affects clinical outcome in acute myelogenous leukemia
[abstract]. Ann Oncol 1990;1 Suppl:67.
Politi PM, Sinha BK. Role of differential drug uptake efflux
and binding of etoposide in sensitive and resistant human
tumor cell lines implications for the mechanisms of drug
resistance. Mol Pharmacol 1989;35(3):271-8.
Pommerenke EW, Osswald H, Hahn EW, Volm M. Activity of various
amphiphilic agents in reversing multidrug resistance of L
1210 cells. Cancer Lett 1990 Nov 19;55(1):17-23.
Pourtier-Manzanedo A, Boesch D, Loor F. FK-506 (fujimycin)
reverses the multidrug resistance of tumor cells in vitro.
Anticancer Drugs 1991 Jun; 2(3):279-83.
Preisler HD, Gottesman M, Raza A, Pastan I, Day R. The clinical
significance of expression of the multidrug resistance (MDR)
gene in acute nonlymphocytic leukemia (ANLL) [abstract].
Proc Annu Meet Am Soc Clin Oncol 1989;8:A782.
Qian XD, Beck WT. Interaction of a photoactive anthracycline
analog, [3H]-N-azido-benzoyldaunomycin (AB-DNR) with P-
glycoprotein (Pgp) from multidrug-resistant human leukemic
lymphoblasts (CEM/VLB5K) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2160.
Qian XD, Beck WT. Progesterone photoaffinity labels P-
glycoprotein in multidrug-resistant human leukemic
lymphoblasts. J Biol Chem 1990 Nov 5; 265(31):18753-6.
Rahman A, Madhu M, Siddiqui J, Yokozaki H, Clair T, Tortora G,
Cho-Chung YS, Center M, Glazer RI. Potentiation of the
cytotoxicity of adriamycin by 8-Cl-cAMP in multidrug
resistant HL-60 leukemia cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2217.
Ramu A, Ramu N, Gorodetsky R. Reduced ouabain-sensitive
potassium entry as a possible mechanism of multidrug-
resistance in P388 cells. Biochem Pharmacol 1991 Oct
9;42(9):1699-704.
Ramu A, Ramu N, Rosario LM. Circumvention of multidrug-
resistance in P388 cells is associated with a rise in the
cellular content of phosphatidylcholine. Biochem Pharmacol
1991 May 15;41(10):1455-61.
Ramu N, Ramu A. Circumvention of adriamycin resistance by
dipyridamole analogues a structure-activity relationship
study. Int J Cancer 1989; 43(3):487-91.
Raymond M, Rose E, Housman DE, Gros P. Physical mapping,
amplification, and overexpression of the mouse mdr gene
family in multidrug-resistant cells. Mol Cell Biol 1990
Apr;10(4):1642-51.
Redner A, Hegewisch S, Haimi J, Steinherz P, Jhanwar S, Andreeff
M. A study of multidrug resistance and cell kinetics in a
child with near-haploid acute lymphoblastic leukemia. Leuk
Res 1990;14(9): 771-7.
Reizenstein P, Gruber A, Luthman H, Kaczorowska M, Norgren S,
Peterson C, Porvit A, Vitols S. Multiple drug resistance:
expression of the MDR1 gene in leukemic blasts in relation
to treatment and effect of verapamil isomers on cellular
vincristine accumulation [abstract]. Anticancer Res 1990;
10(5B):1400-1.
Reymann A, Erttmann KD, Erttmann R, Dietel M. Concentration-
response study of chemosensitizers and of their mutual
interaction in anthracycline accumulation studies performed
in multidrug-resistant Friend leukemia cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2249.
Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks
PA. Characteristics of erythroleukemia cells selected for
vincristine resistance that have accelerated inducer-
mediated differentiation. Proc Natl Acad Sci U S A 1991 Mar
1;88(5):1666-70.
Roberts D, Foglesong PD, Parganas E, Wiggins L. Reduced
formation of lesions in the DNA of a multidrug-resistant
l1210 subline selected for teniposide resistance. Cancer
Chemother Pharmacol 1989;23(3):161-8.
Roninson IB, Shen DW, Chin JE, Choi K, Fojo A, Soffir R, Richert
N, Gros P, Housman DE, Gottesman MM, Pastan I. Multidrug
resistance in human cells the role of the mdr-1 gene. In:
Minna J, Kuehl WM, editors. Cellular and molecular biology
of tumors and potential clinical applications; selected
papers from an Abbott-UCLA Symposium; 1986 Jan 20-25;
Steamboat Springs, CO. New York: Alan R. Liss; 1987. p.
287-96. (UCLA symposia on molecular and cellular biology
new series; 56).
Ross D, Ordonez J, Cuddy D, Wooten P, Lee E, Thompson B, Schiffer
C. Verapamil enhancement of daunorubicin uptake in
subpopulations of blast cells from AML patients: relation to
clinical response [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A806.
Ross D, Wooten P, Ordonez JV, Sridhara R, Lee E, Schiffer C.
MDR1 expression and effects of cyclosporin-A, verapamil and
progesterone on daunorubicin cytotoxicity in blast cells
from acute myelogenous leukemia patients [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2839.
Ross DD. Cellular and pharmacologic aspects of drug resistance
in acute myeloid leukemia. Curr Opin Oncol 1991
Feb;3(1):21-9.
Ross DD, Thompson BW, Ordonez JV, Joneckis CC. Improvement of
flow-cytometric detection of multidrug-resistant cells by
cell-volume normalization of intracellular daunorubicin
content. Cytometry 1989;10(2):185-91.
Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack
DG, Fojo AT. Expression of the mdr-1-p-170 gene in
patients with acute lymphoblastic leukemia. Blood
1989;74(4): 1388-95.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects
of tumor necrosis factor on sensitive and multidrug
resistant human leukemia and myeloma cell lines. Blood
1989;74(5):1723-7.
Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg
AA, Preisler HD. Expression of the multidrug resistance
gene in myeloid leukemias. Leuk Res 1990;14(1):11-21.
Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg
J, Vogler R, Grunwald H, Gottlieb A, et al. MDR1
transcript levels as an indication of resistant disease in
acute myelogenous leukaemia. Br J Haematol 1990
Jul;75(3):340-5.
Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T. Circumvention
of multidrug resistance by a newly synthesized quinoline
derivative, MS-073. Cancer Res 1991 May 1;51(9):2420-4.
Savaraj N, Lu K, Guo T, Castello C, Tapiero H, Lampidis T.
Reduced drug accumulation with increased p-glycoprotein
expression in normal cell line [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1164.
Savaraj N, Teeter L, Kuo MT, Wu CJ, Tapiero H, Lampidis T.
Characteristics of rhodamine and adriamycin-induced
multidrug-resistant cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2187.
Schaefer A, Westendorf J, Lingelbach K, Schmidt C, Marquardt H.
Doxorubicin-resistant Friend erythroleukemia cells are less
resistant towards N,N-dimethylated anthracyclines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2171.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
(PKC) activity and the effects of staurosporine (STSN) in a
multidrug-resistant (MDR) human acute lymphoblastic leukemia
cell line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2111.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
activity and multidrug resistance in MOLT-3 human
lymphoblastic leukemia cells resistant to trimetrexate.
Cancer Res 1991 Jan 1; 51(1):55-61.
Sebolt J, Havlick M, Hamelehle K, Nelson J, Leopold W, Jackson R.
Activity of the pyrazoloacridines against multidrug-
resistant tumor cells. Cancer Chemother Pharmacol
1989;24(4):219-24.
Selassie CD, Hansch C, Khwaja TA. Structure-activity
relationships of antineoplastic agents in multidrug
resistance. J Med Chem 1990 Jul;33(7): 1914-9.
Seneviratne C, Goldenberg GJ. Further characterization of drug-
sensitivity and cross-resistance profiles of cloned cell
lines of Adriamycin-sensitive and -resistant P388 leukemia.
Cancer Commun 1989;1(1):21-7.
Shibata H, Furusawa S, Kawauchi H, Sasaki K, Takayanagi Y.
[Modulation of anthracycline resistance by reserpine in P388
leukemia cells]. Nippon Yakurigaku Zasshi 1991
Jul;98(1):1-6. (Jpn).
Shibata H, Sato T, Gamoh M, Tshioka C, Kanamaru R, Wakui A.
Expression of P-glucoprotein mRNA and erythroid
differentiation in multidrug-resistant K562 cell lines
treated with sodium butyrate [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A1159.
Shimm DS, Olson S, Hill AB. Radiation resistance in a multidrug
resistant human T-cell leukemia line. Int J Radiat Oncol
Biol Phys 1988;15(4):931-6.
Shimoyama M. Detection of multidrug resistant (MDR) cancer
cells by monoclonal antibodies. Paper presented at: Drug
resistance as a biochemical target in cancer chemotherapy.
13th Bristol-Myers Squibb Symposium on Cancer Research; 1990
May 10-11; Tokyo, Japan.
Shinoda H, Inaba M, Tsuruo T. In vivo circumvention of
vincristine resistance in mice with P388 leukemia using a
novel compound, AHC 52. Cancer Res 1989;49(7):1722-6.
Shustik C, Gorulx N, Gros P. Analysis of multidrug resistance
MDR-1 gene expression in chronic lymphocytic leukemia
(CLL). Br J Haematol 1991; 79(1):50-6.
Siddiqui J, Madhu M, Center M, Glazer R, Dritschilo A, Rahman A.
Modulation of multidrug resistance in HL-60 leukemia cells
by adriamycin encapsulated in liposomes [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2230.
Slapak CA, Daniel JC, Levy SB. Sequential emergence of distinct
resistance phenotypes in murine erythroleukemia cells under
adriamycin selection: decreased anthracycline uptake
precedes increased P-glycoprotein expression. Cancer Res
1990 Dec 15;50(24):7895-901.
Slapak CA, Lecerf JM, Daniel JC, Levy SB. Energy-dependent
accumulation of daunorubicin into subcellular compartments
of human leukemia cells and cytoplasts. J Biol Chem 1992
May 25; 267(15):10638-44.
Slapak CA, Levy SB. Frequency and phenotype of early
adriamycin-resistant mammalian leukemia cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2019.
Slater LM, Sweet P, Gupta S. Cyclosporin A (CsA) and verapamil
(Vp) effects on altered mitochondrial potentials (MoP) in
multidrug-resistant (mdr) acute lymphatic leukemia (ALL)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2260.
Slater LM, Sweet P, Hsu TC, Chan PK. Novel nucleolar and
nuclear morphology in a vincristine-dependent human leukemia
cell line (L100). Exp Cell Res 1992 Jan;198(1):170-4.
Slater LM, Wetzel M, Cho J, Sweet P. Development of cyclosporin
A mediated immunity in L1210 leukaemia. Br J Cancer 1991
Dec;64(6):1098-102.
Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy
H. Sufficient levels of quinine in the serum circumvent
the multidrug resistance of the human leukemic cell line
K562/ADM. Cancer 1991 Oct 15;68(8):1714-9.
Solary E, Velay I, Chauffert B, Caillot D, Bidan JM, Dumas M,
Casasnovas O, Guy H. Quinine circumvents the doxorubicin
resistance of a multidrug resistant human leukemic cell-
line, K562/DXR. Nouv Rev Fr Hematol 1990;32(5): 361-3.
Sonneveld P, Nooter K. Reversal of drug-resistance by
cyclosporin-A in a patient with acute myelocytic leukaemia.
Br J Haematol 1990 Jun;75(2):208-11.
Sonneveld P, Nooter K, Burghouts JT, Herweijer H, Adriaansen HJ,
van Dongen JJ. High expression of the mdr3 multidrug-
resistance gene in advanced-stage chronic lymphocytic
leukemia. Blood 1992 Mar 15;79(6):1496-500.
Sonneveld P, Nooter K, Herweyer H, te Boekhorst P, van Kapel J,
Lowenberg B. Multidrug resistance (mdr1) in leukemia and
myeloma: detection, clinical relevance and circumvention
[abstract]. Haematologica 1991;76 Suppl 4:74.
Staats J, Marquardt D, Center MS. Characterization of a
membrane-associated protein kinase of multidrug-resistant
HL60 cells which phosphorylates P-glycoprotein. J Biol Chem
1990 Mar 5;265(7):4084-90.
Steinhoff A, Muenchmeyer M, Looft G, Erttmann R. Measurements
of anthracycline-accumulation in multidrug-resistant (MDR)
and sensitive leukemia cells by fluorometry effect of
verapamil and other membrane-transport modulation drugs
[abstract]. Naunyn Schmiedebergs Arch Pharmacol 1989;339
Suppl:R42.
Su IJ, Chang IC, Cheng AL. Expression of growth related genes
and drug resistance genes in HTLV-I positive and HTLV-I
negative post thymic T-cell malignancies. Ann Oncol 1991;2
Suppl 2:151-5.
Sugawara I, Ikeuchi T, Fukuchi K, Yoshikai Y, Sugiyama H, Kodo H,
Mori S. Establishment and characterization of a non-T,
non-B cell lymphoma cell line with T cell receptor beta- and
gamma-chain gene rearrangement and possessing MRK 20
monoclonal antibody-defined 85KD protein. Hum Cell 1990
Mar;3(1):57-64.
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama
S, Mori S. Tissue distribution of P-glycoprotein encoded
by a multidrug-resistant gene as revealed by a monoclonal
antibody MRK 16. Cancer Res 1988;48(7):1926-9.
Sugawara I, Nakahama M, Hamada H, Tsuruo T, Mori S. Apparent
stronger expression in the human adrenal cortex than in the
human adrenal medulla of MR 170000-180000 P-glycoprotein.
Cancer Res 1988;48(16):4611-4.
Sugimoto Y, Asami N, Tsuruo T. Expression of P-glycoprotein
mRNA in human gastric tumors. Jpn J Cancer Res 1989
Oct;80(10):993-9.
Sukhanov VA, D'Yakov VL, Lalaev VV, Yakh'Yaev AV, Voronkova IM,
Donenko FV, Borovkova NB, Moroz LV. [P-glycoprotein
expression in P-388 leukemia cell with induced resistance to
doxorubicin]. Byull Eksp Biol Med 1991;111(3): 290-1.
(Rus).
Sunkara PS, Zwolshen JH, Stemerick DM, Edwards ML. 1-(2,5-
dimethoxy phenyl)-3-[4(dimethylamino)phenyl]-2-methyl-2-
propen-1-one (DDMP, MDL 27,048): novel antimitotic agent
with activity against vinca alkaloid resistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A1954.
Sweatman TW, Koseki Y, Seshadri R, Israel M, Beck WT. Activity
of n-benzyladriamicin-14-valerate (AD 198) in vitro against
mechanistically different multidrug-resistant CEM cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1076.
Sweet P, Chan PK, Slater LM. Cyclosporin a and verapamil
enhancement of daunorubicin-produced nucleolar protein b23
translocation in daunorubicin-resistant and sensitive human
and murine tumor cells. Cancer Res 1989;49(3):677-80.
Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y,
Niitani H, Saijo N. Establishment of a human leukemia
subline resistant to the growth-inhibitory effect of 12-O-
tetradecanoylphorbol 13-acetate (TPA) and showing non-P-
glycoprotein-mediated multi-drug resistance. Int J Cancer
1991 Jul 30;48(6):931-7.
Takemura Y, Ohnuma T, Miyachi H, Sekiguchi S. A human leukemia
cell line made resistant to two folate analogues,
trimetrexate and N10-propargyl-5,8-dideazafolic acid
(CB3717). J Cancer Res Clin Oncol 1991;117(6):519-25.
Tong W, Berman E, Lin S. Pharmacokinetic study of high-dose
tamoxifen with daunorubicin: a phase I trial with escalation
of tamoxifen [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A3156.
Treichel RS, Olken S. The relationship between multi-drug
resistance and resistance to natural-killer-cell and
lymphokine-activated killer-cell lysis in human leukemic
cell lines. Int J Cancer 1992 Jan 21; 50(2):305-10.
Trevorrow KW, Valet G, Lampidis TJ. Effects of carboxylic
ionophores on the uptake and retention of rhodamine 123 in
sensitive and multidrug-resistant Friend leukemia cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2108.
Tsuruo T, Naito M, Takamori R, Tsukahara S, Yamabe-Mitsuhashi J,
Yamazaki A, Oh-hara T, Sudo Y, Nakaike S, Yamagishi T. A
benzophenazine derivative, N-beta-dimethylaminoethyl 9-
carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-
carboxamide, as a new antitumor agent against multidrug-
resistant and sensitive tumors. Cancer Chemother Pharmacol
1990;26(2):83-7.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987;78(12): 1415-9.
Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-
containing anthracycline me-2303 as a new antitumor agent
against murine and human tumors and their multidrug-
resistant sublines. Cancer Res 1989;49(20):5537-42.
Ubezio P, Limonta M, D'Incalci M, Damia G, Masera G, Giudici G,
Wolverton JS, Beck WT. Failure to detect the P-
glycoprotein multidrug resistant phenotype in cases of
resistant childhood acute lymphocytic leukaemia. Eur J
Cancer Clin Oncol 1989 Dec;25(12):1895-9.
Umeda Y, Tsuruo T, Mori S, Arimori S, Sugawara I. High-level
expression of P-glycoprotein and 85 kD protein as assessed
by flow cytometry and immunocytochemistry in leukemias and
malignant lymphomas. Tokai J Exp Clin Med 1990 May;
15(2-3):179-87.
Vasanthakumar G, Ahmed NK. Antisense oligonucleoside
methylphosphonate modulates daunorubicin transport in
multidrug-resistant K562 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2121.
Vasanthakumar G, Ahmed NK. Modulation of drug resistance in a
daunorubicin resistant subline with oligonucleoside
methylphosphonates. Cancer Commun 1989;1(4):225-32.
Published erratum appears in Cancer Commun 1990;2(8):295.
Volm M. In vivo multidrug-resistance of animal and human tumors
[abstract]. J Chemother Infect Dis Malig 1989;Suppl 1:A307.
Volm M, Mattern J, Pommerenke EW. Time course of MDR gene
amplification during in vivo selection for doxorubicin-
resistance and during reversal in murine leukemia L 1210.
Anticancer Res 1991 Mar-Apr;11(2):579-85.
Wakusawa S, Nakamura S, Aritsuka K, Miyamoto KI, Koshiura R,
Hagiwara M, Hidaka H. Effect of protein kinase inhibitors
on the drug-efflux system in multidrug-resistant tumor
cells [abstract]. Jpn J Pharmacol 1990;52 Suppl 1:[86p.].
Wakusawa S, Nakamura S, Tajima K, Miyamoto K, Hagiwara M, Hidaka
H. Overcoming of vinblastine resistance by
isoquinolinesulfonamide compounds in adriamycin-resistant
leukemia cells. Mol Pharmacol 1992 Jun;41(6):1034-8.
Waldman S, Savaraj N, Castello C, Lampidis T. Rapid analysis of
rhodamine analogue in multiple drug resistance mdr tumor
cell by high performance liquid chromatography (HPLC)
[abstract]. J Clin Pharmacol 1988;28(10):952.
Warren L, Jardillier JC, Malarska A, Akeli MG. Increased
accumulation of drugs in multidrug-resistant cells induced
by liposomes. Cancer Res 1992 Jun 1;52(11):3241-5.
Warren L, Jardillier JC, Ordentlich P. Secretion of lysosomal
enzymes by drug-sensitive and multiple drug-resistant cells.
Cancer Res 1991 Apr 15; 51(8):1996-2001.
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T.
Cellular pharmacology of MX2, a new morpholino
anthracycline, in human pleiotropic drug-resistant cells.
Cancer Res 1991 Jan 1;51(1): 157-61.
Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Mx-2 a
morpholinoanthracycline as a new antitumor agent against
drug-sensitive and multidrug-resistant human and murine
tumor cells. Cancer Res 1988; 48(23):6653-7.
Watanabe T, Inaba M, Sugiyama Y. Saturable process involved in
active efflux of vincristine as a mechanism of multidrug
resistance in P388 leukemia cells. Pharm Res 1989
Aug;6(8):690-6.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Weide R, Dowding C, Paulsen W, Goldman J. The role of the
MDR-1/P-170 mechanism in the development of multidrug
resistance in chronic myeloid leukemia. Leukemia 1990
Oct;4(10): 695-9.
Willman CL, Kopecky KJ, Weick J, Appelbaum F, Grever MR, Head DR,
Elias L, Balcerzak SP, Mills GM, Hynes HE. Biologic
parameters that predict treatment response in de novo acute
myeloid leukemia (AML): CD34, but not multidrug resistance
(MDR) gene expression, is associated with a decreased
complete remission (CR) rate and CD34+ patients more
frequently achieve CR with high-dose cytosine arabinoside
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1992;11:A857.
Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V,
Webster LK, Sawyer WH. Reversal of multidrug resistance by
surfactants. Br J Cancer 1992 Jul;66(1):62-8.
Wooten P, Cuddy D, Felsted P, Pan S, Ross D. Comparison of
anti-P-glycoprotein monoclonal antibodies MRK16, 265/F4 and
C219 in the detection of multidrug resistant cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A2105.
Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a
human medullary thyroid carcinoma cell line: association
with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res 1991;11(3):1065-8.
Yanovich S, Hall RE, Gewirtz DA. Characterization of a k562
multidrug-resistant cell line. Cancer Res
1989;49(16):4499-503.
Yanovich S, Hall RE, Gewirtz DA. Resistance to natural killer
(NK) cell lysis is associated with multiple drug resistance
(MDR) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1082.
Yasuo K, Shuichi H, Tatsuhiko F, Akihiko Y, Tomoyuki S, Atae U,
Kazuaki I, TAkeshi S, Kimiharu U, Masao M, Minoru I,
Terukatsu A, Shin Ichi A. Expression of P-glycoprotein in
adult T-cell leukemia cells. Blood 1990;76(10):2065-71.
Yin MB, Bankusli I, Rustum YM. Effect of verapamil, DMDP
(RO11-2933), a tiapamil analog, and dipyridamole, a
nucleoside transport inhibitor, on the extent and duration
of doxorubicin-induced DNA single strand breaks in
multidrug-resistant P-388 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2103.
Yusa K, Sato W, Yamazaki A, Tsukahara S, Tsuruo T. Cross-
resistance of human multidrug-resistant cells to mitomycin
C. Anticancer Res 1991 May-Jun; 11(3):1301-4.
Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by
verapamil: verapamil binds to P-glycoprotein on specific
sites and is transported outward across the plasma membrane
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A2058.
Zalcberg JR, Krauer K, Hur XF, McKenzie IF, Pietersz G.
Anthracycline conjugates bypass cellular mechanisms of
resistance in multidrug resistant (MDR) cells [abstract].
Paper presented at: Cancer in the 1990's: is more aggressive
treatment better? 17th Annual Scientific Meeting of the
Clinical Oncological Society of Australia Inc.; 1990
Nov 26-28; Melbourne, Australia.
Zamora JM, Pearce HL, Beck WT. Physical-chemical properties
shared by compounds that modulate multidrug resistance in
human leukemic cells. Mol Pharmacol 1988;33(4):454-62.
-Liver neoplasms
Arias IM, Gatmaitan Z, Mazzanti R, Shu H, Kumamoto Y. Structure
and function of P-glycoprotein in the normal liver and
intestine. Int Symp Princess Takamatsu Cancer Res Fund
1990;21:229-39.
Bradley G, Georges E, Ling V. Immunohistochemical localization
of P-glycoprotein isoforms [abstract]. J Chemother Infect
Dis Malig 1989;Suppl 1:A306.
Bradley G, Sharma RK, Rajalakshmi S, Ling V. Expression of P-
glycoprotein (Pgp) during hepatocarcinogenesis [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A582.
Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass
G, Tummler B. Quantitative expression patterns of
multidrug-resistance P-glycoprotein (MDR1) and
differentially spliced cystic-fibrosis transmembrane-
conductance regulator mRNA transcripts in human epithelia.
Eur J Biochem 1992 May 15;206(1):137-49.
Burk RK, Garfield S, Johnson K, Thorgiersson SS. Transformation
of rat liver epithelial cells with V-H-RAS or V-RAF causes
expression of MDR-1 glutathione-S-transferase-P and
increased resistance to cytotoxic chemicals. Carcinogenesis
1988;9(12): 2329-32.
Burt RK, Thorgeirsson SS. Coinduction of MDR-1 multidrug-
resistance and cytochrome P-450 genes in rat liver by
xenobiotics. J Natl Cancer Inst 1988; 80(17):1383-6.
Buscher HP. Defective drug uptake contributing to multidrug
resistance in hepatoma cells can be evaluated in vitro.
Klin Wochenschr 1990 May 4; 68(9):443-6.
Chapekar MS, Huggett AC, Cheng C. Dexamethasone prevents the
growth inhibitory effects of recombinant tumor necrosis
factor in a rat hepatoma cell line Reuber-RC-3: an
association with the changes in the messenger RNA levels for
multidrug resistance gene. Biochem Biophys Res Commun 1991
Dec 31;181(3):1524-31.
Chapekar MS, Huggett AC, Cheng CC, Hampton LL, Lin KH,
Thorgeirsson SS. Isolation and characterization of a rat
liver epithelial cell line resistant to the
antiproliferative effects of transforming growth factor beta
(type 1). Cancer Res 1990 Jun 15;50(12):3600-4.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure
and expression of the human mdr p-glycoprotein gene family.
Mol Cell Biol 1989; 9(9):3808-20.
Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr
RNA levels in response to cytotoxic drugs in rodent cells.
Cell Growth Differ 1990 Aug;1(8):361-5.
Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat
shock and arsenite increase expression of the multidrug
resistance (MDR1) gene in human renal carcinoma cells. J
Biol Chem 1990 Jan 5; 265(1):221-6.
Duensing TD, Slate DL. Characterization of p-glycoprotein
(p170) expression and the multidrug (MDR) phenotype in a
panel of human cell lines representing chemoresistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2801.
Ellis AL, Gewirtz DA, Munger C, Woods KE, Randolph JK, Boise L,
Yanovich S. Multifactorial drug resistance in the rat
hepatoma [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1999.
Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L,
Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol 1992 Jan 22;43(2):331-42.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Fan D, Wilmanns C, O'Brian CA, Kuo MT, Teeter LD, Bucana CD, Ward
NE, Fidler IJ. Orthotopic and ectopic modulation of P-
glycoprotein and resistance to adriamycin of human colon
carcinoma cells in nude mice [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2794.
Fardel O, Ratanasavanh D, Loyer P, Ketterer B, Guillouzo A.
Overexpression of the multidrug resistance gene product in
adult rat hepatocytes during primary culture. Eur J Biochem
1992 Apr 15;205(2):847-52.
Fine RM. Multidrug resistance. Cancer Chemother Biol Response
Modif 1988;10:73-84.
Gant TW, Silverman JA, Thorgeirsson SS. Regulation of P-
glycoprotein gene expression in hepatocyte cultures and
liver cell lines by a trans-acting transcriptional
repressor. Nucleic Acids Res 1992 Jun 11;20(11):2841-6.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular diagnostics of human cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Gruber A, Vitols S, Norgren S, Arestrom I, Bjorkholm M,
Reizenstein P, Peterson C, Luthman H. Quantitative
determination of mdr1 gene expression in leukemic cells from
patients with acute leukemia [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A1408.
Hitchins RN, Harman DH, Davey RA, Bell DR. Identification of a
multidrug resistance associated antigen P-glycoprotein in
normal human tissues. Eur J Cancer Clin Oncol
1988;24(3):449-54.
Ho AD, Thaler J, Stryckmans P, Coiffier B, Luciani M, Sonneveld
P, Lechner K, Rodenhuis S, Peetermans ME, deCataldo F, et
al. Pentostatin in refractory chronic lymphocytic
leukemia: a phase II trial of the European Organization for
Research and Treatment of Cancer. J Natl Cancer Inst 1990
Sep 5;82(17):1416-20.
Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ.
Modulation by verapamil of vincristine pharmacokinetics and
toxicity in mice bearing human tumor xenografts. Biochem
Pharmacol 1989;38(11):1727-36.
Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX, Jiang HQ, Gu JR.
Overexpression of the MDR1 gene and P-glycoprotein in human
hepatocellular carcinoma. J Natl Cancer Inst 1992 Feb
19;84(4):262-4.
Huitfeldt HS, Brandtzaeg P, Poirier MC. Relation between
proliferation, aminofluorene-DNA adduct accumulation, and
multidrug resistance gene expression in rat liver during
continuous acetylaminofluorene feeding [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A452.
Ichikawa M, Yashimura A, Furukawa T, Sumizawa T, Nakazima Y,
Akiyama SI. Glycosylation of P-glycoprotein in a
multidrug-resistant KB cell line and in the human tissues.
Biochim Biophys Acta 1991;1073(2):309-15.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S.
Modulators of the multidrug-transporter, P-glycoprotein,
exist in the human plasma. Biochem Biophys Res Commun 1990
Jan 15;166(1):74-80.
Ikeguchi M, Teeter LD, Eckersberg T, Ganapathi R, Kuo MT.
Structural and functional analyses of the promoter of the
murine multidrug resistance gene mdr3/mdr1a reveal a
negative element containing the AP-1 binding site. DNA Cell
Biol 1991 Nov; 10(9):639-49.
Ishikawa T, Mueller M, Kluenemann C, Schaub T, Keppler D. ATP-
dependent primary active transport of cysteinyl leukotrienes
across liver canalicular membrane. Role of the ATP-
dependent transport system for glutathione S-conjugates.
J Biol Chem 1990;265(31):19279-86.
Kamijo K, Taketani S, Yokota S, Osumi T, Hashimoto T. The 70-
kDa peroxisomal membrane protein is a member of the Mdr (P-
glycoprotein)-related ATP-binding protein superfamily. J
Biol Chem 1990 Mar 15;265(8):4534-40.
Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of gp170
the multidrug resistance gene product in rat liver
canalicular membrane vesicles. J Biol Chem
1989;264(20):11693-8.
Kitamura T, Jansen P, Hardenbrook C, Kamimoto Y, Gatmaitan Z,
Arias IM. Defective ATP-dependent bile canalicular
transport of organic anions in mutant (TR-) rats with
conjugated hyperbilirubinemia. Proc Natl Acad Sci U S A
1990 May;87(9):3557-61.
Larcher F, Aldaz CM, Slaga TJ, Conti CJ. Multidrug resistance
gene in mouse epidermal tumors in vivo and in vitro
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A637.
Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts
T, Smit JJ, Borst P. Multidrug resistance phenotype of
human BRO melanoma cells transfected with a wild-type human
mdr1 complementary DNA. Cancer Res 1990 Mar 15;
50(6):1779-85.
Marino PA, Gottesman MM, Pastan I. Regulation of the multidrug
resistance gene in regenerating rat liver. Cell Growth
Differ 1990 Feb;1(2):57-62.
Merriman RL, Dantzig AH, Engelhardt J, Minor PL, Poore GA,
Shackelford KA, Tanzer LR, VanPelt C, Winter MA, Beck WT, et
al. Increased toxicity of vincristine (VCR) when combined
with the multidrug-resistamce (MDR) modulator,
trimethoxybenzoylyohimbine (TMBY) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31: A2142.
Miyamoto K, Wakusawa S, Nakamura S, Tajima K, Hidaka H.
Multidrug resistance in Yoshida rat ascites hepatoma cell
lines. Anticancer Res 1992 May-Jun;12(3):649-53.
Nakatsukasa H, Evarts RP, Silverman JA, Marsden E, Thorgeirsson
SS. Expression of multidrug-resistance (MDR) and
glutathione-transferase-P (GST-P) genes in rat
hepatocarcinogenesis [abstract]. FASEB J 1991;5(5):A1247.
Noonan KE, Chin JE, Roninson IB. Analysis of multidrug
resistance gene expression by enzymatic amplification of
randomly primed cDNA [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A1982.
Park SC, Kim EG, Kwak SJ, Kim SO, Woo KM, Kim SH, Rha YH, Lee KU,
Kim ST. Induction and mechanism of drug-resistance in
experimental hepatocarcinogenesis and human hepatoma
tissues expression of mdr and cytochrome P-450. Korean J
Biochem 1989;21(1):13-20.
Pastan I, Willingham MC, Gottesman M. Molecular manipulations
of the multidrug transporter: a new role for transgenic
mice. FASEB J 1991 Aug; 5(11):2523-8.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F,
Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et
al. Immunohistochemical detection of the multidrug
transport protein P170 in human normal tissues and malignant
lymphomas. Histopathology 1991 Aug; 19(2):131-40.
Preisegger KH, Brown PC, Silverman JA, Thorgeirsson SS.
Estrahepatic induction of MDR expression in the rat by
xenobiotics [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2827.
Riou GF, Zhou D, Ahomadegbe JC, Gabillot M, Duvillard P, Lhomme
C. Expression of multidrug-resistance (MDR1) gene in
normal epithelia and in invasive carcinomas of the uterine
cervix. J Natl Cancer Inst 1990 Sep 19; 82(18):1493-6.
Published erratum appears in J Natl Cancer Inst 1990 Nov 7;
82(21):1724.
Schrenk D, Gant TW, Silverman JA, Marino PA, Thorgeirsson SS.
Induction of mdr expression by cholestasis: P-glycoprotein
functions as a biliary excretion pump [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A181.
Schuetz J, Schuetz E, Stromm S, Schroeder V. Regulation of P-
glycoprotein in human hepatocytes [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2155.
Schuetz JD, Schuetz EG, Gebhardt R, Burger HJ, Furuya K.
Extracellular matrix regulates p-glycoprotein (PGP)
expression in rat liver [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A9.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human
hepatocellular carcinoma cell lines exhibit multidrug
resistance unrelated to MRD1 gene expression. J Cell Sci
1991 Mar;98(Pt 3):317-22.
Sutter C, Volm M. Genomic organization and expression of
multidrug resistance specific sequences in S-180 mouse
tumor cell lines and normal tissues of mice [abstract]. Eur
J Cell Biol Suppl 1989;(26):86.
Suzuki H, Tomida A, Nishimura T. Cytocidal activity of a
synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-
dimethoxybenzyl)ethylenediamine, and its potentiation of
antitumor drugs against multidrug-resistant and sensitive
cells in vitro. Jpn J Cancer Res 1990 Mar;81(3):298-303.
Tatsuta T, Shimizu K, Nishimura T, Suzuki H. Enhancement of
activities of anti-tumor drugs by dipyridamole against
multidrug-resistant human hepatoma PLC/PRF/5 cells.
Anticancer Drug Des 1991 Jul;6(3):179-88.
Teeter LD, Chan JY, Kuo MT. Coordinate activation of multidrug-
resistance (P-glycoprotein) genes mdr2 and mdr3 during mouse
liver regeneration. Mol Carcinog 1991;4(5):358-61.
Teeter LD, Eckersberg T, Tsai Y, Kuo MT. Analysis of the
Chinese hamster P-glycoprotein/multidrug resistance gene
pgp1 reveals that the AP-1 site is essential for full
promoter activity. Cell Growth Differ 1991 Sep;2(9):429-37.
Teeter LD, Petersen DD, Nebert DW, Kuo MT. Murine mdr-1, mdr-2,
and mdr-3 gene expression: no coinduction with the Cyp1a-1
and Nmo-1 genes in liver by 2,3,7,8-tetrachlorodibenzo-p-
dioxin. DNA Cell Biol 1991 Jul-Aug;10(6):433-41.
Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH. An
immunohistochemical study of pi class glutathione S-
transferase expression in normal human tissue. Am J Pathol
1990 Oct;137(4): 845-53.
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I,
Willingham MC. Immunohistochemical localization in normal
tissues of different epitopes in the multidrug transport
protein p170 evidence for localization in brain capillaries
and crossreactivity of one antibody with a muscle protein.
J Histochem Cytochem 1989;37(2):159-64.
Thorgeirsson SS, Silverman JA, Gant TW, Marino PA. Multidrug
resistance gene family and chemical carcinogens. Pharmacol
Ther 1991;49(3):283-92.
Tran-Paterson R, Davin D, Krauss RD, Rado TA, Miller DM.
Expression and regulation of the cystic fibrosis gene during
rat liver regeneration. Am J Physiol 1992 Jul;263(1 Pt
1):C55-60.
Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the
promotor region of the human multidrug resistance (P-
glycoprotein) gene. J Biol Chem 1987;262(36):17432-6.
Van de Vrie W, Gheuens EE, Bijma A, De Bruijn EA, Marquet RL, Van
Oosterom AT, Eggermont AM. A syngeneic in vivo model of a
multidrug-resistant colon carcinoma, CC531 in the WAG rat
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:
A1270.
Van Der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of
mdr3 complementary DNA encoding a human p-glycoprotein.
Gene 1988; 71(2):401-12.
Wakusawa S, Nakamura S, Miyamoto KI, Koshiura R, Hidaka H.
Effect of calmodulin inhibitors on membrane transport of
vinblastine in multidrug-resistant rat ascites hepatoma
(AH66) cells [abstract]. Jpn J Pharmacol 1991;55 Suppl
1:96p.
Willingham MC. Morphologic aspects of the basic cell biology of
cancer. Acta Histochem Cytochem 1988;21(5):507-18.
Yamashita K, Adachi M, Kato S, Nakagama H, Ochiai M, Wakabayashi
K, Sato S, Nagao M, Sugimura T. DNA adducts formed by 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rat liver:
dose-response on chronic administration. Jpn J Cancer Res
1990 May;81(5):470-6.
-Lung neoplasms
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Arceci RJ, Baas F, Housman D, Croop J. Characterization of a
monoclonal antibody to an external epitope of the multidrug
resistance P-glycoprotein [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:393.
Arvelo F, Hanania N, Mangin C, Baldeyrou P, Arriagada R, Le
Chevalier T, Ruffie P, Poupon MF. Multidrug resistance and
mdr1 gene expression in a human small cell lung carcinoma
before treatment. Paper presented at: Symposium on
Mechanisms of Drug and Radiation Resistance of Tumor Cells;
1989 Jun 28-30; Villejuif, France.
Baas F, Jongsma AP, Broxterman HJ, Arceci RJ, Housman D, Scheffer
GL, Riethorst A, van Groenigen M, Nieuwint AW, Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug
resistance precedes P-glycoprotein expression during in
vitro selection for doxorubicin resistance in a human lung
cancer cell line. Cancer Res 1990 Sep 1;50(17):5392-8.
Bar-Shira-Maymon B, Michowitz M, Gibli O, Klein O, Pinchasov A,
Leibovici J. Effect of a membrane-active agent on uptake
of adriamycin in lewis lung carcinoma cells derived from
'primary' and 'metastatic' growths. Chemotherapy (Basel)
1992; 38(1):66-73.
Barrand MA, Twentyman PR. Differential recognition of mdr1a and
mdr1b gene products in multidrug resistant mouse tumour
cell lines by different monoclonal antibodies. Br J Cancer
1992 Feb; 65(2):239-45.
Biedler JL, Meyers MB, Spengler BA. Collateral sensitivity of
multidrug-resistant Chinese hamster cells to calcium channel
blockers: correlation with P-glycoprotein content
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1171.
Bousquet P, Wardwell S, Keilhauer G, Romerdahl CA. Modulation
of multidrug resistance in human xenograft models
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2886.
Boyle F, Hancox D, Harvie R, Davey R, Friedlander M, McCaughan
BC, Bell DR. Detection of P-glycoprotein in non-small cell
lung cancer and in nonmalignant lung tissue [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2175.
Bradley G, Sharma RK, Rajalakshmi S, Ling V. Expression of P-
glycoprotein (Pgp) during hepatocarcinogenesis [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A582.
Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass
G, Tummler B. Quantitative expression patterns of
multidrug-resistance P-glycoprotein (MDR1) and
differentially spliced cystic-fibrosis transmembrane-
conductance regulator mRNA transcripts in human epithelia.
Eur J Biochem 1992 May 15;206(1):137-49.
Brigham BA, Gazdar AF, Giaccone G, Oie H, Neckers LM, Tsuruo T,
Trepel JB. Doxorubicin exclusion and p170 expression
correlated in single cells by multiparameter flow cytometry
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2074.
Broxterman HJ, Pinedo HM, Kuiper CM, Van Der Hoeven JJM, De Lange
P, Quak JJ, Scheper RJ, Keizer HG, Jan Schuurhuis G,
Lankelma J. Immunohistochemical detection of p-
glycoprotein in human tumor cells with a low degree of drug
resistance. Int J Cancer 1989;43(2):340-3.
Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JP, Pinedo HM.
Towards functional screening for multidrug resistant cells
in human malignancies. Pezcoller Found Symp 1990;1:309-29.
Cantwell B, Carmichael J, Millward M, Chatterjee M, Harris AL.
Intermittent high dose tamoxifen (HDT) with oral etoposide
(EPO): phase I and II clinical studies [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1989;8:A252.
Cantwell BMJ, Bozzino JM, Corris P, Harris AL. The multidrug
resistant phenotype in clinical practice evaluation of cross
resistance to ifosfamide and mesna after VP-16-213
doxorubicin and vincristine VPAV for small cell lung cancer.
Eur J Cancer Clin Oncol 1988;24(2):123-30.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure
and expression of the human mdr p-glycoprotein gene family.
Mol Cell Biol 1989; 9(9):3808-20.
Coley HM, Twentyman PR, Workman P. 9-Alkyl, morpholinyl
anthracyclines in the circumvention of multidrug resistance.
Eur J Cancer 1990;26(6): 665-7.
Coley HM, Twentyman PR, Workman P. Improved cellular
accumulation is characteristic of anthracyclines which
retain high activity in multidrug resistant cell lines,
alone or in combination with verapamil or cyclosporin A.
Biochem Pharmacol 1989 Dec 15;38(24):4467-75.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Boccia J, Bertino JR.
Immunoanatomic and immunopathologic expression of the
multidrug resistance gene product. Cancer Cells 1989;
7:87-93.
Delaporte C, Dautry F, Jacquemin-Sablon A. MYC transfection in
9-OH-ellipticine-resistant cells induces the expression of
the pgp3 gene and reverses the MDR phenotype [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2823.
Delaporte C, Larsen AK, Dautry F, Jacquemin-Sablon A. Influence
of myc overexpression on the phenotypic properties of
Chinese hamster lung cells resistant to antitumor agents.
Exp Cell Res 1991 Dec;197(2):176-82.
Dessy E, Frau G, Mascia R, Mura G, Pusceddu G.
Immunohistochemical detection of P-glycoprotein in lung
cancer [abstract]. Am Rev Respir Dis 1991; 143(4 Pt
2):A202.
Devine SE, Hussain A, Davide JP, Melera PW. Full length and
alternatively spliced pgp1 transcripts in multidrug-
resistant Chinese hamster lung cells. J Biol Chem 1991 Mar
5;266(7):4545-55.
Devine SE, Melera PW. Acquisition of the multidrug resistance
phenotype [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2838.
Dorr RT. Mitomycin, ifosfamide, and mesna in the treatment of
lung cancer. Semin Oncol 1990 Aug;17(4 Suppl 7):2-5.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A,
Normandeau R, Jones A. Addition of verapamil and tamoxifen
to the initial chemotherapy of small cell lung cancer. A
phase I/II study. Cancer 1990 May 1;65(9):1895-902.
Fine RL, Carmichael J, Cowan KH, Chabner BA, Patel J.
Phosphoprotein and protein kinase C changes in human
multidrug-resistant cancer cells. In: Woolley PV 3d, Tew
KD, editors. Mechanisms of drug resistance in neoplastic
cells; 1986 Oct 15-16; Washington, DC. San Diego (CA):
Academic Press, Inc.; 1988. p. 87-96 (Bristol-Myers cancer
symposia; 9).
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Fine RM. Multidrug resistance. Cancer Chemother Biol Response
Modif 1988;10:73-84.
Glisson BG, Alpeter MA. Comparison of SDZ PSC 833 (PSC) with
cyclosporin A (CSA) as resistance modifiers in a multidrug-
resistant small cell lung cancer line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A2908.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Harris AL. Mechanisms of anticancer drug resistance. Dev Oncol
1990;58:107-15.
Hitselberger Kanitz MH, Mastro JM, Starling JJ. In vivo
expression of P-glycoprotein in two human colon carcinoma
xenografts is rapidly modulated following therapy with a
free or monoclonal antibody-conjugated vinca alkaloid
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2805.
Hochhauser D, Harris AL. Drug resistance. Br Med Bull 1991
Jan;47(1):178-96.
Hu XF, Nadalin G, De Luise M, Martin TJ, Wakeling A, Huggins R,
Zalcberg JR. Circumvention of doxorubicin resistance in
multi-drug resistant human leukemia and lung cancer cells
by the pure antiestrogen ICI-164384. Eur J Cancer 1991;
27(6):773-7.
Jung S, Kluge M, Keilhauer G, Traugott U. Dose dependent
circumvention of multidrug resistance MDR in-vitro and in-
vivo by R-verapamil (R-VPM) [abstract]. J Cancer Res Clin
Oncol 1990;116 Suppl Pt 1:419.
Keizer HG, Joenje H. Increased cytosolic pH in multidrug-
resistant human lung tumor cells effect of verapamil. J
Natl Cancer Inst 1989;81(8):706-9.
Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen
WGEJ, Van Rijn J, Pinedo HM, Joenje H. Correlation of
multidrug resistance with decreased drug accumulation
altered subcellular drug distribution and increased p-
glycoprotein expression in cultured sw-1573 human lung
tumor cells. Cancer Res 1989;49(11):2988-93.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Krebes KA, Pross HF, Cole SP. Cross-reactivity of a monoclonal
antibody (MAb) specific for the multidrug resistant small-
cell lung cancer (SCLC) cell line H69AR with peripheral
blood mononuclear cells (PBMCs) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2206.
Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson
BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. Mdr1 gene
expression in lung cancer. J Natl Cancer Inst
1989;81(15):1144-50.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Altered state of transformation and/or differentiation in
multidrug-resistant human neuroblastoma cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1704.
Larsen AK, Jacquemin-Sablon A. Multiple resistance mechanisms
in Chinese hamster cells resistant to 9-hydroxyellipticine.
Cancer Res 1989 Dec 15;49(24 Pt 1):7115-9.
Larsson R, Bergh J, Nygren P. Combination of cyclosporin A and
buthionine sulfoximine (BSO) as a pharmacological strategy
for circumvention of multidrug resistance in small cell lung
cancer cell lines selected for resistance to doxorubicin.
Anticancer Res 1991 Jan-Feb;11(1):455-9.
Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza M.
Mechanisms of resistance to etoposide and teniposide in
acquired resistant human colon and lung carcinoma cell
lines. Cancer Res 1991;51(19):5275-83.
Mattern J, Bak M, Volm M. Intrinsic and acquired multidrug
resistance in human lung carcinomas grown in nude mice.
Anticancer Res 1990 Jan-Feb;10(1):177-80.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Mattern J, Efferth T, Volm M. Overexpression of P-glycoprotein
in human lung carcinoma xenografts after fractionated
irradiation in vivo. Radiat Res 1991 Sep;127(3):335-8.
Meijer C, de Vries EG, Timmer-Bosscha H, Scheper RJ, de Ley L,
Berendsen HH, Mulder NH. Resistance mechanisms in three
human small cell lung cancer cell lines established from one
patient during clinical follow-up [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1221.
Meyers MB, Mendelsohn J. Dephosphorylation of P-glycoprotein in
DC-3F/AD X cells by epidermal growth factor-activated
phosphatase activity [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2188.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR, Cordon-Cardo
C, Biedler JL. The 180-kD resistance-related membrane
protein recognized by monoclonal antibodies raised against
vincristine-resistant human neuroblastoma cells is a P-
glycoprotein [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2008.
Milroy R, Plumb JA, Batstone P, Maclay A, Wishart GC, Hay FG,
Candlish W, Adamson R, Khan MZ, Banham S, et al. Lack of
expression of P-glycoprotein in 7 small cell lung cancer
cell lines established both from untreated and from treated
patients. Anticancer Res 1992 Jan-Feb;12(1): 193-200.
Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N.
Characterization of an etoposide-resistant human small-cell
lung cancer cell line. Cancer Chemother Pharmacol
1990;26(5): 313-7.
Mirski SE, Dicke FP, Cole SP. Non-P-glycoprotein-mediated
multidrug resistance in the small-cell lung cancer (SCLC)
cell line, H69AR [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2196.
Morgan SA, Watson JV, Twentyman PR, Smith PJ. Flow cytometric
analysis to Hoechst 33342 uptake as an indicator of multi-
drug resistance in human lung cancer. Br J Cancer
1989;60(3):282-7.
Mukaiyama T, Mitsui I, Shibata H, Inoue K, Ogawa M. Analysis of
multidrug-resistance gene expression in human cancers:
correlation between expression level and chemosensitivity
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:
A1218.
Muller MR, Twentyman PR, Lambert E, Cox H, Watson JV, Baglin TP
Rees JH. P-glycoprotein (PGp) expression and glutathione
(GSH) content in human leukemia cells determined by flow-
cytometry (FCM). Paper presented at: British Association
for Cancer Research/Association for Cancer
Physicians/Leukaemia Research Fund Joint Winter Meeting on
Leukaemia and Lymphomas; 1989 Dec 11-12; London, UK.
Noonan KE, Chin JE, Roninson IB. Analysis of multidrug
resistance gene expression by enzymatic amplification of
randomly primed cDNA [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A1982.
Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin
selected multidrug-resistant small cell lung cancer cell
lines characterised by elevated cytoplasmic Ca2+ and
resistance modulation by verapamil in absence of P-
glycoprotein overexpression. Br J Cancer 1991 Dec;64(6):
1011-8.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents KT6149, MX 2, SM5887, menogaril, and
liblomycin using cisplatin or adriamycin resistant human
cancer cell lines. Cancer Res 1989;49(15): 4098-102.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a
resistance modifier in vitro in drug resistant human tumour
cell lines is not stereospecific. Biochem Pharmacol 1990
Feb 15; 39(4):787-92.
Plumb JA, Milroy R, Kaye SB. Sequential induction of drug
resistance in an adherent small-cell lung cancer (SCLC) cell
line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2141.
Preisegger KH, Brown PC, Silverman JA, Thorgeirsson SS.
Estrahepatic induction of MDR expression in the rat by
xenobiotics [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2827.
Radosevich JA, Robinson PG, Rittmann-Grauer LS, Wilson B, Leung
JP, Maminta ML, Warren W, Rosen ST, Gould VE.
Immunohistochemical analysis of pulmonary and pleural tumors
with the monoclonal antibody HYB-612 directed against the
multidrug resistance (MDR-1) gene product-glycoprotein.
Tumour Biol 1989;10(5):252-7.
Ramachandran C, Wellham L, Sridhar KS, Krishan A. MDR-1 gene,
P-glycoprotein, and doxorubicin cytotoxicity in human lung
tumor cell lines [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2168.
Reeve JG, Rabbits PH, Twentyman PR. Amplification and
expression of mdr1 gene in a multidrug resistant variant of
small cell lung cancer cell line NCI-h69. Br J Cancer
1989;60(3):339-42.
Rhodes T, Twentyman PR. Effects of cyclosporin A and verapamil
on cellular pharmacokinetics and chemosensitivity in an MDR
cell line which does not express P-glycoprotein [abstract].
Br J Cancer 1991;63 Suppl 13:12.
Roninson IB, Chin JE, Choi K, Morse BS, Noonan KE, Chen CJ, Patel
MC, Coon JS, Lee I, Weinstein RS. Molecular biology of
multidrug resistance in human tumor cells. Paper presented
at: 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy;
1989 Mar 7-10; Amsterdam.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Safa AR. Photoaffinity labeling of the multidrug-resistance-
related P- glycoprotein with photoactive analogs of
verapamil. Proc Natl Acad Sci U S A 1988;85(19):7187-91.
Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of p-
glycoprotein in multidrug resistant cells with photoactive
analogs of colchicine. Biochem Biophys Res Commun
1989;162(3): 1402-8.
Saijo N, Nakagawa K, Fujiwara Y, Bungo M, Horichi N, Sasaki Y,
Yokota J, Terada M. Characteristics of clinical and
experimental resistance to cisplatin. Paper presented at:
1st International Interface of Clinical and Laboratory
Responses to Anticancer Drugs; 1989 Mar 13-15; Villejuif,
France.
Salmon SE, Grogan T, Meltzer PS, Dalton WS. Relevance of
multidrug resistance to neoadjuvant therapy of cancer.
Paper presented at: 2nd International Congress on Neo-
Adjuvant Chemotherapy; 1988 Feb 19-21; Paris.
Savaraj N, Lu K, Taso J, Feun L, Li DJ, Lampidis T, Donnelly E,
Patten J, Kuo M. MDR1 mRNA expression in small cell lung
cancer patients [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A960.
Scagliotti GV, Michelotto F, Kalikatzaros G, Leonardo E, Cappia
S, Gubetta L, Borasio P, Pozzi E. Detection of multidrug
resistance associated P-170 glycoprotein in previously
untreated non small cell lung cancer. Anticancer Res 1991
Nov-Dec;11(6): 2207-10.
Scagliotti GV, Michelotto F, Leonardo E, Borasio P, Gubetta L,
Pozzi E. Immunohistochemical detection of glycoprotein
P-170 and human epidermal growth factor receptor in resected
non-small cell lung cancer [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1991;10:A876.
Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, Van Der Schoot E,
Balm AJM , Meijer CJLM, Broxterman HJ, Kuiper CM, et al.
Monoclonal antibody JSB-1 detects a highly conserved epitope
on the P-glycoprotein associated with multi-drug-resistance.
Int J Cancer 1988;42(3):389-94.
Scotto KW, Palmer D, Li XK. Regulation of P-glycoprotein gene
expression in revertants of verapamil-sensitive MDR cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2834.
Shin HJ, Lee JS, Hong WK, Shin DM. Study of multidrug
resistance (mdr1) gene in non-small-cell lung cancer.
Anticancer Res 1992 Mar-Apr;12(2): 367-70.
Shin HJ, Shin DM, Grant G, Hong WK, Pathak S. Simultaneous
amplification of epidermal growth factor-receptor and
multidrug-resistance genes in a newly established human lung
cancer cell line. Anticancer Res 1991;11(1):241-8.
Shin HJ, Shin DM, Li D, Lee JS, Hong WK, Kuo T. Multidrug
resistance gene (mdr1) amplification and expression in newly
established human lung carcinoma cell lines and fresh human
non-small cell lung carcinomas [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A1680.
Slate DL, Bruno N, Carver LA, Rabier M. Isolation and
characterization of multiple drug resistant carcinoma cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1975.
Smith PJ, Morgan SA, Watson JV. Detection of multidrug
resistance and quantification of responses of human tumour
cells to cytotoxic agents using flow cytometric spectral
shift analysis of Hoechst 33,342-DNA fluorescence. Cancer
Chemother Pharmacol 1991;27(6):445-50.
Spengler BA, Druskin H, Safa A, Meyers MB, Biedler JL. Rapid
loss of resistance and P-glycoprotein expression in
multidrug-resistant cells treated with verapamil [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:376.
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama
S, Mori S. Tissue distribution of P-glycoprotein encoded
by a multidrug-resistant gene as revealed by a monoclonal
antibody MRK 16. Cancer Res 1988;48(7):1926-9.
Tamai I, Safa AR. Azidopine noncompetitively interacts with
vinblastine and cyclosporin A binding to P-glycoprotein in
multidrug resistant cells. J Biol Chem 1991 Sep 5;
266(25):16796-800.
Tsai CM, Lai SL, Ihde DC, Goldstein LJ, Gottesman MM, Pastan I,
Mulshine JL, Gazdar AF. Clinical response to combination
chemotherapy in lung cancer is correlated with in vitro
chemosensitivity but not with expression of the MDR1 gene
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1989;8:A965.
Tsuruo T. Proteins involved in multidrug resistance and their
implication for therapy. Pezcoller Found Symp
1990;1:131-43.
Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-
containing anthracycline me-2303 as a new antitumor agent
against murine and human tumors and their multidrug-
resistant sublines. Cancer Res 1989;49(20):5537-42.
Twentyman PR. Modification of cytotoxic drug resistance by non-
immunosuppressive cyclosporins. Br J Cancer
1988;57(3):254-8.
Twentyman PR, Wright KA, Wallace HM. Cyclosporin A and non-
immunosuppressive analogs inhibit growth of human lung
cancer cells in vitro [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1921.
Twentyman PR, Wright KA, Wallace HM. Effects of cyclosporin A
and a non-immunosuppressive analogue, O-acetyl cyclosporin
A, upon the growth of parent and multidrug resistant human
lung cancer cells in vitro. Br J Cancer 1992
Mar;65(3):335-40.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Timmer-Bosscha H, Mulder NH. Multidrug resistance (MDR)
modulation with amiodarone (AM) in human tumor cell lines
and patients [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2076.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Vellenga E, Mulder PO, Mulder NH. In vitro and in vivo
modulation of multi-drug resistance with amiodarone. Int J
Cancer 1991 Jun 19;48(4):616-22.
Versantvoort CH, Broxterman HJ, Pinedo HM, de Vries EG, Feller N,
Kuiper CM, Lankelma J. Energy-dependent processes involved
in reduced drug accumulation in multidrug-resistant human
lung cancer cell lines without P-glycoprotein expression.
Cancer Res 1992 Jan 1;52(1):17-23.
Volm M. In vivo multidrug-resistance of animal and human tumors
[abstract]. J Chemother Infect Dis Malig 1989;Suppl 1:A307.
Volm M, Bak M, Efferth T, Mattern J. Inherent and induced
multidrug-resistance in human lung carcinoma xenograft lines
[abstract]. J Chemother Infect Dis Malig 1989;Suppl 1:A473.
Volm M, Bak M Jr, Efferth T, Lathan B, Mattern J.
Immunocytochemical detection of a resistance-associated
glycoprotein in tissue culture cells ascites tumors and
human tumor xenografts by MAB-265-F4. Anticancer Res
1988;8(4):531-6.
Volm M, Efferth T. Relationship of DNA ploidy to
chemoresistance of tumors as measured by in vitro tests.
Cytometry 1990;11(3):406-10.
Volm M, Efferth T, Bak M, Ho AD, Mattern J. Detection of the
multidrug resistant phenotype in human tumours by monoclonal
antibodies and the streptavidin-biotinylated phycoerythrin
complex method. Eur J Cancer Clin Oncol 1989 Apr;25(4):
743-9.
Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein
and glutathione S-transferase-pi in resistant non-small cell
lung carcinomas of smokers. Br J Cancer 1991
Oct;64(4):700-4.
Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Mx-2 a
morpholinoanthracycline as a new antitumor agent against
drug-sensitive and multidrug-resistant human and murine
tumor cells. Cancer Res 1988; 48(23):6653-7.
Watson JV, Morgan SA, Smith PJ. Analysis of the Hoechst-33342
fluorescence emission spectrum in individual cells with
reference to multi-drug resistance. In: Poulik MD, editor.
Lipoproteins IGG and IGA subclasses cytofluorometry; 1989
Apr 3-5; London, England. Oxford (England): Pergamon Press;
1989. p. 359-72. (Protides of the biological fluids
proceedings colloquium; 36).
Wooten P, Cuddy D, Felsted P, Pan S, Ross D. Comparison of
anti-P-glycoprotein monoclonal antibodies MRK16, 265/F4 and
C219 in the detection of multidrug resistant cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A2105.
Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA,
Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.
Multidrug-resistant phenotype of disease-oriented panels of
human tumor cell lines used for anticancer drug screening.
Cancer Res 1992 Jun 1;52(11):3029-34.
-Lymphomas
Bar-Shira-Maymon B, Michowitz M, Gibli O, Klein O, Pinchasov A,
Leibovici J. Effect of a membrane-active agent on uptake
of adriamycin in Lewis lung carcinoma cells derived from
`primary' and `metastatic' growths. Chemotherapy (Basel)
1992; 38(1):66-73.
Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B,
Andreeff M. Effect of tamoxifen on cell lines displaying
the multidrug-resistant phenotype. Blood 1991 Feb 15;
77(4):818-25.
Bonadonna G, Santoro A. Current issues in the management of
advanced Hodgkin's disease. Blood Rev 1990 Mar;4(1):69-73.
Brophy NA, Marie JP, Berry JM, Ehsan MN, Smith SD, Warnke RA,
Sikic BI. Expression of the multidrug resistance gene MDR1
in leukemia and lymphoma cells [abstract]. Proc Annu Meet
Am Soc Clin Oncol 1989;8:A211.
Cairo MS, Toy C, Sender L, VandeVen C. The combination of VP-16
and verapamil to chemo-purge multidrug resistant leukemia
cells from human bone marrow: selective tumor cytotoxicity
versus marrow toxicity [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A932.
Cancer chemotherapy: concepts, clinical investigations and
therapeutic advances. Cancer Treat Res 1989;42:1-238.
Carulli G, Petrini M. Multidrug resistance: focus in
hematology. Haematologica 1990 Jul-Aug;75(4): 363-74.
Dalton WS. Approaches to clinical reversal of multidrug
resistance [abstract]. Invest New Drugs 1989;7(4):425.
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor
CW, Miller TP, Salmon SE. Drug resistance in multiple
myeloma and non- Hodgkin's lymphoma: Detection of P-
glycoprotein and potential circumvention by addition of
verapamil to chemotherapy. J Clin Oncol 1989; 7(4):415-24.
Dan S, Esumi M, Sawada U, Hayashi N, Uchida T, Yamazaki T, Ashiya
M, Satoh Y, Ohshim T, Horie T, et al. Expression of a
multidrug-resistance gene in human malignant lymphoma and
related disorders. Leuk Res 1991;15(12):1139-43.
Durivage HJ, Buzaid AC, Todd MB, Poo WJ, March JC, Davis CA, Hait
WN. A phase I-II study of pulse cyclosporin-A (CsA) plus
vinblastine (VBL) in selected refractory malignancies
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A335.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Gieseler F, Boege F, Biersack H, Spohn B, Wilms K.
Characterization of three HL-60 sublines with different
types of multidrug resistance [abstract]. Onkologie 1991;14
Suppl 2:54.
Goldstein L, Galski H, Fojo A, Willingham M, Green A, Crist W,
Gottesman M, Pastan I. Expression of a multidrug-
resistance gene in human tumors [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:A1184.
Goldstein L, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug resistance gene in human cancers. J Natl Cancer
Inst 1989;81(2):116-24.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular diagnostics of human cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Grogan TM, Dalton WS, Rybski J, Miller T, Spier C, Salmon S. P-
glycoprotein staining predicts intrinsic doxorubicin
resistance in patients with myeloma and lymphoma [abstract].
Lab Invest 1989;60(1):36A.
Hochhauser D, Harris AL. Drug resistance. Br Med Bull 1991
Jan;47(1):178-96.
Holte H. [Resistance to chemotherapeutic agents in the
treatment of cancer. Emphasizing the multiresistant
phenotype]. Tidsskr Nor Laegeforen 1991 Aug 20;
111(19):2423-7. (Nor).
Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K,
Tsuruo T, Shimoyama M. Multidrug resistance in cultured
human leukemia and lymphoma cell lines detected by a
monoclonal antibody, MRK16. Jpn J Cancer Res 1989 Oct;
80(10):1006-13.
Kaczorowski S, Porwit A, Christensson B. Expression of P-
glycoprotein in non-Hodgkin's lymphomas. Leuk Lymphoma
1991;5(5-6):379-86.
Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in
hematological malignancies. Blood Rev 1991;5(1):38-41.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE.
P-glycoprotein expression in malignant lymphoma and
reversal of clinical drug resistance with chemotherapy plus
high-dose verapamil. J Clin Oncol 1991 Jan; 9(1):17-24.
Miller TP, Grogan TM, Spier CM, Salmon SE, Dalton WS. High-dose
verapamil infusion added to chemotherapy reverses drug
resistance in lymphoma patients in relapse [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1989;8:A984.
Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K. Detection
of multidrug-resistant protein, P-glycoprotein in childhood
leukaemia and lymphoma. Eur J Pediatr 1991
Apr;150(6):416-8.
Molecular diagnostics of human cancer. Cancer Cells
1989;7:1-414.
Moran EM, Nagourney RA, Ottenheimer EJ, Mahutte KC, Weisenthal
LM. Reversal of acquired drug resistance (ADR) with
lidocaine (L) + verapamil (V): a phase I study [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A868.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC,
Grossman SA, Brem H, Colvin OM. Multidrug resistance gene
(MDR1) expression in human brain tumors. J Neurosurg 1991
Dec; 75(6):941-6.
Neyfakh AA, Serpinskaya AS, Chervonsky AV, Apasov SG, Kazarov AR.
Multidrug-resistance phenotype of a subpopulation of T-
lymphocytes without drug selection. Exp Cell Res 1989 Dec;
185(2):496-505.
Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K,
Wick MR, Tsuruo T, Bloomfield CD. Immunohistochemical
identification of P-glycoprotein in previously untreated,
diffuse large cell and immunoblastic lymphomas. Cancer Res
1992 Jul 1;52(13):3768-75.
Niehans G, Jaszcz W, Wick M, Gajl-Peczalska K, Tsuruo T,
Bloomfield C. Identification of multi-drug resistance-
associated P-glycoprotein in some diffuse large cell
lymphomas by frozen section immunohistochemistry [abstract].
Lab Invest 1990; 62(1):73a.
Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer
H, Valerio D, Hagemeijer A, Baas F. Expression of the mdr3
gene in prolymphocytic leukemia: association with
cyclosporin-A-induced increase in drug accumulation. Int J
Cancer 1990 Apr 15;45(4): 626-31.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F,
Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et
al. Immunohistochemical detection of the multidrug
transport protein P170 in human normal tissues and malignant
lymphomas. Histopathology 1991 Aug; 19(2):131-40.
Reizenstein P, Gruber A, Luthman H, Kaczorowska M, Norgren S,
Peterson C, Porvit A, Vitols S. Multiple drug resistance:
expression of the MDR1 gene in leukemic blasts in relation
to treatment and effect of verapamil isomers on cellular
vincristine accumulation [abstract]. Anticancer Res 1990;
10(5B):1400-1.
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ,
Miller TP. Multidrug-resistant myeloma: laboratory and
clinical effects of verapamil as a chemosensitizer. Blood
1991 Jul 1; 78(1):44-50.
Salmon SE, Grogan T, Meltzer PS, Dalton WS. Relevance of multidrug
resistance to neoadjuvant therapy of cancer . Paper presented at:
2nd International Congress on Neo-Adjuvant Chemotherapy;
1988 Feb 19-21; Paris.
Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS.
Prediction of doxorubicin resistance in-vitro in myeloma
lymphoma and breast cancer by p-glycoprotein staining. J
Natl Cancer Inst 1989; 81(8):696-701.
Salmon SE, Miller T, Grogan T, Dalton WS. Reversal of multidrug
resistance (MDR) with chemosensitizers: an emerging clinical
reality. Paper presented at: Drug resistance as a
biochemical target in cancer chemotherapy. 13th Bristol-
Myers Squibb Symposium on Cancer Research; 1990 May 10-11;
Tokyo, Japan.
Schlaifer D, Laurent G, Chittal S, Tsuruo T, Soues S, Muller C,
Charcosset JY, Alard C, Brousset P, Mazerrolles C, et al.
Immunohistochemical detection of multidrug resistance
associated P-glycoprotein in tumour and stromal cells of
human cancers. Br J Cancer 1990 Aug; 62(2):177-82.
Published erratum appears in Br J Cancer 1991
Jan;63(1):164-5.
Shimoyama M. Detection of multidrug resistant (MDR) cancer
cells by monoclonal antibodies. Paper presented at: Drug
resistance as a biochemical target in cancer chemotherapy.
13th Bristol-Myers Squibb Symposium on Cancer Research; 1990
May 10-11; Tokyo, Japan.
Sikic BI, Brophy NA, Berry JM, Marie JP, Ehsan MN, Tsuruo T,
Roninson IB, Smith SD. Multidrug resistance gene
expression in ovarian and breast cancers, leukemias, and
lymphomas. Paper presented at: 6th NCI-EORTC Symposium on
New Drugs in Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Su IJ, Chang IC, Cheng AL. Expression of growth related genes
and drug resistance genes in HTLV-I positive and HTLV-I
negative post thymic T-cell malignancies. Ann Oncol 1991;2
Suppl 2:151-5.
Sugawara I, Ikeuchi T, Fukuchi K, Yoshikai Y, Sugiyama H, Kodo H,
Mori S. Establishment and characterization of a non-T,
non-B cell lymphoma cell line with T cell receptor beta- and
gamma-chain gene rearrangement and possessing MRK 20
monoclonal antibody-defined 85KD protein. Hum Cell 1990
Mar;3(1):57-64.
Sugawara I, Kodo H, Ohkochi E, Hamada H, Tsuruo T, Mori S.
High-level expression of MRK 16 and MRK 20 murine monoclonal
antibody-define proteins (170,000-180,000 P-glycoprotein and
85,000 protein) in leukaemias and malignant lymphomas. Br J
Cancer 1989 Oct;60(4):538-41.
Ujhazy P, Chen Y, Fredericks W, Ehrke MJ. Collateral
sensitivity to tumor necrosis factor in an adriamycin
resistant EL4 cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1625.
Umeda Y, Tsuruo T, Mori S, Arimori S, Sugawara I. High-level
expression of P-glycoprotein and 85 kD protein as assessed
by flow cytometry and immunocytochemistry in leukemias and
malignant lymphomas. Tokai J Exp Clin Med 1990 May;
15(2-3):179-87.
Vaughan WP, Bierman PJ, Reed EC, Vose J, Kessinger A, Armitage
JO. High-dose hydroxyurea (HU) incorporation into
autologous marrow transplant (ABMT) regimes [abstract].
Proc Annu Meet Am Soc Clin Oncol 1991;10:A344.
Wilson WH, Bryant G, Bates S, Fojo T, Stevenson MA, Kohler D,
Chabner BA. Infusional etoposide (E), vincristine (O) and
adriamycin (H) with cyclophosphamide (C), prednisone (P)
(EPOCH) and R-verapamil (RV) in relapsed lymphoma
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A956.
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI. A
phase I trial of etoposide (E) with cyclosporine (CSA) as a
modulator of multidrug resistance (MDR) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A276.
Young RC. Mechanisms to improve chemotherapy effectiveness.
Cancer 1990 Feb 1;65(3 Suppl): 815-22.
-Myelomas
Alexanian R, Barlogie B. New treatment strategies for
multiple myeloma. Am J Hematol 1990 Nov;35(3): 194-8.
Ariyoshi K, Hamada H, Naito M, Heike Y, Seimiya H, Maezawa K,
Tsuruo T. Mouse-human chimeric antibody MH171 against the
multidrug transporter P-glycoprotein. Jpn J Cancer Res 1992
May; 83(5):515-21.
Bell DR, Friedlander ML, Young G, MA DD. P-glycoprotein
expression in clinically drug-resistant hematologic
malignancies [abstract]. Proc Annu Meet Am Soc Clin Oncol
1988;7:A677.
Bellamy W, Gleason M, Futscher B, Dalton W. Altered P-
glycoprotein (P-170)-mediated doxorubicin (D) resistance in
a verapamil (V)-resistant human multiple myeloma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2181.
Bellamy WT, Dalton WS, Kailey JM, Gleason MC, Mccloskey TM, Dorr
RT, Alberts DS. Verapamil reversal of doxorubicin
resistance in multidrug-resistant human myeloma cells and
association with drug accumulation and DNA damage. Cancer
Res 1988;48(22):6365-70.
Bellamy WT, Dorr RT, Dalton WS, Alberts DS. Direct relation of
DNA lesions in multidrug-resistant human myeloma cells to
intracellular doxorubicin concentration. Cancer Res 1988;
48(22):6360-4.
Carulli G, Petrini M. Multidrug resistance: focus in
hematology. Haematologica 1990 Jul-Aug;75(4): 363-74.
Cervantes A, Benet I, Ortiz De Salazar I, Solano C, Pascual A,
Marugan I, Garcia-Conde J. Immunocytochemical detection of
multidrug resistant P-glycoprotein (GP-170) in blast crisis
of chronic myeloid leukemia (BC-CML), acute leukemia (AL)
and multiple myeloma (MM) [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A1069.
Dalton WS. Approaches to clinical reversal of multidrug
resistance [abstract]. Invest New Drugs 1989;7(4):425.
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor
CW, Miller TP, Salmon SE. Drug resistance in multiple
myeloma and non- Hodgkin's lymphoma: Detection of P-
glycoprotein and potential circumvention by addition of
verapamil to chemotherapy. J Clin Oncol 1989; 7(4):415-24.
Dalton WS, Grogan TM, Miller TP. The role of P-glycoprotein in
drug-resistant hematologic malignancies. Cancer Treat Res
1991;57:187-208.
Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J,
Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical
detection and quantitation of P-glycoprotein in multiple
drug-resistant human myeloma cells: association with level
of drug resistance and drug accumulation. Blood 1989 Feb
15;73(3):747-52.
Dimopoulos MA, Alexanian R. Irreversibility of drug resistance
in VAD-refractory myeloma [letter]. Am J Hematol 1992
Jun;40(2):154-5.
Dorr RT, Alberts DS, Sami SM, Remers WA. Consistent cytotoxic
activity in multidrug resistant tumors for azonafide, a new
anthracene analog of amonafide [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:408.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Epstein J, Xiao H, Oba BK. P-glycoprotein expression in plasma
cell myeloma is associated with resistance to VAD. Blood
1989;74(3):913-7.
Futscher BW, Blake LL, Grogan TM, Dalton WS. Quantitative PCR
analysis of mdr1 mRNA in patients with multiple myeloma
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2792.
Gibson DW, Hughes K, Dalton WS. Flow cytometric analysis of
daunorubicin accumulation in multidrug resistance cell
lines [abstract]. Clin Res 1989; 37(1):142a.
Gore ME, Selby PJ, Millar B, Maitland J, McElwain TJ. The use
of verapamil to overcome drug resistance in myeloma
[abstract] . Proc Annu Meet Am Soc Clin Oncol 1988;7:A882.
Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L,
Gleason M, Pindur J, Cline A, Scheper R, et al.
Optimization of immunocytochemical P-glycoprotein assessment
in multidrug-resistant plasma cell myeloma using three
antibodies. Lab Invest 1990 Dec;63(6):815-24.
Grogan TM, Dalton WS, Rybski J, Miller T, Spier C, Salmon S. P-
glycoprotein staining predicts intrinsic doxorubicin
resistance in patients with myeloma and lymphoma [abstract].
Lab Invest 1989;60(1):36A.
Grogan TM, Weinstein RS. Reactivity of anti-P-glycoprotein
monoclonal antibodies with two proteins in myeloma plasma
cells [abstract]. Lab Invest 1991;64(1):104a.
Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama K,
Kurosawa Y, Tsuruo T. Mouse-human chimeric antibody
against the multidrug transporter P-glycoprotein. Cancer
Res 1990 Jun 1;50(11):3167-71.
Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson
B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.
Autologous bone marrow transplantation in multiple myeloma:
identification of prognostic factors. Blood 1990 Nov
1;76(9): 1860-6.
Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in
hematological malignancies. Blood Rev 1991;5(1):38-41.
Kulkarni SS, Wang ZM, Spitzer G, Taha M, Hamada H, Tsuruo T,
Dicke KA. Elimination of drug-resistant myeloma tumor cell
lines by monoclonal anti-P-glycoprotein antibody and rabbit
complement. Blood 1989 Nov 1;74(6):2244-51.
Lehnert M, Emerson S, Kunke K, Dalton WS, Salmon SE. Combined
chemosensitization for reversing MDR1: synergism of
verapamil with quinine but antagonism with quinidine
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2244.
Lehnert M, Kunke K, Dalton WS, Roe D, Dorr RT, Salmon SE. In
vivo concentration of serum proteins significantly inhibits
reversal of P-glycoprotein-mediated drug resistance by some
chemosensitizers [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1990;31:A2250.
Liddil JD, Dorr RT, Dalton WS, Salmon SE. Correlation of
multidrug resistance (MDR) to recombinant tumor necrosis
factor (RTNF) sensitivity based on lysosomal enzyme activity
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1988;7:A192.
Linsenmeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG,
Woodcock DM. Levels of expression of the mdr1 gene and
glutathione S-transferase genes 2 and 3 and response to
chemotherapy in multiple myeloma. Br J Cancer 1992
Mar;65(3): 471-5.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Moran EM, Nagourney RA, Ottenheimer EJ, Mahutte KC, Weisenthal
LM. Reversal of acquired drug resistance (ADR) with
lidocaine (L) + verapamil (V): a phase I study [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A868.
Musto P, Lombardi G, Matera R, Carotenuto M. The expression of
the multidrug transporter P-170 glycoprotein in remission
phase is associated with early and resistant relapse in
multiple myeloma. Haematologica 1991 Nov-Dec;76(6):513-6.
Natazuka T, Ogawa R, Fujii Y, Suzuki M, Matsui T, Nakao Y, Isobe
T, Fujita T. [Ectopic salivary amylase-producing IgA-
lambda-type multiple myeloma with expression of MDR-1/P-
glycoprotein]. Rinsho Ketsueki 1991 Jun;32(6): 686-9.
(Jpn).
Nooter K, Herweijer H, Sonneveld P, van Dongen J, Mulder A.
Expression of the MDR3 multidrug resistance gene in human B-
cell malignancies [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A1157.
Reizenstein P, Gruber A, Luthman H, Kaczorowska M, Norgren S,
Peterson C, Porvit A, Vitols S. Multiple drug resistance:
expression of the MDR1 gene in leukemic blasts in relation
to treatment and effect of verapamil isomers on cellular
vincristine accumulation [abstract]. Anticancer Res 1990;
10(5B):1400-1.
Riccardi A, Invernizzi R, Ucci G, Luoni R, Danova M, Giordano M,
Zambelli ML, Rastaldi MP, Ascari E. [p170 in multiple
myeloma and acute leukemia]. Haematologica 1991 Jun;76
Suppl 3:177-80. (Ita).
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ,
Miller TP. Multidrug-resistant myeloma: laboratory and
clinical effects of verapamil as a chemosensitizer. Blood
1991 Jul 1; 78(1):44-50.
Salmon SE, Grogan T, Meltzer PS, Dalton WS. Relevance of
multidrug resistance to neoadjuvant therapy of cancer .
Paper presented at: 2nd International Congress on Neo-
Adjuvant Chemotherapy; 1988 Feb 19-21; Paris.
Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS.
Prediction of doxorubicin resistance in-vitro in myeloma
lymphoma and breast cancer by p-glycoprotein staining. J
Natl Cancer Inst 1989; 81(8):696-701.
Salmon SE, Miller T, Grogan T, Dalton WS. Reversal of multidrug
resistance (MDR) with chemosensitizers: an emerging clinical
reality. Paper presented at: Drug resistance as a
biochemical target in cancer chemotherapy. 13th Bristol-
Myers Squibb Symposium on Cancer Research; 1990 May 10-11;
Tokyo, Japan.
Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects
of tumor necrosis factor on sensitive and multidrug
resistant human leukemia and myeloma cell lines. Blood
1989;74(5):1723-7.
Sehested M, Friche E, Ersboll J. Detection of multidrug
resistance (MDR) associated glycoprotein P-170 in human
hematological malignancies. Paper presented at: 6th NCI-
EORTC Symposium on New Drugs in Cancer Therapy; 1989 Mar
7-10; Amsterdam.
Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F,
Gauville C, Tsuruo T, Carli PM, Guy H. P-glycoprotein
expression and in-vitro reversion of doxorubicin resistance
by verapamil in clinical specimens from acute leukemia and
myeloma. Leukemia 1991;5(7):592-7.
Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy
H. Sufficient levels of quinine in the serum circumvent
the multidrug resistance of the human leukemic cell line
K562/ADM. Cancer 1991 Oct 15;68(8):1714-9.
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S,
Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-
resistant multiple myeloma by cyclosporin. The Leukaemia
Group of the EORTC and the HOVON. Lancet 1992 Aug 1;
340(8814):255-9.
Sonneveld P, Nooter K, Herweyer H, te Boekhorst P, van Kapel J,
Lowenberg B. Multidrug resistance (mdr1) in leukemia and
myeloma: detection, clinical relevance and circumvention
[abstract]. Haematologica 1991;76 Suppl 4:74.
Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ.
Elimination of chemoresistant multiple myeloma clonogenic
colony-forming cells by combined treatment with a plasma
cell-reactive monoclonal antibody and a p-glycoprotein-
reactive monoclonal antibody. Cancer Res 1989;49(17):
4829-34.
Trumper LH, Ho AD, Hunstein W. Addition of verapamil to
overcome drug resistance in multiple myeloma: preliminary
clinical observations in 10 patients [abstract]. J
Chemother Infect Dis Malig 1989;Suppl 1:A273.
Wooten P, Cuddy D, Felsted P, Pan S, Ross D. Comparison oa
anti-P-glycoprotein monoclonal antibodies MRK16, 265/F4 and
C219 in the detection of multidrug resistant cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A2105.
-Prostate neoplasms
Kageyama Y, Katoh M, Okada K, Yoshida K, Tsuruo T. Detection of
P-glycoprotein in human urogenital carcinomas and its
relationship to epidermal growth factor receptor expression.
Eur Urol 1991;20(1):58-61.
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman
MM, Pastan I. Measurement of multidrug-resistance
messenger RNA in urogenital cancers elevated expression in
renal cell carcinoma is associated with intrinsic drug
resistance. J Urol 1988;139(4):862-5.
Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC,
Grossman SA, Brem H, Colvin OM. Multidrug resistance gene
(MDR1) expression in human brain tumors. J Neurosurg 1991
Dec;75(6): 941-6.
Trachtenberg J, Keating A, Chronis P. Mode of resistance of
human androgen-independent prostatic cancer to ketoconazole
and VP 16 [abstract]. J Urol 1989;141(4 Pt 2):217A.
van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ,
Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ,
Pinedo HM, et al. Distribution of multi-drug resistance-
associated P-glycoprotein in normal and neoplastic human
tissues. Analysis with 3 monoclonal antibodies recognizing
different epitopes of the P-glycoprotein molecule. Ann
Oncol 1990;1(1):56-64.
-Neoplasms (other specific)
Ades EW, Bosse D, Pruckler J. Potentiation of human natural
killer cell activity by recombinant interleukin-2 towards
multidrug-resistant human epidermoid carcinoma.
Pathobiology 1990;58(2): 84-7.
Anderson L, Cummings J, Bradshaw T, Smyth JF. The role of
protein kinase C and the phosphatidylinositol cycle in
multidrug resistance in human ovarian cancer cells. Biochem
Pharmacol 1991 Sep 12;42(7):1427-32.
Axiotis C, Hijazi Y, Jefferson J, Tsokos M. Expression of P-
glycoprotein in small round cell tumors of childhood
[abstract]. Lab Invest 1991;64(1):[1p.].
Axiotis C, Merino MJ, Campo E, Laporte N, Neumann R. P-
glycoprotein is expressed in thyroid carcinomas but not in
benign conditions [abstract]. Lab Invest 1991;64(1):31A.
Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD.
Immunohistochemical detection of P-glycoprotein in
endometrial adenocarcinoma. Am J Pathol 1991
Apr;138(4):799-806.
Chan HS, Thorner PS, Haddad G, Gallie BL. Therapeutic
implications of P-glycoprotein (P170)-related multidrug
resistance (MDR) in retinoblastoma (RB) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A1101.
Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical
detection of P-glycoprotein: prognostic correlation in soft
tissue sarcoma of childhood. J Clin Oncol 1990
Apr;8(4):689-704.
Chan HS, Thorner PS, Haddad G, Ling V. Outcome of therapy in
osteosarcoma correlates with P-glycoprotein expression
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2173.
Chan HSL, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant
phenotype in retinoblastoma correlates with P- glycoprotein
expression. Ophthalmology 1991;98(9):1425-31.
Fredericks WJ, Chen YF, Baker RM. Immunoblot detection of P-
glycoprotein in human tumors and cell lines. Cancer Treat
Res 1991;57:121-49.
Hijazi Y, Tsokos M, Navarro S, Horowitz M, Axiotis C.
Immunohistochemical detection of P-glycoprotein in Ewing's
sarcoma and peripheral neuroectodermal tumors (PNET) before
and after chemotherapy [abstract]. Lab Invest 1991;64(1):
5A.
Klein EA, Chaganti RSK, Ronison I, Fair WR. Alterations in the
multidrug resistance genes in transitional cell carcinoma
[abstract]. J Urol 1988;139(4 Pt 2):238a.
Lankelma J, Muelder HS, Van Mourik F, Wong Fong Sang HW,
Kraayenhof R, Van Grondelle R. Cellular daunomycin
fluorescence in multidrug resistant 2780A-D cells and its
relation to cellular drug localization. Biochim Biophys
Acta 1991; 1093(2-3):147-52.
Loy TS, Gelven PL, Mullins D, Diaz-Arias AA. Immunostaining for
P-glycoprotein in the diagnosis of thyroid carcinomas. Mod
Pathol 1992 Mar; 5(2):200-2.
Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R. Membrane
gangliosides and immuno-mediated cytolysis in drug sensitive
and treatment-induced multidrug resistant human ovarian
cancer cells. Anticancer Res 1991 Nov-Dec;11(6):2181-5.
Nagata Y, Yamasaki H, Fukuda K, Tanaka S, Tsuruo T, Shuntoh H,
Kuno T. Expression of the multidrug-resistant gene in
human musculoskeletal tumors. J Environ Pathol Toxicol
Oncol 1992 May-Jun;11(3):131-7.
Osborne EJ, Cole SPC, Mackillop WJ. The effect of hyperthermia
on doxorubicin accumulation and cytotoxicity in a human
ovarian carcinoma cell line and its multidrug resistant
variant [abstract]. Br J Cancer 1990;61(1):170-1.
Ramael M, van den Bossche J, Buysse C, van Meerbeeck J, Segers K,
Vermeire P, van Marck E. Immunoreactivity for P-170
glycoprotein in malignant mesothelioma and in non-neoplastic
mesothelium of the pleura using the murine monoclonal
antibody JSB-1. J Pathol 1992 May; 167(1):5-8.
Robey-Cafferty S, Rutledge M, Bruner J. Multidrug resistance
gene expression in adenocarcinomas of esophagus and stomach:
a possible predictor of response to chemotherapy [abstract].
Lab Invest 1989;60(1):79A.
Robey-Cafferty SS, Bruner JM, Cafferty LL. P-glycoprotein
expression in gastroesophageal adenocarcinomas, their
metastases, and surrounding mucosa: a mapping study. Mod
Pathol 1991 Nov; 4(6):694-7.
Robey-Cafferty SS, Rutledge ML, Bruner JM. Expression of a
multidrug resistance gene in esophageal adenocarcinoma.
Correlation with response to chemotherapy and comparison
with gastric adenocarcinoma. Am J Clin Pathol 1990
Jan;93(1):1-7.Rubin SC, Finstad CL, Hoskins WJ, Saigo PE, Provencher DM,
Federici MG, Hakes TB, Markman M, Reichman BS, Lloyd KO, et
al. Expression of P-glycoprotein in epithelial ovarian
cancer: evaluation as a marker of multidrug resistance. Am
J Obstet Gynecol 1990 Jul;163(1 Pt 1):69-73.
Rutledge M, Robey-Cafferty S, Silva E, Bruner J. Monoclonal
antibody C219 detection of the multidrug resistant protein
P-glycoprotein in routinely processed tissues: a study of 36
cases of ovarian carcinoma [abstract]. Lab Invest 1989;
60(1):81A.
Schneider J, Efferth T, Mattern J, Rodriguez-Escudero FJ, Volm M.
Immunohistochemical detection of the multi-drug-resistance
marker P-glycoprotein in uterine cervical carcinomas and
normal cervical tissue. Am J Obstet Gynecol 1992
Mar;166(3): 825-9.
Schwartsmann G, Cerski CT, Sander E, Sprinz E, Kronfeld M. P-
glycoprotein expression and AIDS-related Kaposi's sarcoma
[letter]. J Natl Cancer Inst 1989 Nov 15;81(22):1755-6.
Takano H, Kohno K, Shiraishi N, Sato S, Asoh K, Yakushiniji M,
Ono M, Kuwano M. Altered expression of epidermal growth
factor receptor gene in a classical multidrug-resistant
variant of a human cancer cell line, KB. Jpn J Cancer Res
1989 Apr; 80(4):373-9.
Vollrath V, Chianale J, Duarte I, Prado S, Raddatz A, Ibanez L.
Expression of the multidrug-resistance (MDR1) gene in human
gastric adenocarcinoma [abstract]. Gastroenterology
1989;96(5 Pt 2):A532.
Volm M, Efferth T, Bak M, Mattern J. Detection of drug
resistance in human ovarian carcinoma. Arch Gynecol Obstet
1989;244(2):123-8.
Weinstein RS, Kuszak JR, Ashman JR, Coon JS. P-glycoprotein is
targeted to adhesion plaques retraction fibers and
microspikes in drug resistant KB-VI epidermoid carcinoma
cells [abstract]. J Cell Biol 1989;109(4 Pt 2):75a.
Wunder JS, Keating S, Czitrom AA, Andrulis IL. Molecular
mechanism and detection of multidrug resistance in sarcomas
[abstract]. J Cell Biochem Suppl 1990;14 Pt D:12.
-Neoplasms (general)
Athanassiadou P, Kyrkou K, Giahnaki A, Petrakakou T,
Athanassiades P. Immunocytochemical distribution of P-
glycoprotein in malignant effusions: correlation with
response to chemotherapy. Paper presented at: 19th European
Congress of Cytology; 1991 Jun 17-20; Turku, Finland.
Beck WT. Modulators of P-glycoprotein-associated multidrug
resistance. Cancer Treat Res 1991; 57:151-70.
Bellamy WT. Multidrug resistance in human tumors. Curr Opin
Oncol 1990 Dec;2(6):1126-32.
Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of
multidrug resistance. Cancer Invest 1990;8(5):547-62.
Benard J, Bourhis J, Riou G. Clinical significance of multiple
drug resistance in human cancers. Anticancer Res 1990;10(5
Pt A):1297-302.
Cordon-Cardo C, O'Brien JP. The multidrug resistance phenotype
in human cancer. Important Adv Oncol 1991:19-38.
Demant EJ, Sehested M, Jensen PB. Computer simulation of P-
glycoprotein (P-gp) transmembrane delta ph-mediated, and
exocytotic daunorubicin (DNR) transport in multidrug
resistant (MDR) tumor cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2182.
Elliott LD, Richards JM, Safa A. Immune-mediated cytolysis of
multi-drug resistant human tumor cells [abstract]. Clin Res
1989;37(4):915a.
Fojo AT. Multidrug resistance in human tumors. Cancer Treat
Res 1989;48:27-36.
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S, Gazdar A,
Pirker R, Green A, Crist W, et al. Expression of a
multidrug transporter gene in human tumors [abstract]. J
Cell Biol 1988;107(6 Pt 3):750A.
Goldstein LJ, Gottesman MM, Pastan I. Expression of the MDR1
gene in human cancers. Cancer Treat Res 1991;57:101-19.
Grzelakowska-Sztabert B. [Modulators of multidrug resistance in
neoplastic cells]. Postepy Biochem 1989;35(4):543-61.
(Pol).
Jiang XR, Macey MG, Newland AC. Multidrug resistance in
haematological malignancies. Med Lab Sci 1991;48(4):261-70.
Kane M, Laucius JF, Bellet R, Berd D, Mastrangelo M, Rose L,
Rabinowitz M. Phase I/II trial of etoposide (E) and
cefoperazone (C) in the treatment of refractory neoplasms
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A315.
Kane SE, Pastan I, Gottesman MM. Genetic basis of multidrug
resistance of tumor cells. J Bioenerg Biomembr 1990
Aug;22(4):593-618.
Kartner N, Ling V. Multidrug resistance in cancer. Sci Am 1989
Mar;260(3):44-51.
Ma DD, Bell DR. Multidrug resistance and P-glycoprotein
expression in human cancer. Aust N Z J Med 1989
Dec;19(6):736-43.
Mattern J, Volm M. Prediction of drug resistance in human tumors using
immunohist ochemical techniques. Anticancer Res 1992 Mar-Apr;
12(2):413-8.
Murren JR, Hait WN. Why haven't we cured multidrug resistant
tumors? Oncol Res 1992;4(1): 1-6.
Payne CM, Weinstein RS. Quantitative electron microscopy of
drug-sensitive and multidrug-resistant KB carcinoma cell
lines [abstract]. J Cell Biol 1991;115(3 Pt 2):262a.
Van Der Valk P, Van Kalken CK, Ketelaars H, Broxterman HJ, Kuiper
K, Lankelma J, Tsuruo T, Pinedo HM, Meijer CJLM, Scheper RJ.
Multi-drug resistance-associated P-glycoprotein expression
in normal and malignant human tissues [abstract]. Invest
New Drugs 1989;7(4):439.
By Antineoplastic / Immunosuppressive Agent Type
-Anthracyclines
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI,
Blume KG, Chao NJ. A combined approach for purging
multidrug-resistant leukemic cell lines in bone marrow using
a monoclonal antibody and chemotherapy. Blood 1991 May 1;
77(9):2079-84.
Akman S, Forrest G, Chu FF, Esworthy RS, Stetzler J, Doroshow J.
Antioxidant enzyme gene expression in multidrug-resistant
MCF-7 breast cancer cells (MCF-7/ADR) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A1973.
Alaoui Jamali MA, Yin MB, Mazzoni A, Bankusli I, Rustum YM.
Relationship between cytotoxicity, drug accumulation, DNA
damage and repair of human ovarian cancer cells treated with
doxorubicin: modulation by the tiapamil analog RO11-2933.
Cancer Chemother Pharmacol 1989;25(2):77-83.
Alderson D, Collins CM, Lai T, Symes MO. The effects of
verapamil in potentiating the action of doxorubicin on two
recently derived human pancreatic carcinoma cell lines.
Paper presented at: 3rd International Congress on the Neo-
adjuvant Chemotherapy; 1991 Feb 6-9; Paris. (Eng, Fre).
Alton PA, Fry A, Hickson ID, Harris AL. Use of the MTT assay in
acute myeloid leukemia to assess mechanisms of resistance
[abstract]. Br J Cancer 1991;63 Suppl 13:14.
Andreeff M, Hegewisch-Becker S, Haimi J, Rehermann B, Berman E,
Bertino J. Multidrug resistance, expression of P-
glycoprotein, anthracycline uptake and ARA-C resistance in
acute leukemia: assessment by flow cytometry and correlation
with response to therapy [abstract]. J Chemother Infect Dis
Malig 1989;Suppl 1:A480.
Arceci RJ, Baas F, Housman D, Croop J. Characterization of a
monoclonal antibody to an external epitope of the multidrug
resistance P-glycoprotein [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:393.
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A,
Pogliani EM, Corneo G, Parmiani G. Increased
susceptibility to lymphokine activated killer (LAK) lysis of
relapsing vs. newly diagnosed acute leukemic cells without
changes in drug resistance or in the expression of adhesion
molecules. Ann Oncol 1992;3(2):155-62.
Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S.
Multidrug resistance in a human leukemic cell line selected
for resistance to trimetrexate. Cancer Res 1989 Dec
1;49(23): 6556-61.
Arkin H, Ohnuma T, Schwartz GK, Cuttner J, Holland JF. Lack of
staurosporine (STSN) influence on multidrug resistance (MDR)
in human leukemic cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2004.
Arvelo F, Hanania N, Mangin C, Baldeyrou P, Arriagada R, Le
Chevalier T, Ruffie P, Poupon MF. Multidrug resistance and
mdr1 gene expression in a human small cell lung carcinoma
before treatment. Paper presented at: Symposium on
Mechanisms of Drug and Radiation Resistance of Tumor Cells;
1989 Jun 28-30; Villejuif, France.
Baas F, Jongsma AP, Broxterman HJ, Arceci RJ, Housman D, Scheffer
GL, Riethorst A, van Groenigen M, Nieuwint AW, Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug
resistance precedes P-glycoprotein expression during in
vitro selection for doxorubicin resistance in a human lung
cancer cell line. Cancer Res 1990 Sep 1;50(17):5392-8.
Bak M Jr, Efferth T, Mickisch G, Mattern J, Volm M. Detection
of drug resistance and P-glycoprotein in human renal cell
carcinomas. Eur Urol 1990; 17(1):72-5.
Bar-Shira-Maymon B, Michowitz M, Gibli O, Klein O, Pinchasov A,
Leibovici J. Effect of a membrane-active agent on uptake
of adriamycin in Lewis lung carcinoma cells derived from
'primary' and 'metastatic' growths. Chemotherapy (Basel)
1992;38(1):66-73.
Barrand MA, Twentyman PR. Variations in P-glycoprotein
expression in response to drug treatment in mouse tumor cell
lines [abstract]. Br J Cancer 1991;63 Suppl 13:12.
Beck WT. Strategies to circumvent multidrug resistance due to
P-glycoprotein or to altered DNA topoisomerase II. Bull
Cancer (Paris) 1990; 77(11):1131-41.
Beck WT, Qian X, Danks MK. Circumvention of multidrug
resistance due to P-glycoprotein or to altered DNA
topoisomerase II. Paper presented at: 3rd International
Congress on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9;
France. (Eng, Fre).
Beck WT, Qian XD. Photoaffinity substrates for P-glycoprotein.
Biochem Pharmacol 1992;43(1): 89-93.
Bellamy W, Gleason M, Futscher B, Dalton W. Altered P-
glycoprotein (P-170)-mediated doxorubicin (D) resistance in
a verapamil (V)-resistant human multiple myeloma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2181.
Bellamy WT, Dalton WS, Kailey JM, Gleason MC, Mccloskey TM, Dorr
RT, Alberts DS. Verapamil reversal of doxorubicin
resistance in multidrug-resistant human myeloma cells and
association with drug accumulation and DNA damage. Cancer
Res 1988;48(22):6365-70.
Bellamy WT, Dorr RT, Dalton WS, Alberts DS. Direct relation of
DNA lesions in multidrug-resistant human myeloma cells to
intracellular doxorubicin concentration. Cancer Res 1988;
48(22):6360-4.
Benard J, Bourhis J, Hartmann O, Boccon-Gibod L, Duvillard P,
Lhomme C, Michel G, Lemerle J, Goldstein L, Gottesman M, et
al. Overexpression of human MDR1 gene is related to prior
chemotherapy in ovarian carcinomas and in neuroblastomas.
Paper presented at: Symposium on Mechanisms of Drug and
Radiation Resistance of Tumor Cells; 1989 Jun 28-30;
Villejuif, France.
Benard J, Bourhis J, Riou G. Inducing chemoresistance in the N-
myc oncogene and associated genes. Prognostic value for
neuroblastoma. Bull Cancer 1991;78(1):91-7.
Benard J, Da Silva J, Teyssier JR, Riou G. Over expression of
MDR 1 gene with no DNA amplification in a multiple drug
resistant human ovarian carcinoma cell line. Int J Cancer
1989;43(3):471-7.
Benchekroun MM, Schott B, Bennis S, Montaudon D, Robert J.
Doxorubicin-induced lipid peroxidation (DILP) and
glutathione peroxidase (GPx) activity in multidrug-resistant
(MDR) cell lines [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2208.
Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B,
Andreeff M. Effect of tamoxifen on cell lines displaying
the multidrug-resistant phenotype. Blood 1991 Feb
15;77(4):818-25.
Berman E, McBride M. Comparative cellular pharmacology of
daunorubicin and idarubicin in human multidrug-resistant
leukemia cells. Blood 1992 Jun 15;79(12):3267-73.
Berry JM, Brophy NA, Smith SD, Bergstrom SK, Scudder SA, Roninson
IB, Sikic BI. Increased expression of the multidrug
resistance gene MDR1 in human cancers [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1988;7:A193.
Berry JM, Swensen RE, Brophy NA, Scudder SA, Sikic BI.
Increased expression of the multidrug resistance gene mdr1
in ovarian cancers [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A2051.
Bhushan A, Zhang XK, Chiu JF, Mossman B, Tritton TR. Oncogene
expression in multidrug resistant sarcoma 180 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1207.
Biedler JL, Chang TD, Scotto KW, Melera PW, Spengler BA.
Chromosomal organization of amplified genes in multidrug-
resistant Chinese hamster cells. Cancer Res
1988;48(11):3179-87.
Biedler JL, Meyers MB, Spengler BA. Collateral sensitivity of
multidrug-resistant Chinese hamster cells to calcium channel
blockers: correlation with P-glycoprotein content
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1171.
Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB.
Phase I and pharmacokinetic study of D-verapamil and
doxorubicin. Br J Cancer 1991 Dec;64(6):1168-71.
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger
P, Loor F. In vivo circumvention of P-glycoprotein-
mediated multidrug resistance of tumor cells with SDZ PSC
833. Cancer Res 1991 Aug 15;51(16):4226-33.
Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard
J. Expression of a human multidrug resistance gene in
ovarian carcinomas. Cancer Res 1989;49(18):5062-5.
Boven E, Venema E, Erkelens CA, Van Muijen M, Sanders KH, Pinedo
HM. Enhancement of drug efficacy by the new calcium
channel blocker B8509-035 in the BRO/MDR1.1 model
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1992;33:
A2876.
Brigham BA, Gazdar AF, Giaccone G, Oie H, Neckers LM, Tsuruo T,
Trepel JB. Doxorubicin exclusion and p170 expression
correlated in single cells by multiparameter flow cytometry
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2074.
Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsurou T, Pinedo HM,
Lankelma J. Increase of daunorubicin and vincristine
accumulation in multidrug resistant human ovarian carcinoma
cells by a monoclonal antibody reacting with P-glycoprotein.
Biochem Pharmacol 1988;37(12):2389-94.
Broxterman HJ, Pinedo HM, Kuiper CM, Van Der Hoeven JJM, De Lange
P, Quak JJ, Scheper RJ, Keizer HG, Jan Schuurhuis G,
Lankelma J. Immunohistochemical detection of p-
glycoprotein in human tumor cells with a low degree of drug
resistance. Int J Cancer 1989;43(2):340-3.
Broxterman HJ, Pinedo HM, Schuurhuis GJ, Lankelma J.
Cyclosporin A and verapamil have different effects on energy
metabolism in multidrug-resistant tumour cells. Br J Cancer
1990 Jul;62(1):85-8.
Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JP, Pinedo HM.
Towards functional screening for multidrug resistant cells
in human malignancies. Pezcoller Found Symp 1990;1:309-29.
Busche R, Tuemmler B, Cano-Gauci DF, Riordan JR. Equilibrium
kinetic and photoaffinity labeling studies of daunomycin
binding to p-glycoprotein-containing membranes of multidrug-
resistant Chinese hamster ovary cells. Eur J Biochem 1989;
183(1):189-98.
Busche R, Tuemmler B, Riordan JR, Cano-Gauci DF. Preparation
and utility of a radioiodinated analogue of daunomycin in
the study of multidrug resistance. Mol Pharmacol
1989;35(4):414-21.
Cancer chemotherapy: concepts, clinical investigations and
therapeutic advances. Cancer Treat Res 1989; 42:1-238.
Capranico G, De Isabella P, Castelli C, Supino R, Parmiani G,
Zunino F. P-glycoprotein gene amplification and expression
in multidrug-resistant murine p388 and b16 cell lines. Br
J Cancer 1989; 59(5):682-5.
Carulli G, Petrini M, Marini A, Vaglini F, Caracciolo F, Grassi
B. P-glycoprotein and drug resistance in acute leukemias
and in the blastic crisis of chronic myeloid leukemia.
Haematologica 1990 Nov-Dec; 75(6):516-21.
Casazza AM, Catino JJ. Mechanisms and strategies related to
drug resistance. Paper presented at: Strategies in Cancer
Medical Therapy: Biological Bases and Clinical Implications;
1989 Apr 12-15; Forli, Italy.
Cervantes A, Pinedo HM, Lankelma J, Schuurhuis GJ. The role of
oxygen-derived free radicals in the cytotoxicity of
doxorubicin in multidrug resistant and sensitive human
ovarian cancer cells. Cancer Lett 1988;41(2):169-78.
Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE.
Enhancement of anthracycline growth inhibition in parent and
multidrug-resistant Chinese hamster ovary cells by
cyclosporin A and its analogues. Cancer Res 1989;
49(22):6275-9.
Change BK, Fredericks W, Rustum YM, Baker MR. Levels of P-
glycoprotein in pancreatic cancer cell lines: relation to
inherent drug resistance [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1988;7:A443.
Chao NJ. Combination of monoclonal antibody and chemotherapy
for purging multidrug-resistant cells from bone marrow.
Paper presented at: 3rd International Symposium on Bone
Marrow Purging and Processing; 1991 Oct 3-5; San Diego, CA.
Coley HM, Twentyman PR, Workman P. 9-Alkyl, morpholinyl
anthracyclines in the circumvention of multidrug resistance.
Eur J Cancer 1990;26(6): 665-7.
Coley HM, Twentyman PR, Workman P. Improved cellular
accumulation is characteristic of anthracyclines which
retain high activity in multidrug resistant cell lines,
alone or in combination with verapamil or cyclosporin A.
Biochem Pharmacol 1989 Dec 15;38(24):4467-75.
Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol
HS-15 nontoxic polyoxyethylene esters of 12 hydroxystearic
acid reverses multidrug resistance. Cancer Res
1991;51(3):897-902.
Cox CI, Waring JJ, Singh J. Evidence of a role for calcium in
multidrug resistance in the murine mammary tumor cell line
EMT-6 [abstract]. J Physiol (Lond) 1991;438:194P.
Croop J, Gros P, Housman D. Mutational analysis of a site
involved in colchicine resistance in the mouse MDR1 gene
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2166.
Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA.
Increased drug accumulation ex vivo with cyclosporin in
chronic lymphatic leukemia and its relationship to epitope
masking of P-glycoprotein. Leukemia 1991 Dec;5(12):1050-3.
Cuvier C, Roblot-Treupel L, Millot JM, Couvreur P, Manfait M,
Poupon MF. Doxorubicin, loaded on nanospheres, bypasses
multidrug resistance and is detectable as bound to nuclear
DNA by microspectrofluorometry. Paper presented at:
Symposium on Mechanisms of Drug and Radiation Resistance of
Tumor Cells; 1989 Jun 28-30; Villejuif, France.
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor
CW, Miller TP, Salmon SE. Drug resistance in multiple
myeloma and non Hodgkin's lymphoma: Detection of P
glycoprotein and potential circumvention by addition of
verapamil to chemotherapy. J Clin Oncol 1989; 7(4):415-24.
Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J,
Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical
detection and quantitation of P-glycoprotein in multiple
drug-resistant human myeloma cells: association with level
of drug resistance and drug accumulation. Blood 1989 Feb
15;73(3):747-52.
Danks MK, Funabiki T, Beck WT. Functional assay for multiple
drug resistance (MDR) distinguishes MDR associated with P-
glycoprotein (PGP-MDR) from MDR associated with altered
topoisomerase II (topo II; at-MDR) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2102.
Davis J, Bines S, Economou S, Roninson I, Chaudhary P, Coon J.
Solutol HS 15 reverses multiple drug resistance in a human
MDR-1-mouse melanoma system [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1991;10:A200.
de Vries EG, Zijlstra JG, Mulder NH. Morpholinyl
anthracyclines: option for reversal of anthracycline
resistance. Paper presented at: 3rd International Congress
on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9; Paris.
(Eng, Fre).
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC,
Henner WD, Goldenberg GJ. Multifactorial resistance to
adriamycin relationship of DNA repair glutathione
transferase activity drug efflux and P-glycoprotein in
cloned cell lines of adriamycin-sensitive and adriamycin-
resistant P388 leukemia. Cancer Res 1988;48(13):3595-602.
Degregorio MW, Ford JM, Benz CC, Wiebe VJ. Toremifene
pharmacologic and pharmacokinetic basis of reversing
multidrug resistance. J Clin Oncol 1989;7(9):1359-64.
Demant EJ, Sehested M, Jensen PB. A model for computer
simulation of P-glycoprotein and transmembrane delta pH-
mediated anthracycline transport in multidrug-resistant
tumor cells. Biochim Biophys Acta 1990 Nov 12;1055(2):
117-25.
Demant EJ, Sehested M, Jensen PB. Computer simulation of P-
glycoprotein (P-gp) transmembrane delta ph-mediated, and
exocytotic daunorubicin (DNR) transport in multidrug
resistant (MDR) tumor cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2182.
Demidova NS, Chernova OB, Siyanova EY, Goncharova AS, Kopnin BP.
Newly formed chromosome-like structures in independent mouse
P388 sublines with developed in vivo mdr1 gene
amplification. Somat Cell Mol Genet 1991 Nov; 17(6):581-90.
Devine SE, Ling V, Melera PW. Amino acid substitutions in P-
glycoprotein alter multidrug resistance [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2837.
Devine SE, Ling V, Melera PW. Point mutations in the pgp1 (p-
glycoprotein) gene [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2156.
DiCicco L, Gordon K, Wellham L, Thornburgh T, Krishan A.
Cellular differentiation and daunorubicin retention
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2085.
Dimeric vinca alkaloids that reverse MDR. Curr Opin Ther Pat
1992;2(1):3-4.
Dorr RT. Mitomycin, ifosfamide, and mesna in the treatment of
lung cancer. Semin Oncol 1990 Aug;17(4 Suppl 7):2-5.
Dorr RT, Liddil JD. Modulation of mitomycin C-induced multidrug
resistance in-vitro. Cancer Chemother Pharmacol
1991;27(4):290-4.
Duran GE, Lewis AD, Saad A, Hahn G, Sikic BI. Measurement of
voltage-dependent K+ channels in multidrug resistant and
wild-type human cell lines: effect of triethylammonium on
doxorubicin resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2824.
Durand RE. Slow penetration of anthracyclines into spheroids
and tumors: a therapeutic advantage? Cancer Chemother
Pharmacol 1990;26(3):198-204.
Durand RE, LePard NE. Doxorubicin uptake and efflux in
spheroids of human WiDR versus hamster V79 cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2172.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stohr M,
Volm M. Reversing multidrug resistance in L1210 tumor
cells by hycanthone or chlorophenoxamine in vitro and in
vivo. Anticancer Res 1991 May-Jun;11(3):1275-9.
Efferth T, Lohrke H, Volm M. Correlations between natural
resistance to doxorubicin, proliferative activity, and
expression of P-glycoprotein 170 in human kidney tumor cell
lines. Urol Res 1990; 18(5):309-12.
Ellis AL, Gewirtz DA, Munger C, Woods KE, Randolph JK, Boise L,
Yanovich S. Multifactorial drug resistance in the rat
hepatoma [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1999.
Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L,
Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol 1992 Jan 22;43(2):331-42.
Epstein J, Xiao H, Oba BK. P-glycoprotein expression in plasma
cell myeloma is associated with resistance to VAD. Blood
1989;74(3):913-7.
Fairchild CR, Cowan KH. Keynote address: Multidrug resistance:
a pleiotropic response to cytotoxic drugs. Int J Radiat
Oncol Biol Phys 1991 Feb;20(2):361-7.
Fairchild CR, Ivy SP, Kao Shan CS, Whang Peng J, Rosen N, Israel
MA, Melera PW, Cowan KH, Goldsmith ME. Isolation of
amplified and overexpressed DNA sequences from Adriamycin
resistant human breast cancer cells. Cancer Res
1987;47(19):5141-8.
Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. Multidrug
resistance in cells transfected with human genes encoding a
variant P-glycoprotein and glutathione S-transferase-pi.
Mol Pharmacol 1990 Jun;37(6):801-9.
Fardel O, Ratanasavanh D, Loyer P, Ketterer B, Guillouzo A.
Overexpression of the multidrug resistance gene product in
adult rat hepatocytes during primary culture. Eur J Biochem
1992 Apr 15;205(2):847-52.
Ferguson PJ, Cheng YC. Phenotypic instability of drug
sensitivity in a human colon carcinoma cell line. Cancer
Res 1989;49(5):1148-53.
Ferrandis E, Da Silva J, Renaud L, Riou G, Benard J. Expression
of MDR1 and c-myc genes during the acquisition of a typical
MDR phenotype in human doxorubicin-resistant ovarian cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2158.
Fine RL, Monks A, Patel J, Jett M, Ahn C, Anderson W, Shoemaker
R, Chabner BA. Staurosporine a potent inhibitor of protein
kinase C is equally toxic to sensitive and multidrug-
resistant mdr human cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1988;29:301.
Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug
resistance in human breast cancer cells. Proc Natl Acad Sci
U S A 1988;85(2):582-6.
Fine RM. Multidrug resistance. Cancer Chemother Biol Response
Modif 1988;10:73-84.
Finlay GJ, Baguley BC, Snow K, Judd W. Multiple patterns of
resistance of human leukemia cell sublines to amsacrine
analogues. J Natl Cancer Inst 1990 Apr 18;82(8):662-7.
Fojo T, McAtee N, Allegra C, Bates S, Mickley L, Keiser H,
Linehan M, Steinberg S, Tucker E, Goldstein L, et al. Use
of quinidine and amiodarone to modulate multidrug resistance
mediated by the mdr1 gene [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1989;8:A262.
Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN.
Cellular and biochemical characterization of thioxanthenes
for reversal of multidrug resistance in human and murine
cell lines. Cancer Res 1990 Mar 15;50(6):1748-56.
Ford JM, Hait WN. Further characterization of the thioxanthene
class of multidrug resistance antagonists [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:570.
Ford JM, Prozialeck WC, Hait WN. Identification of active
pharmaceuticals against multi-drug resistance through
structure activity relationships of calmodulin antagonists
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:313.
Ford JM, Prozialeck WC, Hait WN. Structural features
determining activity of phenothiazines and related drugs
for inhibition of cell growth and reversal of multidrug
resistance. Mol Pharmacol 1989;35(1):105-15.
Ford JM, Yang JM, Hait WN. Effect of buthionine sulfoximine on
toxicity of verapamil and doxorubicin to multidrug
resistant cells and to mice. Cancer Res 1991;51(1):67-72.
Frezard F, Garnier-Suillerot A. Comparison of the membrane
transport of anthracycline derivatives in drug-resistant and
drug-sensitive K562 cells. Eur J Biochem 1991 Mar
14;196(2):483-91.
Friche E, Jensen PB, Nissen NI. Comparison of cyclosporin A and
SDZ PSC833 as multidrug-resistance modulators in a
daunorubicin-resistant Ehrlich ascites tumor. Cancer
Chemother Pharmacol 1992;30(3):235-7.
Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN. The
solvents cremophor EL and Tween 80 modulate daunorubicin
resistance in the multidrug resistant Ehrlich ascites tumor.
Cancer Commun 1990;2(9):297-303.
Friche E, Skovsgaard T, Nissen NI. Anthracycline resistance.
Acta Oncol 1989;28(6):877-81.
Fry DW, Besserer JA. Characterization of trimetrexate transport
in human lymphoblastoid cells and development of impaired
influx as a mechanism of resistance to lipophilic
antifolates. Cancer Res 1988;48(24 Pt 1):6986-91.
Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
Progressive resistance to doxorubicin in mouse leukemia
L1210 cells with multidrug resistance phenotype: reductions
in drug-induced topoisomerase II-mediated DNA cleavage.
Cancer Commun 1989;1(4):217-24.
Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship
between expression of P-glycoprotein and efficacy of
trifluoperazine in multidrug-resistant cells. Mol Pharmacol
1991 Jan;39(1):1-8.
Garozzo A, Allegra E. P-glycoprotein expression in relation to
natural resistance in untreated head and neck solid tumours
[abstract]. Eur J Cancer 1991;27 Suppl 3:S42.
Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp
O, Petit JM, Martin F, Chauffert B. Cinchonine, a potent
efflux inhibitor to circumvent anthracycline resistance in
vivo. Cancer Res 1992 May 15;52(10):2797-801.
Geromin A, Signor M, Vigevani E, Michieli M, Michelutti A,
Damiani D, Fasola G, Baccarani M. A prospective evaluation
of P170 glycoprotein in normal blood mononuclear cells
during chemotherapy [abstract]. Haematologica 1991;76 Suppl
4:75.
Gervasoni JE Jr, Fields SZ, Krishna S, Baker MA, Rosado M,
Thuraisamy K, Hindenburg AA, Taub RN. Subcellular
distribution of daunorubicin in P-glycoprotein-positive
and -negative drug-resistant cell lines using laser-assisted
confocal microscopy. Cancer Res 1991 Sep 15;51(18):4955-63.
Gessner T, Arredondo M, Vaughan LA, Welch JJ, Rustum YM.
Effects of model conjugates on accumulation of adriamycin
(ADR) in multidrug-resistant (MDR) cells [abstract]. FASEB
J 1991; 5(6):A1564.
Gheuens EE, van Bockstaele DR, van der Keur M, Tanke HJ, van
Oosterom AT, De Bruijn EA. Flow cytometric double labeling technique
for screening of multidrug resistance. Cytome 1991; 12(7):636-44.
Goldstein LJ, Fojo A, Ueda K, Crist W, Green A, Brodeur G, Pastan
I, Gottesman MM. Expression of a human multidrug
resistance gene in neuroblastomas [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2038.
Goldstein LJ, Fojo AT, Ueda K, Crist W, Green A, Brodeur G,
Pastan I, Gottesman MM. Expression of the multidrug
resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990
Jan;8(1): 128-36.
Gollapudi S, McDonald T, Gardner P, Kang N, Gupta S. Role of
chloride channels in multidrug resistance [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2192.
Gollapudi S, Patel K, Jain V, Gupta S. Protein kinase C
isoforms in multidrug resistant P388/ADR cells: a possible
role in daunorubicin transport. Cancer Lett 1992 Feb
14;62(1):69-75.
Gollapudi S, Patel K, Nguyen E, Gupta S. Effect of calphostin,
a specific inhibitor of protein kinase C (PKC), on
daunorubicin transport and cytotoxicity in multidrug-
resistant (MDR) P388/ADR and HL60/AR cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2734.
Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of
resistance to etoposide, doxorubicin, and vinblastine in
multidrug resistant human sarcoma cells. Cancer Res 1989
Dec 15; 49(24 Pt 1):6901-5.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular diagnostics of human cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. Mechanism and function of the multidrug
transporter [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:517-8.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Grandi M, Capolongo L, Ballinari D, Giuliani FC, Mongelli N.
Cytotoxicity and intracellular levels of distamycin A in
sensitive and DX-resistant cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2015.
Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Domain
mapping of the photoaffinity drug-binding sites in P-
glycoprotein encoded by mouse mdr1b. J Biol Chem 1991 Nov
5;266(31):20744-51.
Greenberger LM, Lothstein L, Hsu SI, Depinho SG, Horwitz SB.
The p-glycoprotein gene family regulated gene switching
correlates with altered phenotype [abstract]. J Cell Biol
1988;107(6 Pt 3): 366A.
Greenberger LM, Yang CP, Gindin E, Horwitz SB. Photoaffinity
probes for the alpha 1-adrenergic receptor and the calcium
channel bind to a common domain in P-glycoprotein. J Biol
Chem 1990 Mar 15;265(8):4394-401.
Grinchuk TM, Ignatova TI, Sorokina EA, Pan'Shina AT, Artsybasheva
IV. [Amplification and structural changes in the
chromosomes of the Chinese hamster V-79 RJK with multiple
drug resistance selected in the presence of adriamycin and
ethidium bromide (abstract)]. Tsitologiya 1988;30(9):1127.
(Rus).
Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L,
Gleason M, Pindur J, Cline A, Scheper R, et al.
Optimization of immunocytochemical P-glycoprotein assessment
in multidrug-resistant plasma cell myeloma using three
antibodies. Lab Invest 1990 Dec;63(6):815-24.
Grogan TM, Dalton WS, Rybski J, Miller T, Spier C, Salmon S. P-
glycoprotein staining predicts intrinsic doxorubicin
resistance in patients with myeloma and lymphoma [abstract].
Lab Invest 1989;60(1):36A.
Gros P, Talbot F, Tang-Wai D, Bibi E, Kaback HR. Lipophilic
cations: a group of model substrates for the multidrug-
resistance transporter. Biochemistry 1992 Feb
25;31(7):1992-8.
Guild BC, Mulligan RC, Gros P, Housman DE. Retroviral transfer
of a murine complementary DNA for multidrug resistance
confers pleiotropic drug resistance to cells without prior
drug selection. Proc Natl Acad Sci U S A 1988;85(5):1595-9.
Guilfoile PG, Hutchinson CR. A bacterial analog of the mdr gene
of mammalian tumor cells is present in Streptomyces
peucetius, the producer of daunorubicin and doxorubicin.
Proc Natl Acad Sci U S A 1991 Oct 1;88(19):8553-7.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Gupta S, Kim J, Gollapudi S. Reversal of daunorubicin
resistance in P388/ADR cells by itraconazole. J Clin Invest
1991 Apr;87(4):1467-9.
Haas C, Born J, Noland B, Wink B, Mann P, Gasparovic C, Matwiyoff
N. Increased killing of multidrug-resistant KBV-1 cells by
a trifluoromethyl acridine analog of quinacrine [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A3136.
Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW.
Resistance to drugs associated with the multidrug resistance
phenotype following selection with high-concentration
methotrexate. J Natl Cancer Inst 1989;81(16):1250-54.
Hait WN, Aftab DT. Rational design and pre-clinical
pharmacology of drugs for reversing multidrug resistance.
Biochem Pharmacol 1992;43(1):103-7.
Hait WN, Choudhury S, Srimatkandada V. Characterization of a
human chronic myelogenous leukemia cell line expressing the
multidrug resistance gene [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2186.
Hait WN, Gesmonde JF, Murren JR, Ahmad H, Reiss M, Yang JM.
Terfenadine (seldane): a potent sensitizer of multidrug-
resistant cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1992;33: A2863.
Hait WN, Stein JM, Koletsky AJ, Harding MW, Handschumacher RE.
Activity of cyclosporin A and a non-immunosuppressive
cyclosporin against multidrug resistant leukemic cell lines.
Cancer Commun 1989;1(1):35-43.
Handler JS, Horio M, Willingham M, Pastan I, Gottesman MM.
Polar localization of the multidrug resistance transporter
in epithelia results in transepithelial transport of
substrates. In: Berliner RW, Honda N, Ullrich KJ, editors.
The frontiers of nephrology. International Forum; 1989 Aug
24-25; Tokyo, Japan. Amsterdam (Netherlands): Elsevier
Science Publishers; 1990. p. 129-38. (International
congress series; 877).
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE. Human
tumor cell line resistance to chemotherapeutic agents does
not predict resistance to natural killer or lymphokine-
activated killer cell-mediated cytolysis. Cancer Res 1990
Sep 15;50(18):5931-6.
Harris AL. Mechanisms of cytotoxic drug resistance in breast
cancer. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992; 31(2):205-13.
Harris JE, Coon JS, Anderson KM. Selective reversal of
multidrug resistance by 5,8,11,14-Eicosatetraynoic acid
(ETYA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2907.
Hasmann M, Valet GK, Tapiero H, Trevorrow K, Lampidis T.
Membrane potential differences between adriamycin-sensitive
and resistant cells as measured by flow cytometry. Biochem
Pharmacol 1989;38(2):305-12.
Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M.
Effects of verapamil enantiomers and major metabolites on
the cytotoxicity of vincristine and daunomycin in human
lymphoma cell lines. Eur J Clin Pharmacol 1991;40(1):53-9.
Hayakawa Y, Ha SC, Kim YJ, Furihata K, Seto H. Studies on the
isotetracenone antibiotics. IV. Hatomarubigins A, B, C and
D, new isotetracenone antibiotics effective against
multidrug-resistant tumor cells. J Antibiot (Tokyo) 1991
Nov;44(11): 1179-86.
Hegewisch-Becker S, Fliegner M, Hossfeld D, Zander A. Clinical
relevance of P-glycoprotein expression and drug uptake
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2584.
Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hendrickson N,
Ullman B. Multidrug resistance in Leishmania donovani is
conferred by amplification of a gene homologous to the
mammalian mdr1 gene. Mol Cell Biol 1992 Jun;12(6):2855-65.
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH.
Effect of P-glycoprotein expression on the accumulation and
cytotoxicity of topotecan (SK&F 104864), a new camptothecin
analogue. Cancer Res 1992 Apr 15; 52(8):2268-78.
Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1
and mdr3 multidrug-resistance genes in human acute and
chronic leukemias and association with stimulation of drug
accumulation by cyclosporine. J Natl Cancer Inst 1990 Jul
4; 82(13):1133-40.
Herweijer H, Van Den Engh G, Nooter K. A rapid and sensitive
flow cytometric method for the detection of multidrug-
resistant cells. Cytometry 1989;10(4):463-8.
Hill B, Deuchars K, Ling V, Hosking L, Whelan RD. Significant
overexpression of P-glycoprotein by mammalian tumor cells
following in vitro exposure to fractionated x-irradiation
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2067.
Hoffmann D, Gerken M, Hermentin P, Sedlacek HH. B 880308 -- a
new anthracycline derivative demonstrating maintained
activity against multidrug resistant cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2410.
Hofmann J, Ueberall F, Egle A, Grunicke H. B-859-35, a new drug
with anti-tumor activity reverses multi-drug resistance.
Int J Cancer 1991;47(6):870-4.
Hofsli E. Multimedikamentresistens - teoretiske og kliniske
aspekter [Multidrug resistance - theoretical and clinical
aspects]. Tidsskr Nor Laegeforen 1992;112(4):472-4. (Nor).
Hofsli E, Nissen-Meyer J. Effect of erythromycin and tumor
necrosis factor on the drug resistance of multidrug-
resistant cells reversal of drug resistance by erythromycin.
Int J Cancer 1989;43(3):520-5.
Hofsli E, Nissen-Meyer J. Reversal of drug resistance by
erythromycin. Erythromycin increases the accumulation of
actinomycin D and doxorubicin in multidrug-resistant cells.
Int J Cancer 1989; 44(1):149-54.
Hofsli E, Nissen-Meyer J. Reversal of multidrug resistance by
lipophilic drugs. Cancer Res 1990 Jul 1;50(13):3997-4002.
Horio M, Gottesman MM, Pastan I. ATP dependent transport of
vinblastine in vesicles from human multidrug resistant
cells. Proc Natl Acad Sci U S A 1988;85(10):3580-4.
Howell SB, Vick JS, Sanga R. Synergistic potentiation of
etoposide, doxorubicin, and vinblastine activity by
dipyridamole [abstract]. Proc Annu Meet Am Soc Clin Oncol
1988;7:A213.
Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the
multidrug-resistance gene product, in the brush border of
rat intestinal mucosa. Gastroenterology 1992
Mar;102(3):879-85.
Hu XF, Nadalin G, De Luise M, Martin TJ, Wakeling A, Huggins R,
Zalcberg JR. Circumvention of doxorubicin resistance in
multi-drug resistant human leukemia and lung cancer cells
by the pure antiestrogen ICI-164384. Eur J Cancer
1991;27(6): 773-7.
Huet S, Schott B, Robert J. P-glycoprotein overexpression
cannot explain the complete doxorubicin-resistance phenotype
in rat glioblastoma cell lines. Br J Cancer 1992
Apr;65(4):538-44.
Husain SR, Sela S, Rafaeloff R, Potkul RK, Rahman A. Combination
of verapamil and liposomal encapsulated doxorubicin (LED)
potentiates cytotoxicity in MCF-7/ADR cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2882.
Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K,
Tsuruo T, Shimoyama M. Multidrug resistance in cultured
human leukemia and lymphoma cell lines detected by a
monoclonal antibody, MRK16. Jpn J Cancer Res 1989 Oct;
80(10):1006-13.
Ishii S, Nagasawa M, Kariya Y, Yamamoto H, Inouye S, Kondo S.
Antitumor activity of pyrindamycins A and B. J Antibiot
(Tokyo) 1989 Nov;42(11): 1713-7.
Ishikawa T, Mueller M, Kluenemann C, Schaub T, Keppler D. ATP-
dependent primary active transport of cysteinyl leukotrienes
across liver canalicular membrane. Role of the ATP-
dependent transport system for glutathione S-conjugates.
J Biol Chem 1990;265(31):19279-86.
Jackson RC, Leopold WR, Sebolt JS. Biochemical and experimental
chemotherapy studies of the pyrazoloacridines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:536-8.
Jaffrezou JP, Herbert JM, Levade T, Chatelain P, Laurent G.
Reversal of multidrug resistance by novel indolizine calcium
channel blockers: relationship with sphingosine content and
modulation of protein kinase C activity [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32: A2222.
Jaffrezou JP, Herbert JM, Levade T, Gau MN, Chatelain P, Laurent
G. Reversal of multidrug resistance by calcium channel
blocker SR33557 without photoaffinity labeling of P-
glycoprotein. J Biol Chem 1991 Oct 15;266(29):19858-64.
Jamali MAA, Yin MB, Mazzoni A, Bankusli I, Rustum YM.
Relationship between cytotoxicity drug accumulation DNA
damage and repair of human ovarian cancer cells treated with
doxorubicin modulation by the tiapamil analog RO-11-2933.
Cancer Chemother Pharmacol 1989;25(2):77-83.
Jolicoeur-Paquet L, Naismith AL, Costello PC, Riordan JR. P-
glycoprotein is expressed in the brain and recognizes some
analgesic drugs [abstract]. FASEB J 1989;3(3):A424.
Kaida S. [Study about the mechanism of drug resistance in
hematopoietic tumor cells the expression of multidrug-
resistance gene 1 and proto-oncogene c-myc]. Tokyo Jikeikai
Med J 1989; 104(5):843-52. (Jpn).
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman
MM, Pastan I. Measurement of multidrug-resistance
messenger RNA in urogenital cancers elevated expression in
renal cell carcinoma is associated with intrinsic drug
resistance. J Urol 1988;139(4):862-5.
Kamath N, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun 1991
Feb;3(2):37-44.
Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman
MM. Mdr1 RNA levels in human renal cell carcinomas
correlation with grade and prediction of reversal of
doxorubicin resistance by quinidine in tumor explants. J
Natl Cancer Inst 1989;81(11):844-9.
Kane SE, Gottesman MM. Multidrug resistance in the laboratory
and clinic. Cancer Cells Mon Rev 1989;1(1):33-6.
Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in
hematological malignancies. Blood Rev 1991;5(1):38-41.
Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-pi in
human breast tumours: comparison to in vitro
chemosensitivity. Br J Cancer 1990 May; 61(5):712-6.
Keizer HG, Joenje H. Increased cytosolic pH in multidrug-
resistant human lung tumor cells effect of verapamil. J
Natl Cancer Inst 1989;81(8):706-9.
Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen
WGEJ, Van Rijn J, Pinedo HM, Joenje H. Correlation of
multidrug resistance with decreased drug accumulation
altered subcellular drug distribution and increased p-
glycoprotein expression in cultured sw-1573 human lung
tumor cells. Cancer Res 1989;49(11):2988-93.
Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA,
Bollinger P, Hiestand PC. SDZ PSC-833, a non-
immunosuppressive cyclosporine: its potency in overcoming P-
glycoprotein-mediated multidrug resistance of murine
leukemia. Int J Cancer 1992 Feb 20;50(4):593-7.
Kessel D. Effects of phorbol esters on doxorubicin transport
systems. Biochem Pharmacol 1988; 37(11):2297-3000.
Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of
multidrug resistance by fluorescent dyes. Cancer Res 1991
Sep 1;51(17): 4665-70.
Kessel D, Erickson C. Porphyrin photosensitization of multi-
drug resistant cell types. Photochem Photobiol 1992
Mar;55(3):397-9.
Kim R, Hirabayashi N, Nishiyama M, Aogi K, Toge T. Clinical
significance of P-glycoprotein expression analyzed by
immunohistochemical staining in cancer tissues. Jpn J Surg
1991;21(5):590-3.
Kim R, Saeki T, Takagami S, Kirihara Y, Jinushi K, Nishiyama M,
Niimoto M, Hattori T, Okada K. Prediction of the
resistance of human tumors to adriamycin by chemosensitivity
tests and DNA analysis of the multidrug resistance gene.
Jpn J Surg 1990 Mar;20(2):192-6.
Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J,
Tsuruo T. Establishment and characterization of
doxorubicin-resistant human bladder cancer cell liKK47/ADM.
J Urol 1992 Aug;148(2 Pt 1):441-5.
Klohs WD, Steinkampf RW. The effect of lysosomotropic agents
and secretory inhibitors on anthracycline retention and
activity in multiple drug-resistant cells. Mol Pharmacol
1988;34(2): 180-5.
Klugmann FB, Decorti G, Crivellato E, Candussio L, Mallardi F,
Baldini L. Effect of lysosomotropic and membrane active
substances on adriamycin uptake and histamine release.
Anticancer Res 1990 Nov-Dec;10(6):1571-7.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Knight C, Slade DL, Harker WG. Multidrug resistance in
mitoxantrone-selected CEM leukemia cells appears to be
unrelated to P-glycoprotein expression [abstract]. Clin Res
1991;39(1):68A.
Krapcho AP, Getahun Z, Avery KL Jr, Vargas KJ, Hacker MP,
Spinelli S, Pezzoni G, Manzotti C. Synthesis and antitumor
evaluations of symmetrically and unsymmetrically substituted
1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-
bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
J Med Chem 1991 Aug;34(8):2373-80.
Kulkarni SS, Wang ZM, Spitzer G, Taha M, Hamada H, Tsuruo T,
Dicke KA. Elimination of drug-resistant myeloma tumor cell
lines by monoclonal anti-P-glycoprotein antibody and rabbit
complement. Blood 1989 Nov 1;74(6):2244-51.
Lahmy S, Salmon JM, Vigo J, Viallet P. Identification of multi-
drug resistant cells in sensitive Friend leukemia cells by
quantitative videomicrofluorimetry. Cell Biochem Funct 1992
Mar;10(1):9-17.
Lampidis TJ, Fourcade A, Tapiero H. Relationship of membrane
potential to acquired and intrinsic multiple drug
resistance. In: Jacquillat C, Weil M, Khayat D, editors.
Chimiotherapie neo-adjuvante [Neo-adjuvant chemotherapy].
2nd International Congress; 1988 Feb 19-21; Paris. Paris:
Les Editions Inserm; 1988. p. 655-60. (Colloque INSERM;
169).
Lampidis TJ, Kolonias D, Tapiero H, Savaraj N, Cahn J. In-vitro
cardiac potencies of multi-drug resistance modulators
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1990;31:373.
Lankelma J, Muelder HS, Van Mourik F, Wong Fong Sang HW,
Kraayenhof R, Van Grondelle R. Cellular daunomycin
fluorescence in multidrug resistant 2780A-D cells and its
relation to cellular drug localization. Biochim Biophys
Acta 1991; 1093(2-3):147-52.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Multidrug resistance in human neuroblastoma cells. J
Pediatr Surg 1991 Sep;26(9):1107-12.
Larsen AK, Jacquemin-Sablon A. Multiple resistance mechanisms
in Chinese hamster cells resistant to 9-hydroxyellipticine.
Cancer Res 1989 Dec 15;49(24 Pt 1):7115-9.
Larsson R, Bergh J, Nygren P. Combination of cyclosporin A and
buthionine sulfoximine (BSO) as a pharmacological strategy
for circumvention of multidrug resistance in small cell lung
cancer cell lines selected for resistance to doxorubicin.
Anticancer Res 1991 Jan-Feb;11(1):455-9.
Lee KY, Park JG, Gazdar AF, Goldstein LJ, Hwang ES, Kim JP.
Correlation between MDR1 gene expression and in vitro drug
sensitivity testing (DST) of human cancer cell lines
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1990;9:A219.
Lehnert M, Emerson S, Kunke K, Dalton WS, Salmon SE. Combined
chemosensitization for reversing MDR1: synergism of
verapamil with quinine but antagonism with quinidine
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2244.
Lehnert M, Kunke K, Dalton WS, Roe D, Dorr RT, Salmon SE. In
vivo concentration of serum proteins significantly inhibits
reversal of P-glycoprotein-mediated drug resistance by some
chemosensitizers [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1990;31:A2250.
Lemontt JF, Azzaria M, Gros P. Increased mdr gene expression
and decreased drug accumulation in multidrug-resistant
human melanoma cells. Cancer Res 1988;48(22):6348-53.
Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R,
Mertelsmann R. Induction of multiple-drug resistance
during anti-neoplastic chemotherapy in vitro. Int J Cancer
1991 Oct 21; 49(4):630-7.
Liddil JD, Dorr RT, Dalton WS, Salmon SE. Correlation of
multidrug resistance (MDR) to recombinant tumor necrosis
factor (RTNF) sensitivity based on lysosomal enzyme activity
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1988;7:A192.
Liley DTJ, Wiggins PM, Baguley BC. Localization of a
nonintercalative DNA binding antitumor drug in mitochondria
relationship to multidrug resistance. Eur J Cancer Clin
Oncol 1989;25(9):1287-94.
Limonta M, Ubezio P. [Anthracycline resistance:
cytofluorometric study on infantile lymphoblastic leukemia].
Medicina (Firenze) 1989 Oct-Dec;9(4): 406-8. (Ita).
Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts
T, Smit JJ, Borst P. Multidrug resistance phenotype of
human BRO melanoma cells transfected with a wild-type human
mdr1 complementary DNA. Cancer Res 1990 Mar 15;
50(6):1779-85.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
Lock RB, Hill BT. Differential patterns of anti-tumour drug
responses and mechanisms of resistance in a series of
independently derived VP 16 resistant human tumour cell
lines. Int J Cancer 1988; 42(3):373-81.
Long BH, Wang L, Lorico A, Brattain MG, Casazza AM. Mechanisms
of resistance to etoposide VP-16 and teniposide VM-26 in
acquired resistant human colon and lung carcinoma cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:507.
Long JP Jr, Prout GR Jr, Wong YK, Lin CW. The effect of
verapamil on a multi-drug resistant bladder carcinoma cell
line and its potential as an intravesical chemotherapeutic
agent. J Urol 1990 May;143(5):1053-6.
Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Emmer G. SDZ 280-446, a novel semi-synthetic
cyclopeptolide: in vitro and in vivo circumvention of the P-
glycoprotein-mediated tumour cell multidrug resistance. Br
J Cancer 1992 Jan;65(1):11-8.
Lothstein L, Hsu SIH, Horwitz SB, Greenberger LM. Alternate
overexpression of two phosphoglycoprotein genes is
associated with changes in multidrug resistance in a j774.2
cell line. J Biol Chem 1989;264(27):16054-8.
Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin
accumulation in cells from human and rodent cell lines. J
Natl Cancer Inst 1989 Jan 4; 81(1):55-9.
Lutzky J, Canada AL, Yamanishi DT, Bhalla K, Hindenburg AA.
Effect of verapamil and buthionine sulfoximine (BSO) on
daunorubicin (DNR) cytotoxicity of multidrug-resistant human
melanoma cell lines overexpressing P-glycoprotein and
glutathione-s-transferases [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A3315.
Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro
effect of P-glycoprotein (P-gp) modulators on drug
sensitivity of leukemic progenitors (CFU-L) in acute
myelogenous leukemia (AML). Exp Hematol 1992
Jun;20(5):565-8.
Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene
expression in adult acute leukemias: correlations with
treatment outcome and in vitro drug sensitivity. Blood 1991
Aug 1;78(3):586-92.
Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Yamamoto Y,
Sakamoto H, Furuyama J. Amplification and expression of a
multidrug resistance gene in human glioma cell lines.
J Neurosurg 1990 Jan;72(1):96-101.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Maurya AK, Nair S, Mian AM, Singh SV. Mechanism of cross-
resistance to mitomycin C in multidrug-resistant mouse
leukemic P388 cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2100.
Mazzoni A, Trave F, Canti G, Franco P. Effect of the
tiapamil analog ro-11-2933 on cellular sensitivity to
antitumor drugs in sensitive and multidrug resistant human
ovarian cancer cells. Anticancer Res 1989; 9(2):367-72.
McCrady CW, Huang X, Massey GV, Yanovich S, Pettit GR, Carchman
RA. Expression of the multidrug resistance (MDR) gene does
not confer resistance to the cytostatic effects of
bryostatin 1 [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2210.
McLachlin JR, Eglitis MA, Ueda K, Kantoff PW, Pastan IH, Anderson
WF, Gottesman MM. Expression of a human complementary DNA
for the multidrug resistance gene in murine hematopoietic
precursor cells with the use of retroviral gene transfer. J
Natl Cancer Inst 1990 Aug 1;82(15): 1260-3.
Mechetner EB, Roninson IB. Efficient inhibition of P-
glycoprotein-mediated multidrug resistance with a monoclonal
antibody [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2913.
Mechetner EB, Roninson IB. Efficient inhibition of P-
glycoprotein-mediated multidrug resistance with a monoclonal
antibody. Proc Natl Acad Sci U S A 1992 Jul
1;89(13):5824-8.
Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, Mcguire WL.
Electrophoretic analysis of 248 clinical breast cancer
specimens for p-glycoprotein overexpression of gene
amplification. J Clin Oncol 1989;7(8):1129-36.
Michaeli J, Lebedev YB, Leng L, Tong WP, Richon VM, Marks PA,
Rifkind RA. A multidrug resistance (MDR) phenotype in
response to phorbol ester: role of P-glycoprotein and
protein kinase C beta (PKC-beta) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2224.
Michel AD, Kunysz EA, Whiting RL. Interaction of cytotoxic
agents with tritiated PN-200-110 binding sites of rat
cerebrocortical and skeletal muscle membranes [abstract].
Br J Pharmacol 1989;96 Suppl:240P.
Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R,
Raspadori D, Russo D, Visani G, Dinota A, Pileri S, et al.
Overexpression of multidrug resistance-associated p170-
glycoprotein in acute non-lymphocytic leukemia. Eur J
Haematol 1992 Feb;48(2):87-92.
Michieli M, Geromin A, Michelutti A, Damiani D, Savignano C,
Patriarca F, Velisig M, Raspadori D, Baccarani M.
Multidrug resistance (MDR)-associated P-170 glycoprotein in
acute nonlymphocytic leukemia (ANLL) [abstract].
Haematologica 1991;76 Suppl 4:75.
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M.
MDR-1 gene amplification in acute lymphoblastic leukemia
prior to antileukemic treatment. Br J Haematol
1991;78(2):288-9.
Mickisch G, Keilhauer G, Schlick E, Tschada R, Alken P. Effects
of R-verapamil (R-vpm) on P-170-mediated multidrug
resistance (mdr) of human renal cell carcinoma (rcc)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2423.
Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski
H, Stahle C, Sachs DH, Pastan I, Gottesman MM.
Transplantation of bone marrow cells from transgenic mice
expressing the human MDR1 gene results in longterm
protection against the myelosuppressive effect of
chemotherapy in mice. Blood 1992 Feb 15;79(4):1087-93.
Mickisch GH, Gottesman MM, Pastan I, Alken PM. New potent
verapamil derivatives that reverse multidrug resistance in
human renal carcinoma cells and in transgenic mice
expressing the human MDR1 gene [abstract]. J Urol
1991;145(4 Suppl): 379a.
Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I.
Transgenic mice that express the human multidrug-resistance
gene in bone marrow enable a rapid identification of agents
that reverse drug resistance. Proc Natl Acad Sci U S A 1991
Jan 15; 88(2):547-51.
Mickisch GH, Rahman A, Pastan I, Gottesman MM. Increased
effectiveness of liposome-encapsulated doxorubicin in
multidrug-resistant-transgenic mice compared with free
doxorubicin. J Natl Cancer Inst 1992 May 20;84(10):804-5.
Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken
PM. Mechanisms and modulation of multidrug resistance in
primary human renal cell carcinoma. J Urol 1990 Sep;
144(3):755-9.
Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F,
Rosen N, Fojo AT. Modulation of the expression of a
multidrug resistance gene mdr-1-P-glycoprotein by
differentiating agents. J Biol Chem 1989;264(30):18031-40.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE.
P-glycoprotein expression in malignant lymphoma and
reversal of clinical drug resistance with chemotherapy plus
high-dose verapamil. J Clin Oncol 1991 Jan;9(1): 17-24.
Millot JM, Debal V, Morjani H, Merle S, Kiss R, Manfait M.
Characterization of a vinca-alkaloid resistance phenotype in
J82 cells following selection with navelbine [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2201.
Milroy R, Plumb JA, Banham SW, Kaye SB. Variable response to
the resistance modifier verapamil in newly established
small-cell lung cancer (SCLC) cell lines [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:572.
Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK. Biochemical
and pharmacological characterization of MCF-7 drug-sensitive
and AdrR multidrug-resistant human breast tumor xenografts
in athymic nude mice. Biochem Pharmacol 1991 Jul 5;42(2):
391-402.
Mimnaugh EG, Sinha BK, Rajagopolan S, Myers CE. Subcellular
sites of enzymatic doxorubicin activation, oxyradical
production and detoxification in sensitive and multidrug
resistant MCF-7 human breast tumors [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2233.
Mirski SE, Dicke FP, Cole SP. Non-P-glycoprotein-mediated
multidrug resistance in the small-cell lung cancer (SCLC)
cell line, H69AR [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2196.
Miyamoto K, Wakusawa S, Nakamura S, Tajima K, Hidaka H.
Multidrug resistance in Yoshida rat ascites hepatoma cell
lines. Anticancer Res 1992 May-Jun;12(3):649-53.
Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano
T, Tomoda Y. Mitomycin C cross-resistance induced by
adriamycin in human ovarian cancer cells in vitro. Cancer
Chemother Pharmacol 1990;26(5):333-9.
Montaudon D, Benchekroun MN, Londos-Gagliardi D, Robert J.
Chromosomal modifications of a rat glioblastoma cell line
during the acquisition and reversal of doxorubicin
resistance. Anticancer Res 1990 Nov-Dec;10(6):1667-75.
Mukaiyama T, Minowa S, Ogawa M. Analysis of MDR1 mRNA
expression in breast cancer specimens by reverse-
transcription polymerase chain reaction (RT-PCR) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2786.
Muller C, Laval F, Soues S, Birck C, Charcosset JY. High cell
density-dependent resistance and P-glycoprotein-mediated
multidrug resistance in mitoxantrone-selected Chinese
hamster cells. Biochem Pharmacol 1992 May
28;43(10):2091-102.
Muller C, Laval F, Soues S, Charcosset JY. Inducible
amplification and increased expression of MDR genes in
mitoxantrone-resistant hamster cells selected in one step
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2197.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Myers CE. Anthracyclines. Cancer Chemother Biol Response Modif
1988;10:33-9.
Nakagawa M, Dixon KH, Gilbert L, Goldsmith ME, Cowan KH.
Characterization of mitoxantrone resistant human breast
cancer cell line [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2204.
Narayana K, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun
1991;3(2): 37-44.
Nelson EJ, Hinkle PM. Characterization of multidrug-resistant
pituitary tumor cells. Endocrinology 1992
Jun;130(6):3246-56.
Nooter K, Herweijer H, Sonneveld P, Verweij J, Hagenbeek A,
Stoter G. Detection of multidrug resistance (MDR) in
refractory cancer patients [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2092.
Nooter K, Oostrum R, Jonker R, Van Dekken H, Stokdijk W, Van Den
Engh G. Effect of cyclosporin A on daunorubicin
accumulation in multidrug-resistant p388 leukemia cells
measured by real-time flow cytometry. Cancer Chemother
Pharmacol 1989;23(5):296-300.
Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer
H, Valerio D, Hagemeijer A, Baas F. Expression of the mdr3
gene in prolymphocytic leukemia: association with
cyclosporin-A-induced increase in drug accumulation. Int J
Cancer 1990 Apr 15;45(4): 626-31.
Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T,
Valerio D. Overexpression of the mdr1 gene in blast cells
from patients with acute myelocytic leukemia is associated
with decreased anthracycline accumulation that can be
restored by cyclosporin-A. Int J Cancer 1990 Feb 15;45(2):
263-8.
Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin
selected multidrug-resistant small cell lung cancer cell
lines characterised by elevated cytoplasmic Ca2+ and
resistance modulation by verapamil in absence of P-
glycoprotein overexpression. Br J Cancer 1991 Dec;64(6):
1011-8.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents KT6149, MX 2, SM5887, menogaril, and
liblomycin using cisplatin or adriamycin resistant human
cancer cell lines. Cancer Res 1989;49(15): 4098-102.
Osann K, Sweet P, Slater LM. Synergistic interaction of
cyclosporin A and verapamil on vincristine and daunorubicin
resistance in multidrug-resistant human leukemia cells in
vitro. Cancer Chemother Pharmacol 1992;30(2):152-4.
Osborne EJ, Cole SPC, Mackillop WJ. The effect of hyperthermia
on doxorubicin accumulation and cytotoxicity in a human
ovarian carcinoma cell line and its multidrug resistant
variant [abstract]. Br J Cancer 1990;61(1):170-1.
Oudard S, Thierry A, Jorgensen TJ, Rahman A. Sensitization of
multidrug-resistant colon cancer cells to doxorubicin
encapsulated in liposomes. Cancer Chemother Pharmacol
1991;28(4):259-65.
Ozols RF. Reversal of drug resistance: clinical trials based on
experimental studies in human tumor model systems. Paper
presented at: Symposium on Mechanisms of Drug and Radiation
Resistance of Tumor Cells; 1989 Jun 28-30; Villejuif,
France.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and therapy of
breast cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young RC.
Reversal of alkylating agent and platinum resistance in
ovarian cancer [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:526-7.
Park JG, Kramer BS, Henslee JG, Lai S, Goldstein L, Gottesman MM,
Gazdar AF. Characteristics and drug sensitivity patterns
of human gastric carcinoma cell lines--comparison with
colorectal carcinoma lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A432.
Park JG, Kramer BS, Lai SL, Goldstein LJ, Gazdar AF.
Chemosensitivity patterns and expression of human multidrug
resistance-associated MDR1 gene by human gastric and
colorectal carcinoma cell lines. J Natl Cancer Inst 1990
Feb 7;82(3):193-8.
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV,
Willingham MC. A retrovirus carrying an mdr1 complementary
DNA confers multidrug resistance and polarized expression of
P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A
1988;85(12):4486-90.
Pastan I, Willingham MC, Gottesman M. Molecular manipulations
of the multidrug transporter: a new role for transgenic
mice. FASEB J 1991 Aug; 5(11):2523-8.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia
P, Miller TP, Salmon SE. Systemic toxic effects associated
with high-dose verapamil infusion and chemotherapy
administration. J Natl Cancer Inst 1991 Jan 16;
83(2):105-10.
Pincus R, Goldman ID. Decreased tight binding of mitoxantrone
in P388 leukemia cells with multiple drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1185.
Pincus R, Goldman ID. Evidence for impaired mitoxantrone and
vinblastine binding in P388 murine leukemia cells with
multidrug resistance. Biochem Pharmacol 1990 Dec
15;40(12):2625-35.
Pinedo HM, van Groeningen CJ, van Kalken CK. Cellular
pharmacology and drug resistance in breast cancer. Paper
presented at: Biology and therapy of breast cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Pirker R, Wallner J, Geissler K, Valent P, Bettelheim P, Lechner
K, Hopfner M, Linkesch W, Ludwig H. MDR1 gene expression
affects clinical outcome in acute myelogenous leukemia
[abstract]. Ann Oncol 1990;1 Suppl:67.
Plumb JA, Milroy R, Kaye SB. Sequential induction of drug
resistance in an adherent small-cell lung cancer (SCLC) cell
line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2141.
Politi PM, Sinha BK. Role of differential drug uptake efflux
and binding of etoposide in sensitive and resistant human
tumor cell lines implications for the mechanisms of drug
resistance. Mol Pharmacol 1989;35(3):271-8.
Pommerenke EW, Osswald H, Hahn EW, Volm M. Activity of various
amphiphilic agents in reversing multidrug resistance of L
1210 cells. Cancer Lett 1990 Nov 19;55(1):17-23.
Priebe W, Van T, Perez-Soler R. Activity of 3'-deaminated
anthracyclines against MDR cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2245.
Qian XD, Beck WT. Binding of an optically pure photoaffinity
analogue of verapamil, LU-49888, to P-glycoprotein from
multidrug-resistant human leukemic cell lines. Cancer Res
1990 Feb 15; 50(4):1132-7.
Qian XD, Beck WT. Interaction of a photoactive anthracycline
analog, [3H]-N-azido-benzoyldaunomycin (AB-DNR) with P-
glycoprotein (Pgp) from multidrug-resistant human leukemic
lymphoblasts (CEM/VLB5K) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2160.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Rahman A, Mickisch G, Pastan I, Gottesman M. Liposomal
encapsulated doxorubicin (LED) circumvents doxorubicin (DOX)
resistance in MDR transgenic mice [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A2813.
Ramu A, Pollard HB, Rosario LM. Doxorubicin resistance in p388
leukemia evidence for reduced drug influx. Int J Cancer
1989;44(3):539-47.
Ramu A, Ramu N, Gorodetsky R. Reduced ouabain-sensitive
potassium entry as a possible mechanism of multidrug-
resistance in P388 cells. Biochem Pharmacol 1991 Oct
9;42(9):1699-704.
Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM.
Photosensitized labeling of a functional multidrug
transporter in living drug-resistant tumor cells. J Biol
Chem 1990 Mar 5; 265(7):3975-80.
Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang HP,
Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant
fibroblast interferon and recombinant immune interferon on
growth and the antigenic phenotype of multidrug-resistant
human glioblastoma multiforme cells. J Natl Cancer Inst
1991 Sep 18;83(18):1307-15.
Redmond A, Moran E, Clynes M. Analysis of the mechanism of
resistance of 7 novel MDR variants. Biochem Soc Trans
1992;20(1):57s.
Remnick RA, Gervasoni JE Jr, Hindenburg AA, Lutzky J, Krishna S,
Rosado M, Taub RN. The subcellular distribution of
daunorubicin in drug-resistant cell lines that do and do not
overexpress the P-glycoprotein [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2032.
Rhodes T, Twentyman PR. Effects of cyclosporin A and verapamil
on cellular pharmacokinetics and chemosensitivity in an MDR
cell line which does not express P-glycoprotein [abstract].
Br J Cancer 1991;63 Suppl 13:12.
Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks
PA. Characteristics of erythroleukemia cells selected for
vincristine resistance that have accelerated inducer-
mediated differentiation. Proc Natl Acad Sci U S A 1991 Mar
1;88(5):1666-70.
Ries F, Dicato M. Treatment of advanced and refractory breast
cancer with doxorubicin, vincristine and continuous infusion
of verapamil. A phase I-II clinical trial. Med Oncol Tumor
Pharmacother 1991;8(1):39-43.
Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal
of Vinca alkaloid resistance by anti-P-glycoprotein
monoclonal antibody HYB-241 in a human tumor xenograft.
Cancer Res 1992 Apr 1; 52(7):1810-6.
Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T,
Parmiani G. Modulation of multidrug resistance by
verapamil or mdr1 anti-sense oligodeoxynucleotide does not
change the high susceptibility to lymphokine-activated
killers in mdr-resistant human carcinoma (LoVo) line. Int J
Cancer 1990 Oct 15;46(4):727-32.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M.
Immunohistochemical analysis of P-glycoprotein expression
correlated with chemotherapy resistance in locally advanced
breast cancer. Hum Pathol 1990 Aug;21(8):787-91.
Roberts D, Foglesong PD, Parganas E, Wiggins L. Reduced
formation of lesions in the DNA of a multidrug-resistant
l1210 subline selected for teniposide resistance. Cancer
Chemother Pharmacol 1989;23(3):161-8.
Ross D, Ordonez J, Cuddy D, Wooten P, Lee E, Thompson B, Schiffer
C. Verapamil enhancement of daunorubicin uptake in
subpopulations of blast cells from AML patients: relation to
clinical response [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A806.
Ross D, Wooten P, Ordonez JV, Sridhara R, Lee E, Schiffer C.
MDR1 expression and effects of cyclosporin-A, verapamil and
progesterone on daunorubicin cytotoxicity in blast cells
from acute myelogenous leukemia patients [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2839.
Ross DD. Cellular and pharmacologic aspects of drug resistance
in acute myeloid leukemia. Curr Opin Oncol 1991
Feb;3(1):21-9.
Ross DD, Ordonez JV, Joneckis CC, Testa JR, Thompson BW.
Isolation of highly multidrug-resistant P388 cells from
drug-sensitive P388-S cells by flow cytometric cell sorting.
Cytometry 1988; 9(4):359-67.
Ross DD, Thompson BW, Ordonez JV, Joneckis CC. Improvement of
flow-cytometric detection of multidrug-resistant cells by
cell-volume normalization of intracellular daunorubicin
content. Cytometry 1989;10(2):185-91.
Ross KL, Sikic BI, Kercso KM, Owicki JC, Hafeman DG, Muir VC,
Parce JW. Potentiometric monitoring of tumor cell
chemosensitivity with a silicon based biosensor [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2410.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Ruszala-Mallon V, Silva J, Raventos-Suarez C, Durr FE. P-
glycoprotein-mediated multidrug resistance in ovarian
carcinoma cells selected for resistance to bisantrene, a
synthetic anticancer drug [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31: A2110.
Sadasivan R, Morgan R, Fabian C, Stephens R. Reversal of
multidrug resistance in HL-60 cells by verapamil and
liposome-encapsulated doxorubicin. Cancer Lett 1991 May
1;57(2):165-71.
Saeki T, Shimabuku AM, Azuma Y, Shibano Y, Komano T, Ueda K.
Expression of human P-glycoprotein in yeast cells - effects
of membrane component sterols on the activity of P-
glycoprotein. Agric Biol Chem 1991;55(7):1859-66.
Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug-
resistant cells. Cancer Invest 1992;10(4): 295-305.
Safa AR. Photoaffinity labeling of the multidrug-resistance-
related P-glycoprotein with photoactive analogs of
verapamil. Proc Natl Acad Sci U S A 1988;85(19):7187-91.
Safa AR, Agresti M, Tamai I, Mehta ND, Vahabi S. The alpha 1-
adrenergic photoaffinity probe [125I]arylazidoprazosin binds
to a specific peptide of P-glycoprotein in multidrug-
resistant cells. Biochem Biophys Res Commun 1990 Jan 15;
166(1):259-66.
Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of p-
glycoprotein in multidrug resistant cells with photoactive
analogs of colchicine. Biochem Biophys Res Commun
1989;162(3): 1402-8.
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ,
Miller TP. Multidrug-resistant myeloma: laboratory and
clinical effects of verapamil as a chemosensitizer. Blood
1991 Jul 1; 78(1):44-50.
Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS.
Prediction of doxorubicin resistance in-vitro in myeloma
lymphoma and breast cancer by p-glycoprotein staining. J
Natl Cancer Inst 1989; 81(8):696-701.
Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects
of tumor necrosis factor on sensitive and multidrug
resistant human leukemia and myeloma cell lines. Blood
1989;74(5):1723-7.
Samuels BL, Murray JL, Safa AR. Additive reversal of multidrug
resistance by combinations of non-cross-toxic modulating
agents [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2138.
Sanfilippo O, Di Fronzo G, Ronchi E. Natural or acquired drug
resistance and GP170 (GP) expression in human breast cancers
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2209.
Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R.
Expression of P-glycoprotein in breast cancer tissue and in
vitro resistance to doxorubicin and vincristine. Eur J
Cancer 1991; 27(2):155-8.
Santostasi G, Kutty RK, Krishna G. Increased toxicity of
anthracycline antibiotics induced by calcium entry blockers
in cultured cardiomyocytes. Toxicol Appl Pharmacol 1991 Mar
15;108(1):140-9.
Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg
AA, Preisler HD. Expression of the multidrug resistance
gene in myeloid leukemias. Leuk Res 1990;14(1):11-21.
Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg
J, Vogler R, Grunwald H, Gottlieb A, et al. MDR1
transcript levels as an indication of resistant disease in
acute myelogenous leukaemia. Br J Haematol 1990
Jul;75(3):340-5.
Satta T, Isobe K, Yamauchi M, Nakashima I, Akiyama S, Itou K,
Watanabe T, Takagi H. Establishment of drug resistance in
human gastric and colon carcinoma xenograft lines. Jpn J
Cancer Res 1991 May;82(5):593-8.
Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression
of MDR1 and glutathione S transferase-pi genes and
chemosensitivities in human gastrointestinal cancer. Cancer
1992 Feb 15;69(4):941-6.
Savaraj N, Teeter L, Kuo MT, Wu CJ, Tapiero H, Lampidis T.
Characteristics of rhodamine and adriamycin-induced
multidrug-resistant cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2187.
Saxena M, Sharma R, Singhal SS, Ahmad H, Awasthi YC. The effect
of doxorubicin on the transport of glutathione conjugates
from human erythrocytes. Biochem Arch 1991;7(4):285-92.
Schaefer A, Westendorf J, Lingelbach K, Schmidt C, Marquardt H.
Doxorubicin-resistant Friend erythroleukemia cells are less
resistant towards N,N-dimethylated anthracyclines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2171.
Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, Van Der Schoot E,
Balm AJM , Meijer CJLM, Broxterman HJ, Kuiper CM, et al.
Monoclonal antibody JSB-1 detects a highly conserved epitope
on the P-glycoprotein associated with multi-drug-resistance.
Int J Cancer 1988;42(3):389-94.
Schinkel AH, Roelofs EM, Borst P. Characterization of the human
MDR3 P-glycoprotein and its recognition by P-glycoprotein-
specific monoclonal antibodies. Cancer Res 1991 May
15;51(10): 2628-35.
Schoenlein PV, Shen DW, Johnson BP, Pastan I, Gottesman MM. The
amplification of the human MDR1 gene occurs via episome
formation in KB carcinoma cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2107.
Schurr E, Raymond M, Bell JC, Gros P. Characterization of the
multidrug resistance protein expressed in cell clones stably
transfected with the mouse mdr1 complementary DNA. Cancer
Res 1989;49(10):2729-34.
Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen TH, de
Lange JH, Baak JP, Pinedo HM, Lankelma J. Quantitative
determination of factors contributing to doxorubicin
resistance in multidrug-resistant cells. J Natl Cancer Inst
1989 Dec 20;81(24):1887-92.
Schuurhuis GJ, Pinedo HM, Broxterman HJ, van Kalken CK, Kuiper
CM, Lankelma J. Differential sensitivity of multi-drug-
resistant and -sensitive cells to resistance-modifying
agents and the relation with reversal of anthracycline
resistance. Int J Cancer 1990 Aug 15;46(2):330-6.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
activity and multidrug resistance in MOLT-3 human
lymphoblastic leukemia cells resistant to trimetrexate.
Cancer Res 1991 Jan 1; 51(1):55-61.
Scudder SA, Brown JM, Sikic BI. DNA cross-linking and
cytotoxicity of the alkylating cyanomorpholino derivative
of doxorubicin in multidrug-resistant cells. J Natl Cancer
Inst 1988;80(16):1294-8.
Scudder SA, Saunders KA, Andreotti VA, White RWD. Rhodamine 123
efflux as a measure of drug resistance [abstract]. Clin Res
1991;39(1):68a.
Sehested M, Bindslev N, Demant EJF, Skovsgaard T, Jensen PB.
Daunorubicin and vincristine binding to plasma membrane
vesicles from daunorubicin-resistant and wild type Ehrlich
ascites tumor cells. Biochem Pharmacol 1989;38(18):3017-28.
Sehested M, Friche E, Jensen PB, Demant EJ. Relationship
of VP-16 to the classical multidrug resistance
phenotype. Cancer Res 1992 May 15; 52(10):2874-9.
Sehested M, Jensen PB, Skovsgaard T, Bindslev N, Demant EJ,
Friche E, Vindelv L. Inhibition of vincristine binding to
plasma membrane vesicles from daunorubicin-resistant Ehrlich
ascites cells by multidrug resistance modulators. Br J
Cancer 1989 Dec;60(6):809-14.
Sehested M, Simpson D, Skovsgaard T. Freeze fracture study of
plasma membranes of daunorubicin sensitive and resistant
Ehrlich ascites tumor cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1988;29:A1228.
Sehested M, Skovsgaard T, Jensen PB, Demant EJ, Friche E,
Bindslev N. Transport of the multidrug resistance
modulators verapamil and azidopine in wild type and
daunorubicin resistant Ehrlich ascites tumour cells. Br J
Cancer 1990 Jul;62(1):37-41.
Seidman AD, Scher HI. The evolving role of chemotherapy for
muscle infiltrating bladder cancer. Semin Oncol 1991
Dec;18(6):585-95.
Sekiya S, Nunoyama T, Shirasawa H, Kimura H, Kawata M, Iijima N,
Sugimoto Y, Tsuruo T, Takamizawa H. Expression of a human
multidrug resistance gene in human ovarian carcinoma cell
lines. Arch Gynecol Obstet 1992;251(2):79-86.
Seneviratne C, Goldenberg GJ. Further characterization of drug-
sensitivity and cross-resistance profiles of cloned cell
lines of Adriamycin-sensitive and -resistant P388 leukemia.
Cancer Commun 1989;1(1):21-7.
Shalinsky DR, Howell SB. Synergistic enhancement of the
cytotoxicity of vinblastine (VBL) and colchicine (COL) by
dipyridamole (DPM) in drug-resistant KB carcinoma cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2097.
Sheldon K, Marks A, Baumal R. Sensitivity of multidrug
resistant KB-C1 cells to an antibody dextran adriamycin
conjugate. Anticancer Res 1989;9(3):637-42.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human
hepatocellular carcinoma cell lines exhibit multidrug
resistance unrelated to MRD1 gene expression. J Cell Sci
1991 Mar;98(Pt 3): 317-22.
Shibata H, Furusawa S, Kawauchi H, Sasaki K, Takayanagi Y.
[Modulation of anthracycline resistance by reserpine in P388
leukemia cells]. Nippon Yakurigaku Zasshi 1991
Jul;98(1):1-6. (Jpn).
Shimm DS, Olson S, Hill AB. Radiation resistance in a multidrug
resistant human T-cell leukemia line. Int J Radiat Oncol
Biol 1988;15(4):931-6.
Shimoyama M. Detection of multidrug resistant (MDR) cancer
cells by monoclonal antibodies. Paper presented at: Drug
resistance as a biochemical target in cancer chemotherapy.
13th Bristol-Myers Squibb Symposium on Cancer Research; 1990
May 10-11; Tokyo, Japan.
Shinoda H, Inaba M, Tsuruo T. In vivo circumvention of
vincristine resistance in mice with P388 leukemia using a
novel compound, AHC 52. Cancer Res 1989;49(7):1722-6.
Shoji Y, Fisher MH, Periasamy A, Herman B, Juliano RL.
Verapamil and cyclosporin A modulate doxorubicin toxicity by
distinct mechanisms. Cancer Lett 1991 May 24;57(3):209-18.
Sikic BI, Brophy NA, Berry JM, Marie JP, Ehsan MN, Tsuruo T,
Roninson IB, Smith SD. Multidrug resistance gene
expression in ovarian and breast cancers, leukemias, and
lymphomas. Paper presented at: 6th NCI-EORTC Symposium on
New Drugs in Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Silbermann MH, Boersma AW, Janssen AL, Scheper RJ, Herweijer H,
Nooter K. Effects of cyclosporin A and verapamil on the
intracellular daunorubicin accumulation in Chinese hamster
ovary cells with increasing levels of drug-resistance. Int
J Cancer 1989 Oct 15;44(4):722-6.
Sinha BK, Politi PM. Anthracyclines. Cancer Chemother Biol
Response Modif 1990;11:45-57.
Sinicrope FA, Dudeja PK, Safa AR, Brasitus TA. Modulation of P-
glycoprotein-dependent tritiated daunomycin uptake in rat
liver canalicular membrane vesicles [abstract]. Clin Res
1991; 39(3):743a.
Skovsgaard T. Drug transport in multidrug-resistant tumor cells a revision
of the pump hypothesis. In: Tapiero H, Robert J, Lampidis TJ, editors.
1st International Interface of Clinical and Laboratory Responses to
Anticancer Drugs;1989 Mar 13-15; Villejuif, France. Paris: Les
Editions Inserm; 1989. p. 233-44. (Colloque INSERM; 191).
Skovsgaard T. Transport and multidrug resistance: indications
of a changed pH-gradient across the membrane. Pezcoller
Found Symp 1990;1:209-31.
Slapak CA, Daniel JC, Levy SB. Sequential emergence of distinct
resistance phenotypes in murine erythroleukemia cells under
adriamycin selection: decreased anthracycline uptake
precedes increased P-glycoprotein expression. Cancer Res
1990 Dec 15;50(24):7895-901.
Slapak CA, Lecerf JM, Daniel JC, Levy SB. Energy-dependent
accumulation of daunorubicin into subcellular compartments
of human leukemia cells and cytoplasts. J Biol Chem 1992
May 25;267(15): 10638-44.
Slate DL, Bruno N, Carver LA, Rabier M. Isolation and
characterization of multiple drug resistant carcinoma cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1975.
Slovak ML, Coccia M, Meltzer PS, Trent JM. Molecular analysis
of two human doxorubicin-resistant cell lines: evidence for
differing multidrug resistance mechanisms. Anticancer Res
1991 Jan-Feb;11(1):423-8.
Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and
biological evidence for differing mechanisms of doxorubicin
resistance in two human tumor cell lines. Cancer Res 1988;
48(10):2793-7.
Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F,
Gauville C, Tsuruo T, Carli PM, Guy H. P-glycoprotein
expression and in-vitro reversion of doxorubicin resistance
by verapamil in clinical specimens from acute leukemia and
myeloma. Leukemia 1991;5(7):592-7.
Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy
H. Sufficient levels of quinine in the serum circumvent
the multidrug resistance of the human leukemic cell line
K562/ADM. Cancer 1991 Oct 15;68(8):1714-9.
Solary E, Velay I, Chauffert B, Caillot D, Bidan JM, Dumas M,
Casasnovas O, Guy H. Quinine circumvents the doxorubicin
resistance of a multidrug resistant human leukemic cell-
line, K562/DXR. Nouv Rev Fr Hematol 1990;32(5): 361-3.
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S,
Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-
resistant multiple myeloma by cyclosporin. The Leukaemia
Group of the EORTC and the HOVON. Lancet 1992 Aug 1;
340(8814):255-9.
Sonneveld P, Nooter K. Reversal of drug-resistance by
cyclosporin-A in a patient with acute myelocytic leukaemia.
Br J Haematol 1990 Jun;75(2):208-11.
Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, Lankelma J.
P-glycoprote in drug efflux pump involved in the mechanisms of intrinsic
drug resistance in various colon cancer cell lines. Evidence for a
saturation of active daunorubic in transport. Biochem Pharmacol 1991;
41(3):349-60.
Spoelstra EC, Westerhoff HV, Dekker H, Lankelma J. Kinetics of
daunorubicin transport by P-glycoprotein of intact cancer
cells. Eur J Biochem 1992 Jul 15;207(2):567-79.
Steinhoff A, Muenchmeyer M, Looft G, Erttmann R. Measurements
of anthracycline-accumulation in multidrug-resistant (MDR)
and sensitive leukemia cells by fluorometry effect of
verapamil and other membrane-transport modulation drugs
[abstract]. Naunyn Schmiedebergs Arch Pharmacol 1989;
339 Suppl:R42.
Stewart J, Gorman NT. Multi-drug resistance genes in the
management of neoplastic disease. J Vet Intern Med 1991
Jul-Aug;5(4):239-47.
Sugawara I, Hamada H, Nakahama M, Okamoto S, Tsuruo T, Mori S.
Further characterization of the human adrenal-derived P-
glycoprotein recognized by monoclonal antibody MRK 16
reacting with only human P-glycoprotein. Jpn J Cancer Res
1989 Dec;80(12):1199-205.
Sugimoto Y, Asami N, Tsuruo T. Expression of P-glycoprotein
mRNA in human gastric tumors. Jpn J Cancer Res 1989
Oct;80(10):993-9.
Sukhanov VA, D'Yakov VL, Lalaev VV, Yakh'Yaev AV, Voronkova IM,
Donenko FV, Borovkova NB, Moroz LV. [P-glycoprotein
expression in P-388 leukemia cell with induced resistance to
doxorubicin]. Byull Eksp Biol Med 1991;111(3): 290-1.
(Rus).
Sutter C, Volm M. Genomic organization and expression of
multidrug resistance specific sequences in S-180 mouse
tumor cell lines and normal tissues of mice [abstract]. Eur
J Cell Biol Suppl 1989;(26):86.
Suzuki H, Tomida A, Nishimura T. Cytocidal activity of a
synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-
dimethoxybenzyl)ethylenediamine, and its potentiation of
antitumor drugs against multidrug-resistant and sensitive
cells in vitro. Jpn J Cancer Res 1990 Mar;81(3):298-303.
Sweatman TW, Koseki Y, Seshadri R, Israel M, Beck WT. Activity
of n-benzyladriamicin-14-valerate (AD 198) in vitro against
mechanistically different multidrug-resistant CEM cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1076.
Sweet P, Chan PK, Slater LM. Cyclosporin A and verapamil
enhancement of daunorubicin-produced nucleolar protein b23
translocation in daunorubicin-resistant and sensitive human
and murine tumor cells. Cancer Res 1989;49(3):677-80.
Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y,
Niitani H, Saijo N. Establishment of a human leukemia
subline resistant to the growth-inhibitory effect of 12-O-
tetradecanoylphorbol 13-acetate (TPA) and showing non-P-
glycoprotein-mediated multi-drug resistance. Int J Cancer
1991 Jul 30;48(6):931-7.
Taylor CW, Dalton WS. Multiple mechanisms of drug resistance in
MCF-7 human breast cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2109.
Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT,
Thompson FH, Roe DJ, Trent JM. Different mechanisms of
decreased drug accumulation in doxorubicin and mitoxantrone
resistant variants of the MCF7 human breast cancer cell
line. Br J Cancer 1991 Jun;63(6):923-9.
te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P.
Reversal of typical multidrug resistance by cyclosporin and
its non-immunosuppressive analogue SDZ PSC 833 in Chinese
hamster ovary cells expressing the mdr1 phenotype. Cancer
Chemother Pharmacol 1992;30(3):238-42.
Tetu B, Lacasse B, Bouchard HL, Lagace R, Huot J, Landry J. P-
glycoprotein and HSP-27 expression in malignant fibrous
histiocytoma, a clinicopathologic and immunohistochemical
study [abstract]. Lab Invest 1991;64(1):9A.
Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A, Rahman
A. Modulation of multidrug resistance in Chinese hamster
cells by liposome-encapsulated doxorubicin. Cancer Commun
1989;1(5):311-6. Published erratum appears in Cancer Commun
1989 Dec;1(6):395.
Thierry AR, Rahman A, Vige D, Notario V, Dritschilo A.
Modulation of multidrug resistance by antisense
oligodeoxynucleotides encapsulated in liposomes [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2578.
Thierry AR, Vige D, Dritschilo A, Rahman A. Modulation of
multidrug resistance by liposomally encapsulated doxorubicin
in two human MDR tumor cell lines [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2214.
Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F,
Picci P, Boiocchi M. Expression of MDR1 and GST-pi in
human soft tissue sarcomas: relation to drug resistance and
biological aggressiveness. Ann Oncol 1992 Jan;3(1):63-9.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Boiocchi M.
Multidrug-resistance in human colon carcinoma cell lines
[abstract]. Anticancer Res 1990;10(5B):1406-7.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Rossi C, Boiocchi M.
Pleiotropic-resistant phenotype is a multifactorial
phenomenon in human colon carcinoma cell lines. Br J Cancer
1991 Jan; 63(1):51-6.
Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi
M. Expression of the mdr1 gene in human colorectal
carcinomas: relationship with multidrug resistance inferred
from analysis of human colorectal carcinoma cell lines.
Cancer Chemother Pharmacol 1992;29(4):283-9.
Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi
M. Prognostic significance of mdr-1 mRNA expression in
untreated human colon carcinomas. Paper presented at:
Symposium on Mechanisms of Drug and Radiation Resistance of
Tumor Cells; 1989 Jun 28-30; Villejuif, France.
Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ.
Elimination of chemoresistant multiple myeloma clonogenic
colony-forming cells by combined treatment with a plasma
cell-reactive monoclonal antibody and a p-glycoprotein-
reactive monoclonal antibody. Cancer Res 1989;49(17):
4829-34.
Tong W, Berman E, Lin S. Pharmacokinetic study of high-dose
tamoxifen with daunorubicin: a phase I trial with escalation
of tamoxifen [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A3156.
Toth K, Vaughan MM, Slocum HK, Fredericks WJ, Chen Y, Karakousis
C, Baker RM, Rustum YM. Comparison of immunocytochemical
and Western blot detection of P-glycoprotein in 15 human
cell lines and 47 sarcoma biopsies [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2190.
Toth K, Vaughan MM, Slocum HK, Fredericks WJ, Chen YF, Arredondo
MA, Harstrick A, Karakousis C, Baker RM, Rustum YM.
Comparison of an immunoperoxidase "sandwich" staining method
and Western blot detection of P-glycoprotein in human cell
lines and sarcomas. Am J Pathol 1992 May; 140(5):1009-16.
Treupel L, Poupon MF, Couvreur P, Puisieux F. [Vectorisation of
doxorubicin in nanospheres and reversion of pleiotropic
resistance of tumor cells]. C R Acad Sci III
1991;313(3):171-4. (Fre).
Tsuruo T. Multidrug resistance: a transport system of antitumor
agents and xenobiotics. Int Symp Princess Takamatsu Cancer
Res Fund 1990;21: 241-51.
Tsuruo T. Proteins involved in multidrug resistance and their
implication for therapy. Pezcoller Found Symp
1990;1:131-43.
Tsuruo T, Hamada H, Sato S, Heike Y. Inhibition of multidrug-
resistant human tumor growth in athymic mice by anti-P-
glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989
Jul;80(7):627-31.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987;78(12): 1415-9.
Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-
containing anthracycline me-2303 as a new antitumor agent
against murine and human tumors and their multidrug-
resistant sublines. Cancer Res 1989;49(20):5537-42.
Twentyman PR. Anthracycline distribution in multicellular tumor
spheroids of parental and MDR cells studied by confocal
microscopy [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33: A2804.
Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a
novel non-immunosuppressive cyclosporin [corrected]. Eur J
Cancer 1991; 27(12):1639-42. Published erratum appears in
Eur J Cancer 1992;28(2-3):616.
Twentyman PR, Wright KA. Derivation and characterization of a
cell line with acquired resistance to cyclosporin A
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2250.
Ujhazy P, Chen Y, Fredericks W, Ehrke MJ. Collateral
sensitivity to tumor necrosis factor in an adriamycin
resistant EL4 cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1625.
Van de Vrie W, Gheuens EE, Bijma A, De Bruijn EA, Marquet RL, Van
Oosterom AT, Eggermont AM. A syngeneic in vivo model of a
multidrug-resistant colon carcinoma, CC531 in the WAG rat
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:
A1270.
Van de Vrie W, Gheuens EE, Durante NM, De Bruijn EA, Marquet RL,
Van Oosterom AT, Eggermont AM. Cyclosporin-A and its
analog PSC 833 can reverse intrinsic multidrug resistance in
a rat colon carcinoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2893.
Van Der Bliek AM, Baas F, Van Der Velde Koerts T, Biedler JL,
Meyers MB, OzoLs RF, Hamilton TC, Joenje H, Borst P. Genes
amplified and overexpressed in human multidrug resistant
cell lines. Cancer Res 1988;48(21):5927-32.
van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ,
Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ,
Pinedo HM, et al. Distribution of multi-drug resistance-
associated P-glycoprotein in normal and neoplastic human
tissues. Analysis with 3 monoclonal antibodies recognizing
different epitopes of the P-glycoprotein molecule. Ann
Oncol 1990;1(1):56-64.
van Kalken CK, Kuiper CM, Broxterman HJ, Feller N, Scheper RJ,
Lankelma J, Meijer CJ, Pinedo HM, Giaccone G. Expression
of P-glycoprotein in the human fetal adrenal is related to
secretion of specific steroids [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2825.
van Kalken CK, van der Hoeven JJ, de Jong J, Giaccone G,
Schuurhuis GJ, Maessen PA, Blokhuis WM, van der Vijgh WJ,
Pinedo HM. Bepridil in combination with anthracyclines to
reverse anthracycline resistance in cancer patients. Eur J
Cancer 1991;27(6):739-44.
Vasanthakumar G, Ahmed NK. Antisense oligonucleoside
methylphosphonate modulates daunorubicin transport in
multidrug-resistant K562 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2121.
Vasanthakumar G, Ahmed NK. Modulation of drug resistance in a
daunorubicin resistant subline with oligonucleoside
methylphosphonates. Cancer Commun 1989;1(4):225-32.
Published erratum appears in Cancer Commun 1990;2(8):295.
Versantvoort CH, Broxterman HJ, Pinedo HM, de Vries EG, Feller N,
Kuiper CM, Lankelma J. Energy-dependent processes involved
in reduced drug accumulation in multidrug-resistant human
lung cancer cell lines without P-glycoprotein expression.
Cancer Res 1992 Jan 1;52(1):17-23.
Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS,
Seynaeve C, Stoter G, Nooter K. A phase II study of
epidoxorubicin in colorectal cancer and the use of
cyclosporin-A in an attempt to reverse multidrug resistance.
Br J Cancer 1991 Aug;64(2):361-4.
Volm M, Bak M Jr, Efferth T, Lathan B, Mattern J.
Immunocytochemical detection of a resistance-associated
glycoprotein in tissue culture cells ascites tumors and
human tumor xenografts by MAB-265-F4. Anticancer Res
1988;8(4):531-6.
Volm M, Bak M Jr, Efferth T, Mattern J. Induced multidrug
resistance in murine leukemia l1210 and associated changes
in a surface-membrane glycoprotein. J Cancer Res Clin Oncol
1989; 115(1):17-24.
Volm M, Efferth T. Relationship of DNA ploidy to
chemoresistance of tumors as measured by in vitro tests.
Cytometry 1990;11(3):406-10.
Volm M, Mattern J, Pommerenke EW. Time course of MDR gene
amplification during in vivo selection for doxorubicin-
resistance and during reversal in murine leukemia L 1210.
Anticancer Res 1991 Mar-Apr;11(2):579-85.
Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein
and glutathione S-transferase-pi in resistant non-small cell
lung carcinomas of smokers. Br J Cancer 1991
Oct;64(4):700-4.
Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J.
Circumvention of multi-drug resistance in human kidney and
kidney carcinoma in vitro. Cancer 1991 May
15;67(10):2484-9.
Von Hoff D, VanDevanter D, Forseth B, Davidson K, Waddelow T,
Wahl G. Hydroxyurea can decrease drug resistance gene copy
numbers in tumor cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2243.
Wadler S, Wiernik PH. Partial reversal of doxorubicin
resistance by forskolin and 1,9-dideoxyforskolin in murine
sarcoma S180 variants. Cancer Res 1988; 48(3):539-43.
Wadler S, Yang CP. Reversal of doxorubicin resistance by
hydrophobic, but not hydrophilic, forskolins. Mol Pharmacol
1991 Dec;40(6):960-4.
Wall DM, Hu XF, Zalcberg JR, Parkin JD. Rapid functional assay for
multidrug resistance in human tumor cell lines using the fluorescent
indicator fluo-3. J Natl Cancer Inst 1991 Feb 6;83(3):206-7.
Wallace RE, Lindh D, Greenberger L, Raventos-Suarez C, Durr FE.
Development of a human breast carcinoma (MX-1E) cell line
resistant to calicheamicin [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2163.
Ward NE, O'Brian CA. Distinct patterns of phorbol-ester-induced
downregulation of protein kinase C activity in adriamycin-
selected multidrug resistant and parental murine
fibrosarcoma cells. Cancer Lett 1991;58(3):189-94.
Warrington RC, Fang WD. Reversal of the multidrug-resistant
phenotype of Chinese hamster ovary cells by l-histidinol. J
Natl Cancer Inst 1989;81(10): 798-803.
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T.
Cellular pharmacology of MX2, a new morpholino
anthracycline, in human pleiotropic drug-resistant cells.
Cancer Res 1991 Jan 1;51(1): 157-61.
Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Mx-2 a
morpholinoanthracycline as a new antitumor agent against
drug-sensitive and multidrug-resistant human and murine
tumor cells. Cancer Res 1988; 48(23):6653-7.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Weaver JL, Pine PS, Aszalos A, Schoenlein PV, Currier SJ,
Padmanabhan R, Gottesman MM. Laser scanning and confocal
microscopy of daunorubicin, doxorubicin, and rhodamine 123
in multidrug-resistant cells. Exp Cell Res 1991
Oct;196(2):323-9.
Weber JM, Sircar S, Horvath J, Dion P. Non P-glycoprotein
mediated multidrug resistance in detransformed rat cells
selected for resistance to methylglyoxal
bis(guanylhydrazone). Cancer Res 1989;49(21):5779-83.
Whelan RD, Deuchars K, Hosking LK, Ling V, Hill BT.
Overexpression of P-glycoprotein in Chinese hamster ovary
cells following fractionated X-irradiation in vitro
[abstract]. Br J Cancer 1990; 62(3):491.
Willman CL, Kopecky KJ, Weick J, Appelbaum F, Grever MR, Head DR,
Elias L, Balcerzak SP, Mills GM, Hynes HE. Biologic
parameters that predict treatment response in de novo acute
myeloid leukemia (AML): CD34, but not multidrug resistance
(MDR) gene expression, is associated with a decreased
complete remission (CR) rate and CD34+ patients more
frequently achieve CR with high-dose cytosine arabinoside
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1992;11:A857.
Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese
hamster ovary cells during recovery from severe hypoxia. J
Natl Cancer Inst 1989;81(16):1235-40.
Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V,
Webster LK, Sawyer WH. Reversal of multidrug resistance by
surfactants. Br J Cancer 1992 Jul;66(1):62-8.
Yang JM, Hait WN. Use of multidrug resistant L1210 cell line
for in vitro and in vivo drug screening [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2161.
Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a
human medullary thyroid carcinoma cell line: association
with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res 1991;11(3):1065-8.
Yanovich S, Gewirtz DA, Hall RE, Pickard P, Boise L, Westin E.
Reactivity and functional properties of a monoclonal
antibody developed against an MDR K562 subline [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1998.
Yanovich S, Hall RE, Gewirtz DA. Characterization of a k562
multidrug-resistant cell line. Cancer Res
1989;49(16):4499-503.
Yanovich S, Hall RE, Gewirtz DA. Resistance to natural killer
(NK) cell lysis is associated with multiple drug resistance
(MDR) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1082.
Yin MB, Bankusli I, Rustum YM. Effect of verapamil, DMDP
(RO11-2933), a tiapamil analog, and dipyridamole, a
nucleoside transport inhibitor, on the extent and duration
of doxorubicin-induced DNA single strand breaks in
multidrug-resistant P-388 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2103.
Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki
K, Tsuruo T, Cowan KH, Glazer RI. Transfection with
protein kinase C alpha confers increased multidrug
resistance to MCF-7 cells expressing P-glycoprotein. Cancer
Commun 1991 Jun;3(6):181-9.
Yuan ZK, Sauerteig A, Krishan A. Multiple drug resistance
markers and chemosensitivity of human melanoma cells to
doxorubicin [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2112.
Zalcberg JR, Krauer K, Hur XF, McKenzie IF, Pietersz G.
Anthracycline conjugates bypass cellular mechanisms of
resistance in multidrug resistant (MDR) cells [abstract].
Paper presented at: Cancer in the 1990's: is more aggressive
treatment better? 17th Annual Scientific Meeting of the
Clinical Oncological Society of Australia Inc.; 1990
Nov 26-28; Melbourne, Australia.
Zamora JM, Pearce HL, Beck WT. Physical-chemical properties
shared by compounds that modulate multidrug resistance in
human leukemic cells. Mol Pharmacol 1988;33(4):454-62.
Zou CP, Van NT, Kuo MT. Isolation and characterization of
putative intrinsic multidrug resistant Chinese hamster ovary
cells by fluorescence activated cell sorting. Anticancer
Res 1992 Mar-Apr;12(2):427-32.
Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E,
Mayes J, Sie KL, Meltzer PS, Trent JM. HT1080/DR4: a P-
glycoprotein-negative human fibrosarcoma cell line
exhibiting resistance to topoisomerase II-reactive drugs
despite the presence of a drug-sensitive topoisomerase II.
J Natl Cancer Inst 1990 Oct 3;82(19):1553-61.
-Antimetabolites
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A,
Pogliani EM, Corneo G, Parmiani G. Increased
susceptibility to lymphokine activated killer (LAK) lysis of
relapsing vs. newly diagnosed acute leukemic cells without
changes in drug resistance or in the expression of adhesion
molecules. Ann Oncol 1992;3(2):155-62.
Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S.
Multidrug resistance in a human leukemic cell line selected
for resistance to trimetrexate. Cancer Res 1989 Dec
1;49(23): 6556-61.
Arkin H, Ohnuma T, Schwartz GK, Cuttner J, Holland JF. Lack of
staurosporine (STSN) influence on multidrug resistance (MDR)
in human leukemic cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2004.
Assaraf YG, Molina A, Schimke RT. Cross-resistance to the
lipid-soluble antifolate trimetrexate in human carcinoma
cells with the multidrug-resistant phenotype. J Natl Cancer
Inst 1989 Feb 15; 81(4):290-4.
Assaraf YG, Molina A, Schimke RT. Sequential amplification of
dihydrofolate reductase and multidrug resistance genes in
Chinese hamster ovary cells selected for stepwise resistance
to the lipid-soluble antifolate trimetrexate. J Biol Chem
1989 Nov 5;264(31):18326-34.
Bhushan A, Abramson R, Chiu JF, Tritton TR. Expression of c-fos
in human and murine multidrug-resistant cells. Mol
Pharmacol 1992 Jul;42(1):69-74.
Borst P. Genetic mechanisms of drug resistance. A review. Acta
Oncol 1991;30(1):87-105.
Casazza AM, Catino JJ. Mechanisms and strategies related to
drug resistance. Paper presented at: Strategies in Cancer
Medical Therapy: Biological Bases and Clinical Implications;
1989 Apr 12-15; Forli, Italy.
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss
of multiple drug resistance by hydroxyurea [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A209.
Ellenberger TE, Beverley SM. Multiple drug resistance and
conservative amplification of the H region in leishmania-
major. J Biol Chem 1989; 264(25):15094-103.
Ferguson PJ, Cheng YC. Phenotypic instability of drug
sensitivity in a human colon carcinoma cell line. Cancer
Res 1989;49(5):1148-53.
Fry DW, Besserer JA. Characterization of trimetrexate transport
in human lymphoblastoid cells and development of impaired
influx as a mechanism of resistance to lipophilic
antifolates. Cancer Res 1988;48(24 Pt 1):6986-91.
Fuchs B, Ostmeier H, Suter L. P-glycoprotein expression in
malignant melanoma. J Cancer Res Clin Oncol
1991;117(2):168-71.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991; 12(5):359-73.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW.
Resistance to drugs associated with the multidrug resistance
phenotype following selection with high-concentration
methotrexate. J Natl Cancer Inst 1989;81(16):1250-4.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Henderson GB. Mediation of cellular anion detoxification in
leukemic cells by unidirectional efflux pumps. Adv Enzyme
Regul 1989;29:61-72.
Ito T, Ohnuma T, Holland JF, Mattern MR. Altered DNA
topoisomerase (TOPO) II activity in human leukemia sublines
resistant to trimetrexate (TMQ) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2078.
Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J,
Tsuruo T. Establishment and characterization of
doxorubicin-resistant human bladder cancer cell line,
KK47/ADM. J Urol 1992 Aug;148(2 Pt 1):441-5.
Klohs WD, Sebolt JS, Steinkampf RW, Havlick MJ, Berman EM, Werbel
LM, Leopold WR, Jackson RC. Correlation between in vitro
and in vivo testing of DNA-binders versus antifolates in
multiple drug resistant (MDR) P388 cells (P388R) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1271.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Kobayashi H, Takemura Y, Miyachi H, Ohnuma T. Alterations of
MDR1 and dihydrofolate reductase genes in human leukemia
sublines resistant to various folate analogs [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A1932.
Koh EH, Chung HC, Kim JH, Roh JK, Kim BS, Min JS, Lee KS. Value
of immunohistochemical detection of P-glycoprotein in breast
cancer before and after induction chemotherapy [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:182.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
Lutzky J, Canada AL, Yamanishi DT, Bhalla K, Hindenburg AA.
Effect of verapamil and buthionine sulfoximine (BSO) on
daunorubicin (DNR) cytotoxicity of multidrug-resistant human
melanoma cell lines overexpressing P-glycoprotein and
glutathione-s-transferases [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A3315.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Mazzoni A, Trave F, Canti G, Franco P. Effect of the tiapamil
analog ro-11-2933 on cellular sensitivity to antitumor
drugs in sensitive and multidrug resistant human ovarian
cancer cells. Anticancer Res 1989; 9(2):367-72.
Mechetner EB, Roninson IB. Efficient inhibition of P-
glycoprotein-mediated multidrug resistance with a monoclonal
antibody. Proc Natl Acad Sci U S A 1992 Jul
1;89(13):5824-8.
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M.
MDR-1 gene amplification in acute lymphoblastic leukemia
prior to antileukemic treatment. Br J Haematol
1991;78(2):288-9.
Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I.
Transgenic mice that express the human multidrug-resistance
gene in bone marrow enable a rapid identification of agents
that reverse drug resistance. Proc Natl Acad Sci U S A 1991
Jan 15; 88(2):547-51.
Miyachi H, Takemura Y, Kobayashi H, Ohnuma T. CB3717 induced
enhancement of multidrug resistance (MDR) in a trimetrexate
(TMQ)-resistant human acute lymphoblastic leukemia cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2251.
Molina A, Assaraf YG, Schimke RT. Acquisition of resistance to
the lipophilic antifolate trimetrexate in human breast
carcinoma cells [abstract]. Clin Res 1989;37(2):469a.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Norris MD, Haber M, Gilbert J, Madafiglio J, Kavallaris M,
Stewart BW, Mechetner EB, Gudkov AV, Roninson IB.
Selection for MDR1 gene expression by high concentration
methotrexate [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2840.
Okabe Kado J, Hayashi M, Honma Y, Hozumi M, Tsuruo T.
Inhibition by erythroid differentiation factor (activin A)
of P- glycoprotein expression in multidrug resistant human
K562 erythroleukemia cells. Cancer Res 1991;51(10):2582-6.
Ouellette M, Fase-Fowler F, Borst P. The amplified H circle of
methotrexate-resistant leishmania tarentolae contains a
novel P-glycoprotein gene. EMBO J 1990 Apr;9(4):1027-33.
Park JG, Kramer BS, Lai SL, Goldstein LJ, Gazdar AF.
Chemosensitivity patterns and expression of human multidrug
resistance-associated MDR1 gene by human gastric and
colorectal carcinoma cell lines. J Natl Cancer Inst 1990
Feb 7;82(3):193-8.
Pinedo HM, van Groeningen CJ, van Kalken CK. Cellular
pharmacology and drug resistance in breast cancer. Paper
presented at: Biology and therapy of breast cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Ross DD. Cellular and pharmacologic aspects of drug resistance
in acute myeloid leukemia. Curr Opin Oncol 1991
Feb;3(1):21-9.
Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of p-
glycoprotein in multidrug resistant cells with photoactive
analogs of colchicine. Biochem Biophys Res Commun
1989;162(3): 1402-8.
Sharma RC, Assaraf YG, Schimke RT. Verapamil potentiation of
trimetrexate cytotoxicity and dihydrofolate reductase gene
amplification in CHO cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2012.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human
hepatocellular carcinoma cell lines exhibit multidrug
resistance unrelated to MRD1 gene expression. J Cell Sci
1991 Mar;98(Pt 3):317-22.
Shimm DS, Olson S, Hill AB. Radiation resistance in a multidrug
resistant human T-cell leukemia line. Int J Radiat Oncol
Biol Phys 1988;15(4):931-6.
Shinoda H, Inaba M, Tsuruo T. In vivo circumvention of
vincristine resistance in mice with P388 leukemia using a
novel compound, AHC 52. Cancer Res 1989;49(7):1722-6.
Sonneveld P, Nooter K. Reversal of drug-resistance by
cyclosporin-A in a patient with acute myelocytic leukaemia.
Br J Haematol 1990 Jun;75(2):208-11.
Takemura Y, Ohnuma T, Miyachi H, Sekiguchi S. A human leukemia cell line
made resistant to two folate analogues, trimetrexate and
N10-propargyl-5, 8-dideazafolic acid (CB3717). J Cancer Res Clin
Oncol 1991;117(6):519-25.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987;78(12): 1415-9.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese
hamster ovary cells during recovery from severe hypoxia. J
Natl Cancer Inst 1989;81(16):1235-40.
-Immunosuppressive agents
Arvelo F, Hanania N, Mangin C, Baldeyrou P, Arriagada R, Le
Chevalier T, Ruffie P, Poupon MF. Multidrug resistance and
mdr1 gene expression in a human small cell lung carcinoma
before treatment. Paper presented at: Symposium on
Mechanisms of Drug and Radiation Resistance of Tumor Cells;
1989 Jun 28-30; Villejuif, France.
Beck WT, Qian X, Danks MK. Circumvention of multidrug
resistance due to P-glycoprotein or to altered DNA
topoisomerase II. Paper presented at: 3rd International
Congress on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9;
France. (Eng, Fre).
Benard J, Bourhis J, Hartmann O, Boccon-Gibod L, Duvillard P,
Lhomme C, Michel G, Lemerle J, Goldstein L, Gottesman M, et
al. Overexpression of human MDR1 gene is related to prior
chemotherapy in ovarian carcinomas and in neuroblastomas.
Paper presented at: Symposium on Mechanisms of Drug and
Radiation Resistance of Tumor Cells; 1989 Jun 28-30;
Villejuif, France.
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger
P, Loor F. In vivo circumvention of P-glycoprotein-
mediated multidrug resistance of tumor cells with SDZ PSC
833. Cancer Res 1991 Aug 15;51(16):4226-33.
Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration
of daunomycin retention in multidrug-resistant P388 cells by
submicromolar concentrations of SDZ PSC 833, a
nonimmunosuppressive cyclosporin derivative. Exp Cell Res
1991 Sep;196(1):26-32.
Boscoboinik D, Epand RM. Increased cellular internalization of
amphiphiles in a multidrug-resistant CHO cell line. Biochim
Biophys Acta 1989;1014(1):53-6.
Boscoboinik D, Epand RM. Increased rate of transbilayer
diffusion of amphiphiles in multidrug-resistant cell lines
[abstract]. Cancer Chemother Pharmacol 1989;24 Suppl 2:S78.
Boscoboinik D, Gupta RS, Epand RM. Investigation of the
relationship between altered intracellular pH and multidrug
resistance in mammalian cells. Br J Cancer 1990
Apr;61(4):568-72.
Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard
J. Expression of a human multidrug resistance gene in
ovarian carcinomas. Cancer Res 1989;49(18):5062-5.
Broxterman HJ, Pinedo HM, Schuurhuis GJ, Lankelma J.
Cyclosporin A and verapamil have different effects on energy
metabolism in multidrug-resistant tumour cells. Br J Cancer
1990 Jul;62(1):85-8.
Cantwell BMJ, Bozzino JM, Corris P, Harris AL. The multidrug
resistant phenotype in clinical practice evaluation of cross
resistance to ifosfamide and mesna after VP-16-213
doxorubicin and vincristine VPAV for small cell lung cancer.
Eur J Cancer Clin Oncol 1988;24(2):123-30.
Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE.
Enhancement of anthracycline growth inhibition in parent and
multidrug-resistant Chinese hamster ovary cells by
cyclosporin A and its analogues. Cancer Res 1989;
49(22):6275-9.
Chan HS, Thorner PS, Weitzman S, Solh H, Koren G, Thiessen J,
Haddad G, Giesbrecht E, Verjee Z, Greenberg ML, et al.
Cyclosporin A for reversal of multidrug resistance in
childhood malignancies [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2854.
Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide
(VP-16) cytotoxicity by verapamil or cyclosporine in
multidrug-resistant human leukemic cell lines and normal
bone marrow. Exp Hematol 1990 Dec;18(11):1193-8.
Coley HM, Twentyman PR, Workman P. Improved cellular
accumulation is characteristic of anthracyclines which
retain high activity in multidrug resistant cell lines,
alone or in combination with verapamil or cyclosporin A.
Biochem Pharmacol 1989 Dec 15;38(24):4467-75.
Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA.
Increased drug accumulation ex vivo with cyclosporin in
chronic lymphatic leukemia and its relationship to epitope
masking of P-glycoprotein. Leukemia 1991 Dec;5(12):1050-3.
Dietel M, Bunge A, Heidebrecht HJ, Reymann A, Seidel A.
Resistance to the adriamycin-resistance reversing potency of
cyclosporin A in P-glycoprotein-positive Friend leukemia
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2906.
Dorr RT. Mitomycin, ifosfamide, and mesna in the treatment of
lung cancer. Semin Oncol 1990 Aug;17(4 Suppl 7):2-5.
Dorr RT, Liddil JD. Modulation of mitomycin C-induced multidrug
resistance in-vitro. Cancer Chemother Pharmacol
1991;27(4):290-4.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Durivage HJ, Buzaid AC, Todd MB, Poo WJ, March JC, Davis CA, Hait
WN. A phase I-II study of pulse cyclosporin-A (CsA) plus
vinblastine (VBL) in selected refractory malignancies
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A335.
Erlichman C, Bjarnason G, Bunting P, DeAngelis C, Kerr I, Maki E,
Moore M, Rahemtulla C, Thiessen J, Walker S. Cyclosporin A
(CyA) modulation of doxorubicin (D): a pharmacokinetic/
pharmacodynamic trial [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A314.
Fardel O, Ratanasavanh D, Loyer P, Ketterer B, Guillouzo A.
Overexpression of the multidrug resistance gene product in
adult rat hepatocytes during primary culture. Eur J Biochem
1992 Apr 15;205(2):847-52.
Ferguson LR, Turner PM, Baguley BC. Stimulation of bacterial
mutagenicity by inhibitors of mammalian cell multidrug
resistance. Mutat Res 1991 Dec;264(4):231-4.
Foxwell BM, Mackie A, Ling V, Ryffel B. Identification of the
multidrug resistance-related P-glycoprotein as a
cyclosporine binding protein. Mol Pharmacol 1989
Oct;36(4):543-6.
Friche E, Jensen PB, Nissen NI. Comparison of cyclosporin A and
SDZ PSC833 as multidrug-resistance modulators in a
daunorubicin-resistant Ehrlich ascites tumor. Cancer
Chemother Pharmacol 1992;30(3):235-7.
Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN. The
solvents cremophor EL and Tween 80 modulate daunorubicin
resistance in the multidrug resistant Ehrlich ascites tumor.
Cancer Commun 1990;2(9):297-303.
Fuchs B, Ostmeier H, Suter L. P-glycoprotein expression in
malignant melanoma. J Cancer Res Clin Oncol
1991;117(2):168-71.
Gaveriaux C, Boesch D, Boelsterli JJ, Bollinger P, Eberle MK,
Hiestand P, Payne T, Traber R, Wenger R, Loor F.
Overcoming multidrug resistance in Chinese hamster ovary
cells in vitro by cyclosporin A (Sandimmune) and non-
immunosuppressive derivatives. Br J Cancer 1989
Dec;60(6):867-71.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991;12(5): 359-73.
Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporin
accumulation in multidrug-resistant cells. Biochem Biophys
Res Commun 1988;152(2): 552-8.
Gosland MP, Brophy NA, Duran GE, Yahanda AM, Adler KM, Hardy RI,
Halsey J, Sikic BI. Bilirubin: a physiological substrate
for the multidrug transporter [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2533.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Gupta S, Tsuruo T, Gollapudi S. Induction of P-glycoprotein
expression in T cells and inhibition by cyclosporin A. A
role of PKC isoforms [abstract]. FASEB J 1991;5(5):A995.
Hait WN, Aftab DT. Rational design and pre-clinical
pharmacology of drugs for reversing multidrug resistance.
Biochem Pharmacol 1992;43(1):103-7.
Hait WN, Stein JM, Koletsky AJ, Harding MW, Handschumacher RE.
Activity of cyclosporin A and a non-immunosuppressive
cyclosporin against multidrug resistant leukemic cell lines.
Cancer Commun 1989;1(1):35-43.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992; 31(2):205-13.
Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1
and mdr3 multidrug-resistance genes in human acute and
chronic leukemias and association with stimulation of drug
accumulation by cyclosporine. J Natl Cancer Inst 1990 Jul
4; 82(13):1133-40.
Herweijer H, Van Den Engh G, Nooter K. A rapid and sensitive
flow cytometric method for the detection of multidrug-
resistant cells. Cytometry 1989;10(4):463-8.
Herzog CE, Tsokos M, Fojo AT, Bates SE. Calcium channel
blockers (CCBs) induce P-glycoprotein (Pgp) in human colon
carcinoma (HCC) cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2185.
Hofsli E. Multimedikamentresistens - teoretiske og kliniske
aspekter [Multidrug resistance - theoretical and clinical
aspects]. Tidsskr Nor Laegeforen 1992;112(4):472-4. (Nor).
Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR. Combined use
of cyclosporin A and verapamil in modulating multidrug
resistance in human leukemia cell lines. Cancer Res 1990
May 15;50(10):2953-7.
Ishida Y, Shimada Y, Shimoyama M. Synergistic effect of
cyclosporin A and verapamil in overcoming vincristine
resistance of multidrug-resistant cultured human leukemia
cells. Jpn J Cancer Res 1990 Aug;81(8):834-41.
Jancis EM, Carbone R, Loechner KJ, Dannies PS. Estradiol
induction of rhodamine 123 efflux and multidrug-resistance
pump mRNA in rat pituitary tumor cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2820.
Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA,
Hiestand PC. Pharmacologic interactions between the
resistance-modifying cyclosporine SDZ PSC 833 and etoposide
(VP 16-213) enhance in vivo cytostatic activity and
toxicity. Int J Cancer 1992 May 28;51(3):433-8.
Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA,
Bollinger P, Hiestand PC. SDZ PSC-833, a non-
immunosuppressive cyclosporine: its potency in overcoming P-
glycoprotein-mediated multidrug resistance of murine
leukemia. Int J Cancer 1992 Feb 20;50(4):593-7.
Kemnitz J, Uysal A, Haverich A, Heublein B, Cohnert TR, Stangel
W, Georgii A. Multidrug resistance in heart transplant
patients: a preliminary communication on a possible
mechanism of therapy-resistant rejection. J Heart Lung
Transplant 1991 Mar-Apr;10(2):201-10.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Koh EH, Chung HC, Kim JH, Roh JK, Kim BS, Min JS, Lee KS. Value
of immunohistochemical detection of P-glycoprotein in breast
cancer before and after induction chemotherapy [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:182.
Larsson R, Bergh J, Nygren P. Combination of cyclosporin A and
buthionine sulfoximine (BSO) as a pharmacological strategy
for circumvention of multidrug resistance in small cell lung
cancer cell lines selected for resistance to doxorubicin.
Anticancer Res 1991 Jan-Feb;11(1):455-9.
Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R,
Mertelsmann R. Induction of multiple-drug resistance
during anti-neoplastic chemotherapy in vitro. Int J Cancer
1991 Oct 21; 49(4):630-7.
Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts
T, Smit JJ, Borst P. Multidrug resistance phenotype of
human BRO melanoma cells transfected with a wild-type human
mdr1 complementary DNA. Cancer Res 1990 Mar 15;
50(6):1779-85.
List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S,
Futscher B, Dalton W. Biochemical modulation of
anthracycline resistance in acute leukemia with cyclosporin-
A (CSA) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A865.
Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Emmer G. SDZ 280-446, a novel semi-synthetic
cyclopeptolide: in vitro and in vivo circumvention of the P-
glycoprotein-mediated tumour cell multidrug resistance. Br
J Cancer 1992 Jan;65(1):11-8.
Lum BL, Kaubisch S, Adler KM, Yahanda AM, Gosland MP, Sikic BI.
Enhanced leukopenia by cyclosporine in a phase I clinical
trial of modulation of etoposide resistance: pharmacokinetic
and pharmacodynamic analysis [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A1413.
Lum BL, Kaubisch S, Gosland MP, Jew LL, Ehsan MN, Schnur DP,
Yahanda AM, Adler KM, Hardy R, Brophy NA, et al. The
effect of cyclosporin (CSA) on etoposide (E)
pharmacokinetics in a phase I trial of E with CSA as a
modulator of multidrug resistance [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1991;10:A277.
Marie JP, Bastie JN, Coloma F, Just-Landi S, Filleul A, Catalin
J, Zittoun R. A phase I-II trial of cyclosporine (CSA)
with etoposide (E) and mitoxantrone (M) in advanced acute
leukemia (AL) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11:A911.
Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro
effect of P-glycoprotein (P-gp) modulators on drug
sensitivity of leukemic progenitors (CFU-L) in acute
myelogenous leukemia (AML). Exp Hematol 1992
Jun;20(5):565-8.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
McMichael A, Klohs W, Steinkampf R, Elliott W, Ramu A.
Tioperidone: a new chemosensitizer for multidrug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2243.
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M.
MDR-1 gene amplification in acute lymphoblastic leukemia
prior to antileukemic treatment. Br J Haematol
1991;78(2):288-9.
Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski
H, Stahle C, Sachs DH, Pastan I, Gottesman MM.
Transplantation of bone marrow cells from transgenic mice
expressing the human MDR1 gene results in long-term
protection against the myelosuppressive effect of
chemotherapy in mice. Blood 1992 Feb 15;79(4):1087-93.
Mickisch GH, Aksentijevich Y, Gottesman MM, Pastan I.
Transplantation of bone marrow cells expressing the human
MDR1 gene results in long-term protection against the
myelosuppressive effect of chemotherapy in mice [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2803.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE.
P-glycoprotein expression in malignant lymphoma and
reversal of clinical drug resistance with chemotherapy plus
high-dose verapamil. J Clin Oncol 1991 Jan; 9(1):17-24.
Miller TP, Grogan TM, Spier CM, Salmon SE, Dalton WS. High-dose
verapamil infusion added to chemotherapy reverses drug
resistance in lymphoma patients in relapse [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1989;8:A984.
Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano
T, Tomoda Y. Mitomycin C cross-resistance induced by
adriamycin in human ovarian cancer cells in vitro. Cancer
Chemother Pharmacol 1990;26(5):333-9.
Mizuno K, Furuhashi Y, Misawa T, Iwata M, Kawai M, Kikkawa F,
Kano T, Tomoda Y. Modulation of multidrug resistance by
immunosuppressive agents: cyclosporin analogues, FK506 and
mizoribine. Anticancer Res 1992 Jan-Feb; 12(1):21-5.
Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of
multidrug resistance by an immunosuppressive agent FK-506.
Cancer Chemother Pharmacol 1992;29(3):195-200.
Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-
dependent high affinity vincristine binding to the plasma
membrane of multidrug-resistant K562 cells without calcium
ion involvement. Cancer Res 1989;49(6):1452-5.
Nooter K, Herweijer H, Sonneveld P, Verweij J, Hagenbeek A,
Stoter G. Detection of multidrug resistance (MDR) in
refractory cancer patients [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2092.
Nooter K, Oostrum R, Jonker R, Van Dekken H, Stokdijk W, Van Den
Engh G. Effect of cyclosporin A on daunorubicin
accumulation in multidrug-resistant p388 leukemia cells
measured by real-time flow cytometry. Cancer Chemother
Pharmacol 1989;23(5):296-300.
Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer
H, Valerio D, Hagemeijer A, Baas F. Expression of the mdr3
gene in prolymphocytic leukemia: association with
cyclosporin-A-induced increase in drug accumulation. Int J
Cancer 1990 Apr 15;45(4): 626-31.
Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T,
Valerio D. Overexpression of the mdr1 gene in blast cells
from patients with acute myelocytic leukemia is associated
with decreased anthracycline accumulation that can be
restored by cyclosporin-A. Int J Cancer 1990 Feb 15;45(2):
263-8.
Nygren P, Larsson R. Verapamil and cyclosporin A sensitize
human kidney tumor cells to vincristine in absence of
membrane P-glycoprotein and without apparent changes in the
cytoplasmic free Ca2+ concentration. Biosci Rep 1990
Apr;10(2):231-7.
Onishi Y, Handel LM, Hall L, Fojo AT, Young RC, Ozols RF,
Hamilton TC. Multidrug resistance (mdr-1) gene
amplification and overexpression (OE) in human ovarian
cancer (HOC) cell lines from untreated patients (pts) and
pts refractory to combination chemotherapy (CC) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2280.
Osann K, Sweet P, Slater LM. Synergistic interaction of
cyclosporin A and verapamil on vincristine and daunorubicin
resistance in multidrug-resistant human leukemia cells in
vitro. Cancer Chemother Pharmacol 1992;30(2):152-4.
Petrini M, Carulli G, Mattii L, Sabbatini A, Pardi C, Caracciolo
F, Grassi B. [The pleiotropic drug resistance phenotype:
role of reverting agents "in vitro" and "in vivo"].
Haematologica 1991 Jun;76 Suppl 3:173-6. (Ita).
Pierre A, Perez V, Leonce S, Anstett M, Atassi G. In vitro
circumvention of multidrug resistance by cyclosporin A,
cremophor EL, reserpine or verapamil [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2241.
Pinedo HM, van Groeningen CJ, van Kalken CK. Cellular
pharmacology and drug resistance in breast cancer. Paper
presented at: Biology and therapy of breast cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Pourtier-Manzanedo A, Boesch D, Loor F. FK-506 (fujimycin)
reverses the multidrug resistance of tumor cells in vitro.
Anticancer Drugs 1991 Jun; 2(3):279-83.
Rhodes T, Twentyman PR. Effects of cyclosporin A and verapamil
on cellular pharmacokinetics and chemosensitivity in an MDR
cell line which does not express P-glycoprotein [abstract].
Br J Cancer 1991;63 Suppl 13:12.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M.
Immunohistochemical analysis of P-glycoprotein expression
correlated with chemotherapy resistance in locally advanced
breast cancer. Hum Pathol 1990 Aug;21(8):787-91.
Ross D, Wooten P, Ordonez JV, Sridhara R, Lee E, Schiffer C.
MDR1 expression and effects of cyclosporin-A, verapamil and
progesterone on daunorubicin cytotoxicity in blast cells
from acute myelogenous leukemia patients [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2839.
Ruszala-Mallon V, Silva J, Raventos-Suarez C, Durr FE. P-
glycoprotein-mediated multidrug resistance in ovarian
carcinoma cells selected for resistance to bisantrene, a
synthetic anticancer drug [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31: A2110.
Ryffel B, Woerly G, Rodriguez C, Foxwell BM. Identification of
the multidrug resistance-related membrane glycoprotein as an
acceptor for cyclosporine. J Recept Res
1991;11(1-4):675-86.
Safa AR. P-glycoprotein as a target for chemosensitizing
agents. Paper presented at: 1st International Interface of
Clinical and Laboratory Responses to Anticancer Drugs; 1989
Mar 13-15; Villejuif, France.
Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug-
resistant cells. Cancer Invest 1992;10(4): 295-305.
Salminen A, Elson HF, Mickley LA, Fojo AT, Gottesman MM.
Implantation of recombinant rat myocytes into adult skeletal
muscle: a potential gene therapy. Hum Gene Ther 1991
Spring;2(1): 15-26.
Salmon SE, Miller T, Grogan T, Dalton WS. Reversal of
multidrug resistance (MDR) with chemosensitizers: an
emerging clinical reality. Paper presented at: Drug
resistance as a biochemical target in cancer
chemotherapy. 13th Bristol-Myers Squibb
Symposium on Cancer Research; 1990 May 10-11; Tokyo, Japan.
Samuels B, Murray J, Sherman J, Agresti M, Safa A. Combination
multidrug resistance modulation: synergism and additivity
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2236.
Samuels B, Ratain M, Mick R, Vogelzang NJ, Schilsky R, O'Brien S,
Harrison H. Phase I trial of multidrug resistance
modulation with cyclosporine A [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A1163.
Samuels BL, Murray JL, Safa AR. Additive reversal of multidrug
resistance by combinations of non-cross-toxic modulating
agents [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2138.
Schluesener HJ, Koeppel C, Jung S. Multidrug transport in human
autoimmune T line cells and peripheral blood lymphocytes.
Immunopharmacology 1992 Jan-Feb;23(1):37-48.
Schuurhuis GJ, Pinedo HM, Broxterman HJ, van Kalken CK, Kuiper
CM, Lankelma J. Differential sensitivity of multi-drug-
resistant and -sensitive cells to resistance-modifying
agents and the relation with reversal of anthracycline
resistance. Int J Cancer 1990 Aug 15;46(2):330-6.
Shimoyama M. Detection of multidrug resistant (MDR) cancer
cells by monoclonal antibodies. Paper presented at: Drug
resistance as a biochemical target in cancer chemotherapy.
13th Bristol-Myers Squibb Symposium on Cancer Research; 1990
May 10-11; Tokyo, Japan.
Shoji Y, Fisher MH, Periasamy A, Herman B, Juliano RL.
Verapamil and cyclosporin A modulate doxorubicin toxicity by
distinct mechanisms. Cancer Lett 1991 May 24;57(3):209-18.
Silbermann MH, Boersma AW, Janssen AL, Scheper RJ, Herweijer H,
Nooter K. Effects of cyclosporin A and verapamil on the
intracellular daunorubicin accumulation in Chinese hamster
ovary cells with increasing levels of drug-resistance. Int
J Cancer 1989 Oct 15;44(4):722-6.
Slater LM, Sweet P, Gupta S. Cyclosporin a (CsA) and verapamil
(Vp) effects on altered mitochondrial potentials (MoP) in
multidrug-resistant (mdr) acute lymphatic leukemia (ALL)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2260.
Slater LM, Wetzel M, Cho J, Sweet P. Development of cyclosporin
A mediated immunity in L1210 leukaemia. Br J Cancer 1991
Dec;64(6):1098-102.
Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy
H. Sufficient levels of quinine in the serum circumvent
the multidrug resistance of the human leukemic cell line
K562/ADM. Cancer 1991 Oct 15;68(8):1714-9.
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S,
Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-
resistant multiple myeloma by cyclosporin. The Leukaemia
Group of the EORTC and the HOVON. Lancet 1992 Aug 1;
340(8814):255-9.
Sonneveld P, Nooter K. Reversal of drug-resistance by
cyclosporin-A in a patient with acute myelocytic leukaemia.
Br J Haematol 1990 Jun;75(2):208-11.
Sonneveld P, Nooter K, Burghouts JTM, Herweijer H, Adriaansen
HJ, Van Dongen JJM. High expression of the mdr3 multidrug-
resistance gene in advanced-stage chronic lymphocytic
leukemia. Blood 1992;79(6):1496-500.
Sonneveld P, Nooter K, Herweyer H, te Boekhorst P, van Kapel J,
Lowenberg B. Multidrug resistance (mdr1) in leukemia and
myeloma: detection, clinical relevance and circumvention
[abstract]. Haematologica 1991;76 Suppl 4:74.
Spoelstra EC, Dekker H, Broxterman HJ, Lankelma J. The effect
of cyclosporin A and verapamil on daunomycin accumulation
rate in the murine colon carcinoma cell line C-26
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1929.
Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, Lankelma J.
P-glycoprotein drug efflux pump involved in the mechanisms
of intrinsic drug resistance in various colon cancer cell
lines. Evidence for a saturation of active daunorubicin
transport. Biochem Pharmacol 1991;41(3):349-60.
Stow MW, Warr JR. Amplification and expression of MDR genes and
flanking sequences in verapamil hypersensitive hamster cell
lines. Biochim Biophys Acta 1991;1092(1):7-14.
Sweet P, Chan PK, Slater LM. Cyclosporin A and verapamil
enhancement of daunorubicin-produced nucleolar protein b23
translocation in daunorubicin-resistant and sensitive human
and murine tumor cells. Cancer Res 1989;49(3):677-80.
Tamai I, Safa AR. Azidopine noncompetitively interacts with
vinblastine and cyclosporin A binding to P-glycoprotein in
multidrug resistant cells. J Biol Chem 1991 Sep 5;
266(25):16796-800.
Tamai I, Safa AR. Competitive interaction of cyclosporins with
the Vinca alkaloid-binding site of P-glycoprotein in
multidrug-resistant cells. J Biol Chem 1990 Sep
25;265(27):16509-13.
te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P.
Reversal of typical multidrug resistance by cyclosporin and
its non-immunosuppressive analogue SDZ PSC 833 in Chinese
hamster ovary cells expressing the mdr1 phenotype. Cancer
Chemother Pharmacol 1992;30(3):238-42.
Tebbi CK, Chervinsky D, Baker RM. Modulation of drug resistance
in homoharringtonine-resistant C-1300 neuroblastoma cells
with cyclosporine A and dipyridamole. J Cell Physiol 1991
Sep;148(3): 464-71.
Tickman RJ, Holoye P, Robey-Cafferty S, Bruner J. P-
glycoprotein (PGP) in small cell carcinoma of lung
expression before and after chemotherapy and its influence
upon responsiveness to a preoperative chemotherapy regimen
[abstract]. Lab Invest 1990; 62(1):99a.
Tobe S, Lieberman D, Goldberg H, Skorecki K, Reithmeier R.
Detection and localization of P-glycoprotein (P-gp) in the
kidney [abstract]. Kidney Int 1990;37(1):234.
Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F,
Picci P, Boiocchi M. Expression of MDR1 and GST-pi in
human soft tissue sarcomas: relation to drug resistance and
biological aggressiveness. Ann Oncol 1992;3(1):63-9.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987;78(12): 1415-9.
Twentyman PR. Anthracycline distribution in multicellular tumor
spheroids of parental and MDR cells studied by confocal
microscopy [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33: A2804.
Twentyman PR. Cyclosporins as drug resistance modifiers.
Biochem Pharmacol 1992 Jan 9; 43(1):109-17.
Twentyman PR. Modification of cytotoxic drug resistance by non-
immunosuppressive cyclosporins. Br J Cancer
1988;57(3):254-8.
Twentyman PR. Strategies for circumventing resistance to
cytotoxic drugs. Paper presented at: 5th Biennial
Conference of the Indian Association of Cancer
Chemotherapists; 1989 Feb 17-19; Bombay, India.
Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a
novel non-immunosuppressive cyclosporin [corrected]. Eur J
Cancer 1991; 27(12):1639-42. Published erratum appears in
Eur J Cancer 1992;28(2-3):616.
Twentyman PR, Wright KA. Derivation and characterization of a
cell line with acquired resistance to cyclosporin A
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2250.
Twentyman PR, Wright KA, Wallace HM. Cyclosporin A and non-
immunosuppressive analogs inhibit growth of human lung
cancer cells in vitro [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1921.
Twentyman PR, Wright KA, Wallace HM. Effects of cyclosporin A
and a non-immunosuppressive analogue, O-acetyl cyclosporin
A, upon the growth of parent and multidrug resistant human
lung cancer cells in vitro. Br J Cancer 1992
Mar;65(3):335-40.
Van de Vrie W, Gheuens EE, Durante NM, De Bruijn EA, Marquet RL,
Van Oosterom AT, Eggermont AM. Cyclosporin-A and its
analog PSC 833 can reverse intrinsic multidrug resistance in
a rat colon carcinoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2893.
Van Der Zee AGJ, Hollema H, De Jong S, Boonstra H, Gouw A,
Willemse PHB, Zijlstra JG, De Vries EGE. P-glycoprotein
expression and DNA topoisomerase I and II activity in benign
tumors of the ovary and in malignant tumors of the ovary
before and after platinum cyclophosphamide chemotherapy.
Cancer Res 1991;51(21):5915-20.
van Kalken CK, Kuiper CM, Broxterman HJ, Feller N, Scheper RJ,
Lankelma J, Meijer CJ, Pinedo HM, Giaccone G. Expression
of P-glycoprotein in the human fetal adrenal is related to
secretion of specific steroids [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2825.
Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS,
Seynaeve C, Stoter G, Nooter K. A phase II study of
epidoxorubicin in colorectal cancer and the use of
cyclosporin-A in an attempt to reverse multidrug resistance.
Br J Cancer 1991 Aug;64(2):361-4.
Volm M, Bak M Jr, Efferth T, Mattern J. Induced multidrug
resistance in murine leukemia l1210 and associated changes
in a surface-membrane glycoprotein. J Cancer Res Clin Oncol
1989; 115(1):17-24.
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI. A
phase I trial of etoposide (E) with cyclosporine (CSA) as a
modulator of multidrug resistance (MDR) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A276.
Yang JM, Hait WN. Use of multidrug resistant L1210 cell line
for in vitro and in vivo drug screening [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2161.
-Nitrogen mustard compounds
Alexanian R, Barlogie B. New treatment strategies for
multiple myeloma. Am J Hematol 1990 Nov;35(3): 194-8.
Cantwell BMJ, Bozzino JM, Corris P, Harris AL. The multidrug
resistant phenotype in clinical practice: evaluation of
cross resistance to ifosfamide and mesna after VP-16-213
doxorubicin and vincristine VPAV for small cell lung cancer.
Eur J Cancer Clin Oncol 1988;24(2):123-30.
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC,
Henner WD, Goldenberg GJ. Multifactorial resistance to
adriamycin relationship of DNA repair glutathione
transferase activity drug efflux and P-glycoprotein in
cloned cell lines of adriamycin-sensitive and adriamycin-
resistant P388 leukemia. Cancer Res 1988;48(13):3595-602.
Dorr RT. Mitomycin, ifosfamide, and mesna in the treatment of
lung cancer. Semin Oncol 1990 Aug;17(4 Suppl 7):2-5.
Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor
activity and murine pharmacokinetics of parenteral
acronycine. Cancer Res 1989;49(2):340-4.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug
resistance in human breast cancer cells. Proc Natl Acad Sci
U S A 1988;85(2):582-6.
Grandi M, Capolongo L, Ballinari D, Giuliani FC, Mongelli N.
Cytotoxicity and intracellular levels of distamycin A in
sensitive and DX-resistant cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2015.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Harris AL. Mechanisms of cytotoxic drug resistance in breast
cancer. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992; 31(2):205-13.
Hoffmann D, Gerken M, Hermentin P, Sedlacek HH. B 880308 -- a
new anthracycline derivative demonstrating maintained
activity against multidrug resistant cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2410.
Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson
B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.
Autologous bone marrow transplantation in multiple myeloma:
identification of prognostic factors. Blood 1990 Nov
1;76(9): 1860-6.
Knight C, Slade DL, Harker WG. Multidrug resistance in
mitoxantrone-selected CEM leukemia cells appears to be
unrelated to P-glycoprotein expression [abstract]. Clin Res
1991;39(1):68A.
Lee FYF, Sciandra J, Siemann DW. A study of the mechanism of
resistance to adriamycin in-vivo glutathione metabolism P-
glycoprotein expression and drug transport. Biochem
Pharmacol 1989; 38(21):3697-706.
Lincke CR, Van Der Bliek AM, Van Der Velde-Koerts T, Borst P.
The multidrug resistant phenotype of the wild-type human
MDR1 gene [abstract]. J Chemother Infect Dis Malig
1989;Suppl 1:A309.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Meijer C, de Vries EG, Timmer-Bosscha H, Scheper RJ, de Ley L,
Berendsen HH, Mulder NH. Resistance mechanisms in three
human small cell lung cancer cell lines established from one
patient during clinical follow-up [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1221.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Ozols RF. Reversal of drug resistance: clinical trials based on
experimental studies in human tumor model systems. Paper
presented at: Symposium on Mechanisms of Drug and Radiation
Resistance of Tumor Cells; 1989 Jun 28-30; Villejuif,
France.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and therapy of
breast cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young RC.
Reversal of alkylating agent and platinum resistance in
ovarian cancer [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:526-7.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Seneviratne C, Goldenberg GJ. Further characterization of drug-
sensitivity and cross-resistance profiles of cloned cell
lines of Adriamycin-sensitive and -resistant P388 leukemia.
Cancer Commun 1989;1(1):21-7.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human
hepatocellular carcinoma cell lines exhibit multidrug
resistance unrelated to MRD1 gene expression. J Cell Sci
1991 Mar;98(Pt 3):317-22.
Sonneveld P, Nooter K, Burghouts JTM, Herweijer H, Adriaansen HJ,
Van Dongen JJM. High expression of the mdr3 multidrug-
resistance gene in advanced-stage chronic lymphocytic
leukemia. Blood 1992;79(6):1496-500.
Tebbi CK, Chervinsky D, Baker RM. Modulation of drug resistance
in homoharringtonine-resistant C-1300 neuroblastoma cells
with cyclosporine A and dipyridamole. J Cell Physiol 1991
Sep;148(3): 464-71.
Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F,
Picci P, Boiocchi M. Expression of MDR1 and GST-pi in
human soft tissue sarcomas: relation to drug resistance and
biological aggressiveness. Ann Oncol 1992;3(1):63-9.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
-Phytogenic compounds
Abraham I, Wolf CL, Sampson KE, McGovren JP, DeKoning TF.
Tirilazad mesylate, a 21 aminosteroid, and the reversal of
multidrug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2866.
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Aftab DT, Hait WN. Effects of phorbol 12-myristate 13-acetate
on drug accumulation and P-glycoprotein phosphorylation in
sensitive and multidrug-resistant MCF-7 cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2821.
Agarwala S, Bahnson R, Wilson J, Szumowski J, Downs M, Ernstoff
M. Evaluation of the combination of vinblastine and
quinidine in patients with metastatic renal cell carcinoma -
a phase I study [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A1161.
Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI,
Blume KG, Chao NJ. A combined approach for purging
multidrug-resistant leukemic cell lines in bone marrow using
a monoclonal antibody and chemotherapy. Blood 1991 May 1;
77(9):2079-84.
Akiyama SI, Cornwell MM, Kuwano M, Pastan I, Gottesman MM. Most
drugs that reverse multidrug resistance also inhibit
photoaffinity labeling of P-glycoprotein by a vinblastine
analog. Mol Pharmacol 1988;33(2):144-7.
Akiyama SI, Yoshimura A, Kikuchi H, Sumizawa T, Kuwano M, Tahara
Y. Synthetic isoprenoid photoaffinity labeling of P-
glycoprotein specific to multidrug-resistant cells. Mol
Pharmacol 1989; 36(5):730-5.
Alexanian R, Barlogie B. New treatment strategies for multiple
myeloma. Am J Hematol 1990 Nov;35(3): 194-8.
Allen CN, Harpur ES, Gray TJ, Simmons NL, Hirst BH. Efflux of
bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-
dependent transport mechanism in epithelial cells. Biochem
Biophys Res Commun 1990 Oct 15;172(1):262-7.
Anderson M, Warr JR. Expression of verapamil hypersensitivity
in multidrug-resistant cells grown as multicellular
spheroids. Cancer Chemother Pharmacol 1990;26(2):151-4.
Andreeff M, Hegewisch-Becker S, Haimi J, Rehermann B, Berman E,
Bertino J. Multidrug resistance, expression of P-
glycoprotein, anthracycline uptake and ARA-C resistance in
acute leukemia: assessment by flow cytometry and correlation
with response to therapy [abstract]. J Chemother Infect Dis
Malig 1989;Suppl 1:A480.
Arias IM, Gatmaitan Z, Mazzanti R, Shu H, Kumamoto Y. Structure
and function of P-glycoprotein in the normal liver and
intestine. Int Symp Princess Takamatsu Cancer Res Fund
1990;21:229-39.
Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A,
Pogliani EM, Corneo G, Parmiani G. Increased
susceptibility to lymphokine activated killer (LAK) lysis of
relapsing vs. newly diagnosed acute leukemic cells without
changes in drug resistance or in the expression of adhesion
molecules. Ann Oncol 1992;3(2):155-62.
Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S.
Multidrug resistance in a human leukemic cell line selected
for resistance to trimetrexate. Cancer Res 1989 Dec
1;49(23): 6556-61.
Arkin H, Ohnuma T, Schwartz GK, Cuttner J, Holland JF. Lack of
staurosporine (STSN) influence on multidrug resistance (MDR)
in human leukemic cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2004.
Asoh K, Saburi Y, Sato S, Nogae I, Kohno K, Kuwano M.
Potentiation of some anticancer agents by dipyridamole
against drug-sensitive and drug-resistant cancer cell lines.
Jpn J Cancer Res 1989 May;80(5):475-81.
Assaraf YG, Molina A, Schimke RT. Sequential amplification of
dihydrofolate reductase and multidrug resistance genes in
Chinese hamster ovary cells selected for stepwise resistance
to the lipid-soluble antifolate trimetrexate. J Biol Chem
1989 Nov 5;264(31):18326-34.
Azzaria M, Schurr E, Gros P. Discrete mutations introduced in
the predicted nucleotide-binding sites of the mdr1 gene
abolish its ability to confer multidrug resistance. Mol
Cell Biol 1989 Dec; 9(12):5289-97.
Baas F, Jongsma AP, Broxterman HJ, Arceci RJ, Housman D, Scheffer
GL, Riethorst A, van Groenigen M, Nieuwint AW, Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug
resistance precedes P-glycoprotein expression during in
vitro selection for doxorubicin resistance in a human lung
cancer cell line. Cancer Res 1990 Sep 1;50(17):5392-8.
Barrand MA, Twentyman PR. Variations in P-glycoprotein
expression in response to drug treatment in mouse tumor cell
lines [abstract]. Br J Cancer 1991;63 Suppl 13:12.
Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-
glycoprotein phosphorylation and drug transport by sodium
butyrate. Biochemistry 1992 Jul 21;31(28):6366-72.
Bates SE, Currier SJ, Fojo AT. Modulation of P-glycoprotein
(Pgp) specificity by sodium butyrate (NaB) [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2164.
Bates SE, Denicoff AM, Cowan K, Tucker E, Begley M, Goldspiel B,
Myers C, Fojo T. A study of MDR-1 expression and
pharmacologic reversal in human breast cancer [abstract].
Proc Annu Meet Am Soc Clin Oncol 1991;10:A148.
Bates SE, Scala S, Dickstein B, Fojo AT. Modulation of P-
glycoprotein (Pgp) function by dephosphorylation [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2905.
Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL,
Fojo AT. Mitotane enhances cytotoxicity of chemotherapy in
cell lines expressing a multidrug resistance gene (mdr-1/P-
glycoprotein) which is also expressed by adrenocortical
carcinomas. J Clin Endocrinol Metab 1991 Jul; 73(1):18-29.
Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. Effects of
indole alkaloids on multidrug resistance and labeling of P-
glycoprotein by a photoaffinity analog of vinblastine.
Biochem Biophys Res Commun 1988;153(3):959-66.
Beck WT, Qian XD. Photoaffinity substrates for P-glycoprotein.
Biochem Pharmacol 1992;43(1): 89-93.
Bellamy W, Gleason M, Futscher B, Dalton W. Altered P-
glycoprotein (P-170)-mediated doxorubicin (D) resistance in
a verapamil (V)-resistant human multiple myeloma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2181.
Belli JA, Zhang Y. P-glycoprotein fused to the membrane of
sensitive cells imparts transient resistance to adriamycin
[abstract]. Cancer Chemother Pharmacol 1989;24 Suppl 2:S77.
Belli JA, Zhang Y, Fritz P. Transfer of adriamycin resistance
by fusion of Mr 170,000 P-glycoprotein to the plasma
membrane of sensitive cells. Cancer Res 1990 Apr
1;50(7):2191-7.
Benard J, Bourhis J, Hartmann O, Boccon-Gibod L, Duvillard P,
Lhomme C, Michel G, Lemerle J, Goldstein L, Gottesman M, et
al. Overexpression of human MDR1 gene is related to prior
chemotherapy in ovarian carcinomas and in neuroblastomas.
Paper presented at: Symposium on Mechanisms of Drug and
Radiation Resistance of Tumor Cells; 1989 Jun 28-30;
Villejuif, France.
Benard J, Bourhis J, Riou G. Inducing chemoresistance in the N-
myc oncogene and associated genes. Prognostic value for
neuroblastoma. Bull Cancer 1991;78(1):91-7.
Benard J, Da Silva J, Renaud L. Differential expression of drug
resistance in a human ovarian tumor cell line, IGR-OV1,
following in vitro treatment with doxorubicin (DXR),
vincristine (VCR), or cis-platinum (CDDP). Paper presented
at: 2nd International Congress on Neo-Adjuvant Chemotherapy;
1989 Feb 19-21; Paris.
Benard J, Da Silva J, Teyssier JR, Riou G. Over expression of
MDR 1 gene with no DNA amplification in a multiple drug
resistant human ovarian carcinoma cell line. Int J Cancer
1989; 43(3):471-7.
Benard J, Teyssier JR, Riou G. Loss of tumorigenicity in a
multiple drug resistant human ovarian carcinoma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1224.
Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B,
Andreeff M. Effect of tamoxifen on cell lines displaying
the multidrug-resistant phenotype. Blood 1991 Feb
15;77(4):818-25.
Berman E, McBride M. Comparative cellular pharmacology of
daunorubicin and idarubicin in human multidrug-resistant
leukemia cells. Blood 1992 Jun 15;79(12):3267-73.
Berry JM, Brophy NA, Smith SD, Bergstrom SK, Scudder SA, Roninson
IB, Sikic BI. Increased expression of the multidrug
resistance gene MDR1 in human cancers [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1988;7:A193.
Berry JM, Swensen RE, Brophy NA, Scudder SA, Sikic BI.
Increased expression of the multidrug resistance gene mdr1
in ovarian cancers [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30: A2051.
Bhushan A, Abramson R, Chiu JF, Tritton TR. Expression of c-fos
in human and murine multidrug-resistant cells. Mol
Pharmacol 1992 Jul;42(1):69-74.
Bhuyan BK, Smith KS, Sampson KE, Abraham I. V79 cells resistant
to the alkylating agent U-73975 are multidrug resistant
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2179.
Biedler JL. Genetic aspects of multidrug resistance (MDR).
Paper presented at: American Cancer Society National
Conference on Integration of Molecular Genetics into Cancer
Management; 1991 Apr 10-12; Miami, FL.
Biedler JL, Chang TD, Scotto KW, Melera PW, Spengler BA.
Chromosomal organization of amplified genes in multidrug-
resistant Chinese hamster cells. Cancer Res
1988;48(11):3179-87.
Biedler JL, Meyers MB, Spengler BA. Collateral sensitivity of
multidrug-resistant Chinese hamster cells to calcium channel
blockers: correlation with P-glycoprotein content
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1171.
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger
P, Loor F. In vivo circumvention of P-glycoprotein-
mediated multidrug resistance of tumor cells with SDZ PSC
833. Cancer Res 1991 Aug 15;51(16):4226-33.
Boscoboinik D, Debanne MT, Stafford AR, Jung CY, Gupta RS, Epand
RM. Radiation inactivation studies of membranes from
multidrug resistant cells [abstract]. Cancer Chemother
Pharmacol 1989;24 Suppl 2:S78.
Boscoboinik D, Gupta RS, Epand RM. Altered intracellular ph and
Na+/H+ antiport activity in multidrug-resistant cell lines
[abstract]. Cancer Chemother Pharmacol 1989;24 Suppl 2:S86.
Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard
J. Expression of a human multidrug resistance gene in
ovarian carcinomas. Cancer Res 1989;49(18):5062-5.
Boven E, Venema E, Erkelens CA, Van Muijen M, Sanders KH, Pinedo
HM. Enhancement of drug efficacy by the new calcium
channel blocker B8509-035 in the BRO/MDR1.1 model
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1992;33:
A2876.
Bradley G, Naik M, Ling V. P-glycoprotein expression in
multidrug-resistant human ovarian carcinoma cell lines.
Cancer Res 1989;49(10): 2790-6.
Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsurou T, Pinedo HM,
Lankelma J. Increase of daunorubicin and vincristine
accumulation in multidrug resistant human ovarian carcinoma
cells by a monoclonal antibody reacting with P-glycoprotein.
Biochem Pharmacol 1988;37(12):2389-94.
Broxterman HJ, Pinedo HM, Kuiper CM, Van Der Hoeven JJM, De Lange
P, Quak JJ, Scheper RJ, Keizer HG, Jan Schuurhuis G,
Lankelma J. Immunohistochemical detection of p-
glycoprotein in human tumor cells with a low degree of drug
resistance. Int J Cancer 1989;43(2):340-3.
Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JP, Pinedo HM.
Towards functional screening for multidrug resistant cells
in human malignancies. Pezcoller Found Symp 1990;1:309-29.
Burk RK, Garfield S, Johnson K, Thorgiersson SS. Transformation
of rat liver epithelial cells with V-H-RAS or V-RAF causes
expression of MDR-1 glutathione-S-transferase-P and
increased resistance to cytotoxic chemicals. Carcinogenesis
1988; 9(12):2329-32.
Busche R, Tuemmler B, Cano-Gauci DF, Riordan JR. Equilibrium
kinetic and photoaffinity labeling studies of daunomycin
binding to p-glycoprotein-containing membranes of multidrug-
resistant Chinese hamster ovary cells. Eur J Biochem 1989;
183(1):189-98.
Busche R, Tuemmler B, Riordan JR, Cano-Gauci DF. Preparation
and utility of a radioiodinated analogue of daunomycin in
the study of multidrug resistance. Mol Pharmacol
1989;35(4):414-21.
Cairo MS, Plunkett JM, Gillan E, Weinthal J, Knoppel E, van de
Ven C, Sender L. A novel preparative and purging regimen
employing verapamil to modulate multiple drug resistance
during autologous bone marrow transplant in acute
lymphoblastic leukemia: a pilot study [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A1191.
Cairo MS, Plunkett JM, Kantawala S, Knoppel E, Nguyen A, van de
Ven C. Purging of multiple drug resistant acute
lymphoblastic leukemia (L100) for autologous bone marrow
transplantation with vincristine (V) and VP-16: selective
modulation by verapamil (VPL) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A1017.
Callahan HL, Beverley SM. Heavy metal resistance: a new role
for P-glycoproteins in Leishmania. J Biol Chem 1991 Oct
5;266(28):18427-30.
Cano-Gauci DF, Busche R, Tummler B, Riordan JR. Fast kinetic
analysis of drug transport in multidrug resistant cells
using a pulsed quench-flow apparatus. Biochem Biophys Res
Commun 1990 Feb 28; 167(1):48-53.
Cantwell BMJ, Bozzino JM, Corris P, Harris AL. The multidrug
resistant phenotype in clinical practice evaluation of cross
resistance to ifosfamide and mesna after VP-16-213
doxorubicin and vincristine VPAV for small cell lung cancer.
Eur J Cancer Clin Oncol 1988;24(2):123-30.
Capranico G, De Isabella P, Castelli C, Supino R, Parmiani G,
Zunino F. P-glycoprotein gene amplification and expression
in multidrug-resistant murine p388 and b16 cell lines. Br
J Cancer 1989; 59(5):682-5.
Carulli G, Petrini M, Marini A, Vaglini F, Caracciolo F, Grassi
B. P-glycoprotein and drug resistance in acute leukemias
and in the blastic crisis of chronic myeloid leukemia.
Haematologica 1990 Nov-Dec; 75(6):516-21.
Cass CE, Janowska-Wieczorrek A, Lynch MA, Sheinin H, Hindenburg
AA, Beck WT. Effect of duration of exposure to verapamil
on vincristine activity against multidrug-resistant human
leukemic cell lines. Cancer Res 1989;49(21):5798-804.
Castillo G, Vera JC, Yang CP, Horwitz SB, Rosen OM. Functional
expression of murine multidrug resistance in Xenopus laevis
oocytes. Proc Natl Acad Sci U S A 1990 Jun;87(12):4737-41.
Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C
phosphorylates P-glycoprotein in multidrug resistant human
KB carcinoma cells. J Biol Chem 1990 May 5;265(13):7679-86.
Chambers TC, Zheng B, Kuo JF. Regulation by phorbol ester and
protein kinase C inhibitors, and by a protein phosphatase
inhibitor (okadaic acid), of P-glycoprotein phosphorylation
and relationship to drug accumulation in multidrug-resistant
human KB cells. Mol Pharmacol 1992 Jun;41(6):1008-15.
Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL, Ling V.
Methods in laboratory investigation. A sensitive method for
immunocytochemical detection of P-glycoprotein in multidrug
resistant human ovarian carcinoma cell lines. Lab Invest
1988;59(6):870-5.
Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL, Ling V. A
sensitive method for immunocytochemical detection of p-
glycoprotein in multidrug-resistant human ovarian carcinoma
cell lines. Lab Invest 1988;59(6):870-5.
Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH, Cheng YC. Effect of
4 beta-arylamino derivatives of 4'-O-
demethylepipodophyllotoxin on human DNA topoisomerase II,
tubulin polymerization, KB cells, and their resistant
variants. Cancer Res 1991 Apr 1;51(7):1755-9.
Chao NJ. Combination of monoclonal antibody and chemotherapy
for purging multidrug-resistant cells from bone marrow.
Paper presented at: 3rd International Symposium on Bone
Marrow Purging and Processing; 1991 Oct 3-5; San Diego, CA.
Chapekar MS, Huggett AC, Cheng CC, Hampton LL, Lin KH,
Thorgeirsson SS. Isolation and characterization of a rat
liver epithelial cell line resistant to the
antiproliferative effects of transforming growth factor beta
(type 1). Cancer Res 1990 Jun 15;50(12):3600-4.
Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF.
Camptothecin overcomes MDR1-mediated resistance in human KB
carcinoma cells. Cancer Res 1991 Nov 15;51(22):6039-44.
Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat
shock and arsenite increase expression of the multidrug
resistance (MDR1) gene in human renal carcinoma cells. J
Biol Chem 1990 Jan 5; 265(1):221-6.
Choi K, Chen CJ, Kriegler M, Roninson IB. An altered pattern of
cross-resistance in multidrug-resistant human cells results
from spontaneous mutations in the mdr1 P-glycoprotein gene.
Cell 1988;53(4):519-30.
Choi K, Frommel TO, Stern RK, Perez CF, Kriegler M, Tsuruo T,
Roninson IB. Multidrug resistance after retroviral
transfer of the human MDR1 gene correlates with P-
glycoprotein density in the plasma membrane and is not
affected by cytotoxic selection. Proc Natl Acad Sci U S A
1991 Aug 15; 88(16):7386-90.
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss
of multiple drug resistance by hydroxyurea [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A209.
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss
of multiple drug resistance by hydroxyurea. Semin Oncol
1992 Jun;19(3 Suppl 9):94-100.
Cohen D, Yang CP, Horwitz SB. The products of the mdr1a and
mdr1b genes from multidrug resistant murine cells have
similar degradation rates. Life Sci 1990;46(7):489-95.
Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol
HS-15 nontoxic polyoxyethylene esters of 12 hydroxystearic
acid reverses multidrug resistance. Cancer Res
1991;51(3):897-902.
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR,
Melamed MR. Expression of the multidrug resistance gene
product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem 1990 Sep;38(9):1277-87.
Cordon-Cardo C, O'Brien JP, Casals D, Boccia J, Bertino JR.
Immunoanatomic and immunopathologic expression of the
multidrug resistance gene product. Cancer Cells 1989;
7:87-93.
Croop J, Gros P, Housman D. Mutational analysis of a site
involved in colchicine resistance in the mouse MDR1 gene
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2166.
Cumber P, Padua RA, Holmes J, Carter G, Jacobs A. Multidrug
resistance in chronic lymphatic leukemia. Paper presented
at: British Association for Cancer Research/Association for
Cancer Physicians/ Leukaemia Research Fund Joint Winter
Meeting on Leukaemia and Lymphomas; 1989 Dec 11-12; London,
UK.
Cuvier C, Roblot-Treupel L, Millot JM, Couvreur P, Manfait M,
Poupon MF. Doxorubicin, loaded on nanospheres, bypasses
multidrug resistance and is detectable as bound to nuclear
DNA by microspectrofluorometry. Paper presented at:
Symposium on Mechanisms of Drug and Radiation Resistance of
Tumor Cells; 1989 Jun 28-30; Villejuif, France.
Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor
CW, Miller TP, Salmon SE. Drug resistance in multiple
myeloma and non Hodgkin's lymphoma: Detection of P
glycoprotein and potential circumvention by addition of
verapamil to chemotherapy. J Clin Oncol 1989; 7(4):415-24.
Dalton WS, Grogan TM, Miller TP. The role of P-glycoprotein in
drug-resistant hematologic malignancies. Cancer Treat Res
1991;57:187-208.
Davis J, Bines S, Economou S, Roninson I, Chaudhary P, Coon J.
Solutol HS 15 reverses multiple drug resistance in a human
MDR-1-mouse melanoma system [abstract]. Proc Annu Meet Am
Soc Clin Oncol 1991;10:A200.
DeHerdt SV, Andrews EL, Marder P, Moore RE, Hoskins J, Bumol TF.
Characterization of the multiple drug resistance phenotype
of several human colorectal carcinoma cell lines selected
with vinca alkaloids [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1419.
Delaporte C, Larsen AK, Dautry F, Jacquemin-Sablon A. Influence
of myc overexpression on the phenotypic properties of
Chinese hamster lung cells resistant to antitumor agents.
Exp Cell Res 1991 Dec;197(2):176-82.
Demidova NS, Chernova OB, Siyanova EY, Goncharova AS, Kopnin BP.
Newly formed chromosome-like structures in independent mouse
P388 sublines with developed in vivo mdr1 gene
amplification. Somat Cell Mol Genet 1991 Nov; 17(6):581-90.
Devine SE, Ling V, Melera PW. Amino acid substitutions in P-
glycoprotein alter multidrug resistance [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2837.
Devine SE, Ling V, Melera PW. Point mutations in the pgp1 (p-
glycoprotein) gene [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2156.
Dhainaut A, Regnier G, Atassi G, Pierre A, Leonce S, Kraus-
Berthier L, Prost JF. New triazine derivatives as potent
modulators of multidrug resistance. J Med Chem 1992 Jun
26;35(13): 2481-96.
Dhir R, Gros P. Functional analysis of chimeric proteins
constructed by exchanging homologous domains of two P-
glycoproteins conferring distinct drug resistance profiles.
Biochemistry 1992 Jul 7; 31(26):6103-10.
Dimeric vinca alkaloids that reverse MDR. Curr Opin Ther Pat
1992;2(1):3-4.
Dimopoulos MA, Alexanian R. Irreversibility of drug resistance
in VAD-refractory myeloma [letter]. Am J Hematol 1992
Jun;40(2):154-5.
Dorr RT. Mitomycin, ifosfamide, and mesna in the treatment
of lung cancer. Semin Oncol 1990 Aug; 17(4 Suppl 7):2-5.
Doz F, Michon J, Quintana E, Pacquement H, Zucker JM.
[Multidrug resistance of solid tumors in children]. Arch Fr
Pediatr 1991 Oct;48(8):585-8. (Fre).
Dupuis ML, Ramoni C, Yassen A, Samoggia P, Tombesi M, Caserta M,
Cianfriglia M. The over-expression of P-glycoprotein in
K-562 and DAUDI cells, is associated with a high
susceptibility to NK and LAK cells. J Biol Regul Homeost
Agents 1991 Oct-Dec;5(4):137-41.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Durivage HJ, Buzaid AC, Todd MB, Poo WJ, March JC, Davis CA, Hait
WN. A phase I-II study of pulse cyclosporin-A (CsA) plus
vinblastine (VBL) in selected refractory malignancies
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A335.
Eietel M, Arps H, Niendorf A. Immunocytochemical evidence of
p170 positive, mitoxantrone (DHAD) containing vesicles and
structurally altered microtubules in a human gastric
carcinoma cell line with atypical multidrug resistance (MDR)
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A704.
Eliason JF, Ramuz H, Kaufmann F. Human multi-drug-resistant
cancer cells exhibit a high degree of selectivity for
stereoisomers of verapamil and quinidine. Int J Cancer 1990
Jul 15;46(1):113-7.
Elliott WL, Roberts BJ, Steinkampf RW, Leopold WR, Klohs WD. In
vivo studies on multidrug-resistant (MDR) tumors with the
new chemosensitizer, tioperidone [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2858.
Ellis AL, Gewirtz DA, Munger C, Woods KE, Randolph JK, Boise L,
Yanovich S. Multifactorial drug resistance in the rat
hepatoma [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1999.
Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L,
Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol 1992 Jan 22;43(2):331-42.
Epand RF, Epand RM. The new potent immunosuppressant FK-506
reverses multidrug resistance in Chinese hamster ovary
cells. Anticancer Drug Des 1991 Jul;6(3):189-93.
Epand RF, Epand RM, Gupta RS, Cragoe EJ Jr. Reversal of
intrinsic multidrug resistance in Chinese hamster ovary
cells by amiloride analogs. Br J Cancer 1991;63(2):247-51.
Epstein J, Xiao H, Oba BK. P-glycoprotein expression in plasma
cell myeloma is associated with resistance to VAD. Blood
1989;74(3):913-7.
Etievant C, Breillout F, Kiss R. Monitoring by means of digital
cell image analysis of verapamil-induced morphonuclear
modifications in chemosensitive as opposed to chemoresistant
neoplastic cell lines [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2713.
Evans SS, Rustum YM. The combined effects of alpha-interferon
with doxorubicin (DOX) and vinblastine (VLB) on multidrug-
resistant ovarian carcinoma and leukemic cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2101.
Fairchild CR, Cowan KH. Keynote address: Multidrug resistance:
a pleiotropic response to cytotoxic drugs. Int J Radiat
Oncol Biol Phys 1991 Feb;20(2):361-7.
Fairchild CR, Ivy SP, Kao Shan CS, Whang Peng J, Rosen N, Israel
MA, Melera PW, Cowan KH, Goldsmith ME. Isolation of
amplified and overexpressed DNA sequences from Adriamycin
resistant human breast cancer cells. Cancer Res
1987;47(19):5141-8.
Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. Multidrug
resistance in cells transfected with human genes encoding a
variant P-glycoprotein and glutathione S-transferase-pi.
Mol Pharmacol 1990 Jun;37(6):801-9.
Fan D, Fidler IJ, Ward NE, Seid C, Earnest LE, Housey GM, O'Brian
CA. Stable expression of a cDNA encoding rat brain protein
kinase C-beta I confers a multidrug-resistant phenotype on
rat fibroblasts. Anticancer Res 1992 May-Jun; 12(3):661-7.
Fardel O, Ratanasavanh D, Loyer P, Ketterer B, Guillouzo A.
Overexpression of the multidrug resistance gene product in
adult rat hepatocytes during primary culture. Eur J Biochem
1992 Apr 15;205(2):847-52.
Ferguson PJ, Cheng YC. Phenotypic instability of drug
sensitivity in a human colon carcinoma cell line. Cancer
Res 1989;49(5):1148-53.
Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A,
Normandeau R, Jones A. Addition of verapamil and tamoxifen
to the initial chemotherapy of small cell lung cancer. A
phase I/II study. Cancer 1990 May 1;65(9):1895-902.
Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug
resistance in human breast cancer cells. Proc Natl Acad Sci
U S A 1988;85(2):582-6.
Fine RL, Sachs CW, Albers M, Williams A. Tamoxifen potentiates
the cytotoxicity of vinblastine by increasing intracellular
drug accumulation [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2226.
Fine RM. Multidrug resistance. Cancer Chemother Biol Response
Modif 1988;10:73-84.
Fleming GF, Amato JM, Agresti M, Safa AR. Megestrol acetate
reverses multidrug resistance and interacts with P-
glycoprotein. Cancer Chemother Pharmacol 1992;29(6):445-9.
Fleming GF, Amato JM, Agresti M, Safa AR. Reversal of multidrug
resistance by megestrol acetate [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2253.
Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN.
Cellular and biochemical characterization of thioxanthenes
for reversal of multidrug resistance in human and murine
cell lines. Cancer Res 1990 Mar 15;50(6):1748-56.
Ford JM, Hait WN. Further characterization of the thioxanthene
class of multidrug resistance antagonists [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:570.
Friche E, Jensen PB, Nissen NI. Comparison of cyclosporin A and
SDZ PSC833 as multidrug-resistance modulators in a
daunorubicin-resistant Ehrlich ascites tumor. Cancer
Chemother Pharmacol 1992;30(3):235-7.
Friche E, Skovsgaard T, Nissen NI. Anthracycline resistance.
Acta Oncol 1989;28(6):877-81.
Friedlander ML, Bell DR, Leary J, Davey RA. Comparison of
Western blot analysis and immunocytochemical detection of P-
glycoprotein in multidrug resistant cells. J Clin Pathol
1989 Jul; 42(7):719-22.
Fry DW, Besserer JA. Characterization of trimetrexate transport
in human lymphoblastoid cells and development of impaired
influx as a mechanism of resistance to lipophilic
antifolates. Cancer Res 1988;48(24 Pt 1):6986-91.
Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
Progressive resistance to doxorubicin in mouse leukemia
L1210 cells with multidrug resistance phenotype: reductions
in drug-induced topoisomerase II-mediated DNA cleavage.
Cancer Commun 1989;1(4):217-24.
Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship
between expression of P-glycoprotein and efficacy of
trifluoperazine in multidrug-resistant cells. Mol Pharmacol
1991 Jan;39(1):1-8.
Garozzo A, Allegra E. P-glycoprotein expression in relation to
natural resistance in untreated head and neck solid tumours
[abstract]. Eur J Cancer 1991; 27 Suppl 3:S42.
Gaveriaux C, Boesch D, Boelsterli JJ, Bollinger P, Eberle MK,
Hiestand P, Payne T, Traber R, Wenger R, Loor F.
Overcoming multidrug resistance in Chinese hamster ovary
cells in vitro by cyclosporin A (Sandimmune) and non-
immunosuppressive derivatives. Br J Cancer 1989
Dec;60(6):867-71.
Gekeler V, Handgretinger R, Weger S, Wilisch A, Kruenpelmann S,
Niethammer D, Probst H. MDR1 P-glycoprotein expression in
NK cells. Nat Immun Cell Growth Regul 1991;10(3):123-4.
Germann UA, Willingham MC, Pastan I, Gottesman MM. Expression
of the human multidrug transporter in insect cells by a
recombinant baculovirus. Biochemistry 1990 Mar 6;29(9):
2295-303.
Geromin A, Signor M, Vigevani E, Michieli M, Michelutti A,
Damiani D, Fasola G, Baccarani M. A prospective evaluation
of P170 glycoprotein in normal blood mononuclear cells
during chemotherapy [abstract]. Haematologica 1991;76 Suppl
4:75.
Gewirtz DA, Grant S, Woods KE. Modulation of adriamycin
sensitivity in multidrug-resistant MCF-7 breast tumor cells
by tomoxifen [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2898.
Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporin
accumulation in multidrug-resistant cells. Biochem Biophys
Res Commun 1988;152(2): 552-8.
Goldstein LJ, Fojo AT, Ueda K, Crist W, Green A, Brodeur G,
Pastan I, Gottesman MM. Expression of the multidrug
resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990
Jan;8(1): 128-36.
Gore ME, Selby PJ, Millar B, Maitland J, McElwain TJ. The use
of verapamil to overcome drug resistance in myeloma
[abstract] . Proc Annu Meet Am Soc Clin Oncol 1988;7:A882.
Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of
resistance to etoposide, doxorubicin, and vinblastine in
multidrug resistant human sarcoma cells. Cancer Res 1989
Dec 15; 49(24 Pt 1):6901-5.
Gottesman MM, Goldstein LJ, Pastan I. Expression of the
multidrug-resistance (MDR1) gene in breast cancer and other
cancers. Paper presented at: Biennial International Breast
Cancer Research Conference; 1989 Mar 5-9; Tel Aviv
University, Tel Aviv.
Gottesman MM, Goldstein LJ, Willingham MC, Pastan I. Molecular
biology of a human multidrug transporter. Paper presented
at: Molecular diagnostics of human cancer. Cold Spring
Harbor Meeting on Cancer Cells; 1988 Sep 7-11; Cold Spring
Harbor, NY.
Gottesman MM, Pastan I. Mechanism and function of the multidrug
transporter [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:517-8.
Gottesman MM, Pastan I. A membrane protein that transports
natural product cytotoxic drugs. Serono Symp Publ Raven
Press 1989;64:81-7.
Greenberger L, Lothstein L, Mellado W, Yang CP, Han E, Horwitz
SB. Structural analysis of distinct P-glycoproteins
overproduced in murine multidrug resistant cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1174.
Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Domain
mapping of the photoaffinity drug-binding sites in P-
glycoprotein encoded by mouse mdr1b. J Biol Chem 1991 Nov
5;266(31):20744-51.
Greenberger LM, Lothstein L, Hsu SI, Depinho SG, Horwitz SB.
The p-glycoprotein gene family regulated gene switching
correlates with altered phenotype [abstract]. J Cell Biol
1988;107(6 Pt 3): 366A.
Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct
P-glycoprotein precursors are overproduced in independently
isolated drug-resistant cell lines. Proc Natl Acad Sci U S
A 1988;85(11):3762-6.
Greenberger LM, Williams SS, Georges E, Ling V, Horwitz SB.
Electrophoretic analysis of P-glycoproteins produced by
mouse J774.2 and Chinese hamster ovary multidrug-resistant
cells. J Natl Cancer Inst 1988;80(7):506-10.
Greenberger LM, Yang CP, Gindin E, Horwitz SB. Photoaffinity
probes for the alpha 1-adrenergic receptor and the calcium
channel bind to a common domain in P-glycoprotein. J Biol
Chem 1990 Mar 15;265(8):4394-401.
Gros P, Dhir R, Croop J, Talbot F. A single amino acid
substitution strongly modulates the activity and substrate
specificity of the mouse mdr1 and mdr3 drug efflux pumps.
Proc Natl Acad Sci U S A 1991 Aug 15;88(16):7289-93.
Gros P, Talbot F, Tang-Wai D, Bibi E, Kaback HR. Lipophilic
cations: a group of model substrates for the multidrug-
resistance transporter. Biochemistry 1992 Feb
25;31(7):1992-8.
Gruber A, Vitols S, Norgren S, Arestrom I, Bjorkholm M,
Reizenstein P, Peterson C, Luthman H. Quantitative
determination of mdr1 gene expression in leukemic cells from
patients with acute leukemia [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A1408.
Gupta RS. Intrinsic multidrug resistance phenotype of Chinese
hamster rodent cells in comparison to human cells. Biochem
Biophys Res Commun 1988; 153(2):598-605.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Gutierrez PL, Wilder PJ, Biswal N. In vitro multidrug
resistance of P388 murine leukemia selected for resistance
to diaziquone. Cancer Commun 1989; 1(3):181-90.
Haas C, Born J, Noland B, Wink B, Mann P, Gasparovic C, Matwiyoff
N. Increased killing of multidrug-resistant KBV-1 cells by
a trifluoromethyl acridine analog of quinacrine [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A3136.
Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW.
Resistance to drugs associated with the multidrug resistance
phenotype following selection with high-concentration
methotrexate. J Natl Cancer Inst 1989;81(16):1250-4.
Hagiwara M, Wakusawa S, Miyamoto K, Hidaka H. Obviation of drug
resistance and affinity purification of P-glycoprotein by
isoquinolinesulfonamides. Cancer Lett 1991 Nov;
60(2):103-7.
Hait WN, Choudhury S, Srimatkandada V. Characterization of a
human chronic myelogenous leukemia cell line expressing the
multidrug resistance gene [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2186.
Hamada H, Tsuruo T. Characterization of the ATPase activity of
the M-R 170000 to 180000 membrane glycoprotein P-
glycoprotein associated with multidrug resistance in K562-
ADM cells. Cancer Res 1988;48(17):4926-32.
Hammond JR, Johnstone RM, Gros P. Enhanced efflux of tritiated
vinblastine from Chinese hamster ovary cells transfected
with a full-length complementary DNA clone for the mdr1
gene. Cancer Res 1989;49(14):3867-71.
Harder S. Verapamil, a promising agent for circumvention of
multidrug-resistance. Onkologie 1991;14(3):212-7.
Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE. Human
tumor cell line resistance to chemotherapeutic agents does
not predict resistance to natural killer or lymphokine-
activated killer cell-mediated cytolysis. Cancer Res 1990
Sep 15;50(18):5931-6.
Harris JE, Coon JS, Anderson KM. Selective reversal of
multidrug resistance by 5,8,11,14-Eicosatetraynoic acid
(ETYA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2907.
Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M.
Effects of verapamil enantiomers and major metabolites on
the cytotoxicity of vincristine and daunomycin in human
lymphoma cell lines. Eur J Clin Pharmacol 1991;40(1):53-9.
Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hendrickson N,
Ullman B. Multidrug resistance in Leishmania donovani is
conferred by amplification of a gene homologous to the
mammalian mdr1 gene. Mol Cell Biol 1992 Jun;12(6):2855-65.
Henderson GB. Mediation of cellular anion detoxification in
leukemic cells by unidirectional efflux pumps. Adv Enzyme
Regul 1989;29:61-72.
Henderson GB, Strauss BP. Evidence for cyclic AMP and cholate
extrusion in C6 rat glioma cells by a common anion efflux
pump. J Biol Chem 1991; 266(3):1641-5.
Hill AB, Beck WT, Trent JM. Cytogenetic and molecular
characterization of tumors in nude mice derived from a
multidrug resistant human leukemia cell line. Cancer Res
1988;48(2):393-8.
Hill B, Deuchars K, Ling V, Hosking L, Whelan RD. Significant
overexpression or P-glycoprotein by mammalian tumor cells
following in vitro exposure to fractionated x-irradiation
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2067.
Hill BT, Whelan RD, Hosking LK, de Vries EG, Mulder NH, Dunn T.
Evaluation of S9788 as a potential modulator of drug
resistance against human tumor sublines expressing differing
resistance mechnaisms in vitro [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2881.
Hitselberger Kanitz MH, Mastro JM, Starling JJ. In vivo
expression of P-glycoprotein in two human colon carcinoma
xenografts is rapidly modulated following therapy with a
free or monoclonal antibody-conjugated vinca alkaloid
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2805.
Hitselberger MH, Starling JJ. Two human colon tumor cell lines
which express comparable P-glycoprotein display a five
thousand-fold difference in in vitro sensitivity to a vinca
alkaloid [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2207.
Hoffmann D, Gerken M, Hermentin P, Sedlacek HH. B 880308 -- a
new anthracycline derivative demonstrating maintained
activity against multidrug resistant cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2410.
Hofsli E. Multimedikamentresistens - teoretiske og kliniske
aspekter [Multidrug resistance - theoretical and clinical
aspects]. Tidsskr Nor Laegeforen 1992;112(4):472-4. (Nor).
Hofsli E, Nissen-Meyer J. Effect of erythromycin and tumor
necrosis factor on the drug resistance of multidrug-
resistant cells reversal of drug resistance by erythromycin.
Int J Cancer 1989;43(3):520-5.
Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium
antagonists which differ markedly in their potencies as
calcium blockers are equally effective in modulating drug
transport by P-glycoprotein. Biochem Pharmacol 1992 Jun 23;
43(12):2601-8.
Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA.
Multidrug resistance in hemopoietic cell lines
myelodysplastic syndromes and acute myeloblastic leukaemia.
Br J Haematol 1989; 72(1):40-4.
Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I,
Gottesman MM, Handlers J. Transepithelial transport of
drugs by the multidrug transporter in cultured Madin-Darby
canine kidney cell epithelia. J Biol Chem
1989;264(25):14880-4.
Horio M, Gottesman MM, Pastan I. ATP dependent transport of
vinblastine in vesicles from human multidrug resistant
cells. Proc Natl Acad Sci U S A 1988;85(10):3580-4.
Horio M, Lovelace E, Pastan I, Gottesman MM. Agents which
reverse multidrug-resistance are inhibitors of
[3H]vinblastine transport by isolated vesicles. Biochim
Biophys Acta 1991 Jan 9; 1061(1):106-10.
Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ.
Modulation by verapamil of vincristine pharmacokinetics and
toxicity in mice bearing human tumor xenografts. Biochem
Pharmacol 1989;38(11):1727-36.
Howell SB, Vick JS, Sanga R. Synergistic potentiation of
etoposide, doxorubicin, and vinblastine activity by
dipyridamole [abstract]. Proc Annu Meet Am Soc Clin Oncol
1988;7:A213.
Hsu SIH, Lothstein L, Horwitz SB. Differential overexpression
of three mdr gene family members in multidrug-resistant
j774.2 mouse cells evidence that distinct p-glycoprotein
precursors are encoded by unique mdr genes. J Biol Chem
1989;264(20): 12053-62.
Huet S, Schott B, Robert J. P-glycoprotein overexpression
cannot explain the complete doxorubicin-resistance phenotype
in rat glioblastoma cell lines. Br J Cancer 1992
Apr;65(4):538-44.
Hunter J, Hirst BH, Simmons NL. Epithelial secretion of
vinblastine by human intestinal adenocarcinoma cell (HCT-8
and T84) layers expressing P-glycoprotein. Br J Cancer 1991
Sep;64(3):437-44.
Hunter J, Hirst BH, Simmons NL. Transepithelial vinblastine
secretion mediated by P-glycoprotein is inhibited by
forskolin derivatives. Biochem Biophys Res Commun 1991 Dec
16;181(2):671-6.
Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S.
Modulators of the multidrug-transporter, P-glycoprotein,
exist in the human plasma. Biochem Biophys Res Commun 1990
Jan 15;166(1):74-80.
Ichikawa M, Yoshimura A, Sumizawa T, Shudo N, Kuwazuru Y,
Furukawa T, Akiyama S. Interaction of organic chemicals
with P-glycoprotein in the adrenal gland, kidney, and a
multidrug-resistant KB cell. J Biol Chem 1991 Jan 15;
266(2):903-8.
Ikeda S, Sugita M, Yoshimura A, Sumizawa T, Douzono H, Nagata Y,
Akiyama S. Aspergillus species strain M39 produces two
naphtho-gamma-pyrones that reverse drug resistance in human
KB cells. Int J Cancer 1990 Mar 15;45(3):508-13.
Ikeda SI. [Aspergillus-SP strain M39 produces two naphtho-
gamma-pyrones that reverse drug resistance in human KB
cells]. Med J Kagoshima Univ 1991; 42(4):367-78. (Jpn).
Ince P, Appleton DR, Finney KJ, Moorghen M, Sunter JP, Watson AJ.
Verapamil sensitizes normal and neoplastic rodent
intestinal tissues to the stathmokinetic effect of
vincristine in-vivo. Br J Cancer 1988;57(4):348-52.
Ince P, Elliot K, Moorghen M, Finney KJ, Appleton DR, Watson AJ,
Sunter JP. Possible role for p-glycoprotein in normal rat
colon [abstract]. J Pathol 1988;155(4):351a.
Ince P, Elliott K, Appleton DR, Moorghen M, Finney KJ, Sunter JP,
Harris AL, Watson AJ. Modulation by verapamil of
vincristine pharmacokinetics and sensitivity to metaphase
arrest of the normal rat colon in organ culture. Biochem
Pharmacol 1991 Apr 15;41(8):1217-25.
Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K,
Tsuruo T, Shimoyama M. Multidrug resistance in cultured
human leukemia and lymphoma cell lines detected by a
monoclonal antibody, MRK16. Jpn J Cancer Res 1989 Oct;
80(10):1006-13.
Ishida Y, Shimada Y, Shimoyama M. Synergistic effect of
cyclosporin A and verapamil in overcoming vincristine
resistance of multidrug-resistant cultured human leukemia
cells. Jpn J Cancer Res 1990 Aug;81(8):834-41.
Iwahashi T, Okochi E, Ono K, Sugawara I, Tsuruo T, Mori S.
Establishment of multidrug resistant human colorectal
carcinoma HCT-15 cell lines and their properties.
Anticancer Res 1991 May-Jun; 11(3):1309-12.
Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson
B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.
Autologous bone marrow transplantation in multiple myeloma:
identification of prognostic factors. Blood 1990 Nov
1;76(9): 1860-6.
Jamis-Dow CA, Myers CE, Yeh GC. Increased lactate production
associated with early stages of adriamycin resistance in
human breast cancer cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A1991.
Jardillier JC, Warren L, Colin M, Madoulet C. Effect of
vanadate on multidrug resistance in CEM cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2833.
Jolicoeur-Paquet L, Naismith AL, Costello PC, Riordan JR. P-
glycoprotein is expressed in the brain and recognizes some
analgesic drugs [abstract]. FASEB J 1989;3(3):A424.
Kakehi Y, Kanamaru H, Yoshida O. Elevated expression of
multidrug-resistance gene mdr in renal cell carcinomas is
associated with intrinsic drug resistance [abstract]. J
Urol 1988;139(4 Pt 2): 422a.
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman
MM, Pastan I. Measurement of multidrug-resistance
messenger RNA in urogenital cancers elevated expression in
renal cell carcinoma is associated with intrinsic drug
resistance. J Urol 1988;139(4):862-5.
Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of gp170
the multidrug resistance gene product in rat liver
canalicular membrane vesicles. J Biol Chem
1989;264(20):11693-8.
Kamiwatari M, Nagata Y, Kikuchi H, Yoshimura A, Sumizawa T, Shudo
N, Sakoda R, Seto K, Akiyama SI. Correlation between
reversing of multidrug resistance and inhibiting of
tritiated azidopine photolabeling of p-glycoprotein by newly
synthesized dihydropyridine analogues in a human cell line.
Cancer Res 1989;49(12):3190-5.
Kane M, Laucius JF, Bellet R, Berd D, Mastrangelo M, Rose L,
Rabinowitz M. Phase I/II trial of etoposide (E) and
cefoperazone (C) in the treatment of refractory neoplasms
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A315.
Kane SE, Gottesman MM. Multidrug resistance in the laboratory
and clinic. Cancer Cells Mon Rev 1989;1(1):33-6.
Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Mechanisms
involved in the development of adriamycin resistance in
human leukemic cells. Leuk Res 1990;14(6):567-73.
Kawada M, Sumi S, Umezawa K, Inouye S, Sawa T, Seto H.
Circumvention of multidrug resistance in human carcinoma KB
cells by polyether antibiotics. J Antibiot (Tokyo) 1992
Apr;45(4):556-62.
Kawada M, Umezawa K. Long lasting accumulation of vinblastine
in inostamycin treated multidrug resistant KB cells. Jpn J
Cancer Res 1991;82(10): 1160-4.
Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in
hematological malignancies. Blood Rev 1991;5(1):38-41.
Khleif SN, Gazdar A, Bates SE. P-glycoprotein (Pgp) expression
and function in an adrenocortical carcinoma (ACC) cell
line: A model for studying the normal function of Pgp
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:359.
Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J,
Tsuruo T. Establishment and characterization of
doxorubicin-resistant human bladder cancer cell line,
KK47/ADM. J Urol 1992 Aug;148(2 Pt 1):441-5.
Kiue A, Sano T, Naito A, Inada H, Suzuki K, Okumura M, Kikuchi J,
Sato S, Takano H, Kohno K, et al. Reversal by two
dihydropyridine compounds of resistance to multiple
anticancer agents in mouse P388 leukemia in vivo and in
vitro. Jpn J Cancer Res 1990 Oct;81(10):1057-64.
Klohs WD, Steinkampf RW. The effect of lysosomotropic agents
and secretory inhibitors on anthracycline retention and
activity in multiple drug-resistant cells. Mol Pharmacol
1988;34(2): 180-5.
Klopman G, Srivastava S, Kolossvary I, Epand RF, Ahmed N, Epand
RM. Structure-activity study and design of multidrug-
resistant reversal compounds by a computer automated
structure evaluation methodology. Cancer Res 1992 Aug 1;
52(15):4121-9.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Knight C, Slade DL, Harker WG. Multidrug resistance in
mitoxantrone-selected CEM leukemia cells appears to be
unrelated to P-glycoprotein expression [abstract]. Clin Res
1991;39(1):68A.
Kohno K, Kikuchi J, Sato SI, Takano H, Saburi Y, Asoh KI, Kuwano
M. Vincristine-resistant human cancer KB cell line and
increased expression of multidrug-resistance gene. Jpn J
Cancer Res 1988; 79(11):1238-46.
Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct
activation of human multidrug resistance gene (MDR1) by
anticancer agents. Biochem Biophys Res Commun 1989 Dec
29;165(3): 1415-21.
Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M. Tissue-
specific enhancer of the human multidrug-resistance (MDR1)
gene. J Biol Chem 1990 Nov 15;265(32):19690-6.
Konen PL, Currier SJ, Rutherford AV, Gottesman MM, Pastan I,
Willingham MC. The multidrug transporter: rapid modulation
of efflux activity monitored in single cells by the
morphologic effects of vinblastine and daunomycin. J
Histochem Cytochem 1989 Jul;37(7):1141-5.
Koseki Y, Sweatman TW, Seshadri R, Israel M. N-
benzyladriamycin-14-valerate (AD 198) synergizes the
cytotoxic effects of adriamycin (ADR) and vinblastine (VBL)
but not etoposide (VP-16) in multidrug resistant (MDR) cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2892.
Kramer RA, Morse B, Summerhayes I. C-HA-RAS-I oncogene-induced
differentiation and decreased MDR1 gene expression in a
human colorectal carcinoma cell line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2189.
Kuhl JS, Lau D, Duran G, Blume KG, Chao NJ, Sikic BI. Multiple
mechanisms of resistance to etoposide in variants of murine
P388 leukemia [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2150.
Kulkarini SS, Wang Z, Taha M, Hamada H, Tsuruo T, Dalton WS,
Aiken A, Dicke KA, Spitzer G. Complement-dependent lysis
of a drug-resistant human myeloma tumor cell line by a
monoclonal antibody to surface determinant of P-glycoprotein
[abstract]. Exp Hematol 1988;16(6):521.
Kulkarni SS, Wang ZM, Spitzer G, Taha M, Hamada H, Tsuruo T,
Dicke KA. Elimination of drug-resistant myeloma tumor cell
lines by monoclonal anti-P-glycoprotein antibody and rabbit
complement. Blood 1989 Nov 1;74(6):2244-51.
Kuo MT, Hung M, Chen XS. Loss of tumorigenicity of multidrug
resistant NIH3T3 cells transformed with C-ERB2-NEU oncogene
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:292.
Kurelec B, Krca S, Pivcevic B, Ugarkovic D, Bachmann M, Imsiecke
G, Muller WE. Expression of P-glycoprotein gene in marine
sponges. Identification and characterization of the 125 kDa
drug-binding glycoprotein. Carcinogenesis 1992
Jan;13(1):69-76.
Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T,
Utsunomiya A, Ishibashi K, Saito T, Uozumi K, Maruyama M, et
al. Expression of P-glycoprotein in adult T-cell leukemia
cells. Blood 1990 Nov 15;76(10):2065-71.
Lai GM, Currier SJ, Mickley LA, Herzog CE, Tsokos M, Bates SE,
Fojo AT. Modulation of P-glycoprotein (Pgp)
phosphorylation and multidrug resistance (MDR) by sodium
butyrate (NaB) [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2242.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Altered state of transformation and/or differentiation in
multidrug-resistant human neuroblastoma cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1704.
LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Multidrug resistance in human neuroblastoma cells. J
Pediatr Surg 1991 Sep; 26(9):1107-12.
Larsen AK, Jacquemin-Sablon A. Multiple resistance mechanisms
in Chinese hamster cells resistant to 9-hydroxyellipticine.
Cancer Res 1989 Dec 15;49(24 Pt 1):7115-9.
Lee FYF, Sciandra J, Siemann DW. A study of the mechanism of
resistance to adriamycin in-vivo glutathione metabolism P-
glycoprotein expression and drug transport. Biochem
Pharmacol 1989; 38(21):3697-706.
Lee KY, Park JG, Gazdar AF, Goldstein LJ, Hwang ES, Kim JP.
Correlation between MDR1 gene expression and in vitro drug
sensitivity testing (DST) of human cancer cell lines
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1990;9:A219.
Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM,
Willingham MC. Fluorescent verapamil derivative for
monitoring activity of the multidrug transporter. Mol
Pharmacol 1991 Oct; 40(4):490-4.
Lelong IH, Padmanabhan R, Lovelace E, Pastan I, Gottesman MM.
ATP and GTP as alternative energy sources for vinblastine
transport by P-170 in KB-V1 plasma membrane vesicles. FEBS
Lett 1992 Jun 15;304(2-3):256-60.
Lemontt JF, Azzaria M, Gros P. Increased mdr gene expression
and decreased drug accumulation in multidrug-resistant
human melanoma cells. Cancer Res 1988;48(22):6348-53.
Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R,
Mertelsmann R. Induction of multiple-drug resistance
during anti-neoplastic chemotherapy in vitro. Int J Cancer
1991 Oct 21; 49(4):630-7.
Licht T, Fiebig HH, Dreher C, Bross KJ, Herrmann F. Modulation
of multidurg resistance by tumor necrosis factor-alpha and
verapamil [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2852.
Liley DTJ, Wiggins PM, Baguley BC. Localization of a
nonintercalative DNA binding antitumor drug in mitochondria
relationship to multidrug resistance. Eur J Cancer Clin
Oncol 1989;25(9):1287-94.
Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts
T, Smit JJ, Borst P. Multidrug resistance phenotype of
human BRO melanoma cells transfected with a wild-type human
mdr1 complementary DNA. Cancer Res 1990 Mar 15;
50(6):1779-85.
Lincke CR, van der Bliek AM, van der Velde-Koerts T, Borst P.
The multidrug resistant phenotype of the wild-type human
MDR1 gene [abstract]. J Chemother Infect Dis Malig
1989;Suppl 1:A309.
Lock RB, Hill BT. Differential patterns of anti-tumour drug
responses and mechanisms of resistance in a series of
independently derived VP 16 resistant human tumour cell
lines. Int J Cancer 1988;42(3): 373-81.
Loor F, Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Emmer G. SDZ 280-446, a novel semi-synthetic
cyclopeptolide: in vitro and in vivo circumvention of the P-
glycoprotein-mediated tumour cell multidrug resistance. Br
J Cancer 1992 Jan;65(1):11-8.
Lothstein L, Hsu SIH, Horwitz SB, Greenberger LM. Alternate
overexpression of two phosphoglycoprotein genes is
associated with changes in multidrug resistance in a J774.2
cell line. J Biol Chem 1989;264(27):16054-8.
Lothstein L, Sweatman TW, Dockter ME, Israel M. Resistance to
N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-
glycoprotein expression without reduced N-
benzyladriamycin-14-valerate accumulation. Cancer Res 1992
Jun 15;52(12): 3409-17.
Lum BL, Kaubisch S, Gosland MP, Jew LL, Ehsan MN, Schnur DP,
Yahanda AM, Adler KM, Hardy R, Brophy NA, et al. The
effect of cyclosporin (CSA) on etoposide (E)
pharmacokinetics in a phase I trial of E with CSA as a
modulator of multidrug resistance [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1991;10:A277.
Lutzky J, Canada AL, Yamanishi DT, Bhalla K, Hindenburg AA.
Effect of verapamil and buthionine sulfoximine (BSO) on
daunorubicin (DNR) cytotoxicity of multidrug-resistant human
melanoma cell lines overexpressing P-glycoprotein and
glutathione-S-transferases [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A3315.
Ma L, Marquardt D, Takemoto L, Center MS. Analysis of P-
glycoprotein phosphorylation in HL60 cells isolated for
resistance to vincristine. J Biol Chem 1991;266(9):5593-9.
Marino PA, Gottesman MM, Pastan I. Regulation of the multidrug
resistance gene in regenerating rat liver. Cell Growth
Differ 1990 Feb;1(2):57-62.
Marquardt D, McCrone S, Center MS. Mechanisms of multidrug
resistance in HL60 cells: detection of resistance-associated
proteins with antibodies against synthetic peptides that
correspond to the deduced sequence of P-glycoprotein.
Cancer Res 1990 Mar 1;50(5):1426-30.
Masurovsky EB, Horwitz SB. Ultrastructural effects of
colchicine vinblastine and taxol in drug-sensitive and
multidrug-resistant j774.2 cells. Protoplasma
1989;148(2-3):138-49.
Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Yamamoto Y,
Sakamoto H, Furuyama J. Amplification and expression of a
multidrug resistance gene in human glioma cell lines.
J Neurosurg 1990 Jan;72(1):96-101.
Mattern J, Bak M, Efferth T, Volm M. Inherent and induced
multidrug resistance in human lung carcinoma xenograft
[abstract]. Invest New Drugs 1989;7(4):444.
Mattern J, Bak M, Volm M. Intrinsic and acquired multidrug
resistance in human lung carcinomas grown in nude mice.
Anticancer Res 1990 Jan-Feb; 10(1):177-80.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Mazzoni A, Trave F, Canti G, Franco P. Effect of the tiapamil
analog RO-11-2933 on cellular sensitivity to antitumor drugs
in sensitive and multidrug resistant human ovarian cancer
cells. Anticancer Res 1989;9(2):367-72.
McClean S, Dempke WC, Whelan RD, Hosking LK, Hill BT.
Overexpression of P-glycoprotein in human ovarian carcinoma
cells following exposure to fractionated x-irradiation in
vitro [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2811.
McEwan GT, Hunter J, Hirst BH, Simmons NL. Volume-activated Cl-
secretion and transepithelial vinblastine secretion mediated
by P-glycoprotein are not correlated in cultured human T84
intestinal epithelial layers. FEBS Lett 1992 Jun
15;304(2-3): 233-6.
McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS.
Mechanisms of multidrug resistance in HL60 cells. Analysis
of resistance associated membrane proteins and levels of mdr
gene expression. Biochem Pharmacol 1989 Oct 15;
38(20):3611-9.
McGrath T, Marquardt D, Center MS. Multiple mechanisms of
adriamycin resistance in the human leukemia cell line ccrf-
cem. Biochem Pharmacol 1989;38(3):497-502.
McLachlin JR, Eglitis MA, Ueda K, Kantoff PW, Pastan IH, Anderson
WF, Gottesman MM. Expression of a human complementary DNA
for the multidrug resistance gene in murine hematopoietic
precursor cells with the use of retroviral gene transfer. J
Natl Cancer Inst 1990 Aug 1;82(15): 1260-3.
Mechetner EB, Roninson IB. Efficient inhibition of P-
glycoprotein-mediated multidrug resistance with a monoclonal
antibody. Proc Natl Acad Sci U S A 1992 Jul
1;89(13):5824-8.
Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, Mcguire WL.
Electrophoretic analysis of 248 clinical breast cancer
specimens for p-glycoprotein overexpression of gene
amplification. J Clin Oncol 1989;7(8):1129-36.
Merriman RL, Dantzig AH, Engelhardt J, Minor PL, Poore GA,
Shackelford KA, Tanzer LR, VanPelt C, Winter MA, Beck WT, et
al. Increased toxicity of vincristine (VCR) when combined
with the multidrug-resistance (MDR) modulator,
trimethoxybenzoylyohimbine (TMBY) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31: A2142.
Meyers MB, Biedler JL, Scotto K, Sirotnak FM. Antibodies to P-
glycoproetin (PGP) cross-react with a 50- to 55-KD protein
in multidrug-resistant mouse tumor cells and in lumenal
intestinal epithelium of the mouse [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:A2099.
Meyers MB, Center M, Druskin H, Spengler BA, Biedler JL. P-
glycoprotein isoforms in vincristine-resistant murine
erythroleukemia cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33: A2808.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR.
Characterization of monoclonal antibodies recognizing a m-r
180000 p-glycoprotein differential expression of the m-r
180000 and m-r 170000 p-glycoproteins in multidrug-resistant
human tumor cells. Cancer Res 1989;49(12):3209-14.
Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR, Cordon-Cardo
C, Biedler JL. The 180-kD resistance-related membrane
protein recognized by monoclonal antibodies raised against
vincristine-resistant human neuroblastoma cells is a P-
glycoprotein [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2008.
Meyers MB, Scotto KW, Sirotnak FM. P-glycoprotein content and
mediation of vincristine efflux correlation with the level
of differentiation in luminal epithelium of mouse small
intestine. Cancer Commun 1991;3(5):159-66.
Meyers MB, Shen WPV, Spengler BA, Ciccarone V, O'Brien JP, Donner
DB, Furth ME, Biedler JL. Increased epidermal growth
factor receptor in multidrug-resistant human neuroblastoma
cells. J Cell Biochem 1988;38(2):87-98.
Michaeli J, Lebedev YB, Leng L, Tong WP, Richon VM, Marks PA,
Rifkind RA. A multidrug resistance (MDR) phenotype in
response to phorbol ester: role of P-glycoprotein and
protein kinase C beta (PKC-beta) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2224.
Michaeli J, Richon VM, Marks PA, Rifkind RA. Vincristine
resistant murine erythroleukemia and HL-60 cells have marked
sensitivity to induction of differentiation by hexamethylene
bisacetamide [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1703.
Michel AD, Kunysz EA, Whiting RL. Interaction of cytotoxic
agents with tritiated PN-200-110 binding sites of rat
cerebrocortical and skeletal muscle membranes [abstract].
Br J Pharmacol 1989;96 Suppl:240P.
Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R,
Raspadori D, Russo D, Visani G, Dinota A, Pileri S, et al.
Overexpression of multidrug resistance-associated p170-
glycoprotein in acute non-lymphocytic leukemia. Eur J
Haematol 1992 Feb;48(2):87-92.
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M.
MDR-1 gene amplification in acute lymphoblastic leukemia
prior to antileukemic treatment. Br J Haematol
1991;78(2):288-9.
Mickisch G, Keilhauer G, Schlick E, Tschada R, Alken P. Calcium
antagonists reverse multidrug resistance (MDR) of primary
human renal cell carcinomas (RCC) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2116.
Mickisch G, Keilhauer G, Schlick E, Tschada R, Alken P. Effects
of R-verapamil (R-vpm) on P-170-mediated multidrug
resistance (mdr) of human renal cell carcinoma (rcc)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2423.
Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski
H, Stahle C, Sachs DH, Pastan I, Gottesman MM.
Transplantation of bone marrow cells from transgenic mice
expressing the human MDR1 gene results in long-term
protection against the myelosuppressive effect of
chemotherapy in mice. Blood 1992 Feb 15;79(4):1087-93.
Mickisch GH, Aksentijevich Y, Gottesman MM, Pastan I.
Transplantation of bone marrow cells expressing the human
MDR1 gene results in long-term protection against the
myelosuppressive effect of chemotherapy in mice [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2803.
Mickisch GH, Gottesman MM, Pastan I, Alken PM. New potent
verapamil derivatives that reverse multidrug resistance in
human renal carcinoma cells and in transgenic mice
expressing the human MDR1 gene [abstract]. J Urol
1991;145(4 Suppl): 379a.
Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken
PM. Effects of calcium antagonists in multidrug resistant
primary human renal cell carcinomas. Cancer Res 1990 Jun
15; 50(12):3670-4.
Mickisch GH, Kossig J, Tschada RK, Keilhauer G, Schlick E, Alken
PM. Circumvention of multidrug resistance mediated by
P-170 glycoprotein using calcium antagonists in primary
human renal cell carcinoma. Urol Int 1991;47(3):118-25.
Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I.
Chemotherapy and chemosensitization of transgenic mice which
express the human multidrug resistance gene in bone marrow:
efficacy, potency, and toxicity. Cancer Res 1991 Oct
1;51(19): 5417-24.
Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I.
Transgenic mice that express the human multidrug-resistance
gene in bone marrow enable a rapid identification of agents
that reverse drug resistance. Proc Natl Acad Sci U S A 1991
Jan 15; 88(2):547-51.
Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken
PM. Mechanisms and modulation of multidrug resistance in
primary human renal cell carcinoma. J Urol 1990 Sep;
144(3):755-9.
Mickley L, Spengler B, Biedler JL, Fojo AT. Genetic
polymorphism as a tool for examining the evolution of
mdr-1/P-glycoprotein (PGP) expression in multidrug-resistant
cell lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2832.
Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F,
Rosen N, Fojo AT. Modulation of the expression of a
multidrug resistance gene mdr-1-P-glycoprotein by
differentiating agents. J Biol Chem 1989;264(30):18031-40.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE.
P-glycoprotein expression in malignant lymphoma and
reversal of clinical drug resistance with chemotherapy plus
high-dose verapamil. J Clin Oncol 1991 Jan; 9(1):17-24.
Miller TP, Grogan TM, Spier CM, Salmon SE, Dalton WS. High-dose
verapamil infusion added to chemotherapy reverses drug
resistance in lymphoma patients in relapse [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1989;8:A984.
Millot JM, Debal V, Morjani H, Merle S, Kiss R, Manfait M.
Characterization of a vinca-alkaloid resistance phenotype in
J82 cells following selection with navelbine [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2201.
Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N.
Characterization of an etoposide-resistant human small-cell
lung cancer cell line. Cancer Chemother Pharmacol
1990;26(5): 313-7.
Mirski SE, Dicke FP, Cole SP. Non-P-glycoprotein-mediated
multidrug resistance in the small-cell lung cancer (SCLC)
cell line, H69AR [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2196.
Miyamoto K, Wakusawa S, Inoko K, Takagi K, Koyama M. Reversal
of vinblastine resistance by a new staurosporine derivative,
NA-382, in P388/ADR cells. Cancer Lett 1992 Jun 15;64(2):
177-83.
Miyamoto K, Wakusawa S, Nakamura S, Tajima K, Hidaka H.
Multidrug resistance in Yoshida rat ascites hepatoma cell
lines. Anticancer Res 1992 May-Jun;12(3):649-53.
Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects
of the high- and low-molecular-weight anticancer agents on
multidrug-resistant Chinese hamster ovary cells in vitro.
Cancer Res 1990 Mar 1;50(5):1571-5.
Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano
T, Tomoda Y. Mitomycin C cross-resistance induced by
adriamycin in human ovarian cancer cells in vitro. Cancer
Chemother Pharmacol 1990;26(5):333-9.
Morgan PF, Fine RL, Montgomery P, Marangos PJ. Multidrug
resistance in MCF-7 human breast cancer cells is associated
with increased expression of nucleoside transporters and
altered uptake of adenosine. Cancer Chemother Pharmacol
1991; 29(2):127-32.
Mukaiyama T, Minowa S, Ogawa M. Analysis of MDR1 mRNA
expression in breast cancer specimens by reverse-
transcription polymerase chain reaction (RT-PCR) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2786.
Mukaiyama T, Mitsui I, Shibata H, Inoue K, Ogawa M. Analysis of
multidrug-resistance gene expression in human cancers:
correlation between expression level and chemosensitivity
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:
A1218.
Mukhopadhyay T, Kuo MT. Expression of the P- glycoprotein gene
in multidrug-resistant Chinese hamster ovary cells.
Anticancer Res 1989;9(3): 575-8.
Muller C, Laval F, Soues S, Birck C, Charcosset JY. High cell
density-dependent resistance and P-glycoprotein-mediated
multidrug resistance in mitoxantrone-selected Chinese
hamster cells. Biochem Pharmacol 1992 May
28;43(10):2091-102.
Muller C, Laval F, Soues S, Charcosset JY. Inducible
amplification and increased expression of MDR genes in
mitoxantrone-resistant hamster cells selected in one step
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2197.
Naito M, Hamada H, Tsuruo T. ATP-magnesium-dependent binding of
vincristine to the plasma membrane of multidrug-resistant
K562 cells. J Biol Chem 1988;263(24):11887-91.
Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of
multidrug resistance by an immunosuppressive agent FK-506.
Cancer Chemother Pharmacol 1992;29(3):195-200.
Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-
dependent high affinity vincristine binding to the plasma
membrane of multidrug-resistant K562 cells without calcium
ion involvement. Cancer Res 1989;49(6):1452-5.
Naito M, Tsuruo T. Functionally active homodimer of P-
glycoprotein in multidrug-resistant tumor cells. Biochem
Biophys Res Commun 1992 May 29; 185(1):284-90.
Naito M, Yusa K, Tsuruo T. Steroid hormones inhibit binding of
Vinca alkaloid to multidrug resistance related P-
glycoprotein. Biochem Biophys Res Commun 1989 Feb
15;158(3):1066-71.
Nakagawa M, Dixon KH, Gilbert L, Goldsmith ME, Cowan KH.
Characterization of mitoxantrone resistant human breast
cancer cell line [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2204.
Nasioulas G, Granzow C, Stohr M, Ponstingl H. Sensitization of
multidrug-resistant mouse ascites HD33 and Chinese hamster
ovary CHRC5S3 cells by a photoreactive vinblastine
derivative, NAPAVIN. Cancer Res 1990 Jan 15;50(2):403-8.
Nelson EJ, Hinkle PM. Characterization of multidrug-resistant
pituitary tumor cells. Endocrinology 1992
Jun;130(6):3246-56.
Neyfakh AA, Serpinskaya AS, Chervonsky AV, Apasov SG, Kazarov AR.
Multidrug-resistance phenotype of a subpopulation of T-
lymphocytes without drug selection. Exp Cell Res 1989 Dec;
185(2):496-505.
Nielsen D, Skovsgaard T. P-glycoprotein as multidrug
transporter: a critical review of current multidrug
resistant cell lines. Biochim Biophys Acta 1992 Jul
7;1139(3):169-83.
Nogae I, Kohno K, Kikuchi J, Kuwano M, Akiyama SI, Kiue A, Suzuki
KI, Yoshida Y, Cornwell MM, et al. Analysis of structural
features of dihydropyridine analogs needed to reverse
multidrug resistance and to inhibit photoaffinity labeling
of p-glycoprotein. Biochem Pharmacol 1989;38(3):519-28.
Norris MD, Haber M, Gilbert J, Madafiglio J, Kavallaris M,
Stewart BW, Mechetner EB, Gudkov AV, Roninson IB.
Selection for MDR1 gene expression by high concentration
methotrexate [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2840.
Nuessler V, Hasmann M, Pelka-Fleischer R, Loeser R, Wilmanns W.
Droloxifene--a new modulator of the multidrug-resistance
(MDR) phenotype in a human leukemia cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A1544.
Nygren P, Larsson R. Verapamil and cyclosporin A sensitize
human kidney tumor cells to vincristine in absence of
membrane P-glycoprotein and without apparent changes in the
cytoplasmic free Ca2+ concentration. Biosci Rep 1990
Apr;10(2):231-7.
Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin
selected multidrug-resistant small cell lung cancer cell
lines characterised by elevated cytoplasmic Ca2+ and
resistance modulation by verapamil in absence of P-
glycoprotein overexpression. Br J Cancer 1991 Dec;64(6):
1011-8.
O'Brian CA, Fan D, Ward NE, Dong Z, Iwamoto L, Gupta KP, Earnest
LE, Fidler IJ. Transient enhancement of multidrug
resistance by the bile acid deoxycholate in murine
fibrosarcoma cells in vitro. Biochem Pharmacol 1991 Mar
1;41(5): 797-806.
O'Brien JP, Spengler BA, Rittmann-Grauer L, Bertino JR, Biedler
JL. Collateral sensitivity of human multidrug-resistant
cells to verapamil is potentiated by monoclonal antibody
HYB-241 recognizing P-glycoprotein [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2114.
O'Donnell MA, Bubley G, Dewolf WC. Multidrug resistance gene
activity in renal cell carcinoma [abstract]. J Urol
1989;141(4 Pt 2):298a.
Ohkouchi E, Takamori R, Kawabata H, Sugimoto Y, Hamada H, Tsuruo
T. Expression of P-glycoprotein and its mRNA in human
renal and colon tumor cell lines, as a determinant for
natural drug resistance [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1217.
Onishi Y, Handel LM, Hall L, Fojo AT, Young RC, Ozols RF,
Hamilton TC. Multidrug resistance (mdr-1) gene
amplification and overexpression (OE) in human ovarian
cancer (HOC) cell lines from untreated patients (pts) and
pts refractory to combination chemotherapy (CC) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2280.
Osann K, Sweet P, Slater LM. Synergistic interaction of
cyclosporin A and verapamil on vincristine and daunorubicin
resistance in multidrug-resistant human leukemia cells in
vitro. Cancer Chemother Pharmacol 1992;30(2):152-4.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and therapy of
breast cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young RC.
Reversal of alkylating agent and platinum resistance in
ovarian cancer [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:526-7.
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV,
Willingham MC. A retrovirus carrying an mdr1 complementary
DNA confers multidrug resistance and polarized expression of
P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A
1988;85(12):4486-90.
Pastan I, Willingham MC, Gottesman MM. Multidrug resistance.
Paper presented at: 6th NCI-EORTC Symposium on New Drugs in
Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Patel M, Lee I, Kaplan R, Roninson IB. Analysis of MDR1 (P-
glycoprotein) expression in multidrug-resistant cell lines
and tumors by in situ RNA hybridization [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:A1161.
Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT.
Essential features of the p-glycoprotein pharmacophore as
defined by a series of reserpine analogs that modulate
multidrug resistance. Proc Natl Acad Sci U S A 1989;
86(13):5128-32.
Pearce HL, Winter MA, Beck WT. Structural characteristics of
compounds that modulate P-glycoprotein-associated multidrug
resistance. Adv Enzyme Regul 1990;30:357-73.
Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E,
Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T, et al.
Reversal of drug resistance in a human colon cancer
xenograft expressing MDR1 complementary DNA by in vivo
administration of MRK-16 monoclonal antibody. J Natl Cancer
Inst 1991 Oct 2;83(19):1386-91.
Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia
P, Miller TP, Salmon SE. Systemic toxic effects associated
with high-dose verapamil infusion and chemotherapy
administration. J Natl Cancer Inst 1991 Jan 16;
83(2):105-10.
Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K,
Carmichael J, Idle JR, Harris AL. A phase I study on the
reversal of multidrug resistance (MDR) in vivo: nifedipine
plus etoposide. Br J Cancer 1992 Feb;65(2):267-70.
Pierre A, Leonce S, Kraus-Berthier L, Guilbaud N, Saint-Dizier D,
Atassi G. Characterization of the reversal of multidrug
resistance by S 9788, a new triazinoaminopiperidine
derivative [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2879.
Pierre A, Perez V, Leonce S, Anstett M, Atassi G. In vitro
circumvention of multidrug resistance by cyclosporin A,
cremophor EL, reserpine or verapamil [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2241.
Pincus R, Goldman ID. Decreased tight binding of mitoxantrone
in P388 leukemia cells with multiple drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1185.
Pincus R, Goldman ID. Evidence for impaired mitoxantrone and
vinblastine binding in P388 murine leukemia cells with
multidrug resistance. Biochem Pharmacol 1990 Dec
15;40(12):2625-35.
Plumb JA, Milroy R, Kaye SB. Sequential induction of drug
resistance in an adherent small-cell lung cancer (SCLC) cell
line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2141.
Politi PM, Sinha BK. Role of differential drug uptake efflux
and binding of etoposide in sensitive and resistant human
tumor cell lines implications for the mechanisms of drug
resistance. Mol Pharmacol 1989;35(3):271-8.
Pourtier-Manzanedo A, Boesch D, Loor F. FK-506 (fujimycin)
reverses the multidrug resistance of tumor cells in vitro.
Anticancer Drugs 1991 Jun; 2(3):279-83.
Preisler HD, Gottesman M, Raza A, Pastan I, Day R. The clinical
significance of expression of the multidrug resistance (MDR)
gene in acute nonlymphocytic leukemia (ANLL) [abstract].
Proc Annu Meet Am Soc Clin Oncol 1989;8:A782.
Qian XD, Beck WT. Binding characteristics of LU-49888, an
optically pure photoaffinity analog of verapamil, to P-
glycoprotein (Pgp) from a multidrug-resistant (MDR) human
leukemic cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1989.
Qian XD, Beck WT. Binding of an optically pure photoaffinity
analogue of verapamil, LU-49888, to P-glycoprotein from
multidrug-resistant human leukemic cell lines. Cancer Res
1990 Feb 15; 50(4):1132-7.
Qian XD, Beck WT. Interaction of a photoactive anthracycline
analog, [3H]-N-azido-benzoyldaunomycin (AB-DNR) with P-
glycoprotein (Pgp) from multidrug-resistant human leukemic
lymphoblasts (CEM/VLB5K) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2160.
Qian XD, Beck WT. Progesterone photoaffinity labels P-
glycoprotein in multidrug-resistant human leukemic
lymphoblasts. J Biol Chem 1990 Nov 5; 265(31):18753-6.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Rahman A, Madhu M, Siddiqui J, Yokozaki H, Clair T, Tortora G,
Cho-Chung YS, Center M, Glazer RI. Potentiation of the
cytotoxicity of adriamycin by 8-Cl-cAMP in multidrug
resistant HL-60 leukemia cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2217.
Ramu A, Ramu N, Gorodetsky R. Reduced ouabain-sensitive
potassium entry as a possible mechanism of multidrug-
resistance in P388 cells. Biochem Pharmacol 1991 Oct
9;42(9):1699-704.
Rao S, Horwitz SB. A multidrug resistance murine cell line is
partially dependent on taxol for growth and has an increased
tubulin content [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1992;33: A2754.
Rauscher FJ 3d, Beerman TA, Baker RM. Characterization of
auromomycin-resistant hamster cell mutants that display a
multidrug resistance phenotype. Mol Pharmacol 1990
Aug;38(2): 198-206.
Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang HP,
Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant
fibroblast interferon and recombinant immune interferon on
growth and the antigenic phenotype of multidrug-resistant
human glioblastoma multiforme cells. J Natl Cancer Inst
1991 Sep 18;83(18):1307-15.
Reizenstein P, Gruber A, Luthman H, Kaczorowska M, Norgren S,
Peterson C, Porvit A, Vitols S. Multiple drug resistance:
expression of the MDR1 gene in leukemic blasts in relation
to treatment and effect of verapamil isomers on cellular
vincristine accumulation [abstract]. Anticancer Res 1990;
10(5B):1400-1.
Rhodes T, Twentyman PR. Effects of cyclosporin A and verapamil
on cellular pharmacokinetics and chemosensitivity in an MDR
cell line which does not express P-glycoprotein [abstract].
Br J Cancer 1991;63 Suppl 13:12.
Riccardi A, Invernizzi R, Ucci G, Luoni R, Danova M, Giordano M,
Zambelli ML, Rastaldi MP, Ascari E. [p170 in multiple
myeloma and acute leukemia]. Haematologica 1991 Jun;76
Suppl 3:177-80. (Ita).
Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks
PA. Characteristics of erythroleukemia cells selected for
vincristine resistance that have accelerated inducer-
mediated differentiation. Proc Natl Acad Sci U S A 1991 Mar
1;88(5):1666-70.
Ries F, Dicato M. Treatment of advanced and refractory breast
cancer with doxorubicin, vincristine and continuous infusion
of verapamil. A phase I-II clinical trial. Med Oncol Tumor
Pharmacother 1991;8(1):39-43.
Riou GF, Zhou D, Ahomadegbe JC, Gabillot M, Duvillard P, Lhomme
C. Expression of multidrug-resistance (MDR1) gene in
normal epithelia and in invasive carcinomas of the uterine
cervix. J Natl Cancer Inst 1990 Sep 19; 82(18):1493-6.
Published erratum appears in J Natl Cancer Inst 1990 Nov 7;
82(21):1724.
Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal
of Vinca alkaloid resistance by anti-P-glycoprotein
monoclonal antibody HYB-241 in a human tumor xenograft.
Cancer Res 1992 Apr 1; 52(7):1810-6.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M.
Immunohistochemical analysis of P-glycoprotein expression
correlated with chemotherapy resistance in locally advanced
breast cancer. Hum Pathol 1990 Aug;21(8):787-91.
Roller E, Klumpp B, Krause J, Gekeker V, Eichelbaum M, Schumacher
K. Modulation of multidrug resistance in a human leukemic
cell line by different calcium antagonists [abstract].
Onkologie 1991;14 Suppl 2:133.
Romerdahl C, Traugott U, Jung S, Keilhauer G. Modulation of
multidrug resistance in vitro and in vivo by structural
analogs of verapamil [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32: A2535.
Roninson IB, Choi K, Morse BS, Noonan KE, Kaplan R, Safa AS,
Tsuruo T, Perez CF, Kriegler M. Molecular biology and
diagnosis of multidrug resistance [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:518-9.
Ross DD, Ordonez JV, Joneckis CC, Testa JR, Thompson BW.
Isolation of highly multidrug-resistant P388 cells from
drug-sensitive P388-S cells by flow cytometric cell sorting.
Cytometry 1988; 9(4):359-67.
Ross KL, Sikic BI, Kercso KM, Owicki JC, Hafeman DG, Muir VC,
Parce JW. Potentiometric monitoring of tumor cell
chemosensitivity with a silicon based biosensor [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2410.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Ruiz JC, Choi KH, von Hoff DD, Roninson IB, Wahl GM.
Autonomously replicating episomes contain mdr1 genes in a
multidrug-resistant human cell line. Mol Cell Biol 1989
Jan;9(1):109-15.
Ruszala-Mallon V, Silva J, Raventos-Suarez C, Durr FE. P-
glycoprotein-mediated multidrug resistance in ovarian
carcinoma cells selected for resistance to bisantrene, a
synthetic anticancer drug [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31: A2110.
Sachs C, Ballas L, Hannun Y, Loomis C, Carroll I, Bell R, Fine
RL. Protein kinase C inhibitors increase drug accumulation
and decrease resistance of multidrug resistant cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2218.
Sachs C, Schnur D, Ballas L, Hannun Y, Loomis C, Carroll I, Bell
R, Fine RL. Protein kinase C (PKC) inhibitors increase
drug accumulation and are cytotoxic to a human multidrug-
resistant (MDR) breast cancer line [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1990;31:A2128.
Saeki T, Shimabuku AM, Ueda K, Komano T. Specific drug binding
by purified lipid-reconstituted P-glycoprotein: dependence
on the lipid composition. Biochim Biophys Acta 1992 Jun 11;
1107(1):105-10.
Safa AR. P-glycoprotein as a target for chemosensitizing
agents. Paper presented at: 1st International Interface of
Clinical and Laboratory Responses to Anticancer Drugs; 1989
Mar 13-15; Villejuif, France.
Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug-
resistant cells. Cancer Invest 1992; 10(4):295-305.
Safa AR. Photoaffinity labeling of the multidrug-resistance-
related P-glycoprotein with photoactive analogs of
verapamil. Proc Natl Acad Sci U S A 1988;85(19):7187-91.
Safa AR, Agresti M, Tamai I, Mehta ND, Vahabi S. The alpha 1-
adrenergic photoaffinity probe [125I]arylazidoprazosin binds
to a specific peptide of P-glycoprotein in multidrug-
resistant cells. Biochem Biophys Res Commun 1990 Jan 15;
166(1):259-66.
Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of p-
glycoprotein in multidrug resistant cells with photoactive
analogs of colchicine. Biochem Biophys Res Commun
1989;162(3): 1402-8.
Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson
IB. Molecular basis of preferential resistance to
colchicine in multidrug-resistant human cells conferred by
Gly-185----Val-185 substitution in P-glycoprotein. Proc
Natl Acad Sci U S A 1990 Sep;87(18):7225-9.
Sahlinsky DR, Slovak ML, Howell SB. Modulation of vinblastine
sensitivity by dipyridamole in multidrug resistant
fibrosarcoma cells lacking MDR1 expression. Br J Cancer
1991;64(4):705-9.
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland
RM. Hypoxia-induced drug resistance: comparison to P-
glycoprotein-associated drug resistance. Br J Cancer 1991
Nov;64(5):809-14.
Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ,
Miller TP. Multidrug-resistant myeloma: laboratory and
clinical effects of verapamil as a chemosensitizer. Blood
1991 Jul 1; 78(1):44-50.
Salmon SE, Grogan T, Meltzer PS, Dalton WS. Relevance of
multidrug resistance to neoadjuvant therapy of cancer.
Paper presented at: 2nd International Congress on Neo-
Adjuvant Chemotherapy; 1988 Feb 19-21; Paris [France].
Salmon SE, Miller T, Grogan T, Dalton WS. Reversal of multidrug
resistance (MDR) with chemosensitizers: an emerging clinical
reality. Paper presented at: Drug resistance as a
biochemical target in cancer chemotherapy. 13th Bristol-
Myers Squibb Symposium on Cancer Research; 1990 May 10-11;
Tokyo, Japan.
Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects
of tumor necrosis factor on sensitive and multidrug
resistant human leukemia and myeloma cell lines. Blood
1989;74(5):1723-7.
Samuels B, Murray J, Sherman J, Agresti M, Safa A. Combination
multidrug resistance modulation: synergism and additivity
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2236.
Samuels B, Ratain M, Mick R, Vogelzang NJ, Schilsky R, O'Brien S,
Harrison H. Phase I trial of multidrug resistance
modulation with cyclosporine A [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A1163.
Samuels BL, Murray JL, Safa AR. Additive reversal of multidrug
resistance by combinations of non-cross-toxic modulating
agents [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2138.
Sanfilippo O, Di Fronzo G, Ronchi E. Natural or acquired drug
resistance and GP170 (GP) expression in human breast cancers
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2209.
Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R.
Expression of P-glycoprotein in breast cancer tissue and in
vitro resistance to doxorubicin and vincristine. Eur J
Cancer 1991; 27(2):155-8.
Sanfilippo O, Silvestrini R, Ronchi E, Di Fronzo G. P-
glycoprotein (PGP) expression and resistance to doxorubicin
(DX) inhuman tumors [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1989;8:A217.
Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA.
Expression of the human multidrug resistance cDNA in insect
cells generates a high activity drug-stimulated membrane
ATPase. J Biol Chem 1992 Mar 5;267(7):4854-8.
Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg
AA, Preisler HD. Expression of the multidrug resistance
gene in myeloid leukemias. Leuk Res 1990;14(1):11-21.
Sato SI, Watanabe Y, Okamura K, Hamanaka R, Mori T, Kohno K,
Kuwano M. Potentiation of vincristine and actinomycin D by
a new synthetic imidazole anti-tumor agent YM-534 active
against human cancer cells and multidrug-resistant cells.
Anticancer Drug Des 1989;4(2):125-36.
Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T. Circumvention
of multidrug resistance by a newly synthesized quinoline
derivative, MS-073. Cancer Res 1991 May 1;51(9):2420-4.
Sato W, Yusa K, Naito M, Tsuruo T. Staurosporine, a potent
inhibitor of C-kinase, enhances drug accumulation in
multidrug-resistant cells. Biochem Biophys Res Commun 1990
Dec 31;173(3):1252-7.
Savaraj N, Teeter L, Kuo MT, Wu CJ, Tapiero H, Lampidis T.
Characteristics of rhodamine and adriamycin-induced
multidrug-resistant cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2187.
Schinkel AH, Roelofs EM, Borst P. Characterization of the human
MDR3 P-glycoprotein and its recognition by P-glycoprotein-
specific monoclonal antibodies. Cancer Res 1991 May
15;51(10): 2628-35.
Schluesener HJ. Transforming growth factors type beta inhibit
multidrug transport in rat astrocyte cell lines.
Autoimmunity 1991;9(3):269-75.
Schluesener HJ, Meyermann R. Spontaneous multidrug transport in
human glioma cells is regulated by transforming growth
factors type beta. Acta Neuropathol (Berl)
1991;81(6):641-8.
Schoenlein PV, Shen DW, Johnson BP, Pastan I, Gottesman MM. The
amplification of the human MDR1 gene occurs via episome
formation in KB carcinoma cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2107.
Schrenk D, Gant TW, Silverman JA, Marino PA, Thorgeirsson SS.
Induction of mdr expression by cholestasis: P-glycoprotein
functions as a biliary excretion pump [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A181.
Schuetz J, Schuetz E, Stromm S, Schroeder V. Regulation of P-
glycoprotein in human hepatocytes [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2155.
Schurr E, Raymond M, Bell JC, Gros P. Characterization of the
multidrug resistance protein expressed in cell clones stably
transfected with the mouse mdr1 complementary DNA. Cancer
Res 1989;49(10):2729-34.
Schwartsmann G, Cerski CT, Sander E, Sprinz E, Zampese M, Cartel
A, Kronfeld M, Brunetto AL. Multidrug resistance (MDR) in
patients (pts) with AIDS-related Kaposi's sarcoma
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A1248.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
activity and multidrug resistance in MOLT-3 human
lymphoblastic leukemia cells resistant to trimetrexate.
Cancer Res 1991 Jan 1; 51(1):55-61.
Scudder SA, Saunders KA, Andreotti VA, White RWD. Rhodamine 123
efflux as a measure of drug resistance [abstract]. Clin Res
1991;39(1):68a.
Sehested M, Bindslev N, Demant EJF, Skovsgaard T, Jensen PB.
Daunorubicin and vincristine binding to plasma membrane
vesicles from daunorubicin-resistant and wild type Ehrlich
ascites tumor cells. Biochem Pharmacol 1989;38(18):3017-28.
Sehested M, Friche E, Jensen PB, Demant EJ. Relationship of
VP-16 to the classical multidrug resistance phenotype.
Cancer Res 1992 May 15; 52(10):2874-9.
Sehested M, Jensen PB, Skovsgaard T, Bindslev N, Demant EJ,
Friche E, Vindelv L. Inhibition of vincristine binding to
plasma membrane vesicles from daunorubicin-resistant Ehrlich
ascites cells by multidrug resistance modulators. Br J
Cancer 1989 Dec;60(6):809-14.
Sehested M, Skovsgaard T, Jensen PB, Demant EJ, Friche E,
Bindslev N. Transport of the multidrug resistance
modulators verapamil and azidopine in wild type and
daunorubicin resistant Ehrlich ascites tumour cells. Br J
Cancer 1990 Jul;62(1):37-41.
Seid CA, Fidler IJ, Clyne RK, Earnest LE, Fan D. Overcoming
murine tumor cell resistance to vinblastine by presentation
of the drug in multilamellar liposomes consisting of
phosphatidylcholine and phosphatidylserine. Sel Cancer Ther
1991 Fall;7(3):103-12.
Seidman AD, Scher HI. The evolving role of chemotherapy for
muscle infiltrating bladder cancer. Semin Oncol 1991
Dec;18(6):585-95.
Sekiya S, Nunoyama T, Shirasawa H, Kimura H, Kawata M, Iijima N,
Sugimoto Y, Tsuruo T, Takamizawa H. Expression of a human
multidrug resistance gene in human ovarian carcinoma cell
lines. Arch Gynecol Obstet 1992;251(2):79-86.
Sen S, Hittelman WN, Teeter LD, Kuo MT. Model for the formation
of double minutes from prematurely condensed chromosomes of
replicating micronuclei in drug-treated Chinese hamster
ovary cells undergoing DNA amplification. Cancer Res 1989
Dec 1;49(23):6731-7.
Seneviratne C, Goldenberg GJ. Further characterization of drug-
sensitivity and cross-resistance profiles of cloned cell
lines of Adriamycin-sensitive and -resistant P388 leukemia.
Cancer Commun 1989;1(1):21-7.
Shalinsky DR, Andreeff M, Howell SB. Modulation of drug
sensitivity by dipyridamole in multidrug resistant tumor
cells in vitro. Cancer Res 1990 Dec 1;50(23):7537-43.
Shalinsky DR, Howell SB. Synergistic enhancement of the
cytotoxicity of vinblastine (VBL) and colchicine (COL) by
dipyridamole (DPM) in drug-resistant kb carcinoma cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2097.
Shalinsky DR, Slovak ML, Howell SB. Modulation of vinblastine
sensitivity by dipyridamole in multidrug resistant
fibrosarcoma cells lacking mdr1 expression. Br J Cancer
1991 Oct;64(4):705-9.
Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human
hepatocellular carcinoma cell lines exhibit multidrug
resistance unrelated to MRD1 gene expression. J Cell Sci
1991 Mar;98(Pt 3):317-22.
Shibata H, Sato T, Gamoh M, Tshioka C, Kanamaru R, Wakui A.
Expression of P-glucoprotein MRNA and erythroid
differentiation in multidrug-resistant K562 cell lines
treated with sodium butyrate [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A1159.
Shieh CY, Fojo AT, Bates SE. Expression of a multidrug
resistance gene (mdr-1/Pgp) in human breast carcinoma
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2073.
Shimm DS, Olson S, Hill AB. Radiation resistance in a multidrug
resistant human T-cell leukemia line. Int J Radiat Oncol
Biol Phys 1988;15(4):931-6.
Shimoyama M. Detection of multidrug resistant (MDR) cancer
cells by monoclonal antibodies. Paper presented at: Drug
resistance as a biochemical target in cancer chemotherapy.
13th Bristol-Myers Squibb Symposium on Cancer Research; 1990
May 10-11; Tokyo, Japan.
Shinoda H, Inaba M, Tsuruo T. In vivo circumvention of
vincristine resistance in mice with P388 leukemia using a
novel compound, AHC 52. Cancer Res 1989;49(7):1722-6.
Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K,
Sakoda R, Akiyama S. Two pyridine analogues with more
effective ability to reverse multidrug resistance and with
lower calcium channel blocking activity than their
dihydropyridine counterparts. Cancer Res 1990 May
15;50(10):3055-61.
Shuin T, Masuda M, Yao M, Kubota Y, Sugimoto Y, Tsuruo T.
Chemosensitivity and expression of multidrug resistant gene
(MDR1 gene) in human kidney cancer cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:A1222.
Siddiqui J, Madhu M, Center M, Glazer R, Dritschilo A, Rahman A.
Modulation of multidrug resistance in HL-60 leukemia cells
by adriamycin encapsulated in liposomes [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2230.
Sikic BI, Brophy NA, Berry JM, Marie JP, Ehsan MN, Tsuruo T,
Roninson IB, Smith SD. Multidrug resistance gene
expression in ovarian and breast cancers, leukemias, and
lymphomas. Paper presented at: 6th NCI-EORTC Symposium on
New Drugs in Cancer Therapy; 1989 Mar 7-10; Amsterdam.
Skovsgaard T. Transport and multidrug resistance: indications
of a changed pH-gradient across the membrane. Pezcoller
Found Symp 1990;1:209-31.
Skovsgaard T. Drug transport in multidrug-resistant tumor cells
a revision of the pump hypothesis. In: Tapiero H, Robert J,
Lampidis TJ, editors. 1st International Interface of
Clinical and Laboratory Responses to Anticancer Drugs; 1989
Mar 13-15; Villejuif, France. Paris: Les Editions Inserm;
1989. p. 233-44. (Colloque INSERM; 191).
Slapak CA, Daniel JC, Levy SB. Sequential emergence of distinct
resistance phenotypes in murine erythroleukemia cells under
adriamycin selection: decreased anthracycline uptake
precedes increased P-glycoprotein expression. Cancer Res
1990 Dec 15;50(24):7895-901.
Slapak CA, Levy SB. Frequency and phenotype of early
adriamycin-resistant mammalian leukemia cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2019.
Slate DL, Bruno N, Carver LA, Rabier M. Isolation and
characterization of multiple drug resistant carcinoma cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1975.
Slater LM, Sweet P, Hsu TC, Chan PK. Novel nucleolar and
nuclear morphology in a vincristine-dependent human leukemia
cell line (L100). Exp Cell Res 1992 Jan;198(1):170-4.
Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and
biological evidence for differing mechanisms of doxorubicin
resistance in two human tumor cell lines. Cancer Res 1988;
48(10):2793-7.
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S,
Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-
resistant multiple myeloma by cyclosporin. The Leukaemia
Group of the EORTC and the HOVON. Lancet 1992 Aug 1;
340(8814):255-9.
Sonneveld P, Nooter K, Burghouts JTM, Herweijer H, Adriaansen HJ,
Van Dongen JJM. High expression of the mdr3 multidrug-
resistance gene in advanced-stage chronic lymphocytic
leukemia. Blood 1992;79(6):1496-500.
Staats J, Marquardt D, Center MS. Characterization of a
membrane-associated protein kinase of multidrug-resistant
HL60 cells which phosphorylates P-glycoprotein. J Biol Chem
1990 Mar 5;265(7):4084-90.
Stahl F, Martinsson T, Dahllof B, Levan G. Amplification and
overexpression of the P-glycoprotein genes and differential
amplification of three other genes in SEWA murine multidrug-
resistant cells. Hereditas 1988;108(2):251-8.
Stow MW, Warr JR. Amplification and expression of MDR genes and
flanking sequences in verapamil hypersensitive hamster cell
lines. Biochim Biophys Acta 1991;1092(1):7-14.
Sugawara I, Kodo H, Ohkochi E, Hamada H, Tsuruo T, Mori S.
High-level expression of MRK 16 and MRK 20 murine monoclonal
antibody-define proteins (170,000-180,000 P-glycoprotein and
85,000 protein) in leukaemias and malignant lymphomas. Br J
Cancer 1989 Oct;60(4):538-41.
Sunkara PS, Zwolshen JH, Stemerick DM, Edwards ML. 1-(2,5-
dimethoxy phenyl)-3-[4(dimethylamino)phenyl]-2-methyl-2-
propen-1-one (DDMP, MDL 27,048): novel antimitotic agent
with activity against vinca alkaloid resistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A1954.
Suzuki H, Tomida A, Nishimura T. Cytocidal activity of a
synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-
dimethoxybenzyl)ethylenediamine, and its potentiation of
antitumor drugs against multidrug-resistant and sensitive
cells in vitro. Jpn J Cancer Res 1990 Mar;81(3):298-303.
Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y,
Niitani H, Saijo N. Establishment of a human leukemia
subline resistant to the growth-inhibitory effect of 12-O-
tetradecanoylphorbol 13-acetate (TPA) and showing non-P-
glycoprotein-mediated multi-drug resistance. Int J Cancer
1991 Jul 30;48(6):931-7.
Takemura Y, Ohnuma T, Miyachi H, Sekiguchi S. A human leukemia
cell line made resistant to two folate analogues,
trimetrexate and N10-propargyl-5,8-dideazafolic acid
(CB3717). J Cancer Res Clin Oncol 1991;117(6):519-25.
Tamai I, Safa AR. Azidopine noncompetitively interacts with
vinblastine and cyclosporin A binding to P-glycoprotein in
multidrug resistant cells. J Biol Chem 1991 Sep 5;
266(25):16796-800.
Tamai I, Safa AR. Competitive interaction of cyclosporins with
the Vinca alkaloid-binding site of P-glycoprotein in
multidrug-resistant cells. J Biol Chem 1990 Sep
25;265(27):16509-13.
Tatsuta T, Naito M, Oh-hara T, Tsuruo T. Physiological function
of P-glycoprotein in brain capillary endothelial cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2789.
Tatsuta T, Shimizu K, Nishimura T, Suzuki H. Enhancement of
activities of anti-tumor drugs by dipyridamole against
multidrug-resistant human hepatoma PLC/PRF/5 cells.
Anticancer Drug Des 1991 Jul;6(3):179-88.
Taylor CW, Dalton WS. Multiple mechanisms of drug resistance in
MCF-7 human breast cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2109.
Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT,
Thompson FH, Roe DJ, Trent JM. Different mechanisms of
decreased drug accumulation in doxorubicin and mitoxantrone
resistant variants of the MCF7 human breast cancer cell
line. Br J Cancer 1991 Jun;63(6):923-9.
Tebbi CK, Chervinsky D, Baker RM. Modulation of drug resistance
in homoharringtonine-resistant C-1300 neuroblastoma cells
with cyclosporine A and dipyridamole. J Cell Physiol 1991
Sep;148(3): 464-71.
Tebbi CK, Yaeger E, Chervinsky D, Chen Y, Baker R. Dipyrimidole
(DPM) is highly effective in reversing multidrug resistance
of C1300 neuroblastoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1990;31:A2096.
Thiebaut F, Currier SJ, Whitaker J, Haugland RP, Gottesman MM,
Pastan I, Willingham MC. Activity of the multidrug
transporter results in alkalinization of the cytosol:
measurement of cytosolic pH by microinjection of a pH-
sensitive dye. J Histochem Cytochem 1990 May;38(5): 685-90.
Tickman RJ, Holoye P, Robey-Cafferty S, Bruner J. P-
glycoprotein (PGP) in small cell carcinoma of lung
expression before and after chemotherapy and its influence
upon responsiveness to a preoperative chemotherapy regimen
[abstract]. Lab Invest 1990; 62(1):99a.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Boiocchi M.
Multidrug-resistance in human colon carcinoma cell lines
[abstract]. Anticancer Res 1990;10(5B):1406-7.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Rossi C, Boiocchi M.
Pleiotropic-resistant phenotype is a multifactorial
phenomenon in human colon carcinoma cell lines. Br J Cancer
1991 Jan;63(1): 51-6.
Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi
M. Expression of the mdr1 gene in human colorectal
carcinomas: relationship with multidrug resistance inferred
from analysis of human colorectal carcinoma cell lines.
Cancer Chemother Pharmacol 1992;29(4):283-9.
Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ.
Elimination of chemoresistant multiple myeloma clonogenic
colony-forming cells by combined treatment with a plasma
cell-reactive monoclonal antibody and a p-glycoprotein-
reactive monoclonal antibody. Cancer Res 1989;49(17):
4829-34.
Treichel RS, Olken S. The relationship between multi-drug
resistance and resistance to natural-killer-cell and
lymphokine-activated killer-cell lysis in human leukemic
cell lines. Int J Cancer 1992 Jan 21; 50(2):305-10.
Trumper LH, Ho AD, Hunstein W. Addition of verapamil to
overcome drug resistance in multiple myeloma: preliminary
clinical observations in 10 patients [abstract]. J
Chemother Infect Dis Malig 1989;Suppl 1:A273.
Tsuruo T. Multidrug resistance: a transport system of antitumor
agents and xenobiotics. Int Symp Princess Takamatsu Cancer
Res Fund 1990;21: 241-51.
Tsuruo T. Proteins involved in multidrug resistance and their
implication for therapy. Pezcoller Found Symp
1990;1:131-43.
Tsuruo T, Naito M, Takamori R, Tsukahara S, Yamabe-Mitsuhashi J,
Yamazaki A, Oh-hara T, Sudo Y, Nakaike S, Yamagishi T. A
benzophenazine derivative, N-beta-dimethylaminoethyl 9-
carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-
carboxamide, as a new antitumor agent against multidrug-
resistant and sensitive tumors. Cancer Chemother Pharmacol
1990;26(2):83-7.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987; 78(12):1415-9.
Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-
containing anthracycline me-2303 as a new antitumor agent
against murine and human tumors and their multidrug-
resistant sublines. Cancer Res 1989;49(20):5537-42.
Twentyman PR. Modification of cytotoxic drug resistance by non-
immunosuppressive cyclosporins. Br J Cancer
1988;57(3):254-8.
Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a
novel non-immunosuppressive cyclosporin [corrected]
[published erratum appears in Eur J Cancer
1992;28(2-3):616]. Eur J Cancer 1991;27(12):1639-42.
Twentyman PR, Wright KA. Derivation and characterization of a
cell line with acquired resistance to cyclosporin A
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2250.
Twentyman PR, Wright KA, Fox NE. Characterisation of a mouse
tumour cell line with in vitro derived resistance to
verapamil. Br J Cancer 1990 Feb;61(2):279-84.
Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the
promotor region of the human multidrug resistance (P-
glycoprotein) gene. J Biol Chem 1987;262(36):17432-6.
Ujhazy P, Chen Y, Fredericks W, Ehrke MJ. Collateral
sensitivity to tumor necrosis factor in an adriamycin
resistant EL4 cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1625.
Umezawa K, Kawada M. Suppression of multidrug resistance by
polyether antibiotics in human carcinoma KB cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2856.
Van Belle S, Stockman D, De Smet M, Storme G. Influence of
verapamil on the uptake of vinblastine by MO4 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2253.
Van Der Bliek AM, Baas F, Van Der Velde Koerts T, Biedler JL,
Meyers MB, OzoLs RF, Hamilton TC, Joenje H, Borst P. Genes
amplified and overexpressed in human multidrug resistant
cell lines. Cancer Res 1988;48(21):5927-32.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Timmer-Bosscha H, Mulder NH. Multidrug resistance (MDR)
modulation with amiodarone (AM) in human tumor cell lines
and patients [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2076.
van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C,
Vellenga E, Mulder PO, Mulder NH. In vitro and in vivo
modulation of multi-drug resistance with amiodarone. Int J
Cancer 1991 Jun 19;48(4):616-22.
van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ,
Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ,
Pinedo HM, et al. Distribution of multi-drug resistance-
associated P-glycoprotein in normal and neoplastic human
tissues. Analysis with 3 monoclonal antibodies recognizing
different epitopes of the P-glycoprotein molecule. Ann
Oncol 1990;1(1):56-64.
Vasanthakumar G, Ahmed NK. Modulation of drug resistance in a
daunorubicin resistant subline with oligonucleoside
methylphosphonates. Cancer Commun 1989;1(4):225-32.
Published erratum appears in Cancer Commun 1990;2(8):295.
Vera JC, Castillo GR, Rosen OM. A possible role for a mammalian
facilitative hexose transporter in the development of
resistance to drugs. Mol Cell Biol 1991;11(7):3407-18.
Versantvoort CH, Broxterman HJ, Pinedo HM, de Vries EG, Feller N,
Kuiper CM, Lankelma J. Energy-dependent processes involved
in reduced drug accumulation in multidrug-resistant human
lung cancer cell lines without P-glycoprotein expression.
Cancer Res 1992 Jan 1;52(1):17-23.
Volm M, Bak M Jr, Efferth T, Lathan B, Mattern J.
Immunocytochemical detection of a resistance-associated
glycoprotein in tissue culture cells ascites tumors and
human tumor xenografts by MAB-265-F4. Anticancer Res
1988;8(4):531-6.
Volm M, Bak M, Efferth T, Mattern J. Inherent and induced
multidrug-resistance in human lung carcinoma xenograft lines
[abstract]. J Chemother Infect Dis Malig 1989;Suppl 1:A473.
Von Hoff D, VanDevanter D, Forseth B, Davidson K, Waddelow T,
Wahl G. Hydroxyurea can decrease drug resistance gene copy
numbers in tumor cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2243.
Wakusawa S, Nakamura S, Aritsuka K, Miyamoto KI, Koshiura R,
Hagiwara M, Hidaka H. Effect of protein kinase inhibitors
on the drug-efflux system in multidrug-resistant tumor
cells [abstract]. Jpn J Pharmacol 1990;52 Suppl 1:86P.
Wakusawa S, Nakamura S, Miyamoto KI, Koshiura R, Hidaka H.
Effect of calmodulin inhibitors on membrane transport of
vinblastine in multidrug-resistant rat ascites hepatoma
(AH66) cells [abstract]. Jpn J Pharmacol 1991;55 Suppl
1:96P.
Wakusawa S, Nakamura S, Tajima K, Miyamoto K, Hagiwara M, Hidaka
H. Overcoming of vinblastine resistance by
isoquinolinesulfonamide compounds in adriamycin-resistant
leukemia cells. Mol Pharmacol 1992 Jun;41(6):1034-8.
Wallace RE, Lindh D, Greenberger L, Raventos-Suarez C, Durr FE.
Development of a human breast carcinoma (MX-1E) cell line
resistant to calicheamicin [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2163.
Wang L, Yang CP, Trail P, Horwitz SB, Casazza AM. Reversal of
the multidrug resistance (MDR) phenotype with megestrol
acetate (MA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2239.
Warr JR, Anderson M, Fergusson J. Properties of verapamil-
hypersensitive multidrug-resistant Chinese hamster ovary
cells. Cancer Res 1988; 48(16):4477-83.
Warren L, Jardillier JC, Malarska A, Akeli MG. Increased
accumulation of drugs in multidrug-resistant cells induced
by liposomes. Cancer Res 1992 Jun 1;52(11):3241-5.
Warren L, Jardillier JC, Ordentlich P. Secretion of lysosomal
enzymes by drug-sensitive and multiple drug-resistant cells.
Cancer Res 1991 Apr 15; 51(8):1996-2001.
Warrington RC, Fang WD. Reversal of the multidrug-resistant
phenotype of Chinese hamster ovary cells by l-histidinol. J
Natl Cancer Inst 1989;81(10):798-803.
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T.
Cellular pharmacology of MX2, a new morpholino
anthracycline, in human pleiotropic drug-resistant cells.
Cancer Res 1991 Jan 1;51(1):157-61.
Watanabe T, Inaba M, Sugiyama Y. Saturable process involved in
active efflux of vincristine as a mechanism of multidrug
resistance in P388 leukemia cells. Pharm Res 1989
Aug;6(8):690-6.
Watanabe Y, Takano H, Kiue A, Kohno K, Kuwano M. Potentiation
of etoposide and vincristine by two synthetic 1,4-
dihydropyridine derivatives in multidrug-resistant and
atypical multidrug-resistant human cancer cells. Anticancer
Drug Des 1991 Feb;6(1):47-57.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Weber JM, Sircar S, Horvath J, Dion P. Non P-glycoprotein
mediated multidrug resistance in detransformed rat cells
selected for resistance to methylglyoxal
bis(guanylhydrazone). Cancer Res 1989;49(21):5779-83.
Whang-Peng J. Double minutes (DMs) and homogeneously staining
regions (HSRs). Int Congr Ser 1989;807:63-74.
Whelan RD, Deuchars K, Hosking LK, Ling V, Hill BT.
Overexpression of P-glycoprotein in Chinese hamster ovary
cells following fractionated X-irradiation in vitro
[abstract]. Br J Cancer 1990; 62(3):491.
Whelan RD, Hosking LK, Hill BT. A lack of adriamycin (ADR)
resistance in Chinese hamster ovary (CHO) cells
overexpressing P-glycoprotein (Pgp) following in vitro
exposure to fractionated X-irradiation. Biochem Soc Trans
1991 Apr;19(2): 125S.
Wilson WH, Bryant G, Bates S, Fojo T, Stevenson MA, Kohler D,
Chabner BA. Infusional etoposide (E), vincristine (O) and
adriamycin (H) with cyclophosphamide (C), prednisone (P)
(EPOCH) and R-verapamil (RV) in relapsed lymphoma
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A956.
Yang CP, Cohen D, Greenberger LM, Hsu SI, Horwitz SB.
Differential transport properties of two mdr gene products
are distinguished by progesterone. J Biol Chem 1990 Jun
25;265(18):10282-8.
Yang CPH, Depinho SG, Greenberger LM, Arceci RJ, Horwitz SB.
Progesterone interacts with p-glycoprotein in multidrug-
resistant cells and in the endometrium of gravid uterus. J
Biol Chem 1989;264(2):782-8.
Yang JM, Hait WN. Use of multidrug resistant L1210 cell line
for in vitro and in vivo drug screening [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2161.
Yang LY, Su YZ, Trujillo JM, Hai S. Distinct P-glycoprotein (P-
GP) expressions in two different multidrug resistant (MDR)
subclones simultaneously selected from a human colon
carcinoma cell line by cisplatin (CDDP) [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2199.
Yang LY, Trujillo JM. Biological characterization of multidrug-
resistant human colon carcinoma sublines induced/selected by
two methods. Cancer Res 1990 Jun 1;50(11):3218-25.
Yang LY, Trujillo JM. Different mechanisms for multidrug
resistance in two models of adriamycin-resistant subclones
derived from a human colon carcinoma cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2053.
Yanovich S, Gewirtz DA, Hall RE, Pickard P, Boise L, Westin E.
Reactivity and functional properties of a monoclonal
antibody developed against an MDR K562 subline [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1998.
Yanovich S, Hall RE, Gewirtz DA. Characterization of a K562
multidrug-resistant cell line. Cancer Res
1989;49(16):4499-503.
Yanovich S, Hall RE, Gewirtz DA. Resistance to natural killer
(NK) cell lysis is associated with multiple drug resistance
(MDR) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1082.
Yasuo K, Shuichi H, Tatsuhiko F, Akihiko Y, Tomoyuki S, Atae U,
Kazuaki I, TAkeshi S, Kimiharu U, Masao M, Minoru I,
Terukatsu A, Shin Ichi A. Expression of P-glycoprotein in
adult T-cell leukemia cells. Blood 1990;76(10):2065-71.
Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki
K, Tsuruo T, Cowan KH, Glazer RI. Transfection with
protein kinase C alpha confers increased multidrug
resistance to MCF-7 cells expressing P-glycoprotein. Cancer
Commun 1991 Jun;3(6):181-9.
Yusa K, Sato W, Yamazaki A, Tsukahara S, Tsuruo T. Cross-
resistance of human multidrug-resistant cells to mitomycin
C. Anticancer Res 1991 May-Jun; 11(3):1301-4.
Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by
verapamil: verapamil binds to P-glycoprotein on specific
sites and is transported outward across the plasma membrane
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:
A2058.
Zamora JM, Pearce HL, Beck WT. Physical-chemical properties
shared by compounds that modulate multidrug resistance in
human leukemic cells. Mol Pharmacol 1988;33(4):454-62.
Zamora JM, Wells MR, Wolverton JS, Cirtain MC, Edwards H, Beck
WT. Hypersensitivity of human leukemic multidrug resistant
(MDR) cells to intracellular (IC) alkalinization by ouabain
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1166.
-Other antineoplastic agents
Agarwala S, Bahnson R, Wilson J, Szumowski J, Downs M, Ernstoff
M. Evaluation of the combination of vinblastine and
quinidine in patients with metastatic renal cell carcinoma -
a phase I study [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A1161.
Alexanian R, Barlogie B. New treatment strategies for multiple
myeloma. Am J Hematol 1990 Nov;35(3): 194-8.
Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S.
Multidrug resistance in a human leukemic cell line selected
for resistance to trimetrexate. Cancer Res 1989 Dec
1;49(23): 6556-61.
Barrand MA, Twentyman PR. Variations in P-glycoprotein
expression in response to drug treatment in mouse tumor cell
lines [abstract]. Br J Cancer 1991;63 Suppl 13:12.
Bhushan A, Abramson R, Chiu JF, Tritton TR. Expression of c-fos
in human and murine multidrug-resistant cells. Mol
Pharmacol 1992 Jul; 42(1):69-74.
Bhuyan BK, Smith KS, Sampson KE, Abraham I. V79 cells resistant
to the alkylating agent U-73975 are multidrug resistant
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2179.
Capranico G, De Isabella P, Castelli C, Supino R, Parmiani G,
Zunino F. P-glycoprotein gene amplification and expression
in multidrug-resistant murine p388 and b16 cell lines. Br
J Cancer 1989; 59(5):682-5.
Carulli G, Marini A, Caracciolo F. [P-glycoprotein and
treatment with plicamycin + hydroxyurea in myeloid blastic
crisis of chronic myeloid leukemia]. Medicina (Firenze)
1989 Oct-Dec;9(4):409-10. (Ita).
Casazza AM, Catino JJ. Mechanisms and strategies related to
drug resistance. Paper presented at: Strategies in Cancer
Medical Therapy: Biological Bases and Clinical Implications;
1989 Apr 12-15; Forli, Italy.
Chapekar MS, Huggett AC, Cheng C. Dexamethasone prevents the
growth inhibitory effects of recombinant tumor necrosis
factor in a rat hepatoma cell line Reuber-RC-3: an
association with the changes in the messenger RNA levels for
multidrug resistance gene. Biochem Biophys Res Commun 1991
Dec 31;181(3):1524-31.
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss
of multiple drug resistance by hydroxyurea [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A209.
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss
of multiple drug resistance by hydroxyurea. Semin Oncol
1992 Jun;19(3 Suppl 9):94-100.
Durie BGM, Dalton WS. Reversal of drug resistance in multiple
myeloma with verapamil. Br J Haematol 1988;68(2):203-6.
Dutt A, Heath LA, Pan BF, Nelson JA. Role of P-glycoprotein in
organic cation secretion in the mammalian kidney [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A113.
Epstein J, Xiao H, Oba BK. P-glycoprotein expression in plasma
cell myeloma is associated with resistance to VAD. Blood
1989;74(3):913-7.
Evans SS, Rustum YM. The combined effects of alpha-interferon
with doxorubicin (DOX) and vinblastine (VLB) on multidrug-
resistant ovarian carcinoma and leukemic cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2101.
Fuchs B, Ostmeier H, Suter L. P-glycoprotein expression in
malignant melanoma. J Cancer Res Clin Oncol
1991;117(2):168-71.
Gupta RS, Murray W, Gupta R. Cross resistance pattern towards
anticancer drugs of a human carcinoma multidrug-resistant
cell line. Br J Cancer 1988;58(4):441-7.
Hill BT, Whelan RD, Hosking LK, Bedford P, Dempke WC, Shellard
SA. Differential expression of drug resistance following
in vitro exposure of human tumour cell lines to fractionated
X-irradiation. Cancer Treat Rev 1990 Dec;17 Suppl A:21-6.
Hoffmann D, Gerken M, Hermentin P, Sedlacek HH. B 880308 -- a
new anthracycline derivative demonstrating maintained
activity against multidrug resistant cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2410.
Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J,
Tsuruo T. Establishment and characterization of
doxorubicin-resistant human bladder cancer cell line,
KK47/ADM. J Urol 1992 Aug;148(2 Pt 1):441-5.
Knick VC, Miller CG. In vivo derivation of a murine P388
leukemia subline resistant to 5'-nor-anhydrovinblastine
(navelbine) and its cross-resistance profile [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2759.
Kuo-Pao PY, Samaan NA. Intrinsic drug resistance in a human
medullary thyroid carcinoma cell line: association with a
multidrug resistance gene expression and low proliferation
fraction [abstract]. Anticancer Res 1990;10(5B):1404.
Larsen AK, Markovits J, Jacquemin-Sablon A. Increased
sensitivity of 9-hydroxyellipticine-resistant Chinese
hamster cells to alkylating agents [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32: A2071.
Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R,
Mertelsmann R. Induction of multiple-drug resistance
during anti-neoplastic chemotherapy in vitro. Int J Cancer
1991 Oct 21; 49(4):630-7.
Licht T, Fiebig HH, Dreher C, Bross KJ, Herrmann F. Modulation
of multidurg resistance by tumor necrosis factor-alpha and
verapamil [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2852.
Lock RB, Hill BT. Differential patterns of anti-tumour drug
responses and mechanisms of resistance in a series of
independently derived VP 16 resistant human tumour cell
lines. Int J Cancer 1988; 42(3):373-81.
Lutzky J, Canada AL, Yamanishi DT, Bhalla K, Hindenburg AA.
Effect of verapamil and buthionine sulfoximine (BSO) on
daunorubicin (DNR) cytotoxicity of multidrug-resistant human
melanoma cell lines overexpressing P-glycoprotein and
glutathione-s-transferases [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A3315.
Mattern J, Bak M, Volm M. Intrinsic and acquired multidrug
resistance in human lung carcinomas grown in nude mice.
Anticancer Res 1990 Jan-Feb; 10(1):177-80.
Mattern J, Bak M, Volm M. Occurrence of a multidrug resistant
phenotype in human lung xenografts. Br J Cancer
1987;56(4):407-11.
Mazzoni A, Trave F, Canti G, Franco P. Effect of the tiapamil
analog RO-11-2933 on cellular sensitivity to antitumor
drugs in sensitive and multidrug resistant human ovarian
cancer cells. Anticancer Res 1989;9(2):367-72.
Mechetner EB, Roninson IB. Efficient inhibition of P-
glycoprotein-mediated multidrug resistance with a monoclonal
antibody [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2913.
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M.
MDR-1 gene amplification in acute lymphoblastic leukemia
prior to antileukemic treatment. Br J Haematol
1991;78(2):288-9.
Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C,
Michelutti A, Fanin R, Fasola G, Russo D, Tazzari P, et al.
The expression of the multidrug resistance-associated
glycoprotein in B-cell chronic lymphocytic leukaemia. Br J
Haematol 1991 Apr;77(4):460-5.
Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I.
Transgenic mice that express the human multidrug-resistance
gene in bone marrow enable a rapid identification of agents
that reverse drug resistance. Proc Natl Acad Sci U S A 1991
Jan 15; 88(2):547-51.
Moulton TA, Jiang H, Guarini L, Fetell MR, Fisher PB. Induction
of growth suppression and modification of gene expression in
multi-drug-resistant human glioblastoma multiforme cells by
recombinant human fibroblast and immune interferon. Int J
Cancer 1992 May 28;51(3):373-8.
Murren JR, Cooper DL, Honig J, Edelson RL, Hait WN, Flynn SD.
The multidrug-resistant phenotype is prevalent in Sezary
Syndrome (SS) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1992;11: A1130.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents KT6149, MX 2, SM5887, menogaril, and
liblomycin using cisplatin or adriamycin resistant human
cancer cell lines. Cancer Res 1989;49(15): 4098-102.
Onishi Y, Handel LM, Hall L, Fojo AT, Young RC, Ozols RF,
Hamilton TC. Multidrug resistance (mdr-1) gene
amplification and overexpression (OE) in human ovarian
cancer (HOC) cell lines from untreated patients (pts) and
pts refractory to combination chemotherapy (CC) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2280.
Ozols RF. Reversal of drug resistance: clinical trials based on
experimental studies in human tumor model systems. Paper
presented at: Symposium on Mechanisms of Drug and Radiation
Resistance of Tumor Cells; 1989 Jun 28-30; Villejuif,
France.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and therapy of
breast cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young RC.
Reversal of alkylating agent and platinum resistance in
ovarian cancer [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:526-7.
Park JG, Kramer BS, Lai SL, Goldstein LJ, Gazdar AF.
Chemosensitivity patterns and expression of human multidrug
resistance-associated MDR1 gene by human gastric and
colorectal carcinoma cell lines. J Natl Cancer Inst 1990
Feb 7;82(3):193-8.
Park JG, Kramer BS, Henslee JG, Lai S, Goldstein L, Gottesman MM,
Gazdar AF. Characteristics and drug sensitivity patterns
of human gastric carcinoma cell lines--comparison with
colorectal carcinoma lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A432.
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV,
Willingham MC. A retrovirus carrying an mdr1 complementary
DNA confers multidrug resistance and polarized expression of
P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A
1988;85(12):4486-90.
Plumb JA, Milroy R, Kaye SB. Sequential induction of drug
resistance in an adherent small-cell lung cancer (SCLC) cell
line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2141.
Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang HP,
Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant
fibroblast interferon and recombinant immune interferon on
growth and the antigenic phenotype of multidrug-resistant
human glioblastoma multiforme cells. J Natl Cancer Inst
1991 Sep 18;83(18):1307-15.
Ross KL, Sikic BI, Kercso KM, Owicki JC, Hafeman DG, Muir VC,
Parce JW. Potentiometric monitoring of tumor cell
chemosensitivity with a silicon based biosensor [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2410.
Saijo N, Nakagawa K, Fujiwara Y, Bungo M, Horichi N, Sasaki Y,
Yokota J, Terada M. Characteristics of clinical and
experimental resistance to cisplatin . Paper presented at:
1st International Interface of Clinical and Laboratory
Responses to Anticancer Drugs; 1989 Mar 13-15; Villejuif,
France.
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland
RM. Hypoxia-induced drug resistance: comparison to P-
glycoprotein-associated drug resistance. Br J Cancer 1991
Nov; 64(5):809-14.
Satta T, Isobe K, Yamauchi M, Nakashima I, Akiyama S, Itou K,
Watanabe T, Takagi H. Establishment of drug resistance in
human gastric and colon carcinoma xenograft lines. Jpn J
Cancer Res 1991 May;82(5):593-8.
Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression
of MDR1 and glutathione S transferase-pi genes and
chemosensitivities in human gastrointestinal cancer. Cancer
1992 Feb 15;69(4):941-6.
Scala S, Murphy LD, Tortora G, Cho-Chung Y, Bates S. Effects of
differentiating agents (DA) on P-glycoprotein (Pgp)
expression in a multidrug resistant breast cancer cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2240.
Shinoda H, Inaba M, Tsuruo T. In vivo circumvention of
vincristine resistance in mice with P388 leukemia using a
novel compound, AHC 52. Cancer Res 1989;49(7):1722-6.
Tagger AY, Wright JA. Molecular and cellular characterization
of drug resistant hamster cell lines with alterations in
ribonucleotide reductase. Int J Cancer 1988;42(5):760-6.
Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y,
Niitani H, Saijo N. Establishment of a human leukemia
subline resistant to the growth-inhibitory effect of 12-O-
tetradecanoylphorbol 13-acetate (TPA) and showing non-P-
glycoprotein-mediated multi-drug resistance. Int J Cancer
1991 Jul 30;48(6):931-7.
Tanimura H, Kohno K, Sato S, Uchiumi T, Miyazaki M, Kobayashi M,
Kuwano M. The human multidrug resistance 1 promoter has an
element that responds to serum starvation. Biochem Biophys
Res Commun 1992 Mar 16;183(2):917-24.
Toffoli G, Viel A, Tumiotto L, Maestro R, Biscontin G, Boiocchi
M. Expression of the mdr1 gene in human colorectal
carcinomas: relationship with multidrug resistance inferred
from analysis of human colorectal carcinoma cell lines.
Cancer Chemother Pharmacol 1992;29(4):283-9.
Tonini GP, Corrias MV, Di Martino D, Lanino E, Cornaglia-Ferraris
P. Amplification and expression of MDR1 and N-myc genes in
neuroblastoma [abstract]. J Cancer Res Clin Oncol 1990;116
Suppl Pt 1:417.
Treichel RS, Olken S. The relationship between multi-drug
resistance and resistance to natural-killer-cell and
lymphokine-activated killer-cell lysis in human leukemic
cell lines. Int J Cancer 1992 Jan 21; 50(2):305-10.
Trujillo JM, Yang LY, Su YZ, Gercovich G, Hai S, Williams A.
Cytotoxicity synergism of interferon (IFN) and adriamycin
(AdR) on lovo human colon tumor cell line and its multidrug
resistant (MDR) subclone [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2033.
Tsai CM, Lai SL, Ihde DC, Goldstein LJ, Gottesman MM, Pastan I,
Mulshine JL, Gazdar AF. Clinical response to combination
chemotherapy in lung cancer is correlated with in vitro
chemosensitivity but not with expression of the MDR1 gene
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1989;8:A965.
Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K,
Morishima Y, Ohno R. Detection of multidrug resistance
markers, P-glycoprotein and mdr1 and mRNA, in human leukemia
cells. Jpn J Cancer Res 1987;78(12): 1415-9.
Ujhazy P, Chen Y, Fredericks W, Ehrke MJ. Collateral
sensitivity to tumor necrosis factor in an adriamycin
resistant EL4 cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1625.
Van Der Zee AGJ, Hollema H, De Jong S, Boonstra H, Gouw A,
Willemse PHB, Zijlstra JG, De Vries EGE. P-glycoprotein
expression and DNA topoisomerase I and II activity in benign
tumors of the ovary and in malignant tumors of the ovary
before and after platinum cyclophosphamide chemotherapy.
Cancer Res 1991;51(21):5915-20.
Von Hoff D, VanDevanter D, Forseth B, Davidson K, Waddelow T,
Wahl G. Hydroxyurea can decrease drug resistance gene copy
numbers in tumor cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2243.
Wallace RE, Lindh D, Greenberger L, Raventos-Suarez C, Durr FE.
Development of a human breast carcinoma (MX-1E) cell line
resistant to calicheamicin [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2163.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Weide R, Dowding C, Paulsen W, Goldman J. The role of the
MDR-1/P-170 mechanism in the development of multidrug
resistance in chronic myeloid leukemia. Leukemia 1990
Oct;4(10): 695-9.
Other
Abraham I, Chin KV, Gottesman MM, Mayo JK, Sampson KE.
Transfection of a mutant regulatory subunit gene of cAMP-
dependent protein kinase causes increased drug sensitivity
and decreased expression of P-glycoprotein. Exp Cell Res
1990 Jul;189(1):133-41.
Ames GFL, Mimura CS, Shyamala V. Bacterial periplasmic
permeases belong to a family to transport proteins operating
from escherichia-coli to human traffic atpases. FEMS
Microbiol Rev 1990; 75(4):429-46.
Arceci RJ, Baas F, Raponi R, Horwitz SB, Housman D, Croop JM.
Multidrug resistance gene expression is controlled by
steroid hormones in the secretory epithelium of the uterus.
Mol Reprod Dev 1990 Feb;25(2):101-9.
Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding
multidrug resistance is induced and expressed at high levels
during pregnancy in the secretory epithelium of the uterus.
Proc Natl Acad Sci U S A 1988;85(12):4350-4.
Arias IM. Multidrug resistance genes, P-glycoprotein and the
liver. Hepatology 1990 Jul;12(1):159-65.
Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD. P-
glycoprotein expression is increased in human secretory and
gestational endometrium. Lab Invest 1991;65(5):577-81.
Baas F, Borst P. The tissue dependent expression of hamster P-
glycoprotein genes. FEBS Lett 1988; 229(2):329-32.
Baas F, van Groenigen M, Valentijn LJ. Identification of a
functional initiator sequence in the human MDR1 promoter
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2151.
Bhushan A, Tritton TR. Increased tyrosine phosphorylation of
lipocortin I in multidrug-resistant sarcoma 180 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2148.
Blight MA, Holland IB. Structure and function of haemolysin B,
P-glycoprotein and other members of a novel family of
membrane translocators. Mol Microbiol 1990 Jun;4(6):873-80.
Bosch I, Shoemaker CB. Localization studies on the Schistosoma-
mansoni homologues of P- glycoprotein [abstract]. Am J Trop
Med Hyg 1991; 45(3 Suppl):244-5.
Bradley G, Georges E, Ling V. Sex-dependent and independent
expression of the P-glycoprotein isoforms in Chinese
hamster. J Cell Physiol 1990 Dec;145(3):398-408.
Bradley G, Juranka PF, Ling V. Mechanism of multidrug
resistance. Biochim Biophys Acta 1988;948(1):87-128.
Bruggemann EP, Chaudhary V, Gottesman MM, Pastan I. Pseudomonas
exotoxin fusion proteins are potent immunogens for raising
antibodies against P-glycoprotein. Biotechniques 1991
Feb;10(2):202-4, 206, 208-9.
Bruggemann EP, Germann UA, Gottesman MM, Pastan I. Two
different regions of p-glycoprotein are photoaffinity-
labeled by azidopine. J Biol Chem 1989 Sep 15;264(26):
15483-8. Published erratum appears in: J Biol Chem 1990 Mar
5; 265(7):4172.
Budillon A, Clair T, Scala S, Bates S, Cho-Chung YS. Role of
type I regulatory subunit (RI) of cAMP-dependent protein
kinase (PKA) in multidrug resistance (MDR) of cancer cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2836.
Buschman E, Gros P. Functional analysis of chimeric genes
obtained by exchanging homologous domains of the mouse mdr1
and mdr2 genes. Mol Cell Biol 1991 Feb;11(2):595-603.
Cadroy Y, Kelly A, Marzec U, Evatt B, Harker L, Hanson S, Ruggeri
Z. Comparison of the antihemostatic and antithrombotic
effects of monoclonal antibodies (MoA) against von
Willebrand Factor (vWF) and platelet P-glycoprotein IIb-IIIa
(GPIIb/IIIa) [abstract]. Circulation 1989;80(4 Suppl
2):II-24.
Calvo F, de Cremoux P. [Multidrug resistant genes MDR1]. Bull
Cancer (Paris) 1989;76(9):973-7. (Fre).
Cenciarelli C, Currier SJ, Willingham MC, Thiebaut F, Germann UA,
Rutherford AV, Gottesman MM, Barca S, Tombesi M, Morrone S,
et al. Characterization by somatic cell genetics of a
monoclonal antibody to the MDR1 gene product (P-
glycoprotein): determination of P-glycoprotein expression in
multi-drug-resistant KB and CEM cell variants. Int J Cancer
1991 Feb 20;47(4):533-43.
Chabner BA, Fojo A. Multidrug resistance: P-glycoprotein and
its allies--the elusive foes. J Natl Cancer Inst 1989 Jun
21;81(12):910-3.
Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB.
Genomic organization and evolution of the human multidrug
resistance (mdr1) gene [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1983.
Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB.
Genomic organization of the human multidrug resistance
(MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990
Jan 5;265(1): 506-14.
Chin KV, Chauhan SS, Abraham I, Sampson KE, Krolczyk AJ, Wong M,
Schimmer B, Pastan I, Gottesman MM. Reduced mRNA levels
for the multidrug-resistance genes in cAMP-dependent protein
kinase mutant cell lines. J Cell Physiol 1992
Jul;152(1):87-94.
Chin KV, Chauhan SS, Abraham I, Simpson KE, Schimmer B, Wong M,
Pastan I, Gottesman MM. Reduced mRNA levels for the
multidrug-resistance genes in cAMP-dependent protein kinase
mutant cell lines [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2162.
Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity
of the promoter of the human MDR1 gene by Ras and p53.
Science 1992 Jan 24; 255(5043):459-62.
Cornwell MM. The human multidrug resistance gene: sequences
upstream and downstream of the initiation site influence
transcription. Cell Growth Differ 1990 Dec;1(12):607-15.
Cornwell MM. Molecular biology of P-glycoprotein. Cancer Treat
Res 1991;57:37-56.
Cowman AF. The P-glycoprotein homologues of Plasmodium-
falciparum: Are they involved in chloroquine resistance?
Parasitol Today 1991; 7(4):70-6.
Cowman AF, Foote SJ. Chemotherapy and drug resistance in
malaria. Int J Parasitol 1990 Jul;20(4):503-13.
Cowman AF, Karcz S, Galatis D, Culvenor JG. A P-glycoprotein
homologue of Plasmodium-falciparum is localized on the
digestive vacuole. J Cell Biol 1991;113(5):1033-42.
Cowman AF, Karcz SR. The pfmdr gene homologues of Plasmodium
falciparum. Acta Leiden 1991; 60(1):121-9.
Croop JM, Gros P, Housman DE. Genetics of multidrug resistance.
J Clin Invest 1988;81(5): 1303-9.
Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P,
Housman DE. The three mouse multidrug resistance mdr genes
are expressed in a tissue-specific manner in normal mouse
tissues. Mol Cell Biol 1989;9(3):1346-50.
Currier SJ, Ueda K, Willingham MC, Pastan I, Gottesman MM.
Deletion and insertion mutants of the multidrug transporter.
J Biol Chem 1989; 264(24):14376-81.
Currier SJ, Willingham MC, Pastan I, Gottesman MM. Mutational
analysis of the multidrug transporter by the formation of a
chimeric mdr1-mdr2 molecule [abstract]. J Cell Biol
1989;109(4 Pt 2):253a.
Daoud SS, Juliano RL. Modulation of doxorubicin resistance by
valinomycin nsc-122023 and liposomal valinomycin in Chinese
hamster ovary cells. Cancer Res 1989;49(10):2661-7.
De Kant E, Reuter J, Schulz G, Rochlitz CF, Neubauer A, Huhn D,
Herrmann R. R-verapamil (R-VPM) modulation of multidrug
resistance (MDR) and expression of P-glycoprotein (PGP) in
human colorectal xenografts [abstract]. Onkologie 1991;14
Suppl 2:26.
De Vita VT Jr. The problem of resistance. Pezcoller Found Symp
1990;1:7-31.
de Vries EG, Pinedo HM. Clinical implications of multidrug
resistance to chemotherapy. Cancer Treat Res
1991;57:171-86.
DeMars R, Spies T. New genes in the MHC that encode proteins
for antigen processing. Trends Cell Biol 1992;2(3):81-6.
Deuchars KL, Duthie M, Ling V. Identification of distinct P-
glycoprotein gene sequences in rat. Biochim Biophys Acta
1992 Mar 24;1130(2): 157-65.
Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in
cancer chemotherapy. Semin Oncol 1989 Apr;16(2):156-65.
Devault A, Gros P. Two members of the mouse mdr gene family
confer multidrug resistance with overlapping but distinct
drug specificities. Mol Cell Biol 1990 Apr;10(4):1652-63.
Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard
JC. MHC class II region encoding proteins related to the
multidrug resistance family of transmembrane transporters
[see comments]. Nature 1990 Dec 20-27;348(6303): 738-41.
Devine SE, Ling V, Melera PW. Amino acid substitutions in the
sixth transmembrane domain of P-glycoprotein alter multidrug
resistance. Proc Natl Acad Sci U S A 1992 May
15;89(10):4564-8.
Dhir R, Buschman E, Gros P. Structural and functional
characterization of the mouse multidrug resistance gene
family. Bull Cancer (Paris) 1990;77(11):1125-9.
Dickson RB, Gottesman MM. Understanding of the molecular basis
of drug resistance in cancer reveals new targets for
chemotherapy. Trends Pharmacol Sci 1990;11(8):305-7.
Dietel M, Seidel A, Nickelsen M. Microfilaments and vesicle-
associated drug transport in multidrug-resistant EPG85-257
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2749.
Dolci ED, Abramson R, Yassa DS, Tritton TR. Anomalous
expression of P-glycoprotein in highly resistant human KB
cells [abstract]. J Cell Biol 1991;115(3 Pt 2):200a.
Dudler R, Hertig C. Structure of an mdr-like gene from
Arabidopsis thaliana. Evolutionary implications. J Biol
Chem 1992 Mar 25;267(9): 5882-8.
Dutta GP, Bajpai R, Vishwakarma RA. Antimalarial efficacy of
arteether against multiple drug resistant strain of
Plasmodium-yoelii-nigeriensis. Pharmacol Res
1989;21(4):415-20.
Dreesen TD, Johnson DH, Henikoff S. The brown protein of
Drosophila-melanogaster is similar to the white protein and
to components of active transport complexes. Mol Cell Biol
1988;8(12):5206-15.
Efferth T, Lathan B, Volm M. Selective growth-inhibition of
multidrug-resistant CHO-cells by the monoclonal antibody
265-F4. Br J Cancer 1991; 64(1):87-9.
Ellison JA, Hall JJ, Noble LJ. Immunocytochemical localization
of a multidrug-resistant glycoprotein in CNS vasculature of
the rat [abstract]. Soc Neurosci Abstr 1989;15(2):1220.
Endicott JA, Ling V. The biochemistry of P-glycoprotein-
mediated multidrug resistance. Annu Rev Biochem
1989;58:137-71.
Endicott JA, Sarangi F, Georges E, Ling V. P-glycoprotein
phosphorylation and the multidrug resistance phenotype
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:367.
Endicott JA, Sarangi F, Ling V. Complete cDNA sequences
encoding the Chinese hamster P-glycoprotein gene family.
DNA Seq 1991;2(2): 89-101.
Epenetos AA, Kosmas C. Monoclonal antibodies for imaging and
therapy. Br J Cancer 1989;59(2): 152-5.
Fath MJ, Skvirsky RC, Kolter R. Functional complementation
between bacterial MDR-like export systems: colicin V, alpha
hemolysin, and Erwinia protease. J Bacteriol 1991
Dec;173(23): 7549-56.
Finstad CL, Saigo PE, Rubin SC, Federici MG, Provencher DM,
Hoskins WJ, Lewis JL Jr, Lloyd KO. Immunohistochemical
localization of P-glycoprotein in adult human ovary and
female genital tract of patients with benign gynecological
conditions. J Histochem Cytochem 1990;38(11): 1677-82.
Fojo AT. Multidrug resistance. Adv Intern Med 1991;36:195-218.
Fojo AT. Multidrug resistance to chemotherapy. Cancer Bull
1989;41(1):26-30.
Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ,
Cowman AF. Several alleles of the multidrug-resistance
gene are closely linked to chloroquine resistance in
Plasmodium falciparum. Nature 1990 May 17;345(6272): 255-8.
Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the
multidrug resistance gene in some chloroquine-resistant
isolates of P. falciparum. Cell 1989 Jun 16;57(6):921-30.
Ford JM, Hait WN. Pharmacology of drugs that alter multidrug
resistance in cancer. Pharmacol Rev 1990 Sep;42(3):155-99.
Friedlander ML, Bell DR. Multidrug resistance: clinical
findings and implications. Cancer Treat Res 1989;42:63-77.
Fuqua SA, Merkel DE, McGuire WL. Laboratory aspects of
multidrug resistance. Cancer Treat Res 1989;42:45-59.
Galski H, Merlino GT, Gottesman MM, Pastan I. Expression of a
human multidrug-resistance cDNA (MDR1) under the control of
a beta-actin promoter in transgenic mice. Biotechnology
1991;16:103-24.
Galski H, Sullivan M, Willingham MC, Chin KV, Gottesman MM,
Pastan I, Merlino GT. Expression of a human multidrug
resistance cDNA (MDR1) in the bone marrow of transgenic
mice: resistance to daunomycin-induced leukopenia. Mol Cell
Biol 1989 Oct;9(10):4357-63.
Galski H, Sullivan M, Willingham MC, Gottesman MM, Pastan I,
Merlino GT. Increased bone marrow resistance to cytotoxic
drugs in mice carrying a human multidrug-resistant (MDR1)
transgene [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2001.
Gant TW, Schrenk D, Thorgeirsson SS. Two routes for induction
of the mdr gene by xenobiotics [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2828.
Gant TW, Silverman JA, Bisgaard HC, Burt RK, Marino PA,
Thorgeirsson SS. Regulation of 2-acetylaminofluorene- and
3-methylcholanthrene--mediated induction of multidrug
resistance and cytochrome P450IA gene family expression in
primary hepatocyte cultures and rat liver. Mol Carcinog
1991;4(6):499-509.
Gant TW, Silverman JA, Marino PA, Thorgeirsson SS. Receptor and
trans-acting factor mediated transcriptional control of
multidrug resistance gene expression [abstract]. FASEB J
1991;5(4):A824.
Gauci DF, Busche R, Riordan JR. The role of the binding of
drugs to P-glycoprotein in their exclusion from multidrug
resistant cells [abstract]. FASEB J 1988;2(6):8409.
Gautam SC, Finke JH, Lewis I, Grabowski D, Ganapathi R.
Immunological investigation of multi-drug resistant b16-bl6
mouse melanoma cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1620.
Gebel HM, Markham PN, Bines SD, Wang Y, Coon JS, Chong ASF.
Inhibition of natural killer cell mediated cytotoxicity by
agents that reverse multidrug resistance gene function
[abstract]. Hum Immunol 1991;32 Suppl 1:18.
Georges E, Bradley G, Gariepy J, Ling V. Mapping of P-
glycoprotein monoclonal antibody epitopes: application for
immunohistological staining [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2029.
Georges E, Sharom FJ, Ling V. Multidrug resistance and
chemosensitization: therapeutic implications for cancer
chemotherapy. Adv Pharmacol 1990;21: 185-220.
Georges E, Zhang JT, Ling V. Modulation of ATP and drug binding
by monoclonal antibodies against P-glycoprotein. J Cell
Physiol 1991 Sep;148(3): 479-84.
Gerlach JH. Structure and function of P-glycoprotein. Cancer
Treat Res 1989;48:37-53.
Germann UA, Chin KV, Pastan I, Gottesman MM. Retroviral
transfer of a chimeric multidrug resistance-adenosine
deaminase gene. FASEB J 1990 Mar;4(5):1501-7.
Germann UA, Gottesman MM, Pastan I. Expression of a multidrug
resistance-adenosine deaminase fusion gene. J Biol Chem
1989;264(13):7418-24.
Germann UA, Gottesman MM, Pastan I. Stable expression of a
human multidrug resistance-adenosine deaminase fusion gene
after DNA-mediated transfer into human KB cells [abstract].
J Cell Biol 1988;107(6 Pt 3):326A.
Giboda M, Denis MB. Response of Kampuchean strains of
Plasmodium-falciparum to antimalarials: in-vivo assessment
of quinine and quinine plus tetracycline multiple drug
resistance in-vitro. J Trop Med Hyg 1988;91(4):205-11.
Gilson L, Mahanty HK, Kolter R. Genetic analysis of an MDR-like
export system: the secretion of colicin V. EMBO J 1990
Dec;9(12):3875-94.
Gobbi M, Michieli M, Raspadori D, Damiani D, Michelutti A, Pierri
I, Tazzari PL. [Methods for studying pleiotropic drug
resistance (multidrug resistance, MDR)]. Haematologica 1991
Jun;76 Suppl 3:150-3. (Ita).
Gottesman MM. Multidrug resistance during chemical
carcinogenesis: a mechanism revealed. J Natl Cancer Inst
1988;80(17):1352-53.
Gottesman MM, Goldstein LJ, Bruggemann E, Currier SJ, Galski H,
Cardarelli C, Thiebaut F, Willingham MC, Pastan I.
Molecular diagnosis of multidrug resistance. Cancer Cells
1989;7:75-80.
Gottesman MM, Pastan I. Molecular biology and clinical
relevance of multidrug-resistance [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29: 522-3.
Gottesman MM, Pastan I. The multidrug transporter, a double-
edged sword. J Biol Chem 1988;263(25): 12163-6.
Greenberger LM, Croop JM, Horwitz SB, Arceci RJ. P-
glycoproteins encoded by mdr1b in murine gravid uterus and
multidrug resistant tumor cell lines are differentially
glycosylated. FEBS Lett 1989;257(2): 419-21.
Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Site-specific
antibodies for domain mapping of P-glycoprotein [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2184.
Greenberger LM, Lothstein L, Horwitz SB. Heterogeneous forms of
P-glycoprotein in multidrug resistant J774.2 cells. In:
Tapiero H, Robert J, Lampidis TJ, editors. 1st
International Interface of Clinical and Laboratory Responses
to Anticancer Drugs; 1989 Mar 13-15; Villejuif, France.
Paris: Les Editions Inserm; 1989. p. 263-76. (Colloque
INSERM; 191).
Greenberger LM, Yang CPH, Gindin E, Horwitz SB. The multidrug
transporter p-glycoprotein is specifically labeled by an
alpha-1 adrenergic photoaffinity probe iodoarylazidoprazosin
[abstract]. J Cell Biol 1989;109(4 Pt 2):252a.
Grinchuk TM, Ignatova TN, Sorokina EA, Artsybasheva IV, Pan'Shina
Yu T. [Chromosome polymorphism in mammalian cells with
multidrug resistance. 1. Karyotypical analysis of Chinese
hamster cells resistant to ethidium bromide at the early
passages of initial selection steps]. Tsitologiya
1988;30(3):312-20. (Rus).
Grogl M, Martin RK, Oduola AM, Milhous WK, Kyle DE.
Characteristics of multidrug resistance in Plasmodium and
Leishmania: detection of P-glycoprotein-like components. Am
J Trop Med Hyg 1991 Jul;45(1):98-111.
Gros P, Raymond M, Bell J, Housman D. Cloning and
characterization of a second member of the mouse mdr gene
family. Mol Cell Biol 1988;8(7): 2770-8.
Gutheil JC, Melera PW. Megesterol acetate inhibits cell growth
in cells overexpressing P-glycoprotein [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A1284.
Haber DA, Housman DE. MSPI-HAPAII polymorphism in the human
multidrug resistance gene 1. Nucleic Acids Res
1989;17(23):10142.
Hake LE, Bowcock A, King MC, Cavalli-Sforza LL. Genetic markers
on the long arm of chromosome 7 [abstract]. Clin Res
1988;36(3):403a.
Hamada H, Maezawa K, Tsuruo T. Nucleotide sequences of the
variable regions of a mouse monoclonal antibody MRK16.
Nucleic Acids Res 1990;18(7):1900.
Han EKH, Yang CPH, Horwitz SB. Mutagenesis of the protein
kinase A phosphorylation site in P- glycoprotein MDR1B
[abstract]. J Cell Biol 1991;115(3 Pt 2):200A.
Hayes JD, Wolf CR. Molecular mechanisms of drug resistance.
Biochem J 1990 Dec 1;272(2):281-95.
Higgins C. Transport proteins. Export-import family expands
[news]. Nature 1989 Aug 3;340(6232): 342.
Higgins CF, Gottesman MM. Is the multidrug transporter a
flippase? Trends Biochem Sci 1992; 17(1):18-21.
Hoellt V, Becker KF, Kouba M, Vogt G. The multidrug resistance
(MDR) 1 gene and a related transporter gene (NG-TRA) are
expressed in COS monkey kidney cells [abstract]. Pfluegers
Arch Eur J Physiol 1991;418 Suppl 1:R65.
Holland IB, Blight MA, Kenny B. The mechanism of secretion of
hemolysin and other polypeptides from gram-negative
bacteria. J Bioenerg Biomembr 1990 Jun;22(3):473-91.
Holland IB, Possot O, Blight M, Yue K. Bacterial haemolysin and
mammalian P-glycoprotein. Biochem Soc Trans 1991
Apr;19(2):252-5.
Hoof T, Riordan JR, Tummler B. Quantitation of mRNA by the
kinetic polymerase chain reaction assay: a tool for
monitoring P-glycoprotein gene expression. Anal Biochem
1991 Jul;196(1):161-9.
Hsu SI, Cohen D, Kirschner LS, Lothstein L, Hartstein M, Horwitz
SB. Structural analysis of the mouse mdr1a (P-
glycoprotein) promoter reveals the basis for differential
transcript heterogeneity in multidrug-resistant J774.2
cells. Mol Cell Biol 1990 Jul;10(7):3596-606. Published
erratum appears in Mol Cell Biol 1990 Nov;10(11):6101.
Hui FM, Morrison DA. Genetic transformation in Streptococcus-
pneumoniae: nucleotide sequence analysis shows comA, a gene
required for competence induction, to be a member of the
bacterial ATP-dependent transport protein family. J
Bacteriol 1991;173(1):372-81.
Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce
SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF.
Structural model of ATP-binding proteins associated with
cystic fibrosis, multidrug resistance and bacterial
transport. Nature 1990 Jul 26;346(6282):362-5.
Ince TA, Scotto KW. The role of P-glycoprotein mRNA stability
in multidrug-resistant Chinese hamster cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:367.
Jakobsson AH. The semistability of centric chromatin bodies
during long term passage of multidrug resistant mouse
Chinese hamster cell hybrids. Anticancer Res
1988;8(3):307-12.
Jongsma AP, Riethorst A, Aten JA. Determination of the DNA
content of a six-gene amplicon in the multidrug-resistant
Chinese hamster cell line CHRB3 by flow karyotyping. Cancer
Res 1990 May 1;50(9):2803-7.
Juranka P, Zhang F, Kulpa J, Endicott J, Blight M, Holland IB,
Ling V. Characterization of the hemolysin transporter,
HlyB, using an epitope insertion. J Biol Chem 1992 Feb
25;267(6): 3764-70.
Kamitsuka PF, Iovannisci D, Ellenberger TE, Beverley SM.
Rearrangement site for H region amplification conferring
multiple drug resistance in Leishmania is a dispersed
repetitive element [abstract]. J Cell Biochem Suppl 1989;13
Pt E: 107.
Kane SE, Reinhard DH, Fordis CM, Pastan I, Gottesman MM. A new
vector using the human multidrug resistance gene as a
selectable marker enables overexpression of foreign genes in
eukaryotic cells. Gene (Amsterdam) 1989;84(2): 439-46.
Kane SE, Troen BR, Gal S, Ueda K, Pastan I, Gottesman MM. Use
of a cloned multidrug resistance gene for coamplification
and overproduction of major excreted protein A
transformation-regulated secreted acid protease. Mol Cell
Biol 1988;8(8):3316-21.
Karcz S, Cowman AF. Similarities and differences between the
multidrug resistance phenotype of mammalian tumor cells and
chloroquine resistance in Plasmodium falciparum. Exp
Parasitol 1991 Aug;73(2):233-40.
Kellen JA. Drug resistance, the last frontier? Anticancer Res
1991 Mar-Apr;11(2):917-9.
Kim YJ, Furihata K, Yamanaka S, Fudo R, Seto H. Isolation and
structural elucidation of stipiamide, a new antibiotic
effective to multidrug-resistant cancer cells [letter]. J
Antibiot (Tokyo) 1991;44(5):553-6.
Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K, Ueda K.
Quercetin, a bioflavonoid, inhibits the increase of human
multidrug resistance gene (MDR1) expression caused by
arsenite. FEBS Lett 1992 Apr 27;301(3):307-9.
Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I,
Ueda K. P-glycoprotein gene (MDR1) cDNA from human
adrenal: normal P-glycoprotein carries Gly185 with an
altered pattern of multidrug resistance. Biochem Biophys
Res Commun 1989 Jul 14;162(1):224-31.
Kirschner LS, Greenberger LM, Hsu SI, Yang CP, Cohen D, Piekarz
RL, Castillo G, Han EK, Yu LJ, Horwitz SB. Biochemical and
genetic characterization of the multidrug resistance
phenotype in murine macrophage-like J774.2 cells. Biochem
Pharmacol 1992 Jan 9;43(1):77-87.
Knost J, Barnett D, Mo C, Van Dyke C, Van Dyke K. Tetrandrine
(TeT) a plant alkaloid that reverses multiple durg
resistance (MDR-1) [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1991;10:A191.
Konig R, Ashwell G, Hanover JA. Overexpression and biosynthesis
of CD4 in Chinese hamster ovary cells coamplification using
the multiple drug resistance gene. Proc Natl Acad Sci U S A
1989;86(23):9188-92.
Krishan A, Sauerteig A, Stein JH. Comparison of three
commercially available antibodies for flow cytometric
monitoring of P-glycoprotein expression in tumor cells.
Cytometry 1991;12(8):731-42.
Kuchler K, Sterne RE, Thorner J. Saccharomyces cerevisiae STE6
gene product: a novel pathway for protein export in
eukaryotic cells. EMBO J 1989 Dec 20;8(13):3973-84.
Kuchler K, Thorner J. Functional expression of human Mdr1 in
the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S
A 1992 Mar 15;89(6): 2302-6.
Lazarowski AJ. [GP-170 glycoprotein and resistance to
chemotherapy (editorial)]. Medicina (B Aires)
1991;51(3):279-80. (Spa)
Leibovitch IJ, Olsson CA, Goldwasser B, Buttyan R. A novel
multidrug resistance-1 related product synthesized
exclusively during the regression of the rat ventral
prostate gland [abstract]. J Urol 1991; 145(4 Suppl):293a.
Lincke CR, Smit JJ, van der Velde-Koerts T, Borst P. Structure
of the human MDR3 gene and physical mapping of the human MDR
locus. J Biol Chem 1991 Mar 15;266(8):5303-10.
Ling V. The basis of multidrug resistance to anticancer drugs.
Paper presented at: 2nd International Congress on Neo-
Adjuvant Chemotherapy; 1988 Feb 19-21; Paris.
Ling V. Charles F. Kettering Prize. P-glycoprotein and
resistance to anticancer drugs. Cancer 1992 May
15;69(10):2603-9.
Ling V. Expression of P-glycoprotein isoforms in normal and
malignant cells. Paper presented at: Drug resistance as a
biochemical target in cancer chemotherapy. 13th Bristol-
Myers Squibb Symposium on Cancer Research; 1990 May 10-11;
Tokyo, Japan.
Ling V, Juranka PF, Endicott JA, Deuchars K L, Gerlach JH.
Multidrug resistance and P-glycoprotein expression. In:
Woolley PV 3d, Tew KD, editors. Mechanisms of drug
resistance in neoplastic cells; 1986 Oct 15-16;
Washington, DC. San Diego (CA): Academic
Press, Inc.; 1988. p. 197-210. (Bristol-Myers
cancer symposia; 9).
Ling V, Kartner N, inventors ; The Ontario Cancer Institute,
assignee. Method for selecting hybridomas producing
antibodies specific to the P-glycoprotein cell surface
antigen and a complementary DNA clone encoding the carboxyl-
terminal portion of the antigen. US patent 4,837,306. 1989
Jun 6.
Lu K, Savaraj N, Yau J, Li D, Kuo T, Feun L, Freireich EJ. In
situ hybridization for MDR-1 mRNA expression in the
detection of tumor cell heterogeneity [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A1658.
Ludescher C, Hofmann H, Drach J, Grunicke H, Gattringer C. Flow
cytometric analysis of rhodamine-123 uptake and efflux for
the detection of multidrug-resistant cells [abstract].
Onkologie 1991;14 Suppl 2:100.
Marino PA, Gottesman MM, Pastan I. Regulation of the multidrug
resistance gene (MDR1) in regenerating rat liver [abstract].
J Cell Biol 1988;107(6 Pt 3):750A.
Mazzanti JMC, Gatmaitan Z, Arias IM. Benzquinamide (BZQ), a new
inhibitor of P-glycoprotein (P-gp) and drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:
378.
Mazzanti R, Gatmaitan Z, Arias IM. Gp170, the multi-drug
resistance gene product, selectively increases drug efflux
[abstract]. Hepatology 1988;8(5):1250.
McGrath JP, Varshavsky A. The yeast STE6 gene encodes a
homologue of the mammalian multidrug resistance P-
glycoprotein. Nature 1989 Aug 3; 340(6232):400-4.
Meese E, Meltzer P, Trent J. Application of natural partial
digests to pulsed-field gel analysis of the amplified mdr
locus. Genomics 1989;5(2):371-4.
Meese EU, Horwitz SB, Trent JM. Evidence for linear
extrachromosomal elements mediating gene amplification in
the multidrug-resistant J774.2 murine cell line. Cancer
Genet Cytogenet 1992 Mar;59(1):20-5.
Mehta BM, Rosa E, Bading J, Fissekis J, Biedler JL, Larson SM.
In vivo assessment of tumor multidrug-resistance with
radiolabeled colchicine: implications for positron emission
tomographic imaging [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2153.
Mickisch GH, Pastan I, Gottesman MM. Multidrug resistant
transgenic mice as a novel pharmacologic tool. Bioessays
1991 Aug;13(8):381-7.
Mickley LA, Spengler BA, Biedler JL, Fojo AT. Sequence analysis
and regulation of expression of human P-glycoprotein (Pgp)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2140.
Mimmack ML, Gallagher MP, Pearce SR, Hyde SC, Booth IR, Higgins
CF. Energy coupling to periplasmic binding protein-
dependent transport systems: stoichiometry of ATP hydrolysis
during transport in vivo. Proc Natl Acad Sci U S A 1989
Nov;86(21):8257-61.
Mimura CS, Holbrook SR, Ames GF. Structural model of the
nucleotide-binding conserved component of periplasmic
permeases. Proc Natl Acad Sci U S A 1991 Jan 1;88(1):84-8.
Moscow JA, Cowan KH. Multidrug resistance. Cancer Chemother
Biol Response Modif 1991; 12:91-109.
Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst
1988;80(1):14-20.
Muller C, Ling V. P-glycoprotein stability is affected by serum
deprivation and high cell density in multidrug-resistant
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res;
33:A2701 1992.
Neyfakh AA. The multidrug efflux transporter of Bacillus
subtilis is a structural and functional homolog of the
Staphylococcus norA protein. Antimicrob Agents Chemother
1992;36(2):484-5.
Neyfakh AA. Use of fluorescent dyes as molecular probes for the
study of multidrug resistance. Exp Cell Res
1988;174(1):168-76.
Neyfakh AA, Bidnenko VE. MDR-like phenomenon in bacteria
[abstract]. J Cancer Res Clin Oncol 1990;116 Suppl Pt
2:1145.
Neyfakh AA, Bidnenko VE, Chen LB. Efflux-mediated multidrug
resistance in Bacillus subtilis: similarities and
dissimilarities with the mammalian system. Proc Natl Acad
Sci U S A 1991 Jun 1; 88(11):4781-5.
Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V.
Identification of members of the p-glycoprotein multigene
family. Mol Cell Biol 1989;9(3):1224-32.
Ogura M, Takatori T, Sugimoto Y, Tsuruo T. Identification and
characterization of three DNA-binding proteins on the
promoter of the human MDR1 gene in drug-sensitive and -
resistant cells. Jpn J Cancer Res 1991 Oct;82(10):1151-9.
Padmanabhan R, Tsuruo T, Kane SE, Willingham MC, Howard BH,
Gottesman MM, Pastan I. Magnetic-affinity cell sorting of
human multidrug-resistant cells. J Natl Cancer Inst 1991
Apr 17;83(8):565-9.
Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med
1991;42:277-86.
Pavelic ZP, Pavelic L. Distribution of the multi-drug
resistance (MDR) gene product P- glycoprotein (PGP) in human
normal and tumor tissues [abstract]. Pathol Res Pract
1991;187(6):743-4.
Pearce SR, Mimmack ML, Gallagher MP, Gileadi U, Hyde SC, Higgins
CF. Membrane topology of the integral membrane components,
OppB and OppC, of the oligopeptide permease of Salmonella
typhimurium. Mol Microbiol 1992 Jan;6(1):47-57.
Phang JM, Poore CM, Lopaczynska J, Yeh GC. The role of membrane
glycoprotein 170 (P-gp 170)-mediated efflux in cellular
resistance to chemical carcinogens [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A3314.
Prinsep MR, Calplan FR, Moore RE, Patterson GML, Smith CD.
Tolyporphin, a novel multidrug resistance reversing agent
from the blue-green alga Tolypothrix nodosa. J Am Chem Soc
1998;114(1): 385-7.
Ramu A, Ramu N. Reversal of multidrug resistance by
phenothiazines and structurally related compounds. Cancer
Chemother Pharmacol 1992; 30(3):165-73.
Raunio H, Silverman JA, Gant TW, Marino PA, Thorgeirsson SS.
Induction of multidrug resistance genes by carcinogens
[abstract]. Eur J Cancer 1991;27 Suppl 3:S44.
Raymond M, Gros P. Cell-specific activity of cis-acting
regulatory elements in the promoter of the mouse multidrug
resistance gene mdr1. Mol Cell Biol 1990
Nov;10(11):6036-40.
Raymond M, Gros P. Mammalian multidrug-resistance gene
correlation of exon organization with structural domains
and duplication of an ancestral gene. Proc Natl Acad Sci U
S A 1989; 86(17):6488-92.
Raymond M, Gros P, Whiteway M, Thomas DY. Functional
complementation of yeast STE6 by a mammalian multidrug
resistance mdr gene. Science 1992 Apr 10;256(5054):232-4.
Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I.
Stability and covalent modification of P-glycoprotein in
multidrug-resistant KB cells. Biochemistry
1988;27(20):7607-13.
Rittmann-Grauer L, Bischoff E, Huang A, Mackensen D. Inhibition
of growth of multidrug-resistant tumors in athymic nude mice
by anti-p-glycoprotein monoclonal antibodies [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2797.
Roninson IB. From amplification to function: the case of the
MDR1 gene. Mutat Res 1992 May;276(3): 151-61.
Roninson IB. The role of the MDR1 (P-glycoprotein) gene in
multidrug resistance in vitro and in vivo. Biochem
Pharmacol 1992 Jan 9;43(1):95-102.
Roninson IB, Fukumoto M, Chin JE, Choi K, Chen CJ, Morse B,
Noonan KE , Shevrin DH, Estensen RD. Gene amplification in
cancer-multidrug resistance [abstract]. J Cell Biochem
Suppl 1989;13 Pt B:2.
Rothenberg M, Ling V. Multidrug resistance molecular biology
and clinical relevance meeting, Bethesda, Maryland USA, Apr
10-11, 1989. J Natl Cancer Inst 1989;81(12):907-13.
Salminen A, Elson H, Mickley L, Fojo A, Gottesman M.
Retrovirus-mediated gene transfer to myocytes: an approach
to muscle gene therapy [abstract]. Cell Biol Int Rep
1990;14 Suppl:50.
Sampson KE, Abraham I. Identification and characterization of a
170 KDA kinase activity in multidrug resistant cells
[abstract]. J Cell Biol 1991;115(3 Pt 2):437a.
Samuelson J, Ayala P, Orozco E, Wirth D. Emetine-resistant
mutants of Entamoeba histolytica overexpress mRNAs for
multidrug resistance. Mol Biochem Parasitol 1990 Jan
15;38(2):281-90.
Samuelson J, Descoteaux S, Ayala P, Orozco E. P-glycoprotein
genes of Entamoeba-histolytica [abstract]. Am J Trop Med
Hyg 1991;45(3 Suppl): 250.
Scheper RJ, Broxterman HJ, Scheffer GL, Meijer CJ, Pinedo HM.
Drug-transporter proteins in clinical multidrug resistance.
Clin Chim Acta 1992 Mar 13;206(1-2):25-32.
Schinkel AH, Borst P. Multidrug resistance mediated by P-
glycoproteins. Semin Cancer Biol 1991 Aug; 2(4):213-26.
Schinkel AH, Smit JJ, Wagenaar E, van Deemter L, Robanus EM, te
Riele H, van Roon M, Berns AJ, Borst P. Efficient
inactivation of the mouse mdr genes in embryonic stem cells
using homologous recombination [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2787.
Schoenlein PV, Shen DW, Barrett JT, Pastan I, Gottesman MM.
Double minute chromosomes carrying the human multidrug
resistance 1 and 2 genes are generated from the dimerization
of submicroscopic circular DNAs in colchicine-selected KB
carcinoma cells. Mol Biol Cell 1992 May;3(5):507-20.
Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide
transport by the multidrug resistance pump. J Biol Chem
1992 Mar 25;267(9):5731-4.
Sharom FJ, Doige CA, Yu XH. Characterization and lipid
preferences of ATPase-active P-glycoprotein [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2830.
Shen DW, Pastan I, Gottesman MM. In situ hybridization analysis
of acquisition and loss of the human multidrug-resistance
gene. Cancer Res 1988;48(15):4334-9.
Shimabuku AM, Nishimoto T, Ueda K, Komano T. P-glycoprotein.
ATP hydrolysis by the N-terminal nucleotide-binding domain.
J Biol Chem 1992 Mar 5;267(7):4308-11.
Shimabuku AM, Saeki T, Ueda K, Komano T. Production of a site
specifically cleavable P-glycoprotein beta galactosidase
fusion protein. Agric Biol Chem 1991;55(4):1075-80.
Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and
characterization of a member of the rat multidrug resistance
(mdr) gene family. Gene 1991 Oct 15;106(2):229-36.
Slovak M, Ling V, Trent J. Molecular/cytogenetic
characterization of the sequential development of multidrug
resistance (MDR) in a panel of colchicine resistant (CLCR)
cell lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1270.
Slovak ML, Lothstein L, Horwitz SB, Trent JM. Molecular-
cytogenetic alterations accompanying the development of
multidrug resistance in the J774.2 murine cell line.
Leukemia 1988;2(7):453-8.
Smit JJ, Lincke CR, van der Velde-Koerts T, Borst P. Structure
of the human MDR locus [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1990;31:A2667.
Sokova OI, Kopnin BP. [Segments of Djungarian hamster
chromosomes, specific for translocation of integration of
amplified mdr1 genes, do not possess increased instability].
Genetika 1991 Oct;27(10): 1722-5. (Rus).
Sokova OI, Siyanova E Yu, Gudkov AV, Kopnin BP. [Gene
amplification in mammalian somatic cells resistant to
colchicine]. Genetika 1988;24(5): 836-41. (Rus).
Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline
A, Nienhuis AW. Selection of drug-resistant bone marrow
cells in vivo after retroviral transfer of human MDR1.
Science 1992 Jul 3;257(5066):99-103.
Spies T, DeMars R. Restored expression of major
histocompatibility class I molecules by gene transfer of a
putative peptide transporter. Nature 1991 May 23;
351(6324):323-4.
Stahl F, Wettergren Y, Levan G. Amplicon structure in
multidrug-resistant murine cells: a nonrearranged region of
genomic DNA corresponding to large circular DNA. Mol Cell
Biol 1992 Mar;12(3): 1179-87.
Stanfield SW, Ielpi L, O'Brochta D, Helinski DR, Ditta GS. The
NDV-A gene product of Rhizobium-meliloti is required for
beta-1-2 glucan production and has homology to the ATP-
binding export protein HLY-B. J Bacteriol
1988;170(8):3523-30.
Sugawara I, Watanabe M, Masunaga A, Itoyama S, Ueda K. Primer-
dependent amplification of mdr1 mRNA by polymerase chain
reaction. Jpn J Cancer Res 1992;83(2):131-3.
Tanaka S, Currier SJ, Bruggemann EP, Ueda K, Germann UA, Pastan
I, Gottesman MM. Use of recombinant P-glycoprotein
fragments to produce antibodies to the multidrug
transporter. Biochem Biophys Res Commun 1990 Jan
15;166(1):180-6.
Tiirikainen MI, Krusius T. Multidrug resistance. Ann Med
1991;23(5):509-20.
Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A.
Sequences encoded in the class II region of the MHC related
to the 'ABC' superfamily of transporters. Nature 1990
Dec 20-27;348(6303):741-4.
Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF.
Volume-regulated chloride channels associated with the human
multidrug-resistance P-glycoprotein. Nature 1992 Feb;
355(6363):830-3.
van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer
Res 1989;52:165-203.
Van Dijk J, Tsuruo T, Segal DM, Bolhuis RLH, Colognola R, Van
DeGriend RJ, Fleuren GJ, Warnaar SO. Bispecific antibodies
reactive with the multidrug-resistance-related glycoprotein
and CD-3 induce lysis of multidrug-resistant tumor cells.
Int J Cancer 1989;44(4):738-43.
Wadkins RM, Houghton PJ. Mechanism of multi-drug resistance MDR
modulation by phenoxazines. I. Membrane transport
properties [abstract]. FASEB J 1992;6(1):A235.
Weinstein RS, Kuszak JR, Brown H, Coon JS, Roninson IB. Mdr
gene family freeze-fracture studies of multidrug resistant
KBP epidermoid cells [abstract]. J Cell Biol 1989;109(4 Pt
2):33a.
Weinstein RS, Kuszak JR, Coon JS. P-glycoprotein selectively
partitions in lipid-rich domains of multidrug-resistant cell
membranes [abstract]. FASEB J 1989;3(4 Pt 2):A1052.
Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins
in pathology: the multidrug resistance gene family in
humans. Hum Pathol 1990 Jan; 21(1):34-48.
Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, Shankar AH,
Wirth DF. Amplification of a gene related to mammalian mdr
genes in drug-resistant Plasmodium falciparum. Science 1989
Jun 9; 244(4909):1184-6.
Wilson CM, Thaithong S, Wirth DF. The relationship of Pf-mdr1
to mefloquine resistance in Plasmodium-falciparum
[abstract]. Am J Trop Med Hyg 1991; 64(3 Suppl):191.
Wirth DF. Mechanism of drug resistance in Plasmodium-
falciparum: role of MDR-like genes [abstract]. AIDS Res Hum
Retroviruses 1990; 6(11):1354.
Woods G, Lund LA, Naik M, Ling V, Ochi A. Resistance of
multidrug-resistant lines to natural killer-like cell-
mediated cytotoxicity. FASEB J 1988;2(12):2791-6.
Workman P, Dive C. Minimal resistance to the membrane-active
ether lipid SRI 62-834 in multidrug-resistant mouse mammary
tumor cells [abstract]. Cancer Chemother Pharmacol 1989;
24 Suppl 2:S82.
Wu CT, Budding M, Griffin MS, Croop JM. Isolation and
characterization of Drosophila multidrug-resistance gene
homologs. Mol Cell Biol 1991; 11(8):3940-8.
Yang CPH, Mellado W, Horwitz SB. Azidopine photoaffinity
labeling of multidrug resistance-associated glycoproteins.
Biochem Pharmacol 1988;37(7):1417-21.
Yoshimoto K, Iwahana H, Yokogoshi Y, Saito S, Shiraishi M, Sekiya
T, Gottesman MM, Pastan I. A polymorphic HIN-D-III site
within the human multidrug resistance gene 1 (MDR1).
Nucleic Acids Res 1988;16(24):11850.
Yoshimura A, Kuwazuru Y, Sumizawa T, Ichikawa M, Ikeda S, Uda T,
Akiyama S. Cytoplasmic orientation and two-domain
structure of the multidrug transporter, P-glycoprotein,
demonstrated with sequence-specific antibodies. J Biol Chem
1989 Sep 25;264(27):16282-91.
Yoshimura A, Kuwazuru Y, Sumizawa T, Ikeda SI, Ichikawa M,
Usagawa T, Akiyama SI. Biosynthesis processing and half-
life of P-glycoprotein in a human multidrug-resistant KB
cell. Biochim Biophys Acta 1989;992(3):307-14.
Young PR, Krasney PA. Interleukin-1-beta can be secreted from
mammalian cells by the human mdr1 P-glycoprotein
[abstract]. Cytokine 1991;3(5):472.
Zastawny RL, Benchimol S, Ling V. Modulation of P-glycoprotein
promoter activity by P53 [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33: A2700.
Zhang JT, Ling V. Study of membrane orientation and
glycosylated extracellular loops of mouse P-glycoprotein by
in vitro translation. J Biol Chem 1991 Sep
25;266(27):18224-32.
Zsido TJ, Beerman TA, Meegan RL, Woynarowski JM, Baker RM.
Resistance of CHO cells expressing P-glycoprotein to
cyclopropylpyrroloindole (CPI) alkylating agents. Biochem
Pharmacol 1992 Apr 15;43(8):1817-22.
GLUTATHIONE
Akman S, Forrest G, Chu FF, Esworthy RS, Stetzler J, Doroshow J.
Antioxidant enzyme gene expression in multidrug-resistant
MCF-7 breast cancer cells (MCF-7/ADR) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A1973.
Akman SA, Forrest G, Chu FF, Esworthy RS, Doroshow JH.
Antioxidant and xenobiotic-metabolizing enzyme gene
expression in doxorubicin-resistant MCF-7 breast cancer
cells. Cancer Res 1990 Mar 1;50(5):1397-402.
Alaoui-Jamali MA, Panasci L, Schecter RL, Lehnert S, Batist G.
Atypical cross-resistance and multiple mechanisms in
melphalan-resistant rat mammary carcinoma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2130.
Arkin H, Ohnuma T, Holland JF, Averbuch SD. Cellular
glutathione-S-transferase characteristics in differential
multidrug resistant human acute lymphoblastic MOLT-3
leukemia sublines [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A1258.
Averbuch S, Murphrey M, Koch T, Gaudiano G, Stone H, Gamson J,
DeGraff W, Mitchell J. Cellular pharmacology and
radiosensitization properties of the novel aminocarboxy
reducing agent, bi(3,5-dimethyl-5-hydroxymethyl-2-
oxomorpholin-3-yl), in sensitive and multidrug-resistant
human tumor cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2005.
Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione
depletion in human and in rat multi-drug resistant breast
cancer cell lines. Biochem Pharmacol 1991 Feb
15;41(4):631-5.
Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM.
Development and characterization of a melphalan-resistant
human multiple myeloma cell line. Cancer Res 1991 Feb
1;51(3):995-1002.
Bellamy WT, Dalton WS, Meltzer P, Dorr RT. Role of glutathione
and its associated enzymes in multidrug-resistant human
myeloma cells. Biochem Pharmacol 1989;38(5):787-94.
Bellamy WT, Dorr RT, Dalton WS, Meltzer P, Alberts DS. The role
of glutathione (GSH) as a potential detoxification system in
multidrug resistant (MDR) human myeloma cells [abstact].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1259.
Benard J, Bourhis J, Riou G. Inducing chemoresistance in the N-
myc oncogene and associated genes. Prognostic value for
neuroblastoma. Bull Cancer 1991;78(1):91-7.
Benchekroun MN, Catroux P, Montaudon D, Robert J. Development
of mechanisms of protection against oxidative stress in
doxorubicin-resistant rat tumoral cells in culture. Free
Radic Res Commun 1990; 11(1-3):137-44.
Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S,
Matlin SA, Hait WN, Cowan KH. Biochemical correlates of the
antitumor and antimitochondrial properties of gossypol
enantiomers. Mol Pharmacol 1990 Jun;37(6): 840-7.
Board PG, Johnston PN, Ross VL, Webb GC, Coggan M, Suzuki T.
Molecular genetics of the human glutathione S-transferase.
Int Symp Princess Takamatsu Cancer Res Fund 1990;21:199-211.
Brown R, Keith N, Stallard S, Kaye SB. Expression of mdr1 and
gst-pi in breast tumors: correlations with
chemoresponsiveness in vitro [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2054.
Buetler TM, Van Ness KP, Eaton DL. Alignment of multiple
glutathione S-transferase amino acid sequences and
prediction of structure-function relationship [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A1175.
Burk RK, Garfield S, Johnson K, Thorgiersson SS. Transformation
of rat liver epithelial cells with V-H-RAS or V-RAF causes
expression of MDR-1 glutathione-S-transferase-P and
increased resistance to cytotoxic chemicals. Carcinogenesis
1988;9(12): 2329-32.
Chao CCK, Huang YT, Ma CM, Chou WY, Lin-Chao S. Overexpression
of glutathione S-transferase and elevation of thiol pools in
a multidrug-resistant human colon cancer cell line. Mol
Pharmacol 1992;41(1):69-75.
Chen G, Zeller WJ. In vitro investigations on induction and
reversal of cisplatin resistance in a rat ovarian tumor cell
line. J Cancer Res Clin Oncol 1990;116(5):443-7.
Chen TL, Erlichman C, Alaoui-Jamali M. Modulation of adriamycin
(ADR)-induced growth inhibition by cyclosporin A (CSA) and
buthionine sulfoximine (BSO) in human ovarian carcinoma
cells (SKOV3) and its multidrug-resistant variant SKVCR2
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2861.
Cole SP, Downes HF, Mirski SE, Clements DJ. Alterations in
glutathione and glutathione-related enzymes in a multidrug-
resistant small cell lung cancer cell line. Mol Pharmacol
1990 Feb;37(2): 192-7.
Cole SPC, Downes HF, Mirski SEL. Glutathione GSH levels are
diminished but GSH-S-transferase and reductase activities
are elevated in the multidrug resistant small cell lung
cancer cell line H69AR [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:510.
Cowan KH. Glutathione S-transferases and drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:674.
Crescimanno M, D'Alessandro N, Clapper M, Tew K, Tapiero H, Rausa
L. Are the antioxidant and glutathione transferase
activities involved in multidrug resistance? [abstract].
Anticancer Res 1988;8(5 Pt B):1089.
Dalton WS. Mechanisms of drug resistance in breast cancer.
Semin Oncol 1990 Aug;17(4 Suppl 7): 37-9.
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC,
Henner WD, Goldenberg GJ. Multifactorial resistance to
adriamycin relationship of DNA repair glutathione
transferase activity drug efflux and P-glycoprotein in
cloned cell lines of adriamycin-sensitive and adriamycin-
resistant P388 leukemia. Cancer Res 1988;48(13):3595-602.
Dusre L, Mimnaugh EG, Myers CE, Sinha BK. Potentiation of
doxorubicin cytotoxicity by buthionine sulfoximine in
multidrug-resistant human breast tumor cells. Cancer Res
1989;49(3):511-5.
Dusre L, Rajagopalan S, Eliot HM, Covey JM, Sinha BK. DNA
interstrand cross-link and free radical formation in a human
multidrug-resistant cell line from mitomycin C and its
analogues. Cancer Res 1990 Feb 1;50(3):648-52.
Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L,
Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol 1992 Jan 22;43(2):331-42.
Fairchild CR, Moscow JA, Cowan KH. Effect of gst pi expression
on the pattern of multidrug resistance conferred by
transfection of the P-glycoprotein gene [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A2100.
Ford JM, Hait WH. Buthionine sulfoximine supersensitizes
multidrug resistant cells to verapamil [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:570.
Ford JM, Yang JM, Hait WN. Effect of buthionine sulfoximine on
toxicity of verapamil and doxorubicin to multidrug
resistant cells and to mice. Cancer Res 1991;51(1):67-72.
Frankfurt OS, Seckinger D, Sugarbaker EV. Intercellular
transfer of drug resistance. Cancer Res 1991 Feb
15;51(4):1190-5.
Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD,
Saijo N. Determinants of drug response in a cisplatin
resistant human lung cancer cell line. Jpn J Cancer Res
1990;81(5): 527-35.
Gessner T, Vaughan LA, Beehler BC. Increased defenses against
oxidative stress in daunorubicin (dau)-resistant p388
leukemia cells [abstract]. FASEB J 1989;3(3 Pt I):A740.
Gessner T, Vaughan LA, Beehler BC, Bartels CJ, Baker RM.
Elevated pentose cycle and glucuronyltransferase in
daunorubicin-resistant P388 cells. Cancer Res 1990
Jul 1;50(13):3921-7.
Gleason M, Bellamy W, Dalton W. Development of a melphalan
drug-resistant human myeloma cell line [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1989;8:A980.
Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson
ME. High resistance to cisplatin in human ovarian cancer
cell lines is associated with marked increase of glutathione
synthesis. Proc Natl Acad Sci U S A 1992 Apr 1;
89(7):3070-4.
Harris AL. Mechanisms of anticancer drug resistance. Dev Oncol
1990;58:107-15.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992; 31(2):205-13.
Hill B, Whelan R, Hosking L. Differential increased glutathione
S-transferase activity in a range of multidrug resistant
human tumor cell lines [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1989;8:A111.
Hill BT. Modulation of antitumour drug resistance: experimental
laboratory data and results of clinical evaluation. Cancer
Treat Rev 1990 Sep;17(2-3): 197-202.
Hoban PR, Robson CN, Davies SM, Hall AG, Cattan AR, Hickson ID,
Harris AL. Reduced topoisomerase II and elevated alpha
class glutathione S-transferase expression in a multidrug
resistant CHO cell line highly cross-resistant to mitomycin
C. Biochem Pharmacol 1992 Feb 18; 43(4):685-93.
Huitfeldt HS, Brandtzaeg P, Poirier MC. Relation between
proliferation, aminofluorene-DNA adduct accumulation, and
multidrug resistance gene expression in rat liver during
continuous acetylaminofluorene feeding [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A452.
Ishikawa T. Is the glutathione S-conjugate carrier an mdr1 gene
product? [letter]. Trends Biochem Sci 1990
Jun;15(6):219-20.
Ishikawa T, Mueller M, Kluenemann C, Schaub T, Keppler D. ATP-
dependent primary active transport of cysteinyl leukotrienes
across liver canalicular membrane. Role of the ATP-
dependent transport system for glutathione S-conjugates.
J Biol Chem 1990;265(31):19279-86.
Kaye SB. Reversal of multidrug resistance. Cancer Treat Rev
1990 Dec;17 Suppl A:37-43.
Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-pi in
human breast tumours: comparison to in vitro
chemosensitivity. Br J Cancer 1990 May; 61(5):712-6.
Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K.
Factors contributing to adriamycin sensitivity in human
xenograft tumors: the relationship between expression of the
MDR1, GST-pi and topoisomerase II genes and tumor
sensitivity to adriamycin. Anticancer Res 1992 Jan-
Feb;12(1):241-5.
Kramer RA, Zahker J, Newburger P. The role of selenium-
dependent glutathione peroxidase activity in multidrug
resistance [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2071.
Kramer RA, Zakher J. Adriamycin resistance in human breast
cancer cells involves both altered transport and oxygen
radical detoxification mechanisms [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1239.
Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle
in acquired and de novo multidrug resistance. Science
1988;241(4866):694-7.
Krishan A, Sridhar KS, Samy A, Singh SV, Nair S, DiCicco L,
Wellham L, Gordon K, Sauerteig A. Doxorubicin resistance
in a human melanoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2072.
Kuo-Pao PY, Samaan NA. Intrinsic drug resistance in a human
medullary thyroid carcinoma cell line: association with a
multidrug resistance gene expression and low proliferation
fraction [abstract]. Anticancer Res 1990;10(5B):1404.
Kuroda H, Sugimoto T, Ueda K, Tsuchida S, Horii Y, Inazawa J,
Sato K, Sawada T. Different drug sensitivity in two
neuroblastoma cell lines established from the same patient
before and after chemotherapy. Int J Cancer 1991 Mar
12;47(5): 732-7.
Kuzmich S, Vanderveer LA, Tew KD. Post-translational
modification of glutathione S-transferases by glycosylation
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2040.
Kuzmich S, Vanderveer LA, Walsh ES, Tew KD. Elevated
glutathione-S-transferase activity and altered thiol
metabolism in cells resistant to ethacrynic acid [abstract].
Proc Annu Meet Am Assoc Cancer Res 1990;31:A2153.
LaCreta FP, Olszewski J, Tew KD. High performance fast affinity
chromatography of glutathione S-transferases [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1220.
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. Intrinsic and
acquired resistance (R) to adriamycin (Ad) in human colon
carcinoma cell lines (HCCCL) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2254.
Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE. Contribution
of glutathione and glutathione-dependent enzymes in the
reversal of adriamycin resistance in colon carcinoma cell
lines. Int J Cancer 1991 Nov 11;49(5):688-95.
Larsson R, Bergh J, Nygren P. Combination of cyclosporin A and
buthionine sulfoximine (BSO) as a pharmacological strategy
for circumvention of multidrug resistance in small cell lung
cancer cell lines selected for resistance to doxorubicin.
Anticancer Res 1991 Jan-Feb;11(1):455-9.
Lau DHM, Lewis AD, Ehsan MN, Sikic BI. Multifactorial
mechanisms associated with broad cross-resistance of ovarian
carcinoma cells selected by cyanomorpholinodoxorubicin.
Cancer Res 1991; 51(19):5181-7.
Lee FYF, Sciandra J, Siemann DW. A study of the mechanism of
resistance to adriamycin in-vivo glutathione metabolism P-
glycoprotein expression and drug transport. Biochem
Pharmacol 1989; 38(21):3697-706.
Lee FYF, Siemann DW. Isolation by flow cytometry of a human
ovarian tumor cell subpopulation exhibiting a high
glutathione content phenotype and increased resistance to
adriamycin. Int J Radiat Oncol Biol Phys 1989;16(5):1315-9.
Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J, Riou G.
Study of molecular markers of resistance to m-AMSA in a
human breast cancer cell line. Decrease of topoisomerase II
and increase of both topoisomerase I and acidic glutathione
S transferase. Biochem Pharmacol 1991 Jun 15;
41(12):1967-79.
Lewis AD, Duran GE, Lau DH, Sikic BI. Sensitization of drug
resistant human ovarian cancer cells to cyanomorpholino
doxorubicin (MRA-CN) by modulation of glutathione
metabolism. Int J Radiat Oncol Biol Phys 1992;22(4):821-4.
Lewis AD, Lau DH, Ross KL, Wolf CR, Hayes JD, Sikic BI.
Glutathione metabolism in human ovarian cancer cells
resistant to cyanomorpholino doxorubicin (MRA-CN)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1979.
Linsenmeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG,
Woodcock DM. Levels of expression of the mdr1 gene and
glutathione S-transferase genes 2 and 3 and response to
chemotherapy in multiple myeloma. Br J Cancer 1992
Mar;65(3): 471-5.
Luna MC, Gomer CJ. Isolation and initial characterization of
mouse tumor cells resistant to porphyrin-mediated
photodynamic therapy. Cancer Res 1991;51(16):4243-9.
Lutzky J, Canada AL, Yamanishi DT, Bhalla K, Hindenburg AA.
Effect of verapamil and buthionine sulfoximine (BSO) on
daunorubicin (DNR) cytotoxicity of multidrug-resistant human
melanoma cell lines overexpressing P-glycoprotein and
glutathione-s-transferases [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A3315.
Lutzky J, Madrid KK, Krishna S, Bhalla K, Hindenburg AA, Taub RN.
Effect of glutathione depletion plus verapamil on HL60 and
HL60/AR cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2203.
Mannervik B, Berhane K, Castro VM, Olin B, Ridderstrom M, Vignani
R, Kozarich JW, Ringborg U. Glutathione-linked enzymes in
normal and tumor cells and their role in resistance against
genotoxic agents. Int Symp Princess Takamatsu Cancer Res
Fund 1990;21:253-62.
Masters JR. Biochemical basis of resistance to chemotherapy.
Radiother Oncol 1990 Dec; 19(4):297-305.
Mattern J, Volm M. Prediction of drug resistance in human
tumors using immunohistochemical techniques. Anticancer Res
1992 Mar-Apr;12(2): 413-8.
Maurya AK, Nair S, Mian AM, Singh SV. Mechanism of cross-
resistance to mitomycin C in multidrug-resistant mouse
leukemic P388 cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2100.
Mazzoni A, Trave F, Russo P, Nicolin A, Rustum YM. Generation
and characterization of a low-degree drug-resistant human
tumor cell line. Oncology 1990;47(6):488-94.
Medh RD, Gupta V, Zhang Y, Awasthi YC, Belli JA. Glutathione S-
transferase and P-glycoprotein in multidrug resistant
Chinese hamster cells. Biochem Pharmacol 1990 Jun
1;39(11):1641-5.
Meijer C, Mulder NH, Timmer-Bosscha H, Peters WH, de Vries EG.
Combined in vitro modulation of adriamycin resistance. Int
J Cancer 1991 Oct 21; 49(4):582-6.
Mickisch G, Bier H, Bergler W, Bak M, Tschada R, Alken P. P-170
glycoprotein, glutathione and associated enzymes in relation
to chemoresistance of primary human renal cell carcinomas.
Urol Int 1990;45(3):170-6.
Mickisch G, Fajta S, Bier H, Tschada R, Alken P. Cross-
resistance patterns related to glutathione metabolism in
primary human renal cell carcinoma. Urol Res
1991;19(2):99-103.
Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken
PM. Mechanisms and modulation of multidrug resistance in
primary human renal cell carcinoma. J Urol 1990 Sep;
144(3):755-9.
Millar BC, Bell JBG, Maitland JA, Zuiable A, Gore ME, Selby PJ,
McElwain TJ. In vitro studies of ways to overcome
resistance to VAMP high dose melphalan in the treatment of
multiple myeloma. Br J Haematol 1989;71(2):213-22.
Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK. Biochemical
and pharmacological characterization of MCF-7 drug-sensitive
and AdrR multidrug-resistant human breast tumor xenografts
in athymic nude mice. Biochem Pharmacol 1991 Jul 5;42(2):
391-402.
Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK. Biochemical
characterization of MCF-7 sensitive and ADRR multidrug-
resistant human breast tumors in nude mice [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1990;31:A2092.
Molina R, Fuqua SA, Tandon AK, Clark GM, Allred DC, Townsend AJ,
Moscow JA, Cowan KH, McGuire WL. Glutathione transferase
GST-PI in breast tumors evaluated by three techniques
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1990;31:A39.
Moscow JA, Fairchild CR, Madden M, Ransom DT, Wieand HS, O'Brien
E, Poplack DG, Cossmann J, Myers CE, Cowan KH. Expression
of anionic glutathione-S-transferase and p-glycoprotein
genes in human tissues and tumors. Cancer Res 1989;
49(6):1422-8.
Moscow JA, Kovach J, Poisson R, Poplack DG, Wheng-Peng J, Myers
CE, Cowan KH. Heterogeneous expression in human tumors of
anionic glutathione S-transferase, a phase II enzyme
associated with multidrug resistance [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1988;7:A195.
Moscow JA, Morrow CS, He R, Mullenbach GT, Cowan KH. Structure
and function of the 5'-flanking sequence of the human
cytosolic selenium-dependent glutathione peroxidase gene
(hgpx1). J Biol Chem 1992 Mar 25;267(9):5949-58.
Moscow JA, Townsend AJ, Baird WM, Myers CE, Cowan KH.
Transfection of a vector expressing the human anionic
glutathione-S-transferase confers resistance to alkylating
agents [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1249.
Moscow JA, Townsend AJ, Cowan KH. Structure and regulation of
the human glutathione peroxidase gene. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A1922.
Moscow JA, Townsend AJ, Goldsmith ME, Whang-Peng J, Vickers PJ,
Poisson R, Legault-Piosson S, Myers CE, Cowan KH.
Isolation of the human anionic glutathione-S-transferase
complementary DNA and the relation of its gene expression
to estrogen-receptor content in primary breast cancer. Proc
Natl Acad Sci U S A 1988;85(17):6518-22.
Muller MR, Twentyman PR, Lambert E, Cox H, Watson JV, Baglin TP,
Rees JH. P-glycoprotein (PGp) expression and glutathione
(GSH) content in human leukemia cells determined by flow-
cytometry (FCM). Paper presented at: British Association
for Cancer Research/Association for Cancer Physicians/
Leukaemia Research Fund Joint Winter Meeting on Leukaemia
and Lymphomas; 1989 Dec 11-12; London, UK.
Muller MR, Twentyman PR, Lambert E, Cox H, Watson JV, Baglin TP,
Rees JHK. P-glycoprotein (Pgp) expression and glutathione
(GSH) content in human leukemia cells determined by flow-
cytometry (FCM) [abstract]. Br J Cancer 1990:61(6):949-50.
Muramatsu M, Okuda A, Morimura S, Osada S, Imagawa M, Sakai M.
Regulation of glutathione transferase P gene. Implications
in carcinogenesis and drug resistance. Paper presented at:
Drug resistance as a biochemical target in cancer
chemotherapy. 13th Bristol-Myers Squibb Symposium on Cancer
Research; 1990 May 10-11; Tokyo, Japan.
Nair S, Gordon K, Singh SV, Sridhar KS, Wellham L, Sauerteig A,
Krishan A. Cellular glutathione content and glutathione-S-
transferase activity in human lung tumor cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2124.
Nair S, Singh SV, Krishan A. Flow cytometric monitoring of
glutathione content and anthracycline retention in tumor
cells. Cytometry 1991;12(4): 336-42.
Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J,
Muramatsu M, Sato K, Terada M, Tew KD. Glutathione-S-
transferase pi as a determinant of drug resistance in
transfectant cell lines. J Biol Chem 1990 Mar 15;265(8):
4296-301.
Nakagawa K, Sasaki Y, Fujiwara Y, Minato K, Shinkai T, Eguchi K,
Tamura T, Otsu A, Ohe Y, Saijo N. Levels of glutathione S
transferase-II (GST-II) mRNA in human lung cancer cell lines
correlate with the resistance to cisplatin [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1988;7:A781.
Nakamura M, Tsunoda S, Watabe Y, Shimomura T, Sakaki T, Konishi
N, Hiasa Y. [Immunohistochemical study of placental form
of glutathione S-transferase in human brain tumors and fetal
brains]. No To Shinkei 1990 Oct;42(10): 965-70. (Jpn).
Nakatsukasa H, Evarts RP, Silverman JA, Marsden E, Thorgeirsson
SS. Expression of multidrug-resistance (MDR) and
glutathione-transferase-P (GST-P) genes in rat
hepatocarcinogenesis [abstract]. FASEB J 1991;5(5):A1247.
Ozols RF. Reversal of drug resistance: clinical trials based on
experimental studies in human tumor model systems. Paper
presented at: Symposium on Mechanisms of Drug and Radiation
Resistance of Tumor Cells; 1989 Jun 28-30; Villejuif,
France.
Ozols RF. Reversal of drug resistance: laboratory data and
clinical trials. Paper presented at: Biology and therapy of
breast cancer. Joint NCI-IST Symposium/3rd IST
International Symposium; 1989 Sep 25-27; Genoa, Italy.
Parekh H, Chavan S, Chitnis M. Modulation of thiol pools by
vitamin K3 and its effect on survival of sensitive and
resistant murine tumor cells. Anticancer Drugs 1991
Apr;2(2):159-68.
Parekh HK, Mansuri-Torshizi H, Srivastava TS, Chitnis MP.
Circumvention of adriamycin resistance: effect of 2-
methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity
in sensitive and MDR P388 leukemia cells. Cancer Lett 1992
Jan 10;61(2): 147-56.
Peters WH, Boon CE, Roelofs HM, Wobbes T, Nagengast FM, Kremers
PG. Expression of drug-metabolizing enzymes and P-170
glycoprotein in colorectal carcinoma and normal mucosa.
Gastroenterology 1992 Aug;103(2):448-55.
Peters WH, Roelofs HM. Biochemical characterization of
resistance to mitoxantrone and adriamycin in Caco-2 human
colon adenocarcinoma cells: a possible role for glutathione
S-transferases. Cancer Res 1992 Apr 1;52(7):1886-90.
Phillips PC. Antineoplastic drug resistance in brain tumors.
Neurol Clin 1991 May;9(2):383-404.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey
M, Margison G, Cerny T. Assessment of P-glycoprotein,
glutathione-based detoxifying enzymes and O6-alkylguanine-
DNA alkyltransferase as potential indicators of constitutive
drug resistance in human colorectal tumors. Cancer Res 1991
Apr 15;51(8):2092-7.
Riou G, Barrois M, Zhou D. Expression of anionic glutathione S
transferase (GST pi) gene in carcinomas of the uterine
cervix and in normal cervices. Br J Cancer 1991
Feb;63(2):191-4.
Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K,
Kuwano M. Increased expression of glutathione S-
transferase gene in cis-diamminedichloroplatinum(II)-
resistant variants of a Chinese hamster ovary cell line.
Cancer Res 1989 Dec 15;49(24 Pt 1):7020-5.
Saijo N, Nakagawa K, Fujiwara Y, Bungo M, Horichi N, Sasaki Y,
Yokota J, Terada M. Characteristics of clinical and
experimental resistance to cisplatin . Paper presented at:
1st International Interface of Clinical and Laboratory
Responses to Anticancer Drugs; 1989 Mar 13-15; Villejuif,
France.
Saito Y, Nakada Y, Hotta T, Mikami T, Kurisu K, Yamada K, Kiya K,
Kawamoto K, Uozumi T. Cross resistance patterns in ACNU-
resistant glioma sublines in culture. J Neurosurg
1991;75(2): 277-83.
Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ,
Beckett MA, Weichselbaum RR. Increased glutathione
peroxidase activity in a human sarcoma cell line with
inherent doxorubicin resistance. Cancer Res 1991 Jan
15;51(2):521-7.
Sato K, Tsuchida S, Tamai K. [Anti-cancer drug resistance and
glutathione S-transferases]. Gan To Kagaku Ryoho 1989
Mar;16(3 Pt 2):592-8. (Jpn).
Satta T, Isobe K, Yamauchi M, Nakashima I, Akiyama S, Itou K,
Watanabe T, Takagi H. Establishment of drug resistance in
human gastric and colon carcinoma xenograft lines. Jpn J
Cancer Res 1991 May;82(5):593-8.
Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression
of MDR1 and glutathione S transferase-pi genes and
chemosensitivities in human gastrointestinal cancer. Cancer
1992 Feb 15;69(4):941-6.
Saxena M, Sharma R, Singhal SS, Ahmad H, Awasthi YC. The effect
of doxorubicin on the transport of glutathione conjugates
from human erythrocytes. Biochem Arch 1991;7(4):285-92.
Schecter RL, Woo A, Duong M, Batist G. In vivo and in vitro
mechanisms of drug resistance in a rat mammary carcinoma
model. Cancer Res 1991; 51(5):1434-42.
Schisselbauer JC, Crescimanno M, D'Alessandro N, Clapper M,
Toulmond S, Tapiero H, Tew KD. Glutathione, glutathione S-
transferases, and related redox enzymes in Adriamycin-
resistant cell lines with a multidrug resistant phenotype.
Cancer Commun 1989;1(2):133-9.
Schisselbauer JC, Silber R, Papadopoulous E, LaCreta FP, Tew KD.
Characterization of lymphocyte glutathione S-transferase
isozymes in chronic lymphocytic leukemia [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A2039.
Sinha BK, Politi PM. Anthracyclines. Cancer Chemother Biol
Response Modif 1990;11:45-57.
Supino R, Sala E, Binaschi M, Capranico G, Zunino F. Drug
resistance in a multidrug-resistant human small cell lung
carcinoma cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2693.
Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH. An
immunohistochemical study of pi class glutathione S-
transferase expression in normal human tissue. Am J Pathol
1990 Oct;137(4): 845-53.
Tew K. The involvement of glutathione-related enzymes in drug
resistance . Paper presented at: 1st International
Interface of Clinical and Laboratory Responses to Anticancer
Drugs; 1989 Mar 13-15; Villejuif, France.
Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F,
Picci P, Boiocchi M. Expression of MDR1 and GST-pi in
human soft tissue sarcomas: relation to drug resistance and
biological aggressiveness. Ann Oncol 1992 Jan;3(1):63-9.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Boiocchi M.
Multidrug-resistance in human colon carcinoma cell lines
[abstract]. Anticancer Res 1990;10(5B):1406-7.
Townsend AJ, Morrow CS, Sinha BK, Cowan KH. Selenium-dependent
glutathione peroxidase expression is inversely related to
estrogen receptor content of human breast cancer cells.
Cancer Commun 1991 Aug;3(8):265-70.
Trujillo JM, Yang LY, Su YZ, Gercovich G, Hai S, Williams A.
Cytotoxicity synergism of interferon (IFN) and adriamycin
(AdR) on lovo human colon tumor cell line and its multidrug
resistant (MDR) subclone [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2033.
Twentyman PR. Strategies for circumventing resistance to
cytotoxic drugs. Paper presented at: 5th Biennial
Conference of the Indian Association of Cancer
Chemotherapists; 1989 Feb 17-19; Bombay, India.
Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein
and glutathione S-transferase-pi in resistant non-small cell
lung carcinomas of smokers. Br J Cancer 1991
Oct;64(4):700-4.
Wang Y, Teicher BA, Shea TC, Holden SA, Rosbe KW, Al Achi A,
Henner WD. Cross resistance and glutathione-S-transferase
pi levels among four human melanoma cell lines selected for
alkylating agent resistance. Cancer Res
1989;49(22):6185-92.
Welch PJ, Manoharan TH, Lathrop AL, Puchalski RB, Fahl WE.
Tandem expression of two glutathione-S-transferase cDNAs to
achieve resistance to multiple, structurally diverse
alkylating molecules [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A680.
Whelan RD, Hosking LK, Townsend AJ, Cowan KH, Hill BT.
Differential increases in glutathione S-transferase
activities in a range of multidrug-resistant human tumor
cell lines. Cancer Commun 1989;1(6):359-65.
Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a
human medullary thyroid carcinoma cell line: association
with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res 1991;11(3):1065-8.
Young RC. Mechanisms to improve chemotherapy effectiveness.
Cancer 1990 Feb 1;65(3 Suppl): 815-22.
Yusa K, Hamada H, Tsuruo T. Comparison of glutathione-S-
transferase activity between drug-resistant and sensitive
human tumor cells. Is glutathione-S-transferase associated
with multidrug resistance? Cancer Chemother Pharmacol 1988;
22(1):17-20.
TOPOISOMERASE
Alton PA, Fry A, Hickson ID, Harris AL. Use of the MTT assay in
acute myeloid leukemia to assess mechanisms of resistance
[abstract]. Br J Cancer 1991;63 Suppl 13:14.
Baguley BC, Holdaway KM, Fray LM. Design of DNA intercalators
to overcome topoisomerase II-mediated multidrug resistance.
J Natl Cancer Inst 1990 Mar 7;82(5):398-402.
Beck WT. Mechanisms of multidrug resistance in human tumor
cells. The roles of P-glycoprotein, DNA topoisomerase II,
and other factors. Cancer Treat Rev 1990 Dec;17 Suppl
A:11-20.
Beck WT. Strategies to circumvent multidrug resistance due to
P-glycoprotein or to altered DNA topoisomerase II. Bull
Cancer (Paris) 1990;77(11): 1131-41.
Beck WT. Unknotting the complexities of multidrug resistance
the involvement of DNA topoisomerases in drug action and
resistance. J Natl Cancer Inst 1989;81(22):1683-5.
Beck WT, Danks MK, Suttle DP. The role of DNA topoisomerases in
multidrug resistance [abstract]. J Cell Biochem Suppl
1991;15 Pt F:15.
Beck WT, Danks MK, Wolverton JS, Chen M, Bugg BY, Suttle DP,
Catapano CV, Fernandes DJ. Altered DNA topoisomerase II in
multidrug resistance (MDR) [abstract]. Eur J Cancer 1991;
27 Suppl 3:S7.
Beck WT, Danks MK, Yalowich JC, Zamora JM, Cirtain MC.
Different mechanisms of multiple drug resistance in two
human leukemic cell lines. In: Woolley PV 3rd, Tew KD,
editors. Mechanisms of drug resistance in neoplastic cells;
1986 Oct 15-16; Washington, DC. San Diego (CA): Academic
Press, Inc.; 1988. p. 211-22. (Bristol-Myers cancer
symposia; 9).
Beck WT, Qian X, Danks MK. Circumvention of multidrug
resistance due to P-glycoprotein or to altered DNA
topoisomerase II. Paper presented at: 3rd International
Congress on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9;
France. (Eng, Fre).
Boege F, Gieseler F, Biersack H, Clark M. Use of anion-exchange
chromatography and chromatofocusing to reveal the structural
and functional heterogeneity of topoisomerase II in a HL-60
cell line resistant to multi-drug treatment. J Chromatogr
1991 Nov 29;587(1):3-9.
Boege F, Gieseler F, Biersack H, Meyer P. The measurement of
nuclear topoisomerase II inhibition in vitro: a possible
tool for detecting resistance on a subcellular level in
haematopoietic malignancies. Eur J Clin Chem Clin Biochem
1992 Feb;30(2): 63-8.
Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant
DNA topoisomerase II in CCRF-CEM human leukemic cells
selected for resistance to teniposide. Proc Natl Acad Sci U
S A 1991;88(17):7654-8.
Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH, Cheng YC. Effect of
4 beta-arylamino derivatives of 4'-O-
demethylepipodophyllotoxin on human DNA topoisomerase II,
tubulin polymerization, KB cells, and their resistant
variants. Cancer Res 1991 Apr 1;51(7):1755-9.
Chen HX, Chang JY, Wang ZQ, Lee KH, Cheng YC. In vitro and in
vivo studies on the toxicity and antitumor activity of
etoposide (VP-16) and its analogs [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2254.
Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr
RNA levels in response to cytotoxic drugs in rodent cells.
Cell Growth Differ 1990 Aug;1(8):361-5.
Cole SP. The 1991 Merck Frosst Award. Multidrug resistance in
small cell lung cancer. Can J Physiol Pharmacol 1992
Mar;70(3):313-29.
Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL. Non-P-
glycoprotein-mediated multidrug resistance in a small cell
lung cancer cell line evidence for decreased susceptibility
to drug-induced DNA damage and reduced levels of
topoisomerase II. Cancer Res 1991;51(13): 3345-52.
Dalton WS. Mechanisms of drug resistance in breast cancer.
Semin Oncol 1990 Aug;17(4 Suppl 7): 37-9.
Danks MK, Funabiki T, Beck WT. Functional assay for multiple
drug resistance (MDR) distinguishes MDR associated with P-
glycoprotein (PGP-MDR) from MDR associated with altered
topoisomerase II (topo II; at-MDR) [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2102.
Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered
catalytic activity of and DNA cleavage by DNA topoisomerase
II from human leukemic cells selected for resistance to
VM-26. Biochemistry 1988;27(24):8861-9.
Davies SM, Robson CN, Davies SL, Hoban PR, Harris AL, Hickson ID.
Isolation of CHO cell lines hypersensitive to adriamycin:
identification of abnormalities in topoisomerase II and drug
transport [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1100.
De Isabella P, Capranico G, Binaschi M, Tinelli S, Zunino F.
Evidence of DNA topoisomerase II-dependent mechanisms of
multidrug resistance in P388 leukemia cells. Mol Pharmacol
1990 Jan; 37(1):11-6.
De Isabella P, Capranico G, Zunino F. Minireview: the role of
topoisomerase II in drug resistance. Life Sci
1991;48(23):2195-205.
De Jong S, Withoff S, Smit EF, De Vries EG, Mulder NH.
Mechanisms of resistance to VM-26 and m-AMSA in an
adriamycin-resistant human sclc cell line, GLC4/ADR
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2687.
de Jong S, Zijlstra JG, de Vries EG, Mulder NH. Reduced DNA
topoisomerase II activity and drug-induced DNA cleavage
activity in an adriamycin-resistant human small cell lung
carcinoma cell line. Cancer Res 1990 Jan 15;50(2):304-9.
de Jong S, Zijlstra JG, Mulder NH, de Vries EG. Lack of cross-
resistance to fostriecin in a human small-cell lung
carcinoma cell line showing topoisomerase II-related drug
resistance. Cancer Chemother Pharmacol 1991;28(6):461-4.
de Vries EG, Zijlstra JG, Mulder NH. Morpholinyl
anthracyclines: option for reversal of anthracycline
resistance. Paper presented at: 3rd International Congress
on the Neo-adjuvant Chemotherapy; 1991 Feb 6-9; Paris,
France. (Eng, Fre).
Delaporte C, Charcosset JY, Jacquemin-Sablon A. Effects of
verapamil on the cellular accumulations and toxicity of
several antitumor drugs in 9 hydroxyellipticine-resistant
cells. Biochem Pharmacol 1988;37(4):613-20.
Delaporte C, Larsen AK, Dautry F, Jacquemin-Sablon A. Influence
of myc overexpression on the phenotypic properties of
Chinese hamster lung cells resistant to antitumor agents.
Exp Cell Res 1991 Dec;197(2):176-82.
Doyle LA, Kaufmann SH, Long BH, Goldstein LH, Ross D, Hamburger
AW, Giaccone G, Gazdar AF. Evaluation of topoisomerase II
expression in relation to sensitivity to etoposide in small-
cell lung cancer (SCLC) [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1991;10:A184.
Ellis AL, Gewirtz DA, Munger C, Woods KE, Randolph JK, Boise L,
Yanovich S. Multifactorial drug resistance in the rat
hepatoma [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1999.
Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L,
Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol 1992 Jan 22;43(2):331-42.
Evans CD, Mirski SE, Danks MK, Beck WT, Cole SP. Alterations in
topoisomerase II in multidrug resistance in the small cell
lung cancer cell line H69AR [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2694.
Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA
topoisomerase II (topo II) in VM-26-resistant human leukemia
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30: A1996.
Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA
topoisomerase II in human leukemia cells resistant to VM-26
and m-AMSA. Biochemistry 1990 May 1;29(17):4235-41.
Finlay GJ, Baguley BC, Snow K, Judd W. Multiple patterns of
resistance of human leukemia cell sublines to amsacrine
analogues. J Natl Cancer Inst 1990 Apr 18;82(8):662-7.
Friche E, Danks MK, Schmidt CA, Beck WT. Decreased DNA
topoisomerase II in daunorubicin-resistant Ehrlich ascites
tumor cells. Cancer Res 1991 Aug 15;51(16):4213-8.
Ganapathi R, Kamath N, Constantinou A, Grabowski D, Ford J,
Anderson A. Effect of the calmodulin inhibitor
trifluoperazine on phosphorylation of P-glycoprotein and
topoisomerase II: Relationship to modulation of subcellular
distribution, DNA damage and cytotoxicity of doxorubicin in
multidrug resistant L1210 mouse leukemia cells. Biochem
Pharmacol 1991 Jun 15;41(12):R21-6.
Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug
sensitivity phenotype of human lung cancer cells associated
with topoisomerase II expression. Cancer Res 1992 Apr
1;52(7):1666-74.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991;12(5): 359-73.
Gieseler F, Boege F, Biersack H, Spohn B, Wilms K.
Characterization of three HL-60 sublines with different
types of multidrug resistance [abstract]. Onkologie 1991;14
Suppl 2:54.
Glisson BS. Multidrug resistance mediated through alterations
in topoisomerase II. Cancer Bull 1989;41(1):37-40.
Glisson BS, Ross WE, Woodward J, Siciliano MJ. Reconstitution
of topoisomerase II-mediated drug sensitivity in somatic
cell hybrids of resistant CHO cells and normal human
lymphocytes [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29: A1993.
Grandi M, Ballinari D, Capolongo L, Pastori A, Ripamonti M,
Suarato A, Spreafico F. [New anthracyclines and multidrug
resistance]. Haematologica 1991 Jun;76 Suppl 3:181-3.
(Ita).
Granzen B, Beck WT. DNA topoisomerases in human
rhabdomyosarcoma cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2580.
Harker WG, Knight C, Slade DL, Kapoor R, Parr R. Reduced
topoisomerase II activity in human CEM leukemia cells
selected for resistance to mitoxantrone [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1992;33:A2698.
Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance
in HL-60 leukemia cells: reduced nuclear topoisomerase II
catalytic activity and drug-induced DNA cleavage in
association with reduced expression of the topoisomerase II
beta isoform. Biochemistry 1991 Oct 15;30(41): 9953-61.
Harris AL. Mechanisms of anticancer drug resistance. Dev Oncol
1990;58:107-15.
Harris AL, Hickson ID. The molecular mechanisms of sensitivity
to anticancer drugs. In: Bleasdale C, Golding BT, editors.
Molecular mechanisms in bioorganic processes. Symposium;
1989 Jul 17-20; Newcastle-Upon-Tyne, England. Cambridge
[England]: Royal Society of Chemistry; 1990. p. 83-99.
Harris AL, Hochhauser D. Mechanisms of multidrug resistance in
cancer treatment. Acta Oncol 1992; 31(2):205-13.
Hofsli E. Multimedikamentresistens - teoretiske og kliniske
aspekter [Multidrug resistance - theoretical and clinical
aspects]. Tidsskr Nor Laegeforen 1992;112(4):472-4. (Nor).
Ito T, Ohnuma T, Holland JF, Mattern MR. Altered DNA
topoisomerase (TOPO) II activity in human leukemia sublines
resistant to trimetrexate (TMQ) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2078.
Jacquemin-Sablon A, Dautry F, Delaporte C, Larsen AK. The
influence of c-myc expression on tumorigenicity and drug
resistance in 9-hydroxy-ellipticine-resistant Chinese
hamster lung cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2030.
Jensen PB, Jensen PS, Demant EJ, Friche E, Srensen BS, Sehested
M, Wassermann K, Vindelv L, Westergaard O, Hansen HH.
Antagonistic effect of aclarubicin on daunorubicin-induced
cytotoxicity in human small cell lung cancer cells:
relationship to DNA integrity and topoisomerase II. Cancer
Res 1991 Oct 1;51(19):5093-9.
Jensen PB, Jensen PS, Sehested M, Demant EJ, Sorensen BS,
Vindelov L, Hansen HH. Lack of cross-resistance to
aclarubicin in an altered topoisomerase II multidrug-
resistant (at-MDR) small-cell lung cancer (SCLC) cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1991;32:
A2077.
Johnson RK, McCabe FL, Faucette LF, Hertzberg RP, Kingsbury WD,
Boehm JC, Caranfa MJ, Holden KG. SKF 104864, a water-
soluble analog of camptothecin with broad-spectrum activity
in preclinical tumor models [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2482.
Kamath N, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun 1991
Feb; 3(2):37-44.
Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K.
Factors contributing to adriamycin sensitivity in human
xenograft tumors: the relationship between expression of the
MDR1, GST-pi and topoisomerase II genes and tumor
sensitivity to adriamycin. Anticancer Res 1992 Jan-
Feb;12(1):241-5.
Kuhl JS, Lau D, Duran G, Blume KG, Chao NJ, Sikic BI. Multiple
mechanisms of resistance to etoposide in variants of murine
p388 leukemia [abstract]. Proc Annu Meet An Assoc Cancer
Res 1991;32:362.
Larsen AK, Jacquemin-Sablon A. Multiple resistance mechanisms
in Chinese hamster cells resistant to 9-hydroxyellipticine.
Cancer Res 1989 Dec 15;49(24 Pt 1):7115-9.
Larsen AK, Markovits J, Jacquemin-Sablon A. Increased
sensitivity of 9-hydroxyellipticine-resistant Chinese
hamster cells to alkylating agents [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32: A2071.
Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J, Riou G.
Study of molecular markers of resistance to m-AMSA in a
human breast cancer cell line. Decrease of topoisomerase II
and increase of both topoisomerase I and acidic glutathione
S transferase. Biochem Pharmacol 1991 Jun 15;
41(12):1967-79.
Liu LF. DNA topoisomerases in drug resistance and cancer
chemotherapy. Paper presented at: 3rd Conference on DNA
Topoisomerases in Therapy; 1990 Oct 15-18; New York, NY.
Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza M.
Mechanisms of resistance to etoposide and teniposide in
acquired resistant human colon and lung carcinoma cell
lines. Cancer Res 1991;51(19):5275-83.
Masters JR. Biochemical basis of resistance to chemotherapy.
Radiother Oncol 1990 Dec; 19(4):297-305.
Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N.
Characterization of an etoposide-resistant human small-cell
lung cancer cell line. Cancer Chemother Pharmacol
1990;26(5): 313-7.
Mirski SE, Evans CD, Almquist KC, Cole SP. A novel
topoisomerase II in the drug-resistant small cell lung
cancer (SCLC) cell line H209/V6 [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2695.
Muller C, Laval F, Soues S, Birck C, Charcosset JY. High cell
density-dependent resistance and P-glycoprotein-mediated
multidrug resistance in mitoxantrone-selected Chinese
hamster cells. Biochem Pharmacol 1992 May
28;43(10):2091-102.
Narayana K, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y,
Ganapathi R. Trifluoperazine modulation of resistance to
the topoisomerase II inhibitor etoposide in doxorubicin
resistant L1210 murine leukemia cells. Cancer Commun
1991;3(2): 37-44.
Norris MD, Haber M, King M, Davey RA. Atypical multidrug
resistance in CCRF-CEM cells selected for high level
methotrexate resistance: reactivity to monoclonal antibody
C219 in the absence of P-glycoprotein expression. Biochem
Biophys Res Commun 1989 Dec 29;165(3):1435-41.
Phillips PC. Antineoplastic drug resistance in brain tumors.
Neurol Clin 1991 May;9(2):383-404.
Potmesil M, Wall ME, Wani MC, Silber R, Cordon-Cardo C, Stehlin
JS, Kozielski A, Giovanella BC. DNA topoisomerase-I
targeted chemotherapy of human colon cancer xenografts with
MDR phenotype [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1990;31:A2602.
Rabier MJ, Bruno NA, Slate DL. Multifactorial resistance in
LS174T human colon carcinoma cells selected with
doxorubicin. Int J Cancer 1991 Oct 21;49(4):601-7.
Seneviratne C, Goldenberg GJ. Further characterization of drug-
sensitivity and cross-resistance profiles of cloned cell
lines of Adriamycin-sensitive and -resistant P388 leukemia.
Cancer Commun 1989;1(1):21-7.
Sinha BK, Eliot HM. Etoposide-induced DNA damage in human tumor
cells: requirement for cellular activating factors. Biochim
Biophys Acta 1991 Sep 23;1097(2):111-6.
Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. DNA strand
breaks produced by etoposide VP-16 213 in sensitive and
resistant human breast tumor cells. Implications for the
mechanism of action. Cancer Res 1988;48(18):5096-100.
Sinha BK, Politi PM. Anthracyclines. Cancer Chemother Biol
Response Modif 1990;11:45-57.
Smith PJ, Morgan SA, Fox ME, Watson JV. Mitoxantrone-DNA
binding and the induction of topoisomerase II associated DNA
damage in multi-drug resistant small cell lung cancer cells.
Biochem Pharmacol 1990 Nov 1;40(9):2069-78.
Smith PJ, Morgan SA, Watson JV. Detection of multidrug
resistance and quantification of responses of human tumour
cells to cytotoxic agents using flow cytometric spectral
shift analysis of Hoechst 33,342-DNA fluorescence. Cancer
Chemother Pharmacol 1991;27(6):445-50.
Snow K, Judd W. Characterisation of adriamycin- and amsacrine-
resistant human leukaemic T cell lines. Br J Cancer 1991
Jan;63(1):17-28.
Stuart N, Houlbrook S, Kirk J, Philip P, Lien E, Harris A,
Carmichael J. Tamoxifen as an enhancer of etoposide
cytotoxicity in lung cancer: in vitro and clinical effects
[abstract]. Br J Cancer 1991;63 Suppl 13:13.
Su IJ, Chang IC, Cheng AL. Expression of growth related genes
and drug resistance genes in HTLV-I positive and HTLV-I
negative post thymic T-cell malignancies. Ann Oncol 1991;2
Suppl 2:151-5.
Sugawara I, Iwahashi T, Okamoto K, Sugimoto Y, Ekimoto H, Tsuruo
T, Ikeuchi T, Mori S. Characterization of an etoposide-
resistant human K562 cell line, K/eto. Jpn J Cancer Res
1991 Sep; 82(9):1035-43.
Sullivan DM, Latham MD, Feldhoff PW. Cross-resistance to
inhibitors of DNA topoisomerase II (topo II) and collateral
sensitivity to alkylating agents in a mitoxantrone (Mtz)-
resistant Chinese hamster ovary (CHO) cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2684.
Sullivan DM, Ross WE. Resistance to inhibitors of DNA
topoisomerases. Cancer Treat Res 1991; 57:57-99.
Sullivan DM, Webb CD, Cardwell EM, Latham MD, Lock RB.
Mechanisms of resistance to DNA topoisomerase II inhibitors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2067.
Supino R, Sala E, Binaschi M, Capranico G, Zunino F. Drug
resistance in a multidrug-resistant human small cell lung
carcinoma cell line [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2693.
Suttle DP, Bugg BY, Danks MK, Beck WT. Expression of an altered
DNA topoisomerase II (topo II) in multidrug-resistant (AT-
MDR) CEM cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1990;31:A2120.
Toffoli G, Viel A, Tumiotto L, Biscontin G, Boiocchi M.
Multidrug-resistance in human colon carcinoma cell lines
[abstract]. Anticancer Res 1990;10(5B):1406-7.
Tsuruo T, Naito M, Takamori R, Tsukahara S, Yamabe-Mitsuhashi J,
Yamazaki A, Oh-hara T, Sudo Y, Nakaike S, Yamagishi T. A
benzophenazine derivative, N-beta-dimethylaminoethyl 9-
carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-
carboxamide, as a new antitumor agent against multidrug-
resistant and sensitive tumors. Cancer Chemother Pharmacol
1990;26(2):83-7.
Van Der Zee AGJ, Hollema H, De Jong S, Boonstra H, Gouw A,
Willemse PHB, Zijlstra JG, De Vries EGE. P-glycoprotein
expression and DNA topoisomerase I and II activity in benign
tumors of the ovary and in malignant tumors of the ovary
before and after platinum cyclophosphamide chemotherapy.
Cancer Res 1991;51(21):5915-20.
Waud WR, Vasanthakumar G, Schmid SM, Knick VC, Bair KW, Laster WR
Jr, Harrison SD Jr. Characterization of an in vivo murine
P388 leukemia resistant to etoposide [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A2705.
Webb CD, Latham MD, Lock RB, Sullivan DM. Attenuated
topoisomerase II content directly correlates with a low
level of drug resistance in a Chinese hamster ovary cell
line. Cancer Res 1991; 51(24):6543-9.
Wolverton JS, Beck WT. VM-26-resistant CEM cells display
collateral sensitivity to nitrogen mustard, UV irradiation,
and 3-aminobenzamide [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1990;31: A223.
Wolverton JS, Danks MK, Schmidt CA, Beck WT. Genetic
characterization of the multidrug-resistant phenotype of
vm-26-resistant human leukemic cells. Cancer Res
1989;49(9):2422-6.
Yamazaki H, Myers CE, Eliot HM, Sinha BK. Mechanisms of
resistance against anticancer drugs in prostate cancer cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2703.
Young RC. Mechanisms to improve chemotherapy effectiveness.
Cancer 1990 Feb 1;65(3 Suppl): 815-22.
Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E,
Mayes J, Sie KL, Meltzer PS, Trent JM. HT1080/DR4: a P-
glycoprotein-negative human fibrosarcoma cell line
exhibiting resistance to topoisomerase II-reactive drugs
despite the presence of a drug-sensitive topoisomerase II.
J Natl Cancer Inst 1990 Oct 3;82(19):1553-61.
UNKNOWN MECHANISM
Adams DJ, Knick VC. MDR and non-MDR forms of cellular
resistance to 5'-nor-anhydrovinblastine (navelbine)
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2760.
Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced
cancer of the cervix: an update. Semin Oncol 1991 Feb;18(1
Suppl 3):11-24.
Alexanian R, Barlogie B, Gutterman J. Alpha-interferon
combination therapy of resistant myeloma. Am J Clin Oncol
1991 Jun;14(3): 188-92.
Allavena P, Peccatori F, Maggioni D, Pirovano P, Mantovani A.
Killing of tumor cells with pleiotropic drug resistance by
OK432-activated effector cells. Immunopharmacol
Immunotoxicol 1989;11(2-3):257-68.
Allegra CJ, Grem JL, Yeh GC, Chabner BA. Antimetabolites.
Cancer Chemother Biol Response Modif 1988;10:1-22.
Allen CN, Harpur ES, Gray TJ, Simmons NL, Hirst BH. Efflux of
bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-
dependent transport mechanism in epithelial cells. Biochem
Biophys Res Commun 1990 Oct 15;172(1):262-7.
Aquino A, Niu C, Glazer RI. Altered expression of protein
kinase C (PKC) isoforms in multidrug resistant (MDR) cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1177.
Armand JP, Guiochet N, Cappellaere P, Oliveira J, Herait P,
Thomas D, Schneider M, Mathe G. Pirarubicin in solid
tumors. EORTC phase II trials with a 3-day schedule
[abstract]. Paper presented at: 2nd International Congress
on Neo-adjuvant Chemotherapy; 1988 Feb 19-21; Paris,
[France].
Asoh K, Saburi Y, Sato S, Nogae I, Kohno K, Kuwano M.
Potentiation of some anticancer agents by dipyridamole
against drug-sensitive and drug-resistant cancer cell lines.
Jpn J Cancer Res 1989 May;80(5):475-81.
Baas F, Jongsma AP, Broxterman HJ, Arceci RJ, Housman D, Scheffer
GL, Riethorst A, van Groenigen M, Nieuwint AW, Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug
resistance precedes P-glycoprotein expression during in
vitro selection for doxorubicin resistance in a human lung
cancer cell line. Cancer Res 1990 Sep 1;50(17):5392-8.
Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VE, Bhuyan BK.
P388 leukaemia cells resistant to the anthracycline
menogaril lack multidrug resistant phenotype. Br J Cancer
1990 Sep;62(3):378-84.
Baguley BC, Finlay GJ. Relationship between the structure of
analogues of amsacrine and their degree of cross-resistance
to adriamycin-resistant P388 leukemia cells. Eur J Cancer
Clin Oncol 1988;24(2):205-10.
Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ.
Inhibition of growth of colon 38 adenocarcinoma by
vinblastine and colchicine: evidence for a vascular
mechanism. Eur J Cancer 1991;27(4):482-7.
Baird WM, Ferin M, Morgan S, Averbuch SD, Ivy SP, Cowan KH, Myers
CE. Metabolism of benzo(a)pyrene (BaP) in the human breast
adenocarcinoma cell line MCF-7 and an adriamycin resistant
subline Adr(R)MDF-7 [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A486.
Barlogie B, Alexanian R, Smallwood L, Cheson D, Dixon D, Dicke K,
Cabanillas F. Prognostic factors with high dose melphalan
for refractory multiple myeloma. Blood 1988;72(6):2015-9.
Barlogie B, Velasquez WS, Alexanian R, Cabanillas F. Etoposide,
dexamethasone, cytarabine, and cisplatin in vincristine,
doxorubicin, and dexamethasone refractory myeloma. J Clin
Oncol 1989;7(10): 1514-7.
Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS,
Suttle DPTrent JM. Pharmacological, molecular, and
cytogenetic analysis of 'atypical' multidrug resistant human
leukemic cells. Cancer Res 1987;47(20):5455-60.
Beckman RA, Mcfall PJ, Sikic BI, Smith SD. Doxorubicin and the
alkylating anthracycline 3' deamino-3'-3-cyano-4-morpholinyl
doxorubicin comparative in-vitro potency against leukemia
and bone marrow cells. J Natl Cancer Inst 1988;80(5):
361-5.
Berman E, McBride M, Clarkson B. Clinical implications of
idarubicin pharmacology [abstract]. Haematologica 1991;76
Suppl 4:8.
Best D, Baker R, Wilson R, Clark A, Capizzi R, Huber K, Sartiano
GP. Preparation and in vitro cytotoxicity of Multi-
Agent:DNA [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2429.
Bouchelouche P, Lauridsen S, Skovgaard T. Increased activity of
ATP-driven proton pumps in plasma membranes of daunorubicin-
resistant Ehrlich (EA) and P388 cell lines [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2562.
Campain JA, Padmanabhan R, Gottesman MM, Pastan I. An unusual
mechanism of resistance to VP-16 in human melanoma cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2697.
Chan HSL, Canton MD, Gallie BL. Chemosensitivity and multidrug
resistance to antineoplastic drugs in retinoblastoma cell
lines. Anticancer Res 1989; 9(2):469-74.
Chan TC. Cross resistance profiles of human ovarian carcinoma
cells selected for resistance to n-phosphonacetyl-l-
aspartate (PALA) [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:A1188.
Chauffert B, Corda C, Solary E, Bedenne L, Caillot D, Martin F.
Potential usefulness of quinine to overcome the clinical
resistance to anthracyclines. Paper presented at: European
Association for Cancer Research 10th Biennial Meeting; 1989
Sep 10-13; Galway, Ireland.
Chen HX, Guo X, Rosenthal A, Cheng YC. Development of a
dipyridamole analog, BIBW022, as a bifunctional modulator of
the MDR phenotype and nucleoside transport in human tumor
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2534.
Cole SPC, Downes HF, Slovak ML. Effect of calcium antagonists
on the chemosensitivity of two multidrug-resistant human
tumor cell lines which do not overexpress p-glycoprotein.
Br J Cancer 1989; 59(1):42-6.
Coley HM, Workman P, Twentyman PR. Retention of activity by
selected anthracyclines in a multidrug resistant human large
cell lung carcinoma line without P-glycoprotein
hyperexpression. Br J Cancer 1991;63(3):351-7. [Published
erratum appears in Br J Cancer 1991;63(6):1029].
Combination chemotherapy MOCCA in resistant and relapsing
multiple myeloma. Finnish Leukaemia Group. Eur J Haematol
1992 Jan;48(1):37-40.
Dalton WS, Cress AE, Alberts DS, Trent JM. Cytogenetic and
phenotypic analysis of a human colon carcinoma cell line
resistant to mitoxantrone. Cancer Res 1988;48(7):1882-8.
de Jong S, Holtrop M, de Vries H, de Vries EG, Mulder NH.
Increased sensitivity of an adriamycin-resistant human small
cell lung carcinoma cell line to mitochondrial inhibitors.
Biochem Biophys Res Commun 1992 Jan 31; 182(2):877-85.
De Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, De Leiji
L, Scheper RJ, Mulder NH. Resistance mechanisms in three
human small cell lung cancer cell lines established from one
patient during clinical follow-up. Cancer Res
1989;49(15):4175-8.
Dietel M, Bunge A, Heidebrecht HJ, Reymann A, Seidel A.
Resistance to the adriamycin-resistance reversing potency of
cyclosporin A in P-glycoprotein-positive friend leukemia
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2906.
Eijdems EW, Borst P, Jongsma AP, de Jong S, de Vries EG, van
Groenigen M, Versantvoort CH, Nieuwint AW, Baas F. Genetic
transfer of non-P-glycoprotein-mediated multidrug resistance
(MDR) in somatic cell fusion: dissection of a compound MDR
phenotype. Proc Natl Acad Sci U S A 1992 Apr
15;89(8):3498-502.
Eijdems EW, Borst P, van Groenigen M, Jongsma AP, Baas F.
Transfer of the non-P-glycoprotein-mediated multidrug-
resistant (MDR) phenotype to drug-sensitive human lung
cancer cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2209.
Eijdems EW, Borst P, Zaman GJ, De Haas M, Baas F. Investigation
of low-level drug resistance in non-P-glycoprotein-mediated
multidrug-resistant human lung cancer cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2714.
Fidler IJ. The biology of cancer metastasis and its challenge
for therapy. UCLA Symp Mol Cell Biol 1989;89:3-13.
Figueredo A, Arnold A, Findlay B, Goodyear M, Neville A,
Normandeau R, Jones A. Pilot study of verapamil (V) and
tamoxifen (T) added to chemotherapy of extensive small cell
lung cancer (SCLC) [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1988;7:A803.
Finlay GJ, Baguley BC, Snow K, Judd W. Multiple patterns of
resistance of human leukemia cell sublines to amsacrine
analogues. J Natl Cancer Inst 1990 Apr 18;82(8):662-7.
Frenay M, Milano G, Francois E, Khater R, Cassuto JP, Namer M.
Phase II trial of weekly low dose doxorubicin in advanced
breast cancer: clinical and pharmacokinetic results
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1988;7:A102.
Fujii H, Katsura T, Fukaura A, Ohta S, Ohmori T, Horichi N,
Kashima N, Tazawa H, Sugihara S, Mochizuki T, et al.
Establishment and characterization of a MX2-resistant human
leukemia cell line K562 [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1992;33:A2748.
Garcia-Segura LM, Ferragut JA, Ferrer-Montiel AV, Escriba PV,
Gonzalez-Ros JM. Ultrastructural alterations in plasma
membranes from drug-resistant P388 murine leukemia cells.
Biochim Biophys Acta 1990 Nov 2;1029(1):191-5.
Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Stewart VJ,
Knowles DM, Bhalla K, Ross DD, Baker MA, Lutzky J, et al.
Membrane glycoprotein changes associated with anthracycline
resistance in HL-60 cells. Cancer Chemother Pharmacol
1991;28(2):93-101.
Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Lutzky J, Remnick
RA , Baker MA, Hindenburg AA. Surface membrane
glycoprotein alterations associated with multidrug
resistance in a P-glycoprotein negative cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1989;30:506.
Gervasoni JE Jr, Warburton D, Rosado M, Krishna S, Lutzky J,
Remnick R, Baker MA, Hindenburg AA, Taub RN.
Identification of a homogeneously staining region on
chromosome 7 at position q11.2 in an anthracycline-resistant
cell line that does not overexpress the p-glycoprotein
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2013.
Gordon R, Hamilton R, Barnes S. A randomized comparison trial
of non-cross resistant combination chemotherapy vs
cyclophosphamide, adriamycin and platinol for ovarian
carcinoma, stage III suboptimal and stage IV [abstract].
Proc Annu Meet Am Soc Clin Oncol 1988;7:A512.
Grandi M, Giuliani FC. Reduced cytotoxicity of tetracyclines to
a multi-drug resistant human cell line. Biochem Pharmacol
1988;37(15):3038-41.
Greco MA, Madu S, Brattain MG. Differential response by
subclasses of colon carcinoma cells to methotrexate and
vinblastine [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A1988.
Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L,
Stewart BW. Atypical multidrug resistance in a therapy-
induced drug-resistant human leukemia cell line lalw-2
resistance to vinca alkaloids independent of p-glycoprotein.
Cancer Res 1989;49(19):5281-7.
Hamilton TC, Ozols RF, Dabrow MB. Multidrug resistance to
alkylating agents and platinum compounds: state of our
knowledge. Oncology (Williston Park) 1990 Mar;4(3):101-6;
discussion 106, 109.
Head JF, Foster LB. Demonstration of antineoplastic drug cross-
resistance in primary cultures of human tumor cells using
the adhesive tumor cell culture system [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:22.
Henderson GB. Mediation of cellular anion detoxification in
leukemic cells by unidirectional efflux pumps. Adv Enzyme
Regul 1989;29:61-72.
Hickson ID, Turley H, Gattei K, Harris AL. A non-P-
glycoprotein, 150-KD transmembrane protein associated with
multidrug resistance [abstract]. Br J Cancer 1991;63 Suppl
13:13.
Hill BT, Hosking LK, Shellard SA, Whelan RDH. Comparative
effectiveness of mitoxantrone and doxorubicin overcoming
experimentally induced drug resistance in murine and human
tumor cell lines in-vitro. Cancer Chemother Pharmacol
1989; 23(3):140-4.
Hitselberger MH, Starling JJ. Two human colon tumor cell lines
which express comparable P-glycoprotein display a five
thousand-fold difference in in vitro sensitivity to a vinca
alkaloid [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2207.
Hopwood LE, Moulder JE. Enhancement of drug resistance
following irradiation of rif-1 and scc-VII tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1238.
Horton JK, Houghton JA, Houghton PJ. Selection of primary
resistance to melphalan (L-PAM) confers a multidrug-
resistant (MDR) phenotype not reversible by verapamil
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2083.
Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ.
Modulation by verapamil of vincristine pharmacokinetics and
toxicity in mice bearing human tumor xenografts. Biochem
Pharmacol 1989;38(11):1727-36.
Huber KR, Schmidt WF, Al-Assaad B, Neuberg RW, Ettinger RS.
Human tumor cells resistant to verapamil. Biochem Biophys
Res Commun 1989; 161(3):1312-8.
Huet S, Schott B, Robert J. P-glycoprotein overexpression
cannot explain the complete doxorubicin-resistance phenotype
in rat glioblastoma cell lines. Br J Cancer 1992
Apr;65(4):538-44.
Ishikawa T, Mueller M, Kluenemann C, Schaub T, Keppler D. ATP-
dependent primary active transport of cysteinyl leukotrienes
across liver canalicular membrane. Role of the ATP-
dependent transport system for glutathione S-conjugates.
J Biol Chem 1990;265(31):19279-86.
Jensen PB, Roed H, Skovsgaard T, Friche E, Vindelv L, Hansen HH,
Spang-Thomsen M. Antitumor activity of the two
epipodophyllotoxin derivatives VP-16 and VM-26 in
preclinical systems: a comparison of in vitro and in vivo
drug evaluation. Cancer Chemother Pharmacol
1990;27(3):194-8.
Jensen PB, Vindelv L, Roed H, Demant EJ, Sehested M, Skovsgaard
T, Hansen HH. In vitro evaluation of the potential of
aclarubicin in the treatment of small cell carcinoma of the
lung (SCCL). Br J Cancer 1989 Dec;60(6):838-44.
Kadoyama C, Birrer M, Dosaka H, Lai S, Venzon D, Gazdar A.
Transfection with H-ras or c-myc proto-oncogenes results in
induction of the multidrug-resistant phenotype [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A1992.
Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, Cohen JS.
P-31 and C-13 nuclear magnetic resonance studies of 2-
deoxyglucose metabolism in sensitive and resistant breast
tumor cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30: A2213.
Kapoor R, Harker WG, Ohnuma T. Trimetrexate transprot in
multidrug resistant human leukemic cells [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2110.
Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Mechanisms
involved in the development of adriamycin resistance in
human leukemic cells. Leuk Res 1990;14(6):567-73.
Kavallaris M, Haber M, Norris MD, Pittman SM, Reed C, Stewart BW.
Phenotypic and cytogenetic analysis of atypical multidrug
resistance in human leukaemic cells selected with
methotrexate at high concentration. Cancer Lett 1990 Jun
15;51(3): 193-201.
Khokhar AR, al-Baker S, Brown T, Perez-Soler R. Chemical and
biological studies on a series of lipid-soluble (trans-
(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II)
complexes incorporated in liposomes. J Med Chem 1991 Jan;
34(1):325-9.
Kikuchi H, Nishiyama K, Sumizawa T, Furukawa T, Yoshimura A,
Akiyama SI. Verapamil potentiates the effect of adriamycin
and vincristine on human renal adenocarcinoma cells. Med J
Kagoshima Univ 1991;43(1):27-40.
Klohs W, Steinkampf R, McMichael A, Nelson J, Leopold W,
Wolverton J, Beck W. Development of resistance to the
anthrapyrazole CI-937 in L1210 cells [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2080.
Knight C, Slade DL, Harker WG. Multidrug resistance in
mitoxantrone-selected CEM leukemia cells appears to be
unrelated to P-glycoprotein expression [abstract]. Clin Res
1991;39(1):68A.
Kobayashi H, Takemura Y, Miyachi H, Ogawa T. Antitumor
activities of new platinum compounds DWA2114R NK121 and 254-
S against human leukemia cells sensitive or resistant to
cisplatin. Invest New Drugs 1991;9(4):313-20.
Kolaric K, Tomek R. Cis-platinum-based alternating non-cross-
resistant chemotherapy as a first-line treatment in
metastatic breast cancer. A phase II study. Tumori 1990 Oct
31;76(5):472-5.
Komiyama S, Matsui K, Kudoh S, Nogae I, Kuratomi Y, Saburi Y,
Asoh KI, Kohno K, Kuwano M. Establishment of tumor cell
lines from a patient with head and neck cancer and their
different sensitivities to anti-cancer agents. Cancer 1989;
63(4):675-81.
Kopf-Maier P, Kolon B. An organoid culture assay (OCA) for
determining the drug sensitivity of human tumors. Int J
Cancer 1992 Apr 22;51(1): 99-107.
Kuhl JS, Lau D, Duran G, Blume KG, Chao NJ, Sikic BI. Multiple
mechanisms of resistance to etoposide in variants of murine
p388 leukemia [abstract]. Proc Annu Meet An Assoc Cancer
Res 1991;32:362.
Kurelec B, Pivcevic B. Distinct glutathione-dependent enzyme
activities and a verapamil-sensitive binding of xenobiotics
in a fresh-water mussel anodonta-cygnea. Biochem Biophys
Res Commun 1989; 164(2):934-40.
Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson
BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. Mdr1 gene
expression in lung cancer. J Natl Cancer Inst
1989;81(15):1144-50.
Laquaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
Multidrug resistance in human neuroblastoma cells. J
Pediatr Surg 1991; 26(9):1107-12.
Leppert G, McDevitt R, Falco SC, Van Dyk TK, Ficke MB, Golin J.
Cloning by gene amplification of two loci conferring
multiple drug resistance in Saccharomyces. Genetics 1990
May;125(1):13-20.
Liberati AM, Cinieri S, Senatore MG, Portuesi MG, De Angelis V,
Di Clemente F, Schippa M, Ferrajoli A, Arzano S, Berruto P.
Phase I-II trial on natural beta interferon in
chemoresistant and relapsing multiple myeloma.
Haematologica 1990 Sep-Oct;75(5):436-42.
Lu K, Wang A, Jeffe N, Anzai T, Van Eys J. Molecular biology of
human osteosarcoma cell lines [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A1727.
Luk CK, Tannock IF. Tumour response to chemotherapy in animals
that have been treated with the same drugs prior to tumour
implantation: A model for studying host effects on apparent
drug resistance. Br J Cancer 1988;58(2):133-8.
Lyttelton M, Ganeshaguru K, Chiu E, Hoffbrand AV, Mehta AB.
Absence of mdr1 gene amplification in patients with
resistant hematological malignancies [abstract]. Invest New
Drugs 1989;7(4):439.
Marchesini R, Gritti A, Colombo A, Dasdia T, Sichirollo AE.
Effectiveness of photodynamic therapy after photofrin II
sensitization in a multidrug resistant human breast
carcinoma line in vitro [abstract]. Paper presented at: 3rd
Biennial Meeting of the International Photodynamic
Association; 1990 Jul 17-21; Buffalo, NY.
Marks PA, Michaeli J, Jackson J, Richon VM, Rifkind RA. Induced
differentiation of murine erythroleukemia cells (MELC) by
polar compounds: marked increased sensitivity of vincristine
resistant MELC. Prog Clin Biol Res 1989;316B:171-81.
Marquardt D, Center MS. Drug transport mechanisms in HL60 cells
isolated for resistance to adriamycin: evidence for nuclear
drug accumulation and redistribution in resistant cells.
Cancer Res 1992 Jun 1;52(11):3157-63.
Martynenko LD, Vladimirova EV, Loverdo RG, Chertishcheva EV.
[Role of microbiological surveillance in the choice of
antibacterial therapy for intestinal Klebsiella infection in
infants]. Antibiot Khimioter 1990 Sep;35(9):45-7. (Rus).
Matsushima Y, Baba T. The in-vivo effect of cyclosporine A on
macrophages. J Exp Pathol 1990;5(2):39-48.
Mattern J, Bak M, Volm M. Intrinsic and acquired multidrug
resistance in human lung carcinomas grown in nude mice
[abstract]. Anticancer Res 1988;8(5 Pt B):1090.
Mazumder A, Twomey P, Charak B. Novel approach to purging of
resistant tumor cells by photofrin (pfrn) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1990;9:A41.
Mazzoni A, Canti G. Reversal of doxorubicin and cisplatin
resistance in vivo in murine leukemias by the calcium
antagonist RO 11-2933. Sel Cancer Ther 1990
Winter;6(4):167-76.
Mazzoni A, Trave F, Russo P, Nicolin A, Rustum YM. Generation
and characterization of a low-degree drug-resistant human
tumor cell line. Oncology 1990;47(6):488-94.
McGown AT, Murphy DJ, Crowther D, Fox BW. Effect of verapamil
on daunorubicin accumulation in normal lymphocytes isolated
from patients undergoing chemotherapy for epithelial ovarian
cancer [abstract]. Br J Cancer 1990;62(3):514.
Mcgrath T, Center MS. Mechanisms of multidrug resistance in
HL60 cells evidence that a surface membrane protein distinct
from P-glycoprotein contributes to reduced cellular
accumulation of drug. Cancer Res 1988;48(14):3959-63.
McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS.
Mechanisms of multidrug resistance in HL60 cells. Analysis
of resistance associated membrane proteins and levels of mdr
gene expression. Biochem Pharmacol 1989 Oct 15;
38(20):3611-9.
Mcgrath T, Marquardt D, Center MS. Multiple mechanisms of
adriamycin resistance in the human leukemia cell line ccrf-
cem. Biochem Pharmacol 1989;38(3):497-502.
Meijer C, de Vries EG, Timmer-Bosscha H, Scheper RJ, de Ley L,
Berendsen HH, Mulder NH. Resistance mechanisms in three
human small cell lung cancer cell lines established from one
patient during clinical follow-up [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1221.
Michaeli J, Lebedev YB, Richon VM, Chen ZX, Marks PA, Rifkind RA.
Conversion of differentiation inducer resistance to
differentiation inducer sensitivity in erythroleukemia
cells. Mol Cell Biol 1990 Jul;10(7):3535-40.
Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects
of the high- and low-molecular-weight anticancer agents on
multidrug-resistant Chinese hamster ovary cells in vitro.
Cancer Res 1990 Mar 1;50(5):1571-5.
Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, al-Katib A. A
human B-cell lymphoma line with a de novo multidrug
resistance phenotype. Cancer 1992 Mar 15;69(6):1468-74.
Morgan SA, Watson JV, Twentyman PR, Smith PJ. Reduced nuclear
binding of a DNA minor groove ligand (Hoechst 33342) and its
impact on cytotoxicity in drug resistant murine cell lines.
Br J Cancer 1990 Dec;62(6):959-65.
Moscow JA, Cowan KH. Multidrug resistance. Cancer Chemother
Biol Response Modif 1990;11: 97-114.
Muggia FM, Norris K Jr. Drug resistance: implications for
treatment strategies. Pezcoller Found Symp 1990;1:331-6.
Nakagawa M, Dixon KH, Gilbert L, Goldsmith ME, Cowan KH.
Characterization of mitoxantrone resistant human breast
cancer cell line [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32: A2204.
Ning SC, Hahn GM. Cytotoxicity of lonidamine alone and in
combination with other drugs against murine RIF-1 and human
HT1080 cells in vitro. Cancer Res 1990 Dec
15;50(24):7867-70.
Nishio K, Sugimoto Y, Nakagawa K, Niimi S, Fujiwara Y, Bungo M,
Kasahara K, Fujiki H, Saijo N. Cross-resistance to tumour
promoters in human cancer cell lines resistant to adriamycin
or cisplatin. Br J Cancer 1990 Sep;62(3):415-9.
Oguro M, Seki Y, Okada K, Andoh T. Collateral drug sensitivity
induced in CPT-11 (a novel derivative of camptothecin)-
resistant cell lines. Biomed Pharmacother
1990;44(4):209-16.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents KT6149, MX 2, SM5887, menogaril, and
liblomycin using cisplatin or adriamycin resistant human
cancer cell lines. Cancer Res 1989;49(15): 4098-102.
Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi
S, Horichi N, Fukuda M, Saijo N. In vitro evaluation of the
new anticancer agents, KT6149, MX-2, SM5887, menogaril, and
NK313 using CDDP- or ADM-resistant human cancer cell lines
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1989;8:A908.
Onoda JM, Nelson KK, Taylor JD, Honn KV. In-vivo
characterization of combination antitumor chemotherapy with
calcium channel blockers and cis diamminedichloroplatinum-
II. Cancer Res 1989; 49(11):2844-50.
Osmak M. Repeated irradiations of gamma rays change the
sensitivity of human and animal cells to cytotoxic drugs.
Paper presented at: Symposium on Mechanisms of Drug and
Radiation Resistance of Tumor Cells; 1989 Jun 28-30;
Villejuif, France.
Parce JW, Owicki JC, Kercso KM. Biosensors for directly
measuring cell affecting agents. Ann Biol Clin (Paris)
1990;48(9):639-41.
Phillips JK. Use of the MTT assay to assess drug resistance
patterns in acute myeloid leukemia (AML). Paper presented
at: British Association for Cancer Research/Association for
Cancer Physicians/ Leukaemia Research Fund Joint Winter
Meeting on Leukaemia and Lymphomas; 1989 Dec 11-12; London,
UK.
Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hahlen
K, Veerman AJ. Different types of non-P-glycoprotein
mediated multiple drug resistance in children with relapsed
acute lymphoblastic leukaemia. Br J Cancer 1992 May;
65(5):691-7.
Pincus R, Goldman ID. Decreased tight binding of mitoxantrone
in P388 leukemia cells with multiple drug resistance
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1185.
Pinedo HM, van Groeningen CJ, van Kalken CK. Cellular
pharmacology and drug resistance in breast cancer. Paper
presented at: Biology and therapy of breast cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Politi PM, Arnold ST, Felsted RL, Sinha BK. P-glycoprotein-
independent mechanism of resistance to VP-16 in multidrug-
resistant tumor cell lines: pharmacokinetic and
photoaffinity labeling studies. Mol Pharmacol 1990
Jun;37(6):790-6.
Politi PM, Sinha BK. Role of differential drug uptake efflux
and binding of etoposide in sensitive and resistant human
tumor cell lines implications for the mechanisms of drug
resistance. Mol Pharmacol 1989;35(3):271-8.
Pratesi G, Capranico G, Binaschi M, De Isabella P, Pilotti S,
Supino R, Zunino F. Relationships among tumor
responsiveness, cell sensitivity, doxorubicin cellular
pharmacokinetics and drug-induced DNA alterations in two
human small-cell lung cancer xenografts. Int J Cancer 1990
Oct 15; 46(4):669-74.
Priebe TS, Atkinson EN, Pan BF, Nelson JA. Intrinsic resistance
to anticancer agents in the murine pancreatic adenocarcinoma
PANC02. Cancer Chemother Pharmacol 1992;29(6):485-9.
Raghu G, Pierre-Jerome M, Burkhead D, Noble CC, Bauer KD, Winter
JN. Isolation and characterization of a drug-resistant
subclone of the human leukemia cell line HL-60 [abstract].
Clin Res 1990;38(3):843A.
Ramu N, Ramu A, Cole DE, Balis FM, Poplack DG, Pollard HB.
Mechanism of acquired resistance to methotrexate in p388
murine leukemia cells and in their doxorubicin-resistant
subline. Isr J Med Sci 1988;24(9-10):477-82.
Remnick RA, Gervasoni JE Jr, Hindenburg AA, Lutzky J, Krishna S,
Rosado M, Taub RN. The subcellular distribution of
daunorubicin in drug-resistant cell lines that do and do not
overexpress the P-glycoprotein [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2032.
Reymann A, Woermann C. In-vitro study on physiological membrane
transport and diffusional properties in multidrug-resistant
mouse Friend erythroleukemia cells. Naunyn-Schmiedebergs
Arch Pharmacol 1989;339 Suppl:R42.
Rosenberg MC, Colvin OM, Griffith OW, Bigner SH, Elion GB, Horton
JK, Lilley E, Bigner DD, Friedman HS. Establishment of a
melphalan-resistant rhabdomyosarcoma xenograft with cross-
resistance to vincristine and enhanced sensitivity following
buthionine sulfoximine-mediated glutathione depletion.
Cancer Res 1989 Dec 15; 49(24 Pt 1):6917-22.
Ross DD. Cellular and pharmacologic aspects of drug resistance
in acute myeloid leukemia. Curr Opin Oncol 1991
Feb;3(1):21-9.
Salmon JM, Lahmy S, Viallet P. Fluorescence image analysis for
detection of multidrug resistant cells [abstract].
Anticancer Res 1990;10(5 Pt B):1402-3.
Sampson KE, Abraham I. A novel 170-KD protein kinase activity
in multidrug-resistant cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33: A2795.
Samuels B, Weichselbaum R, Tapp S, Safa A, Cohen M, Cowan J,
Beckett M. Clinical inherent doxorubicin resistance in
sarcoma not associated with multidrug resistance [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1244.
Scheck AC, Heston WD, Shapiro JR. Expression of platelet-
derived growth factor, ornithine decarboxylase, and the
multi-drug resistance gene locus in bcnu-resistant human
glioma cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A254.
Schmidt WF, Huber KR, Ettinger RS, Neuberg RW. Verapamil-
resistant human tumor cell lines [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2098.
Sebolt J, Havlick M, Hamelehle K, Nelson J, Leopold W, Jackson R.
Activity of the pyrazoloacridines against multidrug-
resistant tumor cells. Cancer Chemother Pharmacol
1989;24(4):219-24.
Selassie CD, Hansch C, Khwaja TA. Structure activity
relationships of multidrug resistance. In: Curtius H-C,
Ghisla S, Blau N, editors. Chemistry and biology of
pteridines, 1989: pteridines and folic acid derivatives.
9th International Symposium on Pteridines and Folic Acid
Derivatives Chemical, Biological, and Clinical Aspects;
1989 Sep 3-8; Zurich, Switzerland. Berlin: Walter de
Gruyter and Co.; 1990. p. 1217-20.
Shen DW, Mao WW, Pastan I, Gottesman MM. The intrinsic drug
resistance in human hepatocellular carcinoma-derived cell
lines [abstract]. In Vitro Cell Dev Biol 1990;26(3 Pt
2):64a.
Shimm DS, Olson S, Hill AB. Radiation resistance in a multidrug
resistant human T-cell leukemia line. Int J Radiat Oncol
Biol Phys 1988;15(4):931-6.
Slapak CA, Fracasso PM, LeCerf JM, Levy SB. Active efflux of
vincristine without P-glycoprotein in multidrug-resistant
leukemia cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1992;33: A2732.
Slapak CA, Levy SB. Frequency and phenotype of early
adriamycin-resistant mammalian leukemia cells [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2019.
Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and
biological evidence for differing mechanisms of doxorubicin
resistance in two human tumor cell lines. Cancer Res 1988;
48(10):2793-7.
Smith PJ, Sykes HR, Fox ME, Furlong IJ. Subcellular
distribution of the anticancer drug mitoxantrone in human
and drug-resistant murine cells analyzed by flow cytometry
and confocal microscopy and its relationship to the
induction of DNA damage. Cancer Res 1992 Jul
15;52(14):4000-8.
Sognier MA, Zhang Y, Sweet KM, Eberle RL, Belli JA. Further
selection of multidrug resistant LZ-8 cells produces
additional resistance mechanisms [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33:A2746.
Speeg KV, Mcguire WL. Use of noncytotoxic transport probes in a
model of multiple drug resistance [abstract]. Clin Res
1988;36(3):500a.
Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski
RA, Strnad J, Rittmann-Grauer L, DeHerdt SV, Bumol TF, et
al. In vivo selection of human tumor cells resistant to
monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer
Res 1990 Dec 1; 50(23):7634-40.
Stewart BW, Brian MJ, Haber M, Norris MD, White L. Therapy-
induced resistance to both methotrexate and some natural
product drugs in a human leukemia line (LALW-2) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:A1237.
Supino R, Mariani M, Capranico G, Colombo A, Parmiani G.
Doxorubicin cellular pharmacokinetics and DNA breakage in a
multi-drug resistant B16 melanoma cell line. Br J Cancer
1988;57(2):142-6.
Suzuki H. [Antitumor drugs and potentiators aiming
circumvention of drug resistance]. Gan To Kagaku Ryoho 1990
Mar;17(3 Pt 1):335-41. (Jpn).
Tapiero H, Talha S, Trincal G, Fourcade A, Lampidis TJ.
Relationship of membrane potential to acquired and intrinsic
multiple drug resistance [abstract]. Anticancer Res
1988;8(5 Pt B):1088.
Taylor CW, Dalton WS. Multiple mechanisms of drug resistance in
MCF-7 human breast cancer cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2109.
Terashima Y, Hattori T, Kanamori S, Akimoto M. [The analysis of
the difference in anti-cancer drug sensitivity of 3 clones
separated from bladder cancer cell line]. Nippon Hinyokika
Gakkai Zasshi 1989 Dec;80(12):1720-7. (Jpn).
Teyssier JR, Benard J, Ferre D, Da Silva J, Renaud L. Drug-
related chromosomal changes in chemoresistant human ovarian
carcinoma cells. Cancer Genet Cytogenet 1989;39(1):35-44.
Trent JM, Meltzer PS, Slovak ML, Gill AB, Dalton WS, Beck WT,
Coles SPC. Cytogenetic and molecular biologic alterations
associated with anthracycline resistance. In: Woolley PV
3rd, Tew KD, editors. Mechanisms of drug resistance in
neoplastic cells; 1986 Oct 15-16; Washington, DC. San Diego
(CA): Academic Press, Inc.; 1988. p. 259-76. (Bristol-
Myers cancer symposia; 9).
van Kalken CK, Pinedo HM, Giaccone G. Multidrug resistance from
the clinical point of view. Eur J Cancer
1991;27(11):1481-6.
Vassal G, Slocum H, Rustum Y. Enhancement of arabinosylcytosine
metabolism and cytotoxicity by dipyridamole in sensitive and
multidrug-resistant P388 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2284.
Versantvoort CH, Broxterman HJ, Feller N, Dekker H, Kuiper CM,
Lankelma J. Probing daunorubicin accumulation defects in
non-P-glycoprotein expressing multidrug-resistant cell lines
using digitonin. Int J Cancer 1992 Apr 1;50(6):906-11.
Volm M, Bak M, Mattern J. Intrinsic multidrug resistance in
human lung carcinomas grown in nude mice. Strahlenther
Onkol 1989;165(7):524-6.
Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Mx-2 a
morpholinoanthracycline as a new antitumor agent against
drug-sensitive and multidrug-resistant human and murine
tumor cells. Cancer Res 1988; 48(23):6653-7.
Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple
CG Jr, Harrison SD Jr, Griswold DP Jr. Antitumor activity
of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-
b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate
(NSC 370147) against selected tumor systems in culture and
in mice. Cancer Res 1990 Jun 1; 50(11):3239-44.
Waxman S, Wang S, Tan I, Scher W. Combination cytotoxic-
differentiation therapy with 5-fluorouracil, leucovorin and
hexamethylene bisacetamide [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2551.
Weber JM, Sircar S, Horvath J, Dion P. Non P-glycoprotein
mediated multidrug resistance in detransformed rat cells
selected for resistance to methylglyoxal
bis(guanylhydrazone). Cancer Res 1989;49(21):5779-83.
White L, Haber M, Brian MJ, Norris MD, Trickett A, Sosula L,
Tiley C, Stewart BW. Therapy-induced drug resistance in a
human leukemia line lalw-2 a clinically relevant model.
Cancer 1989;63(11): 2103-10.
Wilkoff LJ, Dulmadge EA, Holland LE, McCurdy JB, Donahue JP.
Differential sensitivity to plant alkaloids of cultured
human colon carcinoma and human lung adenocarcinoma cells
exhibiting resistance to etoposide [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1163.
Wright SC, Tam AW, Kumar P. Selection of tumor cell variants
for resistance to tumor necrosis factor also induces a form
of pleiotropic drug resistance. Cancer Immunol Immunother
1992;34(6):399-406.
Wu CJ, Feun L, Lampidis TJ, Savaraj N. Induction of multidrug
resistance (MDR) in cisplatin-resistant cells and induction
of cisplatin resistance in MDR cells [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1992;33:A2730.
Yamazaki H, Myers CE, Eliot HM, Sinha BK. Mechanisms of
resistance against anticancer drugs in prostate cancer cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2703.
Yang LY, Trujillo JM. Different mechanisms for multidrug
resistance in two models of adriamycin-resistant subclones
derived from a human colon carcinoma cell line [abstract].
Proc Annu Meet Am Assoc Cancer Res 1989;30:A2053.
Yang LY, Trujillo JM, Su YZ. Further characterization of two
distinct adriamycin-resistant sublines from LoVo human colon
carcinoma cells. Anticancer Res 1992 Mar-Apr;12(2):473-9.
Zamora JM, Beck WT. Chloroquine enhancement of anticancer drug
cytotoxicity in multiple drug resistant human leukemic
cells. Biochem Pharmacol 1990;35(23):4303-10.
OTHER
Adam S, Kaufmann F. A new class of potent antiproliferative
glycolipids. Chem Phys Lipids 1991;59(3):255-62.
Ades EW, Hooper C, Pruckler JM. Cytoreductive therapy of
multidrug-resistant hepatocellular carcinoma: negative
regulation of growth using combination differentiation
therapy. Pathobiology 1992;60(1):45-8.
Alaoui-Jamali MA, Panasci L, Schecter RL, Lehnert S, Batist G.
Atypical cross-resistance and multiple mechanisms in
melphalan-resistant rat mammary carcinoma cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2130.
Alloing G, Trombe MC, Claverys JP. Cloning of the amia locus of
streptococcus-pneumoniae and identification of its
functional limits. Gene 1989; 76(2):363-8.
Alton PA, Fry A, Hickson ID, Harris AL. Use of the MTT assay in
acute myeloid leukemia to assess mechanisms of resistance
[abstract]. Br J Cancer 1991;63 Suppl 13:14.
Ames GFL. Bacterial periplasmic permeases as model systems for
the superfamily of traffic ATPases which includes MDR and
CFTR [abstract]. FASEB J 1998;6(1):A127.
Aquino A, Johnson-Thompson M, Glazer RI. Enhanced Ca2(+)-
dependent proteolysis associated with Adriamycin-resistant
HL-60 cells. Cancer Commun 1990;2(7):243-7.
Arita N, Hayakawa T. [Chemotherapy of malignant brain tumors--
scientific basis for combination chemotherapy]. Gan To
Kagaku Ryoho 1991 Feb; 18(2):180-7. (Jpn).
Arvelo F, Le Chevalier T, Jacrot M, Brambilla C, Poupon MF.
Drug response of small cell lung carcinomas implanted into
nude mice. Correlation with overexpression of growth-related
genes and multidrug-resistance gene (MDR1). Paper presented
at: 3rd International Congress on the Neo-adjuvant
Chemotherapy; 1991 Feb 6-9; Paris, France. (Eng, Fre).
Ashikari R, Mittelman A, Puccio C, Davidian M, Rojas-Corona R,
Zachrau R, Ahmed T, Clayton E, Arlin Z. Analysis for the
presence of erb B2, Ki67, P-glycoprotein estrogen (ER) and
progesterone (PR) receptor in tissue samples from 45
patients (pts) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1991;10:A86.
Beck WT. Mechanisms of multidrug resistance in human tumor
cells. The roles of P-glycoprotein, DNA topoisomerase II,
and other factors. Cancer Treat Rev 1990 Dec;17 Suppl
A:11-20.
Belli JA. Interaction between radiation and drug damage in
mammalian cells. Radiat Res 1989; 119(1):88-100.
Berkower C, Michaelis S. Mutational analysis of the yeast A-
factor transporter STE6, a member of the ATP binding
cassette (ABC) protein superfamily. EMBO J 1991
Dec;10(12):3777-85.
Beverley SM, Callahan HL. Amplification-prone cassettes provide
a reservoir of multiple drug resistance genes in Leishmania
[abstract]. FASEB J 1992;6(1):A139.
Bhushan A, Katzman PJ, Tritton TR. Involvement of phospholipase
A2 (PLA2) in multidrug-resistant mouse sarcoma S180 cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2675.
Biedler JL, Meyers MB, Spengler BA. Cellular concomitants of
multidrug resistance. In: Woolley PV 3d, Tew KD, editors.
Mechanisms of drug resistance in neoplastic cells; 1986 Oct
15-16; Washington, DC. San Diego (CA): Academic Press,
Inc.; 1988. p. 41-68. (Bristol-Myers cancer symposia; 9).
Bonadonna G, Santoro A. Current issues in the management of
advanced Hodgkin's disease. Blood Rev 1990 Mar;4(1):69-73.
Borellini F, Aquino A, Josephs SF, Glazer RI. Increased
expression and DNA-binding activity of transcription factor
Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol Cell
Biol 1990 Oct; 10(10):5541-7.
Borst P. Genetic mechanisms of drug resistance. A review. Acta
Oncol 1991;30(1):87-105.
Bose R, Lam HYP. Membrane transport changes in an adriamycin-
resistant murine leukemia cell line and in its sensitive
parental cell line. Cancer Chemother Pharmacol
1988;21(1):14-8.
Burt RK, Thorgeirsson SS. Coinduction of MDR-1 multidrug-
resistance and cytochrome P-450 genes in rat liver by
xenobiotics. J Natl Cancer Inst 1988; 80(17):1383-6.
Buscher HP. Defective drug uptake contributing to multidrug
resistance in hepatoma cells can be evaluated in vitro.
Klin Wochenschr 1990 May 4; 68(9):443-6.
Campling BG, Pym J, Baker HM, Cole SP, Lam YM. Chemosensitivity
testing of small cell lung cancer using the MTT assay. Br J
Cancer 1991 Jan;63(1): 75-83.
Cancer chemotherapy and biological response modifiers. Annual 10.
Cancer Chemother Biol Response Modif 1988;10:1-594.
Cancer chemotherapy: concepts, clinical investigations and
therapeutic advances. Cancer Treat Res 1989; 42:1-238.
Cantwell BMJ, Bozzino JM, Corris P, Harris AL. The multidrug
resistant phenotype in clinical practice evaluation of cross
resistance to ifosfamide and mesna after VP-16-213
doxorubicin and vincristine VPAV for small cell lung cancer.
Eur J Cancer Clin Oncol 1988;24(2):123-30.
Casals D, Cordon-Cardo C. [Multiple drug resistance. Biological
and clinica implications]. Med Clin (Barc) 1989 Jul
1;93(5):181-5. (Spa).
Chabner BA, Fojo T, Bates S, Wilson WH. Drug-resistance
considerations in neoadjuvant chemotherapy. Paper presented
at: 3rd International Congress on the Neo-adjuvant
Chemotherapy; 1991 Feb 6-9; Paris, France. (Eng, Fre).
Chabner BA, Wilson W. Reversal of multidrug resistance
[editorial]. J Clin Oncol 1991 Jan; 9(1):4-6.
Chaudhuri MM, Tonin PN, Lewis WH, Srinivasan PR. The gene for a
novel protein, a member of the protein disulphide
isomerase/form I phosphoinositide-specific phospholipase C
family, is amplified in hydroxyurea-resistant cells.
Biochem J 1992 Feb;281(3):645-50.
Chen G, Zeller WJ. In vitro investigations on induction and
reversal of cisplatin resistance in a rat ovarian tumor cell
line. J Cancer Res Clin Oncol 1990;116(5):443-7.
Chen YN, Mickley LA, Hwang JL, Fojo AT. A novel resistance-
related membrane protein is overexpressed in an adriamycin-
resistant MCF-7 cell line [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2078.
Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT.
Characterization of adriamycin-resistant human breast cancer
cells which display overexpression of a novel resistance-
related membrane protein. J Biol Chem 1990 Jun 15;
265(17):10073-80.
Chitnis MP. Drug resistance in cancer. Paper presented at: 5th
Biennial Conference of the Indian Association of Cancer
Chemotherapists; 1989 Feb 17-19; Bombay, India.
Chitnis MP, Viladkar AB, Juvekar AS. Inhibition of DNA
biosynthesis by vincristine and pentoxifylline in murine
P388 leukemia cells resistant to doxorubicin. Neoplasma
1990;37(6):619-26.
Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC,
Allegra CJ. Induction of thymidylate synthase associated
with multidrug resistance in human breast and colon cancer
cell lines. Mol Pharmacol 1991 Feb;39(2):136-43.
Chung YJ, Steen MT, Hansen JN. The subtilin gene of Bacillus
subtilis ATCC 6633 is encoded in an operon that contains a
homolog of the hemolysin B transport protein. J Bacteriol
1992 Feb;174(4): 1417-22.
Cianfriglia M, Cenciarelli C, Tombesi M, Barca S, Mariani M,
Morrone S, Santoni A, Samoggia P, Alessio M, Malavasi F.
Murine monoclonal antibody recognizing a 90-kDa cell-surface
determinant selectively lost by multi-drug-resistant
variants of CEM cells. Int J Cancer 1990 Jan 15;
45(1):95-103.
Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL.
Response of human breast cancer cells to heat shock and
chemotherapeutic drugs. Cancer Res 1992 Jul
1;52(13):3648-54.
Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG. Elevated
expression of annexin II (lipocortin II, p36) in a multidrug
resistant small cell lung cancer cell line. Br J Cancer
1992 Apr;65(4):498-502.
D'Incalci M, Broxterman HJ, van Kalken CK. AACR special
conference in cancer research. Membrane transport in
multidrug resistance, development, and disease. American
Association for Cancer Research. Ann Oncol 1991
Oct;2(9):635-9.
Dalton WS. Mechanisms of drug resistance in breast cancer.
Semin Oncol 1990 Aug;17(4 Suppl 7): 37-9.
Damiani D, Michelutti A, Michieli M, Geromin A, Raspadori D,
Giacca M, Mallardi F, Baccarani M. [Multidrug resistance
in lymphoproliferative syndromes]. Haematologica 1991
Jun;76 Suppl 3:162-4. (Ita).
De Isabella P, Capranico G, Castelli C, Zunino F. Molecular
basis of multifactorial drug resistance in P388 doxorubicin-
resistant cells [abstract]. Invest New Drugs 1989;7(4):440.
Dietel M. What's new in cytostatic drug resistance and
pathology. Pathol Res Pract 1991 Sep;187(7): 892-905.
Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle
formation due to acquired mitoxantrone resistance in human
gastric carcinoma cell line EPG85-257. Cancer Res 1990 Sep
15;50(18): 6100-6.
Druilhe P, Brasseur P. Multi-chimio-resistance du paludisme en
Afrique. I. Donnees epidemiologiques [Multiresistant
malaria in Africa. I. Epidemiologic data]. Sem Hop
1992;68(3):54-9. (Fre).
Druilhe P, Brasseur P. Multi-chimio-resistance du paludisme en
afrique. II. Consequences therapeutiques et attitude
pratique [Multiresistant malaria in Africa. II. Therapeutic
implications and practical approach]. Sem Hop
1992;68(4):90-5. (Fre).
Engelholm SA, Rasmussen DL, Spang-Thomsen M. Human small cell
lung cancer (SCCL) in model systems for investigation of
drug resistance [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1989;30:A2026.
Fairchild CR, Cowan KH. Keynote address: Multidrug resistance:
a pleiotropic response to cytotoxic drugs. Int J Radiat
Oncol Biol Phys 1991 Feb;20(2):361-7.
Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. Multidrug
resistance in cells transfected with human genes encoding a
variant P-glycoprotein and glutathione S-transferase-pi.
Mol Pharmacol 1990 Jun;37(6):801-9.
Fan D, Fidler IJ, Ward NE, Seid C, Earnest LE, Housey GM, O'Brian
CA. Stable expression of a cDNA encoding rat brain protein
kinase C-beta I confers a multidrug-resistance (MDR)
phenotype on rat fibroblasts [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1992;33:A2724.
Ferguson PJ. The role of gene amplification in clinical
resistance to chemotherapy: a review. J Otolaryngol 1991
Apr;20(2):130-6.
Foote SJ, Thompson JK, Marshall V, Cowman AF, Biggs BA, Brown GV,
Kemp DJ. The multidrug resistance gene of Plasmodium-
falciparum. Does it mediate chloroquine resistance? In:
Agabian N, Cerami A, editors. Parasites: molecular biology,
drugs and vaccine design. UCLA Symposia on Molecular and
Cellular Biology New Series, vol. 130; 1989 Apr 3-10;
Keystone, CO. New York: Wiley-Liss; 1990. p. 325-34.
Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD,
Saijo N. Determinants of drug response in a cisplatin
resistant human lung cancer cell line. Jpn J Cancer Res
1990;81(5): 527-35.
Futscher BW, Campbell K, Dalton WS. Collateral sensitivity to
nitrosoureas in multidrug-resistant cells selected with
verapamil [abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2793.
Garcia-Segura LM, Ferragut JA, Ferrer-Montiel AV, Escriba PV,
Gonzalez-Ros JM. Ultrastructural alterations in plasma
membranes from drug-resistant P388 murine leukemia cells.
Biochim Biophys Acta 1990 Nov 2;1029(1):191-5.
Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D,
Wainberg MA, Hiscott J, Bramson J, Panasci L. Increased
DNA synthesis and repair-enzyme expression in lymphocytes
from patients with chronic lymphocytic leukemia resistant to
nitrogen mustards. J Natl Cancer Inst 1991 Apr 17;
83(8):557-64.
Gervasoni JE Jr, Fields SZ, Krishna S, Baker MA, Rosado M,
Thuraisamy K, Hindenburg AA, Taub RN. Subcellular
distribution of daunorubicin in P-glycoprotein-positive
and -negative drug-resistant cell lines using laser-assisted
confocal microscopy. Cancer Res 1991 Sep 15;51(18):4955-63.
Gessner T, Vaughan LA, Beehler BC, Bartels CJ, Baker RM.
Elevated pentose cycle and glucuronyltransferase in
daunorubicin-resistant P388 cells. Cancer Res 1990 Jul
1;50(13):3921-7.
Giaccone G, Fridman R, Kanemoto T, Martin GR, Kurita Y, Linnoila
RI, Jensen S, Mulshine J, Gazdar AF. In vitro interaction
with laminin can result in morphological alterations and
increased drug resistance of small cell lung cancer cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A202.
Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors.
Eur J Gynaecol Oncol 1991;12(5): 359-73.
Ginsburg H. Enhancement of the antimalarial effect of
chloroquine on drug-resistant parasite strains--a critical
examination of the reversal of multidrug resistance. Exp
Parasitol 1991 Aug;73(2):227-32.
Ginsburg H, Krugliak M. Quinoline-containing antimalarials--
mode of action, drug resistance and its reversal. An update
with unresolved puzzles. Biochem Pharmacol 1992 Jan
9;43(1):63-70.
Ginsburg H, Stein WD. Kinetic modelling of chloroquine uptake
by malaria-infected erythrocytes. Assessment of the factors
that may determine drug resistance. Biochem Pharmacol 1991
May 15; 41(10):1463-70.
Goldie JH. Genetic factors in chemotherapy resistance. Paper
presented at: Biology and therapy of breast cancer. Joint
NCI-IST Symposium/3rd IST International Symposium; 1989 Sep
25-27; Genoa, Italy.
Goldie JH, Coldman AJ. The somatic mutation theroy of drug
resistance: the 'Goldie-Coldman' hypothesis revisited.
Cancer Princ Pract Oncol Updates 1989; 3(5):1-12.
Gottesman MM, Pastan I, Akiyama SI, Foho A. T.; Shen DW, Ueda K,
Clark DP, Cardarelli CO, Richert ND, et al. Expression,
amplification, and transfer of DNA sequences associated with
multidrug resistance. In: Woolley PV 3d, Tew KD, editors.
Mechanisms of drug resistance in neoplastic cells; 1986 Oct
15-16; Washington, DC. San Diego (CA): Academic Press,
Inc.; 1988. p. 243-57. (Bristol-Meyers cancer symposia;
9).
Gottesman MM, Pastan I. The multidrug resistance MDR1 gene as a
selectable marker in gene therapy. In: Cohen-Haguenauer O,
Boiron M, editors. Transfert de genes chez l'homme [Human
gene transfer]. International Workshop; 1991 Apr 11-13;
Gouvieux-Chantilly, France. Paris: Editions INSERM; 1991.
p. 185-92. (Colloque INSERM; 219).
Gros P, Shustik C. Multidrug resistance: a novel class of
membrane-associated transport proteins is identified.
Cancer Invest 1991;9(5):563-9.
Gutheil JC, Wong R, Needleman SW, Melera PW. The ras oncogene
imparts a specific multidrug resistance phenotype in NIH-3T3
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32: A2099.
Hamada H, Okochi E, Oh-Hara T, Tsuruo T. Purification of the M-
R 22000 calcium-binding protein sorcin associated with
multidrug resistance and its detection with monoclonal
antibodies. Cancer Res 1988;48(11):3173-8.
Hamada H, Okochi E, Watanabe M, Oh Hara T, Sugimoto Y, Kawabata
H, Tsuruo T. M(r) 85,000 membrane protein specifically
expressed in adriamycin resistant human tumor cells. Cancer
Res 1988;48(24):7082-7.
Hamada H, Tsuruo T. [Expression and function of proteins
associated with multidrug resistance]. Gan To Kagaku Ryoho
1989 Mar;16(3 Pt 2):585-91. (Jpn).
Hantel A, Ayala S. Mechanisms contributing to melphalan (M)
resistance (MR) in human colon cancer cell lines (HCCCL)
selected for MR [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2127.
Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug
resistance in mitoxantrone-selected hl-60 leukemia cells in
the absence of p-glycoprotein overexpression. Cancer Res
1989; 49(16):4542-9.
Harris AL. Mechanisms of anticancer drug resistance. Dev Oncol
1990;58:107-15.
Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Busch R, Modest
EJ, Noseda A, Rastetter J, Vogler WR, Berdel WE. Cross-
resistance pattern of cell lines selected for resistance
towards different cytotoxic drugs to membrane-toxic
phospholipids in vitro. Cancer Chemother Pharmacol
1990;26(6): 437-43.
Hindenburg AA, Gervasoni JE Jr, Krishna S, Stewart VJ, Rosado M,
Lutzky J, Bhalla K, Baker MA, Taub RN. Intracellular
distribution and pharmacokinetics of daunorubicin in
anthracycline-sensitive and resistant hl-60 cells. Cancer
Res 1989;49(16):4607-14.
Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman
P, Harris AL, Hickson ID. Decreased NADPH:cytochrome P-450
reductase activity and impaired drug activation in a
mammalian cell line resistant to mitomycin C under aerobic
but not hypoxic conditions. Cancer Res 1990 Aug
1;50(15):4692-7.
Hochhauser D, Harris AL. Drug resistance. Br Med Bull 1991
Jan;47(1):178-96.
Hofsli E. Multimedikamentresistens - teoretiske og kliniske
aspekter [Multidrug resistance - theoretical and clinical
aspects]. Tidsskr Nor Laegeforen 1992;112(4):472-4. (Nor).
Holden SA, Wright JE, Rosowsky A, Teicher BA, Frei E. Effect of
multiple low-dose radiation exposure on the antifolate
sensitivity of human head and neck squamous cell carcinoma
in culture [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A1937.
Honma Y, Okabe-Kado J, Kasukabe T, Hozumi M, Umezawa K.
Inhibition of ABL oncogene tyrosine kinase induces erythroid
differentiation of human myelogenous leukemia K562 cells.
Jpn J Cancer Res 1990 Nov;81(11):1132-6.
Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade
A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T, et al.
3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin
conquers multidrug resistance by rapid influx following
higher frequency of formation of DNA single- and double-
strand breaks. Cancer Res 1990 Aug 1;50(15):4698-701.
Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical
evaluation of bryostatin as an anticancer agent against
several murine tumor cell lines: in vitro versus in vivo
activity. Cancer Res 1992 Jan 1;52(1):101-7.
Horwitz SB, Goei S, Greenberger L, Lothstein L, Mellado W, Roy
SN, Yang CP, Zeheb R. Multidrug resistance in the mouse
macrophage-like cell line J774.2. In: Woolley PV 3d, Tew
KD, editors. Mechanisms of drug resistance in neoplastic
cells; 1986 Oct 15-16; Washington, DC. San Diego (CA):
Academic Press, Inc.; 1988. p. 197-210. (Bristol-Meyers
cancer symposia; 9).
Huot J, Roy G, Lambert H, Chretien P, Landry J. Increased
survival after treatments with anticancer agents of Chinese
hamster cells expressing the human M-R 27000 heat shock
protein. Cancer Res 1991;51(19):5245-52.
Hurta RA, Wright JA. Mammalian drug resistant mutants with
multiple gene amplifications: genes encoding the M1
component of ribonucleotide reductase, the M2 component of
ribonucleotide reductase, ornithine decarboxylase, p5-8, the
H-subunit of ferritin and the L-subunit of ferritin.
Biochim Biophys Acta 1990 Oct 23;1087(2):165-72.
Isonishi S, Kirmani S, Kim S, Plaxe SC, Braly PS, McClay EF,
Howell SB. Phase I and pharmacokinetic trial of
intraperitoneal etoposide in combination with the multidrug-
resistance-modulating agent dipyridamole. J Natl Cancer
Inst 1991 May 1;83(9):621-6.
Israel M, Koseki Y, Seshadri R. Further in vivo antitumor
studies with 2-chloroethylnitrosoureidodaunorubicin (AD 312)
in murine P388 leukemia systems [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2401.
Ito T, Ohnuma T, Holland JF, Mattern MR. Altered DNA
topoisomerase (TOPO) II activity in human leukemia sublines
resistant to trimetrexate (TMQ) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2078.
Ivy SP, Baird WM, Myers CE, Cowan KH. Inhibition of TCDD
inducible cytochrome P1-450 expression in multidrug
resistant MCF-7 cells by a trans-acting repressor
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1988;29:314.
Ivy SP, Tulpule A, Fairchild CR, Averbuch SD, Myers CE, Nebert D
W, Baird WM, Cowan KH. Altered regulation of P-450IA1
expression in a multidrug-resistant MCF-7 human breast
cancer cell line. J Biol Chem 1988 Dec 15;263(35):19119-25.
Iyengar BS, Dorr RT, Remers WA. Additional nucleotide
derivatives of mitosenes. Synthesis and activity against
parental and multidrug resistant L1210 leukemia. J Med Chem
1991 Jul;34(7): 1947-51.
Jaffe DR, Haraf D, Saeed B, Schwartz JL, Weichselbaum RR, Diamond
AM. Radioresistant derivatives of an x-ray-sensitive CHO
cell line exhibit distinct patterns of sensitivity to DNA
damaging-agents [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1989;30:A13.
Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson
B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.
Autologous bone marrow transplantation in multiple myeloma:
identification of prognostic factors. Blood 1990 Nov
1;76(9): 1860-6.
Jandrig B, Wunderlich V. Membrane transport in multidrug
resistance, development, and disease. AACR Special
Conference in Cancer Research. J Cancer Res Clin Oncol
1992;118(3):238-9.
Jett M, Fine RL, Jelsema C, Cowan KC, Chabner BA. The signal
transduction cascade is more responsive to stimulation in
multidrug-resistant mcf-7 breast cancer cells than in the
wild type cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29: A80.
Jett M, Fine RL, Pallansch L. Modifying multidrug-resistance by
manipulating signal transduction pathways [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1989;30:A1993.
Kamataki T, Kitada M, Komori M, Inaba N. [Resistance to
anticancer drugs in relation to cytochrome P-450]. Gan To
Kagaku Ryoho 1989 Mar;16(3 Pt 2):605-10. (Jpn).
Kaminsky R, Zweygarth E. The effect of verapamil alone and in
combination with trypanocides on multidrug-resistant
Trypanosoma-brucei-brucei. Acta Trop 1991;49(3):215-26.
Kanazawa S, Driscoll M, Struhl K. ATR1, a Saccharomyces-
cerevisiae gene encoding a transmembrane protein required
for aminotriazole resistance. Mol Cell Biol
1988;8(2):664-73.
Kaplan O, van Zijl PC, Cohen JS. Information from combined 1H
and 31P NMR studies of cell extracts: differences in
metabolism between drug-sensitive and drug-resistant MCF-7
human breast cancer cells. Biochem Biophys Res Commun 1990
Jun 15; 169(2):383-90.
Kardono LBS, Angerhofer CK, Tsauri S, Padmawinata K, Pezzuto JM,
Kinghorn AD. Cytotoxic and antimalarial constituents of
the roots of eurycoma-longifolia. J Nat Prod 1991 Sep-
Oct;54(5):1360-7.
Kashani-Sabet M, Rossi JJ, Lu Y, Chen J, Miyachi H, Ma JX,
Blayney D, Leong L, Scanlon KJ. Early detection of
cisplatin resistance in fresh human carcinoma cells by in
vitro enzymatic amplification assay [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1988;29:A1159.
Kawai K, Kamatani N, Georges E, Ling V. Identification of a
membrane glycoprotein overexpressed in murine lymphoma
sublines resistant to cis-diamminedichloroplatinum(II).
J Biol Chem 1990 Aug 5;265(22):13137-42.
Kaye SB. The multidrug resistance phenotype. Br J Cancer
1988;58(6):691-4.
Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K.
Expression of MDR1 GST-pi and topoisomerase II as an
indicator of clinical response to adriamycin. Anticancer
Res 1991;11(1):429-32.
Kobayashi H, Takemura Y, Miyachi H, Ohnuma T. Alterations of
MDR1 and dihydrofolate reductase genes in human leukemia
sublines resistant to various folate analogs [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A1932.
Kramer RA, Zakher J. Characterization of intrinsic mechanisms
of drug resistance in human colorectal carcinoma cell lines
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2070.
Krauer KG, McKenzie IF, Pietersz GA. Antitumor effect of 2'-
deoxy-5-fluorouridine conjugates against a murine thymoma
and colon carcinoma xenografts. Cancer Res 1992 Jan
1;52(1):132-7.
Krishan A. Cellular resistance to drugs. Cancer Invest
1989;7(2):211-2.
Krishnamachary N, Center MS. Detection and characterization of
membrane protein changes in multidrug resistant HL-60 cells.
Oncol Res 1992; 4(1):23-8.
Krishnamachary N, Center MS. Membrane protein changes in
multidrug-resistant HL60 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1992;33: A2721.
Kuppen PJK, Schuitemaker H, Van'T Veer LJ, De Bruijn EA, Van
Oosterom AT , Schrier PI. Cis diamminedichloroplatinum-II-
resistant sublines derived from two human ovarian tumor cell
lines. Cancer Res 1988;48(12):3355-9.
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. Intrinsic and
acquired resistance (R) to adriamycin (Ad) in human colon
carcinoma cell lines (HCCCL) [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2254.
Larsen AK, Markovits J, Jacquemin-Sablon A. Increased
sensitivity of 9-hydroxyellipticine-resistant Chinese
hamster cells to alkylating agents [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32: A2071.
Larsson R, Nygren P. Verapamil and cyclosporin A potentiate the
effects of chemotherapeutic drugs in the human medullary
thyroid carcinoma TT-cell line not expressing the 170 kDa P-
glycoprotein. Cancer Lett 1990 Nov 5;54(3):125-31.
Lazo JS, Bahnson RR. Pharmacological modulators of DNA-
interactive antitumor drugs. Trends Pharmacol Sci
1989;10(9):369-73.
Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B,
Newman RA, KenNedy KA. Characteristics of bleomycin
resistant phenotypes of human cell sublines and
circumvention of bleomycin resistance by liblomycin. Cancer
Res 1989;49(1): 185-90.
Lederer TW, Green KM Jr, Rossio JL, Giardina SL.
Internatization of probe molecules into the cytoplasm of
mammalian cells by electropermeabilization without
compromising cellular functions [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A329.
Lee SA, Karaszkiewicz JW, Anderson WB. Elevated level of
nuclear protein kinase C in multidrug-resistant MCF-7 human
breast carcinoma cells [abstract]. FASEB J 1990;4(7):A2312.
Lenehan P, Milak N, Gutierrez P, Ross D. Enhanced catalase-
mediated antioxidant defenses in multidrug-resistant human
leukemia cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1992;33:A2744.
Levine AS. The biology of human cancer, and the development of
a rational basis for treatment. Cancer Growth Prog
1989;1:1-22.
Li XK, Ohnuma T, Acs G, Cuttner J, Holland JF. Expressions of
dihydrofolate reductase (DHFR) and P-glycoprotein (P-G)
genes in trimetrexate (TMQ)-resistant human leukemia cell
lines [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2683.
Liebert M, Shinohara N, Wedemeyer G, Chang JHC, Grossman HB.
Unselected human bladder cancer cell lines demonstrate
atypical multiple drug resistance [abstract]. J Cancer Res
Clin Oncol 1990;116 Suppl Pt 1:414.
Lin J, Tan C, Rodenhuis S, Bertino JR. Multiple mechanisms for
methotrexate (mtx) resistance in human acute lymphocytic
leukemia (all) [abstract]. Proc Annu Meet Am Soc Clin Oncol
1988;7:A725.
Lock RB, Hill BT. Differential patterns of anti-tumour drug
responses and mechanisms of resistance in a series of
independently derived VP 16 resistant human tumour cell
lines. Int J Cancer 1988;42(3): 373-81.
Lunn JM, Foster BJ, Jones M, Siraky J, Newell DR. Correlation
between chemosensitivity to CB10-277 and 0(6)-alkyl-guanine-
DNA alkyltransferase levels in human melanoma xenografts
[abstract]. Br J Cancer 1990;62(3):514.
Lutzky J, Madrid KK, Krishna S, Bhalla K, Hindenburg AA, Taub RN.
Effect of glutathione depletion plus verapamil on HL60 and
HL60/AR cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2203.
Lyon RC, Daly PF, Faustino PJ, Myers CE, Cohen JS. Regulation of
phospholipid metabolism associated with multidrug resistance
in tumor cells [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29: A43.
Ma L, Center MS. The gene encoding vacuolar H(+)-ATPase subunit
C is overexpressed in multidrug-resistant HL60 cells.
Biochem Biophys Res Commun 1992 Jan 31;182(2):675-81.
Ma L, Marquardt D, Center MS. Involvement of protein P190 in
multidrug resistance in HL60 cells [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1991;32:A2200.
Marquardt D, Center MS. Involvement of vacuolar H(+)-adenosine
triphosphatase activity in multidrug resistance in HL60
cells. J Natl Cancer Inst 1991 Aug 7;83(15):1098-102.
Masters JR. Biochemical basis of resistance to chemotherapy.
Radiother Oncol 1990 Dec;19(4): 297-305.
Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Yamamoto Y,
Sakamoto H, Furuyama J. Amplification and expression of a
multidrug resistance gene in human glioma cell lines.
J Neurosurg 1990 Jan;72(1):96-101.
McCusker JH, Haber JE. Mutations in Saccharomyces cerevisiae
which confer resistance to several amino acid analogs. Mol
Cell Biol 1990 Jun;10(6): 2941-9.
Meltzer P, Leibovitz A, Dalton W, Villar H, Kute T, Davis J,
Nagle R, Trent J. Establishment of two new cell lines
derived from human breast carcinomas with HER-2-neu
amplification. Br J Cancer 1991;63(5):727-35.
Meyers MB. Sorcin is a cardiac calcium-binding protein
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2007.
Meyers MB, Shen WPV, Spengler BA, Ciccarone V, O'Brien JP, Donner
DB , Furth ME, Biedler JL. Increased epidermal growth
factor receptor in multidrug-resistant human neuroblastoma
cells. J Cell Biochem 1988;38(2):87-98.
Michaeli J, Lebedev YB, Leng L, Tong WP, Richon VM, Marks PA,
Rifkind RA. A multidrug resistance (MDR) phenotype in
response to phorbol ester: role of P-glycoprotein and
protein kinase C beta (PKC-beta) [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1990;31:A2224.
Mimnaugh EG, Sinha BK, Rajagopolan S, Myers CE. Subcellular
sites of enzymatic doxorubicin activation, oxyradical
production and detoxification in sensitive and multidrug
resistant MCF-7 human breast tumors [abstract]. Proc Annu
Meet Am Assoc Cancer Res 1989;30:A2233.
Mirski SE, Cole SP. Antigens associated with multidrug
resistance in H69AR, a small cell lung cancer cell line.
Cancer Res 1989 Oct 15;49(20): 5719-24.
Mirski SE, Cole SP. Antigens associated with the development of
resistance in H69AR, a multidrug-resistant small cell lung
cancer cell line [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1989;30: A2043.
Misset JL. Clinical aspect of drug modulation and potentiation.
In: Tapiero H, Robert J, Lampidis TJ, editors. 1st
International Interface of Clinical and Laboratory Responses
to Anticancer Drugs; 1989 Mar 13-15; Villejuif, France.
Paris: Les Editions Inserm; 1989. p. 65-76. (Colloque
INSERM; 191).
Mitchell JB, Gamson J, Russo A, Friedman N, Degraff W, Carmichael
J, Glatstein E. Chinese hamster pleiotropic multidrug-
resistant cells are not radioresistant. NCI Monogr
1988;(6):187-92.
Mitchell JB, Glatstein E, Cowan KH, Russo A. Photodynamic
therapy of multi-drug resistant cell lines [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1988;29:A1254.
Miyachi H, Takemura Y, Kobayashi H, Ohnuma T. CB3717 induced
enhancement of multidrug resistance (MDR) in a trimetrexate
(TMQ)-resistant human acute lymphoblastic leukemia cell line
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2251.
Miyamoto K, Wakusawa S, Nakamura S, Koshiura R, Otsuka K, Naito
K, Hagiwara M, Hidaka H. Circumvention of multidrug
resistance in P388 murine leukemia cells by a novel
inhibitor of cyclic AMP-dependent protein kinase, H-87.
Cancer Lett 1990 May 15;51(1):37-42.
Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano
T, Tomoda Y. Mitomycin C cross-resistance induced by
adriamycin in human ovarian cancer cells in vitro. Cancer
Chemother Pharmacol 1990;26(5):333-9.
Moalli PA, Leikin RE, Rosen ST, Harmon JM. A mechanism of
resistance to glucocorticoids in multiple myeloma
[abstract]. Blood 1990;76(10 Suppl 1):364a.
Morikage T, Bungo M, Inomata M, Yoshida M, Ohmori T, Fujiwara Y,
Nishio K, Saijo N. Reversal of cisplatin resistance with
amphotericin B in a non-small cell lung cancer cell line.
Jpn J Cancer Res 1991 Jun;82(6):747-51.
Morikawa K, Morikawa R, Killion JJ, Fan D, Fidler IJ. Isolation
of human colon carcinoma cells for resistance to a single
interferon associated with cross-resistance to multiple
recombinant interferons: alpha, beta, and gamma. J Natl
Cancer Inst 1990 Mar 21;82(6):517-22.
Moy BC, Petzold GL, Badiner GJ, Kelly RC, Aristoff PA, Adams EG,
Li LH, Bhuyan BK. Characterization of B16 melanoma cells
resistant to the CC-1065 analogue U-71,184. Cancer Res 1990
Apr 15;50(8):2485-92.
Multidrug resistance in cancer. Lancet 1989 Nov 4;
2(8671):1075-6.
Munck JN, Laval F, Tapiero H. Increase in poly adp ribosyl
transferase activity and selective toxicity of agents
interacting with this enzyme in adriamycin (adm) resistant
cells [abstract]. Proc Annu Meet Am Assoc Cancer Res
1988;29:A1156.
Myers CE. Anthracyclines. Cancer Chemother Biol Response Modif
1988;10:33-9.
Nagourney RA, Messenger JC, Kern DH, Weisenthal LM. In vitro
enhancement of doxorubicin (DOX) and nitrogen mustard (NM)
cytotoxicity in drug-resistant human neoplasms by ehtacrynic
acid (EA) [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2283.
Neale ML, Matthews N. Development of tumour cell resistance to
tumour necrosis factor does not confer resistance to
cytotoxic drugs. Eur J Cancer Clin Oncol 1989
Jan;25(1):133-7.
Niethammer D, Diddens H, Gekeler V, Frese G, Handgretinger R,
Henze G, Schmidt H, Probst H. Resistance to methotrexate
and multidrug resistance in childhood malignancies. Adv
Enzyme Regul 1989;29:231-45.
Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama
S, Terashima Y, Saijo N. Mechanism of cross-resistance to
a camptothecin analogue (CPT-11) in a human ovarian cancer
cell line selected by cisplatin. Cancer Res 1992 Jan 15;
52(2):328-33.
Nooter K, Herweijer H, Sonneveld P, Verweij J, Hagenbeek A,
Stoter G. Detection of multidrug resistance (MDR) in
refractory cancer patients [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1989;30:A2092.
Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin
selected multidrug-resistant small cell lung cancer cell
lines characterised by elevated cytoplasmic Ca2+ and
resistance modulation by verapamil in absence of P-
glycoprotein overexpression. Br J Cancer 1991 Dec;64(6):
1011-8.
Ohsaki Y, Ishida S, Fujikane T, Akiba Y, Osanai S, Onodera S.
[Combination effect of caffeine and cisplatin on a cisplatin
resistant human lung cancer cell line]. Gan To Kagaku Ryoho
1990 Jul;17(7): 1339-43. (Jpn).
Ohtsu T, Ishida Y, Tobinai K, Minato K, Hamada H, Ohkochi E,
Tsuruo T, Shimoyama M. A novel multidrug resistance in
cultured leukemia and lymphoma cells detected by a
monoclonal antibody to 85-kDa protein, MRK20. Jpn J Cancer
Res 1989 Nov;80(11):1133-40.
Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young RC.
Reversal of alkylating agent and platinum resistance in
ovarian cancer [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1988;29:526-7.
Pain J, Sirotnak FM, Barrueco JR, Yang CH, Biedler JL. Altered
molecular properties of tubulin in a multidrug-resistant
variant of Chinese hamster cells selected for resistance to
vinca alkaloids. J Cell Physiol 1988;136(2):341-7.
Park SC, Kim EG, Kwak SJ, Kim SO, Woo KM, Kim SH, Rha YH, Lee KU,
Kim ST. Induction and mechanism of drug-resistance in
experimental hepatocarcinogenesis and human hepatoma
tissues expression of mdr and cytochrome P-450. Korean J
Biochem 1989;21(1):13-20.
Parrish PR, Cress AE, Gleason MC, Bellamy WT, Dalton WS.
Enhanced drug efflux in mitoxantrone-resistant human cells
(MCF7/MITOX) is not attributed to P-glycoprotein (P-gp)
[abstract]. Proc Annu Meet Am Assoc Cancer Res 1990;31:
A2241.
Patterson JE, Zervos MJ. High-level gentamicin resistance in
Enterococcus: microbiology, genetic basis, and epidemiology.
Rev Infect Dis 1990 Jul-Aug;12(4):644-52.
Pauwels-Vergely C, Poupon MF. Chlorozotocin-induced selection
of autocrine and multidrug resistant variants from a rat
rhabdomyosarcoma. Anticancer Res 1988;8(1):137-44.
Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P, Martin
F. Mechanisms of resistance of confluent human and rat
colon cancer cells to anthracyclines: alteration of drug
passive diffusion. Cancer Res 1990 Oct 15;50(20):6626-31.
Phillips PC. Antineoplastic drug resistance in brain tumors.
Neurol Clin 1991 May;9(2):383-404.
Pieters R, Loonen AH, Huismans DR, Broxterman HJ, Veerman AJ.
Drug resistance in children with leukemia [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1990;31:A1202.
Pilantanapak A, Bhumiratana A, Jayanetra P, Panbangred W.
Biotinylated probes for epidemiological studies of drug
resistance in Salmonella krefeld. J Antimicrob Chemother
1990 Apr;25(4):593-603.
Pitcher D, Johnson A, Allerberger F, Woodford N, George R. An
investigation of nosocomial infection with Corynebacterium
jeikeium in surgical patients using a ribosomal RNA gene
probe. Eur J Clin Microbiol Infect Dis 1990 Sep;9(9):643-8.
Plumb JA, Milroy R, Bicknell SR, Kaye SB. Glutsthione-S-
transferase (GST), P-glycoprotein, and drug resistance in
small-cell lung cancer (SCLC) cell lines [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1990;31:A2185.
Posada J, Vichi P, Tritton TR. Protein kinase C in adriamycin
action and resistance in mouse sarcoma 180 cells. Cancer
Res 1989 Dec 1;49(23):6634-9.
Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S,
Tritton TR. Human multidrug resistant KB cells overexpress
protein kinase C: involvement in drug resistance. Cancer
Commun 1989;1(5):285-92.
Poyart-Salmeron C, Carlier C, Trieu-Cuot P, Courtieu AL,
Courvalin P. Transferable plasmid-mediated antibiotic
resistance in Listeria monocytogenes. Lancet 1990 Jun
16;335(8703):1422-6.
Rachkova M. Drug resistance and drug toxicity depending on
tyrosinase activity [abstract]. Eur J Cancer 1991;27 Suppl
3:S44.
Ragaz J, Goldie J, Coldman A, Simpson-Herren L, Barnett M,
Phillips G. Kinetic and biological effects of high-dose
intensity consolidation chemotherapy (HDICC) regimens for
solid tumors requiring autologous bone marrow (ABM)-
peripheral stem cell (PBSC) support. Rationale for multiple
transplants [abstract]. Proc Annu Meet Am Soc Clin Oncol
1991;10:A301.
Rahman A, Madhu M, Siddiqui J, Yokozaki H, Clair T, Tortora G,
Cho-Chung YS, Center M, Glazer RI. Potentiation of the
cytotoxicity of adriamycin by 8-Cl-cAMP in multidrug
resistant HL-60 leukemia cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A2217.
Ramachandran C, Wellham L, Sridhar KS, Krishan A. MDR-1 gene,
P-glycoprotein, and doxorubicin cytotoxicity in human lung
tumor cell lines [abstract]. Proc Annu Meet Am Assoc Cancer
Res 1991;32:A2168.
Ramu A, Ramu N, Gorodetsky R. Reduced ouabain-sensitive
potassium entry as a possible mechanism of multidrug-
resistance in P388 cells. Biochem Pharmacol 1991 Oct
9;42(9):1699-704.
Redmond A, Moran E, Clynes M. Analysis of the mechanism of
resistance of 7 novel MDR variants. Biochem Soc Trans
1992;20(1):57s.
Redmond S, Joncourt F, Buser K, Joss RA, Cerny T. Drug
resistance mechanisms in patients with colon or breast
cancer [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2189.
Reeve JG, Rabbitts PH, Twentyman PR. Non-P-glycoprotein-
mediated multidrug resistance with reduced EGF receptor
expression in a human large cell lung cancer cell line. Br
J Cancer 1990 Jun; 61(6):851-5.
Rhodes T, Twentyman PR. Effects of cyclosporin A and verapamil
on cellular pharmacokinetics and chemosensitivity in an MDR
cell line which does not express P-glycoprotein [abstract].
Br J Cancer 1991;63 Suppl 13:12.
Rhodes T, Twentyman PR. A study of ethacrynic acid as a
potential modifier of melphalan and cisplatin sensitivity in
human lung cancer parental and drug-resistant cell lines.
Br J Cancer 1992 May;65(5): 684-90.
Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks
PA. Characteristics of erythroleukemia cells selected for
vincristine resistance that have accelerated inducer-
mediated differentiation. Proc Natl Acad Sci U S A 1991 Mar
1;88(5):1666-70.
Riou GF, Zhou D, Ahomadegbe JC, Gabillot M, Duvillard P, Lhomme
C. Expression of multidrug-resistance (MDR1) gene in
normal epithelia and in invasive carcinomas of the uterine
cervix. J Natl Cancer Inst 1990 Sep 19; 82(18):1493-6.
Published erratum appears in J Natl Cancer Inst 1990 Nov 7;
82(21):1724.
Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T,
Parmiani G. Modulation of multidrug resistance by
verapamil or mdr1 anti-sense oligodeoxynucleotide does not
change the high susceptibility to lymphokine-activated
killers in mdr-resistant human carcinoma (LoVo) line. Int J
Cancer 1990 Oct 15;46(4):727-32.
Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M.
Immunohistochemical analysis of P-glycoprotein expression
correlated with chemotherapy resistance in locally advanced
breast cancer. Hum Pathol 1990 Aug;21(8):787-91.
Roberts D, Meyers MB, Biedler JL, Wiggins LG. Association of
sorcin with drug resistance in L1210 cells. Cancer
Chemother Pharmacol 1988;23(1): 19-25.
Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM.
Histologic observations and P-glycoprotein expression in
gastric and esophageal adenocarcinomas treated with
preoperative chemotherapy. Arch Pathol Lab Med 1991 Aug;
115(8):807-12.
Rosteck PR Jr, Reynolds PA, Hershberger CL. Homology between
proteins controlling Streptomyces fradiae tylosin resistance
and ATP-binding transport. Gene 1991 Jun 15;102(1):27-32.
Rowinsky EK. Current developments in antitumor antibiotics
epipodophyllotoxins and vinca alkaloids. Curr Opin Oncol
1991;3(6):1060-9.
Runde V, Aul G, Hoeller A, Heyll A, Schneider W. Multidrug
resistance in myelodysplastic syndromes, acute leukemia, and
chronic myeloid leukemia [abstract]. Onkologie 1991;14
Suppl 2:135.
Saito Y, Nakada Y, Hotta T, Mikami T, Kurisu K, Yamada K, Kiya K,
Kawamoto K, Uozumi T. Cross resistance patterns in ACNU-
resistant glioma sublines in culture. J Neurosurg
1991;75(2):277-83.
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland
RM. Hypoxia-induced drug resistance: comparison to P-
glycoprotein-associated drug resistance. Br J Cancer 1991
Nov; 64(5):809-14.
Samuels B, Ratain M, Mick R, Vogelzang NJ, Schilsky R, O'Brien S,
Harrison H. Phase I trial of multidrug resistance
modulation with cyclosporine A [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1991;32:A1163.
Sanchez Fayos J, Prieto E, Roman A, Olavarria E. Mieloma
multiple: opciones terapeuticas [The treatment of multiple
myeloma]. An Med Interna 1992;9(Spec Iss):112-8. (Spa).
Santostasi G, Kutty RK, Krishna G. Increased toxicity of
anthracycline antibiotics induced by calcium entry blockers
in cultured cardiomyocytes. Toxicol Appl Pharmacol 1991 Mar
15;108(1):140-9.
Sato W, Yusa K, Naito M, Tsuruo T. Staurosporine, a potent
inhibitor of C-kinase, enhances drug accumulation in
multidrug-resistant cells. Biochem Biophys Res Commun 1990
Dec 31;173(3):1252-7.
Sauter C. [Interactions of cytostatic agents with other drugs].
Schweiz Med Wochenschr 1991 Aug 31; 121(35):1249-53. (Ger).
Scheck AC, Beikman MK, Korn MC, Shapiro JR. Regional analysis
of genes potentially involved in resistance to BCNU in human
malignant gliomas [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2125.
Scheper RJ, Broxterman HJ, Scheffer GL, Baas F, Meijer CJ, Pinedo
HM. New mechanism of multidrug resistance is associated
with overexpression of 110-KD vesicular protein [abstract].
Proc Annu Meet Am Assoc Cancer Res 1992;33:A2738.
Scheper RJ, Broxterman HJ, Scheffer GL, Dalton WS, Dietel M, van
Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer
CJ, et al. Different human multidrug-resistant (MDR) cell
lines not expressing P-glycoprotein (P-gp) share a
cytoplasmic protein recognized by monoclonal antibody LRP56
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2198.
Schott B, Vrignaud P, Ries C, Londos-Gagliardi D, Robert J.
Cellular pharmacology of 4' deoxy-4'-iododoxorubicin and its
13 dihydro derivative in a model of wild and multidrug
resistant rat glioblastoma cells [abstract]. Invest New
Drugs 1989;7(4):391.
Schuetz E, Schaffer D, Flanigan K, Stromm S, Cowan K, Schuetz J.
Effect of matrix on expression of multidrug resistance in
cultured rat and human hepatocytes [abstract]. Hepatology
1989;10(4):606.
Schuurhuis GJ, Broxterman HJ, Pinedo HM, Ossenkoppele GJ, Baak
JP, van Heijningen TH, Kuiper CM, van Kalken CK, Lankelma J.
Multidrug-resistance phenotype in acute myeloid leukemia,
characterized by altered subcellular drug distribution and
decreased drug accumulation, independent of P-glycoprotein
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2715.
Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C
(PKC) activity and the effects of staurosporine (STSN) in a
multidrug-resistant (MDR) human acute lymphoblastic leukemia
cell line [abstract]. Proc Annu Meet Am Assoc Cancer Res
1989;30:A2111.
Sehested M, Friche E, Jensen PB, Demant E, Skovsgaard T. VP-16
transport and binding in wild type and multidrug-resistant
Ehrlich ascites tumor cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2201.
Seidman AD, Scher HI. The evolving role of chemotherapy for
muscle infiltrating bladder cancer. Semin Oncol 1991
Dec;18(6):585-95.
Shalinsky DR, Andreeff M, Howell SB. Modulation of drug
sensitivity by dipyridamole in multidrug resistant tumor
cells in vitro. Cancer Res 1990 Dec 1;50(23):7537-43.
Sharma RC, Assaraf YG, Schimke RT. A phenotype conferring
selective resistance to lipophilic antifolates in Chinese
hamster ovary cells. Cancer Res 1991 Jun 1;51(11):2949-59.
Sharma RC, Assaraf YG, Schimke RT. Verapamil potentiation of
trimetrexate cytotoxicity and dihydrofolate reductase gene
amplification in CHO cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2012.
Sherwood SW, Assaraf YG, Molina A, Schimke RT. Flow cytometric
characterization of antifolate resistance in cultured
mammalian cells using fluoresceinated methotrexate and
daunorubicin. Cancer Res 1990 Aug 15;50(16):4946-50.
Shibata H, Furusawa S, Kawauchi H, Sasaki K, Takayanagi Y.
[Modulation of anthracycline resistance by reserpine in P388
leukemia cells]. Nippon Yakurigaku Zasshi 1991
Jul;98(1):1-6. (Jpn).
Shiryaeva OA, Semenova NA, Sibel'Dina LA, Goncharova SA,
Konovalova NP. [The study of phosphorus-containing
metabolites in anthracycline-resistant murine leukemia P388
cells]. Eksp Onkol 1989;11(4):70-3. (Rus).
Shoji Y, Fisher MH, Periasamy A, Herman B, Juliano RL.
Verapamil and cyclosporin A modulate doxorubicin toxicity by
distinct mechanisms. Cancer Lett 1991 May 24;57(3):209-18.
Shyamala V, Baichwal V, Beall E, Ames GF. Structure-function
analysis of the histidine permease and comparison with
cystic fibrosis mutations. J Biol Chem 1991 Oct 5;
266(28):18714-9.
Siddiqui J, Madhu M, Center M, Glazer R, Dritschilo A, Rahman A.
Modulation of multidrug resistance in HL-60 leukemia cells
by adriamycin encapsulated in liposomes [abstract]. Proc
Annu Meet Am Assoc Cancer Res 1991;32:A2230.
Sinha BK, Atwell J, Politi PM. Role of oxygen free radical
formation in the mechanism of menogaril resistance in
multidrug resistant tumor cells. Chem Biol Interact
1990;76(1):89-99.
Skalski V, Yarosh DB, Batist G, Gros P, Feindel W, Kopriva D,
Panasci LC. Mechanisms of resistance to (2-chloroethyl)-3-
sarcosinamide-1-nitrosourea (SarCNU) in sensitive and
resistant human glioma cells. Mol Pharmacol 1990
Sep;38(3):299-305.
Slapak CA, Daniel JC, Levy SB. Sequential emergence of distinct
resistance phenotypes in murine erythroleukemia cells under
adriamycin selection: decreased anthracycline uptake
precedes increased P-glycoprotein expression. Cancer Res
1990 Dec 15;50(24):7895-901.
Slapak CA, Kharbanda S, Kufe DW. Selective loss of jun-B and C-
jun induction in multidrug-resistant human leukemia cells
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1992;33:A2729.
Slater LM, Sweet P, Hsu TC, Chan PK. Novel nucleolar and
nuclear morphology in a vincristine-dependent human leukemia
cell line (L100). Exp Cell Res 1992 Jan;198(1):170-4.
Slater LM, Wetzel M, Cho J, Sweet P. Development of cyclosporin
A mediated immunity in L1210 leukaemia. Br J Cancer 1991
Dec;64(6):1098-102.
Slovak ML, Coccia M, Meltzer PS, Trent JM. Molecular analysis
of two human doxorubicin-resistant cell lines: evidence for
differing multidrug resistance mechanisms. Anticancer Res
1991 Jan-Feb;11(1):423-8.
Smith PJ, Morgan SA, Watson JV. Detection of multidrug
resistance and quantification of responses of human tumour
cells to cytotoxic agents using flow cytometric spectral
shift analysis of Hoechst 33,342-DNA fluorescence. Cancer
Chemother Pharmacol 1991;27(6):445-50.
Sognier MA, Eberle RL, Zhang Y, Belli JA. Interaction between
radiation and drug damage in mammalian cells. V. DNA damage
and repair induced in LZ cells by adriamycin and/or
radiation. Radiat Res 1991 Apr;126(1):80-7.
Speicher LA, Sheridan VR, Godwin AK, Tew KD. Resistance to the
antimitotic drug estramustine is distinct from the multidrug
resistant phenotype. Br J Cancer 1991 Aug;64(2):267-73.
Spies T, DeMars R. Restored expression of major
histocompatibility class I molecules by gene transfer of a
putative peptide transporter. Nature 1991; 351(6324):323-4.
Stuart N, Houlbrook S, Kirk J, Philip P, Lien E, Harris A,
Carmichael J. Tamoxifen as an enhancer of etoposide
cytotoxicity in lung cancer: in vitro and clinical effects
[abstract]. Br J Cancer 1991;63 Suppl 13:13.
Sugawara I, Ikeuchi T, Fukuchi K, Yoshikai Y, Sugiyama H, Kodo H,
Mori S. Establishment and characterization of a non-T,
non-B cell lymphoma cell line with T cell receptor beta- and
gamma-chain gene rearrangement and possessing MRK 20
monoclonal antibody-defined 85KD protein. Hum Cell 1990
Mar;3(1):57-64.
Sugawara I, Iwahashi T, Okamoto K, Sugimoto Y, Ekimoto H, Tsuruo
T, Ikeuchi T, Mori S. Characterization of an etoposide-
resistant human K562 cell line, K/eto. Jpn J Cancer Res
1991 Sep;82(9):1035-43.
Sugawara I, Kodo H, Ohkochi E, Hamada H, Tsuruo T, Mori S.
High-level expression of MRK 16 and MRK 20 murine monoclonal
antibody-define proteins (170,000-180,000 P-glycoprotein and
85,000 protein) in leukaemias and malignant lymphomas. Br J
Cancer 1989 Oct;60(4):538-41.
Sugawara I, Mizumoto K, Ohkochi E, Hamada H, Tsuruo T, Mori S.
Immunocytochemical identification and localization of the Mr
22,000 calcium-binding protein (sorcin) in an adriamycin-
resistant myelogenous leukemia cell line. Jpn J Cancer Res
1989 May;80(5):469-74.
Sugimoto Y, Okochi E, Hamada H, Oh-hara T, Tsuruo T. Detection
of 300-kilodalton membrane protein in adriamycin-resistant
human tumor cells by a monoclonal antibody MRK18. Biochem
Biophys Res Commun 1990 Jun 15;169(2):686-91.
Sullivan DM, Webb CD, Cardwell EM, Latham MD, Lock RB.
Mechanisms of resistance to DNA topoisomerase II inhibitors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2067.
Sunkara PS, Zwolshen JH, Stemerick DM, Edwards ML. 1-(2,5-
dimethoxy phenyl)-3-[4(dimethylamino)phenyl]-2-methyl-2-
propen-1-one (DDMP, MDL 27,048): novel antimitotic agent
with activity against vinca alkaloid resistant tumors
[abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A1954.
Tagger AY, Wright JA. Molecular and cellular characterization
of drug resistant hamster cell lines with alterations in
ribonucleotide reductase. Int J Cancer 1988;42(5):760-6.
Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y,
Niitani H, Saijo N. Establishment of a human leukemia
subline resistant to the growth-inhibitory effect of 12-O-
tetradecanoylphorbol 13-acetate (TPA) and showing non-P-
glycoprotein-mediated multi-drug resistance. Int J Cancer
1991 Jul 30;48(6):931-7.
Takemura Y, Ohnuma T, Miyachi H, Sekiguchi S. A human leukemia
cell line made resistant to two folate analogues,
trimetrexate and N10-propargyl-5,8-dideazafolic acid
(CB3717). J Cancer Res Clin Oncol 1991;117(6):519-25.
Tapiero H, Fourcade A, Nishiyama M, Horichi N, Saijo N, Lampidis
TJ. Relationship between the accumulation of structurally
different anthracyclines, cytotoxicity, DNA damage and
repair in dox-seneitive and resistant cells [abstract].
Anticancer Res 1990;10(5B):1401-2.
Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT,
Thompson FH, Roe DJ, Trent JM. Different mechanisms of
decreased drug accumulation in doxorubicin and mitoxantrone
resistant variants of the MCF7 human breast cancer cell
line. Br J Cancer 1991 Jun;63(6):923-9.
Tomida A, Tatsuta T, Suzuki H. Novel mechanism of N-solanesyl-
N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine in potentiation
of antitumor drug action on multidrug-resistant and
sensitive Chinese hamster cells. Jpn J Cancer Res 1991
Jan;82(1):127-33.
Torres-Garcia S, Panasci L, DeMuys JM, Greene D, Lehnert S,
Batist G. Enhanced repair mechanism in a melphalan (MLN)
resistant human breast cancer cell line, and also in multi-
drug resistant (MDR) cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1988;29:A1236.
Treichel RS, Olken S. The relationship between multi-drug
resistance and resistance to natural-killer-cell and
lymphokine-activated killer-cell lysis in human leukemic
cell lines. Int J Cancer 1992 Jan 21; 50(2):305-10.
Treupel L, Poupon MF, Couvreur P, Puisieux F. [Vectorisation of
doxorubicin in nanospheres and reversion of pleiotropic
resistance of tumor cells]. C R Acad Sci III
1991;313(3):171-4. (Fre).
Tritton TR. Signal transduction mechanisms in anticancer drug
action and resistance [abstract]. Br J Cancer 1991;63 Suppl
13:4.
Tsuruo T. Chemotherapeutic targets for the modulation of
multidrug resistance. Paper presented at: 1st International
Interface of Clinical and Laboratory Responses to Anticancer
Drugs; 1989 Mar 13-15; Villejuif, France.
Vaughan WP, Bierman PJ, Reed EC, Vose J, Kessinger A, Armitage
JO. High-dose hydroxyurea (HU) incorporation into
autologous marrow transplant (ABMT) regimes [abstract].
Proc Annu Meet Am Soc Clin Oncol 1991;10:A344.
Vera JC, Castillo GR, Rosen OM. A possible role for a mammalian
facilitative hexose transporter in the development of
resistance to drugs. Mol Cell Biol 1991;11(7):3407-18.
Versantvoort CH, Broxterman HJ, Pinedo HM, de Vries EG, Feller N,
Kuiper CM, Lankelma J. Energy-dependent processes involved
in reduced drug accumulation in multidrug-resistant human
lung cancer cell lines without P-glycoprotein expression.
Cancer Res 1992 Jan 1;52(1):17-23.
Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS,
Seynaeve C, Stoter G, Nooter K. A phase II study of
epidoxorubicin in colorectal cancer and the use of
cyclosporin-A in an attempt to reverse multidrug resistance.
Br J Cancer 1991 Aug;64(2):361-4.
Vickers PJ, Dufresne MJ, Cowan KH. Relation between cytochrome
p-450-ia1 expression and estrogen receptor content of human
breast cancer cells. Mol Endocrinol 1989;3(1):157-64.
Wadler S, Wiernik PH. Partial reversal of doxorubicin resistance
by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180
variants. Cancer Res 1988; 48(3):539-43.
Wakusawa S, Nakamura S, Aritsuka K, Miyamoto KI, Koshiura R,
Hagiwara M, Hidaka H. Effect of protein kinase inhibitors
on the drug-efflux system in multidrug-resistant tumor cells
[abstract]. Jpn J Pharmacol 1990;52 Suppl 1:86P.
Ward CL, Krouse MW, Gruenert DC, Kopito RR, Wine JJ. Cystic
fibrosis gene expression is not correlated with rectifying
chloride channels. Proc Natl Acad Sci U S A
1991;88(12):5277-81.
Ward NE, O'Brian CA. Distinct patterns of phorbol-ester-induced
downregulation of protein kinase C activity in adriamycin-
selected multidrug resistant and parental murine
fibrosarcoma cells. Cancer Lett 1991;58(3):189-94.
Warr JR, Atkinson GF. Genetic aspects of resistance to
anticancer drugs. Physiol Rev 1988;68(1):1-26.
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T.
Cellular pharmacology of MX2, a new morpholino
anthracycline, in human pleiotropic drug-resistant cells.
Cancer Res 1991 Jan 1;51(1): 157-61.
Watanabe Y, Takano H, Kiue A, Kohno K, Kuwano M. Potentiation
of etoposide and vincristine by two synthetic 1,4-
dihydropyridine derivatives in multidrug-resistant and
atypical multidrug-resistant human cancer cells. Anticancer
Drug Des 1991 Feb;6(1):47-57.
Waud WR, Harrison SD Jr, Temple CG Jr, Griswold DP Jr.
Antitumor drug cross-resistance in vivo in a murine P388
leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-
phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-
hydroxyethanesulfonate hydrate (NSC 370,147) 370147. Cancer
Chemother Pharmacol 1992;29(3):190-4.
Wellems TE, Panton LJ, Gluzman IY, do Rosario VE, Gwadz RW,
Walker-Jonah A, Krogstad DJ. Chloroquine resistance not
linked to mdr-like genes in a Plasmodium falciparum cross.
Nature 1990 May 17;345(6272):253-5.
Wellhoner HH, Neville DM Jr, Srinivasachar K, Erdmann G. Uptake
and concentration of bioactive macromolecules by K562 cells
via the transferrin cycle utilizing an acid-labile
transferrin conjugate. J Biol Chem 1991 Mar 5;266(7):
4309-14.
Whelan JS, Phear GA, Rohatiner AZ, Lister TA, Meuth M. DNA
sequence determination of CTP synthetase mutations in ara-C-
resistant hamster cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A2104.
Wilson WH, Bryant G, Bates S, Fojo T, Stevenson MA, Kohler D,
Chabner BA. Infusional etoposide (E), vincristine (O) and
adriamycin (H) with cyclophosphamide (C), prednisone (P)
(EPOCH) and R-verapamil (RV) in relapsed lymphoma
[abstract]. Proc Annu Meet Am Soc Clin Oncol 1991;10:A956.
Wishart GC, Plumb JA, Spandidos DA, Kerr DJ. H-RAS transfection
in mink lung epithelial cells may induce atypical multidrug
resistance. Eur J Cancer 1991;27(5):673.
Workman P, Donaldson J. Membrane-active ether lipid SRI 62-834:
in vitro antitumor activity alone or in combination with
doxorubicin [abstract]. Proc Annu Meet Am Assoc Cancer Res
1990;31:A2083
Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY.
Regulation and drug resistance mechanisms of mammalian
ribonucleotide reductase, and the significance to DNA
synthesis. Biochem Cell Biol 1990 Dec;68(12):1364-71.
Wyss PA, Moor MJ, Mathis GA, Bickel MH. Significance of
amiodarone (AM) and its metabolites in rat tissues after
single dose administration [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1991;32:A2056.
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI. A
phase I trial of etoposide (E) with cyclosporine (CSA) as a
modulator of multidrug resistance (MDR) [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A276.
Yang KH, Kim SM. [An analysis of plasmid DNA fingerprint of
multidrug resistant pseudomonas-aeruginosa]. J Cathol Med
Coll 1990;43(2):729-40. (Kor).
Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a
human medullary thyroid carcinoma cell line: association
with overexpression of mdr1 gene and low proliferation
fraction. Anticancer Res 1991;11(3):1065-8.
Yang LY, Trujillo JM. Biological characterization of multidrug-
resistant human colon carcinoma sublines induced/selected by
two methods. Cancer Res 1990 Jun 1;50(11):3218-25.
Yeh GC, Chou JY, Jamis-Dow CA, Occhipinti SJ, Myers CE. Genetic
and biochemical differences of glucose-6-phosphate
dehydrogenase in adriamycin-sensitive and -resistant human
breast cancer cells [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A2087.
Yeh GC, Occhipinti SJ, Myers CE. Biochemical changes of glucose
metabolism in adraimycin-sensitive and -resistant human
breast cancer MCF-7 cells [abstract]. Proc Annu Meet Am
Assoc Cancer Res 1990;31:A2235.
Yin MB, Bankusli I, Rustum YM. Effect of verapamil, DMDP
(RO11-2933), a tiapamil analog, and dipyridamole, a
nucleoside transport inhibitor, on the extent and duration
of doxorubicin-induced DNA single strand breaks in
multidrug-resistant P-388 cells [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:A2103.
Yokozaki H, Clair T, Tortora G, Pepe S, Glazer R, Cho-Chung YS.
Site-selective camp analogs inhibit the growth of multidrug
resistant cell lines and suppress the expression of P-
glycoprotein [abstract]. Proc Annu Meet Am Assoc Cancer Res
1991;32:A2232.
Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki
K, Tsuruo T, Cowan KH, Glazer RI. Transfection with
protein kinase C alpha confers increased multidrug
resistance to MCF-7 cells expressing P-glycoprotein. Cancer
Commun 1991 Jun;3(6):181-9.
Zalcberg JR, Krauer K, Hur XF, McKenzie IF, Pietersz G.
Anthracycline conjugates bypass cellular mechanisms of
resistance in multidrug resistant (MDR) cells [abstract].
Paper presented at: Cancer in the 1990's: is more aggressive
treatment better? 17th Annual Scientific Meeting of the
Clinical Oncological Society of Australia Inc.; 1990 Nov
26-28; Melbourne, Australia.
Zhang Y, Sweet K, Sognier MA, Belli JA. Simultaneous reversion
of radiation sensitivity and adriamycin resistance does not
occur in a multidrug-resistant cell line (LZ) [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A2154.
Zhen W, Link CJ, O'Connor PM, Bohr VA. Formation and repair of
cisplatin lesions in specific genes in cisplatin sensitive
and resistant human ovarian cancer cell lines [abstract].
Proc Annu Meet Am Assoc Cancer Res 1991;32:A37.
MONOGRAPHS
Abramson, R.; Bhushan, A.; Dolci, E.; Tritton, T. R. The
structure of the multidrug resistance P-glycoprotein and its
similarity to other proteins. In: Bristol, J. A., editor.
Annual reports in medicinal chemistry. Vol. 25. San Diego
(CA): Academic Press, Inc.; 1990. p. 253-60.
Akiyama, Shin-Ichi; Tisgunyram, Akihiko; Ichikawa, Misako;
Sumizawa, Tomoyuki; Furukawa, Tatsuhiko. A molecular basis
for multidrug-resistance and reversal of the resistance.
In: Tabuchi, Kazuo, editor. Biological aspects of brain
tumors. 8th Nikko Brain Tumor Conference; 1990 Nov 6-8;
Karatsu-shi, Japan. New York: Springer-Verlag; 1991. p.
63-72.
Bast, Cheryl Barbati. Chromosomal and molecular alterations
associated with fibrosarcoma development in the mouse
[dissertation]. [Knoxville (TN)]: University of Tennessee;
1989. 179 p. Available from: University Microforms, Ann
Arbor, MI; AAD89-19813.
Bellamy, William Tracy. Mechanisms of doxorubicin resistance in
multidrug resistant human myeloma cells [dissertation].
[Tucson (AZ)]: University of Arizona; 1988. 241 p.
Available from: University Microforms, Ann Arbor, MI; AAD88-
22419.
Biedler, J. L.; Meyers, M. B.; Spengler, B. A. Cellular
concomitants of multidrug resistance. In: Woolley, P. V.
3rd; Tew, K. D., editors. Mechanisms of drug resistance in
neoplastic cells; 1986 Oct 15-16; Washington, DC. San Diego
(CA): Academic Press, Inc.; 1988. p. 41-68. (Bristol-Myers
cancer symposia; 9).
Biedler, June L.; Meyers, Marian B. Multidrug resistance (vinca
alkaloids, actinomycin D, and anthracycline antibiotics).
In: Gupta, Radhey S., editor. Drug resistance in mammalian
cells. Vol. 2, Anticancer and other drugs. Boca Raton (FL):
CRC Press; 1989. Chapter 4.
Bourhis, J.; Hartmann, O.; Devathaire, F.; Terrier-Lacombe, M.
J.; Boccon-Gibod, L.; Lemerle, J.; Riou, G.; Benard, J.
Expression of MDR1 and GST-PI genes in 35 advanced
neuroblastomas. In: Evans, A. E., et al., editors.
Advances in neuroblastoma research 3. 5th Symposium; 1990
May 28-30; Philadelphia, PA. New York: John Wiley and Sons,
Inc.; 1991. p. 127-34. (Progress in clinical and
biological research; 366).
Bruchovsky, Nicholas; Goldie, James H., editors. Drug and hormone
resistance in neoplasia. Vol. 1, Basic concepts. Boca Raton
(FL): CRC Press; 1983. 191 p.
Bruchovsky, Nicholas; Goldie, James H., editors. Drug and hormone
resistance in neoplasia. Vol. 2, Clinical concepts. Boca
Raton (FL): CRC Press; 1983. 167 p.
Cheng, Heng-Jie. The studies of mechanisms of multidrug
resistance in murine pancreatic carcinoma [dissertation].
[Detroit (MI)]: Wayne State University; 1991. 186 p.
Available from University Microforms, Ann Arbor, MI;
AAD91-27214.
Chin, Janice Elaine. Structure and expression of the human mdr
(P-glycoprotein) gene family [dissertation]. [Chicago]:
University of Illinois at Chicago, Health Sciences Center;
1989. 148 p. Available from: University Microforms, Ann
Arbor, MI; AAD90-03680.
Choi, Kyunghee. Characterization of the human multidrug
resistance (mdr1) gene [dissertation]. [Chicago]:
University of Illinois at Chicago; 1988. 176 p. Available
from: University Microforms, Ann Arbor, MI; AAD89-14125.
Chou, T. C.; Rideout, D. C., editors. Synergism and antagonism
in chemotherapy. New York: Academic Press; 1991. 752 p.
Collins, Jerry M.; Chabner, Bruce A. Cancer chemotherapy:
principles and practice. Philadelphia: Lippincott; 1990.
Expansion of: Chabner, Bruce A. Pharmacologic principles of
cancer treatment. Philadelphia: Saunders; 1982.
Deppe, Gunter, editor. Chemotherapy of gynecologic cancer. New
York: Wiley-Liss; 1990.
Desai, Pankaj Bhaskar. Chemical modulation of the cytotoxicity
and redox transformations of mitoxantrone [dissertation].
[Columbia (SC)]: University of South Carolina; 1990. 173 p.
Available from: University Microforms, Ann Arbor, MI; AAD91-
01451.
Fairchild, C. R.; Goldsmith, M. E.; Cowan, K. H. Molecular
biology of antineoplastic drug resistance. In: Cossman, J.,
editor. Molecular genetics in cancer diagnosis. New York:
Elsevier; 1990. p. 113-41.
Fine, R. L.; Patel J.; Carmichael, J.; Chabner, B. A. Multidrug
resistance in human cancer cells: changes in protein
phosphorylation and protein kinase. In: Zenser, T.V.; Coe,
R. M., editors. Cancer and aging: progress in research and
treatment. New York: Springer Publishing; 1989. p. 158-70.
The 1st International Symposium on Immunobiology of Renal Cell
Carcinoma; 1989 Nov 6-7; Cleveland, OH. [Cleveland]:
Cleveland Clinic Foundation and Cancer Center; 1989. 128 p.
Foote, S. J.; Thompson, J. K.; Marshall, V.; Cowman, A. F.;
Biggs, B. A.; Brown, G. V.; Kemp, D. J. The multidrug
resistance gene of Plasmodium-falciparum. Does it mediate
chloroquine resistance? In: Agabian, N.; Cerami, A.,
editors. Parasites: molecular biology, drug and vaccine
design; proceedings of a UCLA symposium; 1989 Apr 3-10;
Keystone, CO. New York: Wiley-Liss; 1990. p. 325-34.
(UCLA symposia on molecular and cellular biology; new
series, vol. 130).
Ghione, Mario; Rausa, Luciano, editors. Resistance to antitumor
agents: laboratory and clinical studies: proceedings of a
course held at the International School of Pharmacology;
1988 Apr 13-18; Ettore Majorana Centre for Scientific
Culture, Italy. New York: Harwood Academic Publishers; 1989.
321 p. (Ettore majorana international life sciences series;
7)
Glazer, Robert I., editor. Developments in cancer chemotherapy.
Boca Raton (FL): CRC Press, Inc.; 1984. Multidrug
resistance (MDR); p. 133-8.
Gottesman, M. M.; Pastan, I. The multidrug resistance MDR1 gene
as a selectable marker in gene therapy. In: Cohen-
Haguenauer, O.; Boiron, M., editors. Transfert de genes
chez l'homme [Human gene transfer]. International Workshop;
1991 Apr 11-13; Gouvieux-Chantilly, France. Paris: Editions
Inserm; 1991. p. 185-92. (Colloque INSERM; 219).
Gottesman, M. M.; Pastan, I.; Akiyama, S. I.; Fojo, A. T.; Shen,
D. W.; Ueda, K.; Clark, D. P.; Cardarelli, C. O.; Richert,
N. D., et al. Expression amplification and transfer of DNA
sequences associated with multidrug resistance. In:
Woolley, P. V. 3rd; Tew, K. D., editors. Mechanisms of drug
resistance in neoplastic cells; 1986 Oct 15-16; Washington,
DC. San Diego (CA): Academic Press, Inc.; 1988. p. 242-58.
(Bristol-Myers cancer symposia; 9).
Greenberger, L. M.; Lothstein L.; Horwitz, S. B. Heterogeneous
forms of P-glycoprotein in multidrug resistant J774.2 cells.
In: Tapiero, H.; Robert, J.; Lampidis, T. J., editors. 1st
International Interface of Clinical and Laboratory Responses
to Anticancer Drugs; 1989 Mar 13-15; Villejuif, France.
Paris: Les Editions Inserm; 1989. p. 263-76. (Colloque
INSERM; 191).
Hall, Thomas C., editor. Cancer drug resistance; proceedings of
a workshop held at the 14th International Congress of
Chemotherapy; 1985 Jun 23-28; Kyoto, Japan. New York: Alan
R. Liss, Inc.; 1986. 235 p. (Progress in clinical and
biological research; vol. 223).
Handler, J. S.; Horio, M.; Willingham, M.; Pastan, I.; Gottesman,
M. M. Polar localization of the multidrug resistance
transporter in epithelia results in transepithelial
transport of substrates. In: Berliner, R. W.; Honda, N.;
Ullrich, K. J., editors. The frontiers of nephrology.
International Forum; 1989 Aug 24-25; Tokyo, Japan.
Amsterdam: Elsevier Science Publishers; 1990. p. 129-38.
(International congress series; 877).
Hedley, D. W. Flow cytometry and drug resistance. In: Carney,
D.; Sikora, K., editors. Genes and cancer. New York:
Wiley-Liss; 1990. p. 227-34.
Horwitz, S. B.; Goei, S.; Greenberger, L.; Lothstein, L; Mellado,
W.; Roy, S. N.; Yang, C. P. H.; Zeheb, R. Multidrug
resistance in the mouse macrophage-like cell line J774.2.
In: Woolley, P. V. 3rd; Tew, K. D., editors. Mechanisms of
drug resistance in neoplastic cells; 1986 Oct 15-16;
Washington, DC. San Diego (CA): Academic Press, Inc.; 1988.
p. 223-42. (Briston-Myers cancer symposia; 9).
Jakobsson, Ann-Helene Solveig. Cytogenetic and molecular
analysis of drug resistance in interspecific cell hybrids
[dissertation]. [Goteborg (Sweden)]: University of
Goteborg, Department of Genetics; 1989. 51 p.
Kessel, David, editor. Resistance to antineoplastic drugs. Boca
Raton (FL): CRC Press; 1989. 448 p.
Lampidis, T. J.; Fourcade, A.; Tapiero, H. Relationship of
membrane potential to acquired and intrinsic multiple drug
resistance. In: Jacquillat, C.; Weil, M.; Khayat, D.,
editors. Chimiotherapie neo-adjuvante [Neo-adjuvant
chemotherapy]. 2nd International Congress; 1988 Feb 19-21;
Paris. Paris: Les Editions Inserm; 1988. p. 655-60.
(Colloque INSERM; 169).
Ling, V.; Juranka, P. F.; Endicott, J. A.; Deuchars, K. L.;
Gerlach, J. H. Multidrug resistance and P-glycoprotein
expression. In: Woolley, P. V. 3rd; Tew, K. D., editors.
Mechanisms of drug resistance in neoplastic cells; 1986 Oct
15-16; Washington, DC. San Diego (CA): Academic Press,
Inc.; 1988. p. 197-210. (Briston-Myers cancer symposia;
9).
Lobko, Georgii Nikolaevich; Turbin, N. V.; Porubova, Galia
Mikhailovna. Immunogeneticheskie osnovy rezistentnosti
opukholei. Minsk: Vysheishaia Shkola; 1980. 176 p. (Rus).
Magrath, I., editor. New directions in cancer treatment. New
York: Springer; 1989. Chemotherapy; p. 119-277.
Medh, Rheem Dineshray. Mammalian glutathione S-transferases:
structure, functions, and role in resistance to antitumor
agents [dissertation]. [Galveston]: University of Texas
Graduate School of Biomedical Sciences at Galveston; 1990.
272 p. Available from: University microforms, Ann Arbor,
MI; AAD91-15934.
Mellado, Wilfredo. Phosphorylation of the multidrug resistant
associated glycoprotein (P-glycoprotein): preparation and
characterization of 7-acetyltaxol [dissertation]. [New
York]: Yeshiva University; 1988. 161 p.
Mihich, Enrico, editor. Drug resistance: mechanisms and
reversal. New York: John Libbey CIC; 1990. 342 p.
Moore, R.; Hoskins, J.; Deherdt, S.; Bumol, T. Cloning of full-
length human mdr-1 and its use as a probe to study the
expression of mdr-1 in caco-2 calcium carbonate colorectal
carcinoma cells [abstract]. In: Hershberger, C. L.;
Queener, S. W.; Hegeman, G., editors. Genetics and
molecular biology of industrial microorganisms. 4th ASM
Conference; 1988; Bloomington, IN. Washington (DC):
American Society for Microbiology; 1989. p. 368.
Munger, Craig Evans. Biochemical components of anthracycline
sensitivity and resistance in the H-35 rat hepatoma cell
[dissertation]. [Richmond]: Virginia Commonwealth
University; 1991. 165 p. Available from: University
Microforms, Ann Arbor, MI; AAD91-28600.
Ozols, Robert F., editor. Drug resistance in cancer therapy.
Boston: Kluwer Academic Publishers; 1989. 210 p. (McGuire,
William L., editor. Cancer treatment and research; 48).
Ozols, Robert F., editor. Molecular and clinical advances in
anticancer drug resistance. Boston: Kluwer Academic
Publishers; 1991. 308 p. (McGuire, William L., editor.
Cancer treatment and research; 57).
Pastan, I.; Gottesman, M. Drug resistance: biological warfare
at the cellular level. In: Broder, S., editor. Molecular
foundations of oncology. Baltimore: Williams & Wilkins;
1991. p. 83-93.
Pastan, I. H.; Gottesman, M. M. Molecular biology of multidrug
resistance in human cells. In: Devita, V. T., Jr.; Hellman,
S.; Rosenberg, S. A., editors. Important advances in
oncology, 4. Philadelphia: Lippincott; 1988. p. 3-16.
Perry, Michael Clinton, editor. The chemotherapy source book.
Baltimore: Williams & Wilkins; c1992. 1172 p.
Potmesil, Milan; Kohn, Kurt W., editors. DNA topoisomerases in
cancer. New York: Oxford University Press; 1991. Part IV,
Drug resistance and topoisomerases; p. 249-80.
Progestin Action and Progesterone Receptors in Breast Cancer;
1989 Apr 6-7; Washington, DC. [Bethesda (MD)]: National
Cancer Institute Organ Systems Program; 1989.
Roninson, Igor B., editor. Molecular and cellular biology of
multidrug resistance in tumor cells. New York: Plenum Press;
c1991. 406 p.
Ruiz, Joseph C. Characterization of the initial products of
mammalian gene amplification and the mechanisms of their
formation [dissertation]. [San Diego]: University of
California, San Diego; 1988. 206 p. Available from:
University Microforms, Ann Arbor, MI; AAD89-08002.
Siemann, D. W.; Keng, P. C. Synergistic interactions at the
solid tumor level through targeting of therapies against two
or more different tumor cell subpopulations. In: Chou, T.
C.; Rideout, D. C., editors. Synergism and antagonism in
chemotherapy. New York: Academic Press; 1991. p. 689-713.
Skovsgaard, Torben. Eksperimentel resistens over for
anthracykliner og vincaalkaloider: resistensmekanismer og
omgaelse af disse pa cellulaert niveau. Kbenhavn:
Polyteknisk Forlag; 1981. 64 p. (Dan).
Teeter, Larry Dean. Phenotypic association of gene amplification
with multiple drug resistance in vincristine resistant
Chinese hamster ovary cells [dissertation]. [Houston (TX)]:
University of Texas Health Science Center at Houston School
of Biomedical Science; 1987. 174 p. Available from:
University Microforms, Ann Arbor, MI; AAD88-00590.
Thorgeirsson, S. S. Modulation of gene expression during early
stages of chemical hepatocarcinogenesis. In: King, C. M.,
et al., editors. Carcinogenic and mutagenic responses to
aromatic amines and notroarenes. New York: Elsevier; 1988.
p. 315-20.
Tsuruo, Takashi; Ogawa, Makoto, editors. Drug resistance as a
biochemical target in cancer chemotherapy. San Diego:
Academic Press; 1992. 342 p. (Carter, Stephen K., editor.
Bristol-Myers Squibb cancer symposia; 13).
Veinot-Drebot, L.; Ling, V. The molecular biology of multidrug
resistance. In: Sluyser, M., editor. Molecular biology of
cancer genes. Chichester (England): Ellis Horwood Ltd.;
1990. p. 263-89.
Woolley, Paul V.; Tew, Kenneth D., editors. Mechanisms of drug
resistance in neoplastic cells. San Diego: Academic Press;
1988. 390 p. (Carter, Stephen K., editor. Bristol-Myers
cancer symposia; 13).
Yang, C. P.; Greenberger, L. M.; Horwitz, S. B. Reversal of
multidrug resistance in tumor cells. In: Chou, T. C.;
Rideout, D. C., editors. Synergism and antagonism in
chemotherapy. New York: Academic Press; 1991. p. 311-38.
Zenser, T. V.; Coe, R. M., editors. Cancer and aging: progress
in research and treatment. New York: Springer Publishing;
1989. 251 p.
